1
00:00:05,539 --> 00:00:06,173
I'M MARY GLENSHAW, DESIGNATED

2
00:00:06,173 --> 00:00:09,110
FEDERAL OFFICIAL OF THE AIDS

3
00:00:09,110 --> 00:00:12,997
RESEARCH ADVISORY COUNCIL.

4
00:00:12,997 --> 00:00:14,598
WELCOME AND THANK YOU FOR YOUR

5
00:00:14,598 --> 00:00:15,599
PARTICIPATION TODAY.

6
00:00:15,599 --> 00:00:17,134
A BRIEF REMIND YOU ARE OUR

7
00:00:17,134 --> 00:00:18,736
COUNCIL IS GOVERNED BY

8
00:00:18,736 --> 00:00:20,504
PROVISIONS OF THE FEDERAL

9
00:00:20,504 --> 00:00:22,106
ADVISORY COMMITTEE ACT, FACA, AS

10
00:00:22,106 --> 00:00:23,507
AMENDED WHICH SETS FORTH

11
00:00:23,507 --> 00:00:28,212
STANDARDS FOR FORMATION AND USE

12
00:00:28,212 --> 00:00:29,146
OF ADVISORY COMMITTEES.

13
00:00:29,146 --> 00:00:33,717
MY ROLE IS TO PREPARE MEETING

14
00:00:33,717 --> 00:00:35,986
AGENDAS, ORGANIZE, ATTEND,

15
00:00:35,986 --> 00:00:37,821
APPROVAL COUNCIL AND

16
00:00:37,821 --> 00:00:38,622
SUBCOMMITTEE MEETINGS, ADJOURNED

17
00:00:38,622 --> 00:00:40,024
WHEN DETERMINED IN THE PUBLIC

18
00:00:40,024 --> 00:00:41,392
INTEREST AS WELL AS CHAIR

19
00:00:41,392 --> 00:00:44,194
MEETINGS WHEN DIRECTED BY NIH

20
00:00:44,194 --> 00:00:51,035
DIRECTOR OR OAR DIRECTOR.

21
00:00:51,035 --> 00:00:52,570
AS IN PREVIOUS MEETINGS, LET'S

22
00:00:52,570 --> 00:00:55,706
GO OVER GUIDELINES FOR TODAY.

23
00:00:55,706 --> 00:00:58,108
PLEASE STAY MUTED UNLESS YOU'RE

24
00:00:58,108 --> 00:00:58,375
SPEAKING.

25
00:00:58,375 --> 00:01:00,077
PLEASE KEEP YOUR CAMERA ON FOR

26
00:01:00,077 --> 00:01:01,579
MOST OF THE MEETING, HIDE IT IF

27
00:01:01,579 --> 00:01:03,747
YOU NEED TO STEP AWAY AND PLEASE

28
00:01:03,747 --> 00:01:06,784
PUT IT BACK ON WHEN YOU COME

29
00:01:06,784 --> 00:01:07,084
BACK.

30
00:01:07,084 --> 00:01:08,452
IF YOU WOULD LIKE TO PARTICIPATE

31
00:01:08,452 --> 00:01:10,955
IN DISCUSSIONS WE'LL DO THIS TWO

32
00:01:10,955 --> 00:01:11,755
WAYS.

33
00:01:11,755 --> 00:01:15,359
FOR FOLKS ON THE M.S. TEAMS CALL

34
00:01:15,359 --> 00:01:17,828
USE THE "RAISE HAND" FEATURE SO

35
00:01:17,828 --> 00:01:19,530
WE CAN SEE THAT YOU'RE READY TO

36
00:01:19,530 --> 00:01:22,433
MAKE A COMMENT.

37
00:01:22,433 --> 00:01:23,634
FOR THOSE IN THE ROOM, PLEASE

38
00:01:23,634 --> 00:01:25,169
STAND YOUR NAME CARD UP

39
00:01:25,169 --> 00:01:29,340
VERTICALLY SO I CAN RECOGNIZE

40
00:01:29,340 --> 00:01:29,573
YOU.

41
00:01:29,573 --> 00:01:34,044
LOWER YOUR  HAND OR NAME CARD

42
00:01:34,044 --> 00:01:38,015
WHEN FINISHED SO WE KNOW YOU'RE

43
00:01:38,015 --> 00:01:38,515
DONE.

44
00:01:38,515 --> 00:01:42,353
PLEASE USE THE CHAT FEATURE FOR

45
00:01:42,353 --> 00:01:45,489
LOGISTICS MESSAGES, NOT FOR

46
00:01:45,489 --> 00:01:46,523
SUBSTANTIAL PARTICIPATION.

47
00:01:46,523 --> 00:01:49,560
IF YOU HAVE QUESTIONS OR

48
00:01:49,560 --> 00:01:54,264
CONCERNS E-MAIL US AT

49
00:01:54,264 --> 00:01:55,199
OARACINFO@NIH.GOV.

50
00:01:55,199 --> 00:01:56,233
FOR FOLKS USING THE VIDEOCAST,

51
00:01:56,233 --> 00:01:59,103
IF YOU'D LIKE TO USE THE CLOSED

52
00:01:59,103 --> 00:02:01,205
CAPTION FEATURE, CLICK THE CC I

53
00:02:01,205 --> 00:02:03,974
CON ON THE BOTTOM RIGHT-HAND

54
00:02:03,974 --> 00:02:06,110
CORNER OF THE VIDEO SCREEN.

55
00:02:06,110 --> 00:02:08,379
I'LL REMIND OUR MEMBERS OF OUR

56
00:02:08,379 --> 00:02:10,814
POLICIES REGARDING CONFLICT OF

57
00:02:10,814 --> 00:02:11,248
INTEREST.

58
00:02:11,248 --> 00:02:12,650
COUNCIL MEMBERS MAY NOT

59
00:02:12,650 --> 00:02:13,651
PARTICIPATE IN THE REVIEW OR

60
00:02:13,651 --> 00:02:15,085
DISCUSSION OF A SPECIFIC PROGRAM

61
00:02:15,085 --> 00:02:16,820
OR PROJECT FOR WHICH THEY HAVE A

62
00:02:16,820 --> 00:02:18,789
REAL OR APPARENT CONFLICT OF

63
00:02:18,789 --> 00:02:19,156
INTEREST.

64
00:02:19,156 --> 00:02:21,859
IF A PROGRAM OR PROJECT IS

65
00:02:21,859 --> 00:02:23,227
DISCUSSED THAT PRESENTS A

66
00:02:23,227 --> 00:02:25,896
CONFLICT, EXCUSE YOURSELF FROM

67
00:02:25,896 --> 00:02:26,664
THE MEETING.

68
00:02:26,664 --> 00:02:28,999
SIGNAL ME AND WE'LL MOVE YOU TO

69
00:02:28,999 --> 00:02:30,567
A SEPARATE MEETING SPACE ON

70
00:02:30,567 --> 00:02:33,570
TEAMS OR IN THE ROOM.

71
00:02:33,570 --> 00:02:36,507
AFTER THE MEETING KINDLY SIGN

72
00:02:36,507 --> 00:02:38,042
THE ELECTRONIC CONFLICT OF

73
00:02:38,042 --> 00:02:40,811
INTEREST FORM E-MAILED TO YOU

74
00:02:40,811 --> 00:02:42,513
TODAY TO VERIFY NOTHING

75
00:02:42,513 --> 00:02:44,214
DISCUSSED POSED A CONFLICT FOR

76
00:02:44,214 --> 00:02:44,381
YOU.

77
00:02:44,381 --> 00:02:46,417
BEFORE I MOVE FORWARD ARE THERE

78
00:02:46,417 --> 00:02:51,822
ANY QUESTIONS ABOUT CONFLICTS OF

79
00:02:51,822 --> 00:02:52,523
INTEREST?

80
00:02:52,523 --> 00:02:53,023
OKAY.

81
00:02:53,023 --> 00:02:53,991
HEARING NONE, PLEASE ALSO

82
00:02:53,991 --> 00:02:55,859
REMEMBER TODAY'S MEETING IS OPEN

83
00:02:55,859 --> 00:02:58,696
TO THE GENERAL PUBLIC, AND

84
00:02:58,696 --> 00:02:59,997
CURRENTLY BEING RECORDED AND

85
00:02:59,997 --> 00:03:01,031
VIDEOCAST LIVE.

86
00:03:01,031 --> 00:03:09,039
I WILL NOW WELCOME OUR NEW OARIC

87
00:03:09,039 --> 00:03:11,075
CHAIR, DR. MONTANER AND TURN THE

88
00:03:11,075 --> 00:03:12,142
MEETING OVER.

89
00:03:12,142 --> 00:03:16,747
>> GOOD AFTERNOON,  EVERY
ONE,

90
00:03:16,747 --> 00:03:24,188
THE 68th MEETING IS NOW IN

91
00:03:24,188 --> 00:03:25,089
SESSION, WELCOME, EVERYONE.

92
00:03:25,089 --> 00:03:28,025
WE WILL NOW PROCEED WITH THE

93
00:03:28,025 --> 00:03:31,895
ROLL CALL, DR. GLENSHAW, PLEASE

94
00:03:31,895 --> 00:03:32,329
PROCEED.

95
00:03:32,329 --> 00:03:33,297
>> SURE.

96
00:03:33,297 --> 00:03:34,064
STANDING MEMBERS AND GUESTS,

97
00:03:34,064 --> 00:03:37,034
WHEN I CALL YOUR NAME STATE YOUR

98
00:03:37,034 --> 00:03:38,402
POSITION AND INSTITUTIONAL

99
00:03:38,402 --> 00:03:39,036
AFFILIATION.

100
00:03:39,036 --> 00:03:40,237
WE REALIZE SOME PARTICIPANTS MAY

101
00:03:40,237 --> 00:03:41,739
JOIN A LITTLE BIT LATER.

102
00:03:41,739 --> 00:03:46,376
WE'LL START WITH OUR VOTING

103
00:03:46,376 --> 00:03:46,643
MEMBERS.

104
00:03:46,643 --> 00:03:48,846
DR. COURTNEY FLETCHER.

105
00:03:48,846 --> 00:03:50,314
>> PRESENT, UNIVERSITY OF

106
00:03:50,314 --> 00:03:52,750
NEBRASKA MEDICAL CENTER.

107
00:03:52,750 --> 00:03:53,050
>> GREAT.

108
00:03:53,050 --> 00:03:55,352
THANK YOU.

109
00:03:55,352 --> 00:03:58,255
DR. FLORES.

110
00:03:58,255 --> 00:04:02,192
>> HI, I'M AT UNIVERSITY
OF

111
00:04:02,192 --> 00:04:02,826
COLORADO ANSCHUTZ MEDICAL

112
00:04:02,826 --> 00:04:07,731
CAMPUS, DEPARTMENT OF MEDICINE.

113
00:04:07,731 --> 00:04:09,433
>> DR. ANN NEILEN.

114
00:04:09,433 --> 00:04:12,603
>> GOOD AFTERNOON,
DEPARTMENT OF

115
00:04:12,603 --> 00:04:14,772
PEDIATRICS, DEPARTMENT OF

116
00:04:14,772 --> 00:04:15,305
MEDICINE, HARVARD MEDICAL

117
00:04:15,305 --> 00:04:16,673
SCHOOL, MASSACHUSETTS GENERAL

118
00:04:16,673 --> 00:04:23,413
HOSPITAL IN BOSTON. 

119
00:04:23,413 --> 00:04:23,747
>> WELCOME.

120
00:04:23,747 --> 00:04:25,215
DR. DIANE SANTAMARIA, SCHOOL OF

121
00:04:25,215 --> 00:04:27,518
NURSING, UNIVERSITY OF TEXAS

122
00:04:27,518 --> 00:04:28,886
HEALTH SCIENCE CENTER, HOUSTON.

123
00:04:28,886 --> 00:04:31,889
>> THANK YOU. 

124
00:04:31,889 --> 00:04:33,190
DR. SARAH SAWYER MIGHT BE

125
00:04:33,190 --> 00:04:35,993
JOINING A LITTLE BIT LATER.

126
00:04:35,993 --> 00:04:41,265
MOVING TO THE EX OFFICIOS,

127
00:04:41,265 --> 00:04:42,132
CENTER JULIE AKE.

128
00:04:42,132 --> 00:04:46,837
>> DIRECTOR OF THE U.S.
MILITARY

129
00:04:46,837 --> 00:04:49,673
HIV RESEARCH PROGRAM, WALTER

130
00:04:49,673 --> 00:04:52,776
REED ARMY INSTITUTE, JOINING

131
00:04:52,776 --> 00:04:55,445
FROM HAWAII, SO ALOHA.

132
00:04:55,445 --> 00:04:56,079
>> ALOHA.

133
00:04:56,079 --> 00:04:59,583
THANK YOU.

134
00:04:59,583 --> 00:05:00,417
DR. DIEFFENBACH?

135
00:05:00,417 --> 00:05:04,955
HE MIGHT BE JOINING LATER TOO.

136
00:05:04,955 --> 00:05:06,156
DR. ROHAN HASRA.

137
00:05:06,156 --> 00:05:07,991
>> I'M DIRECTOR OF THE
DIVISION

138
00:05:07,991 --> 00:05:10,794
OF EXTRAMURAL RESEARCH AT THE

139
00:05:10,794 --> 00:05:11,361
NATIONAL INSTITUTE OF CHILD

140
00:05:11,361 --> 00:05:13,630
HEALTH AND HUMAN DEVELOPMENT AT

141
00:05:13,630 --> 00:05:13,831
NIH.

142
00:05:13,831 --> 00:05:15,032
>> THANK YOU.

143
00:05:15,032 --> 00:05:16,099
IT'S MY PLEASURE TO WELCOME TO

144
00:05:16,099 --> 00:05:24,341
THEIR FIRST MEETING TWO NEWEST,

145
00:05:24,341 --> 00:05:32,182
OH 

146
00:05:32,182 --> 00:05:32,616
OFFICIOS.

147
00:05:32,616 --> 00:05:34,084
>> HEATHER HAWK.

148
00:05:34,084 --> 00:05:35,752
>> WELCOME.

149
00:05:35,752 --> 00:05:43,227
>> AND GOOD AFTERNOON,
ROBIN

150
00:05:43,227 --> 00:05:45,362
FANFAIR, AT CDC IN ATLANTA.

151
00:05:45,362 --> 00:05:48,732
>> REPRESENTING OUR FELLOW

152
00:05:48,732 --> 00:05:50,300
ADVISORY COUNCILS DR. DIANNE

153
00:05:50,300 --> 00:05:50,767
RAUSCH.

154
00:05:50,767 --> 00:05:51,435
>> DIANNE RAUSCH, DIRECTOR
OF

155
00:05:51,435 --> 00:05:53,871
THE DIVISION OF AIDS RESEARCH AT

156
00:05:53,871 --> 00:05:56,306
NATIONAL INSTITUTE OF MENTAL

157
00:05:56,306 --> 00:05:56,540
HEALTH.

158
00:05:56,540 --> 00:06:01,645
>> AND NOW TO OAR LEADERS
AND

159
00:06:01,645 --> 00:06:01,912
SPEAKERS.

160
00:06:01,912 --> 00:06:03,113
DR. GERI DONENBERG.

161
00:06:03,113 --> 00:06:07,251
>> HELLO, DIRECTOR OF THE
OFFICE

162
00:06:07,251 --> 00:06:09,386
OF AIDS RESEARCH.

163
00:06:09,386 --> 00:06:16,026
>> INVITED GUESTS, FROM
NIH, DR.

164
00:06:16,026 --> 00:06:19,396
ALICE PAU.

165
00:06:19,396 --> 00:06:23,133
>> ALICE PAU, AT NIAID,
NIH.

166
00:06:23,133 --> 00:06:24,434
>> THANK YOU.

167
00:06:24,434 --> 00:06:25,736
DR. CHACKTORA.

168
00:06:25,736 --> 00:06:26,937
>> AT THE NATIONAL
INSTITUTE OF

169
00:06:26,937 --> 00:06:30,807
CHILD HEALTH AND HUMAN

170
00:06:30,807 --> 00:06:39,116
DEVELOPMENT, PREGNANCY AND

171
00:06:39,116 --> 00:06:47,925
PERINATOLOGY BRANCH. 

172
00:06:47,925 --> 00:06:49,359
>> DR. HENRY MASUR MIGHT
BE

173
00:06:49,359 --> 00:06:53,063
JOINING LATER AND HENRY YATES.

174
00:06:53,063 --> 00:07:02,039
AND IF YOU'RE ON THE LINE LET US

175
00:07:02,039 --> 00:07:09,279
KNOW, DR. LISA ABGO.

176
00:07:09,279 --> 00:07:11,848
STATE YOUR AFFILIATION. 

177
00:07:11,848 --> 00:07:12,816
>> UNIVERSITY OF COLORADO,

178
00:07:12,816 --> 00:07:13,050
DENVER.

179
00:07:13,050 --> 00:07:17,487
>> THANK YOU.

180
00:07:17,487 --> 00:07:21,725
DR. ELAINE ABRAMS. 

181
00:07:21,725 --> 00:07:23,994
DR. CONNIE BENSON.

182
00:07:23,994 --> 00:07:31,168
DR. JOHN BROOKS.

183
00:07:31,168 --> 00:07:33,603
DR. ANDREA SIARANELLO.

184
00:07:33,603 --> 00:07:38,408
DR. CHIP GULIK.

185
00:07:38,408 --> 00:07:40,544
>> HI, I'M HERE.

186
00:07:40,544 --> 00:07:42,245
DIVISION OF INFECTIOUS DISEASES,

187
00:07:42,245 --> 00:07:44,715
WEILL CORNELL, NEW YORK CITY.

188
00:07:44,715 --> 00:07:45,215
>> THANK YOU.

189
00:07:45,215 --> 00:07:51,488
AND DR. KARINA RODRIGUEZ.

190
00:07:51,488 --> 00:07:53,223
>> I'M HERE, UNIVERSITY OF
SOUTH

191
00:07:53,223 --> 00:07:53,590
FLORIDA.

192
00:07:53,590 --> 00:07:54,825
>> THANK YOU, WELCOME.

193
00:07:54,825 --> 00:08:01,264
IS THERE ANYONE WE DID NOT

194
00:08:01,264 --> 00:08:01,698
ANNOUNCE?

195
00:08:01,698 --> 00:08:06,036
THERE ARE TWO PEOPLE, MY

196
00:08:06,036 --> 00:08:06,370
APOLOGIES.

197
00:08:06,370 --> 00:08:10,173
DR. JULIO ALBERTI.

198
00:08:10,173 --> 00:08:11,141
>> HI, SENIOR SCIENCE
ADVISER,

199
00:08:11,141 --> 00:08:13,710
OFFICE OF AIDS RESEARCH, NIH.

200
00:08:13,710 --> 00:08:14,945
>> THANK YOU.

201
00:08:14,945 --> 00:08:17,247
DR. DAVID CHANG.

202
00:08:17,247 --> 00:08:19,349
>> HELLO, DAVID CHANG,
SENIOR

203
00:08:19,349 --> 00:08:22,519
SCIENCE ADVISER, OFFICE OF AIDS

204
00:08:22,519 --> 00:08:23,453
RESEARCH.

205
00:08:23,453 --> 00:08:27,791
>> THANK YOU VERY MUCH. 

206
00:08:27,791 --> 00:08:31,728
DR. DIEFFENBACH, WELCOME. 

207
00:08:31,728 --> 00:08:32,596
>> GLAD TO JOIN.

208
00:08:32,596 --> 00:08:33,463
>> THANK YOU.

209
00:08:33,463 --> 00:08:34,731
DR. MONTANER, BACK TO YOU.

210
00:08:34,731 --> 00:08:35,766
>> THANK YOU.

211
00:08:35,766 --> 00:08:43,707
I FORGOT TO INTRODUCE MYSELF,

212
00:08:43,707 --> 00:08:45,942
LUIS MONTANER, WISTAR INSTITUTE,

213
00:08:45,942 --> 00:08:46,276
PROFESSOR.

214
00:08:46,276 --> 00:08:49,279
THANK YOU FOR JOINING.

215
00:08:49,279 --> 00:08:53,784
FOR OUR CHARTER AND LEGISLATION

216
00:08:53,784 --> 00:08:55,719
OARAC ADVISES ON MATTERS RELATED

217
00:08:55,719 --> 00:08:57,454
TO RESEARCH, PRIORITIES,

218
00:08:57,454 --> 00:08:58,622
STRATEGIC PLANNING INCLUDING

219
00:08:58,622 --> 00:09:01,158
REVIEW OF THE NIH AIDS PROGRAMS.

220
00:09:01,158 --> 00:09:02,993
I WILL NOW PROVIDE A BRIEF

221
00:09:02,993 --> 00:09:05,362
OVERVIEW OF TODAY'S AGENDA WHICH

222
00:09:05,362 --> 00:09:07,731
INCLUDES TO START A REPORT FROM

223
00:09:07,731 --> 00:09:10,300
THE OAR DIRECTOR, DR. GERI

224
00:09:10,300 --> 00:09:11,501
DONENBERG, THEN A PRESENTATION

225
00:09:11,501 --> 00:09:16,807
ON ADVANCED PLATFORMS FOR VIRAL

226
00:09:16,807 --> 00:09:18,675
LOAD MONITORING, POINT OF CARE.

227
00:09:18,675 --> 00:09:21,144
THEN A STRATEGY UPDATE REGARDING

228
00:09:21,144 --> 00:09:23,713
THE HIV CLINICAL PRACTICE

229
00:09:23,713 --> 00:09:24,081
GUIDELINES.

230
00:09:24,081 --> 00:09:27,484
AND FINALLY, AN UPDATE FROM

231
00:09:27,484 --> 00:09:28,952
ADVISORY COUNCIL

232
00:09:28,952 --> 00:09:29,753
REPRESENTATIVES.

233
00:09:29,753 --> 00:09:31,455
THE AGENDA ALSO INCLUDES TIME

234
00:09:31,455 --> 00:09:32,389
FOR REGISTERED PUBLIC COMMENTS

235
00:09:32,389 --> 00:09:33,857
OF WHICH THERE HAVE BEEN QUITE A

236
00:09:33,857 --> 00:09:37,794
FEW SO WE'LL GET TO THEM AT THE

237
00:09:37,794 --> 00:09:38,128
END.

238
00:09:38,128 --> 00:09:38,962
ANYONE LISTENING TODAY WHO

239
00:09:38,962 --> 00:09:44,067
WISHES TO MAKE A PUBLIC COMMENT

240
00:09:44,067 --> 00:09:52,609
SHOULD E-MAIL OARACINFO@NIH.GOV,

241
00:09:52,609 --> 00:09:54,044
WITH YOUR NAME, AFFILIATION, AND

242
00:09:54,044 --> 00:09:56,713
A QUESTION OR COMMENT.

243
00:09:56,713 --> 00:10:00,317
PLEASE SEND COMMENTS BY VISITING

244
00:10:00,317 --> 00:10:02,819
THE OAR WEBSITE OR FEDERAL

245
00:10:02,819 --> 00:10:06,490
REGISTRY NOTICE FOR DETAILS.

246
00:10:06,490 --> 00:10:08,492
WE'LL NOW PROCEED WITH THE

247
00:10:08,492 --> 00:10:11,561
DIRECTOR'S REPORT FROM DR.

248
00:10:11,561 --> 00:10:13,096
DONENBERG.

249
00:10:13,096 --> 00:10:15,899
>> THANK YOU VERY MUCH.

250
00:10:15,899 --> 00:10:16,933
LET'S SEE.

251
00:10:16,933 --> 00:10:18,969
FIRST I JUST WANT TO WELCOME

252
00:10:18,969 --> 00:10:19,236
EVERYONE.

253
00:10:19,236 --> 00:10:21,171
THANK YOU FOR BEING HERE.

254
00:10:21,171 --> 00:10:23,573
AGAIN, APPRECIATE VERY MUCH

255
00:10:23,573 --> 00:10:24,608
EVERYONE'S CONTRIBUTIONS TO

256
00:10:24,608 --> 00:10:24,875
OARAC.

257
00:10:24,875 --> 00:10:27,010
THIS IS MY SECOND MEETING,

258
00:10:27,010 --> 00:10:28,178
OFFICIALLY.

259
00:10:28,178 --> 00:10:29,513
THE FIRST MEETING I SORT OF

260
00:10:29,513 --> 00:10:31,448
JUMPED IN A WEEK AFTER I STARTED

261
00:10:31,448 --> 00:10:31,948
THIS POSITION.

262
00:10:31,948 --> 00:10:33,984
SO I'M A LITTLE BIT MORE

263
00:10:33,984 --> 00:10:36,887
FAMILIAR NOW WITH OAR THAN I WAS

264
00:10:36,887 --> 00:10:39,122
THEN, AND IT'S BEEN A VERY

265
00:10:39,122 --> 00:10:43,560
EVENTFUL RIDE, I WILL SAY THAT.

266
00:10:43,560 --> 00:10:46,296
I WILL ALSO SAY THAT I HAVE BEEN

267
00:10:46,296 --> 00:10:48,932
INCREDIBLY IMPRESSED BY THE

268
00:10:48,932 --> 00:10:51,268
DEDICATION OF ALL OF THE FOLKS

269
00:10:51,268 --> 00:10:54,437
WHO WORK WITH THE HIV AND AIDS

270
00:10:54,437 --> 00:10:55,472
RESEARCH PORTFOLIO, INCLUDING

271
00:10:55,472 --> 00:11:00,977
THE STAFF AT OAR WHO HAVE

272
00:11:00,977 --> 00:11:03,747
DEMONSTRATED GREAT COMMITMENT

273
00:11:03,747 --> 00:11:05,882
AND PERSEVERANCE AND KNOWLEDGE

274
00:11:05,882 --> 00:11:07,450
AND SUPPORT FOR THIS PORTFOLIO

275
00:11:07,450 --> 00:11:10,420
AND FOR ADVANCING THE SCIENCE.

276
00:11:10,420 --> 00:11:12,455
AND I'M EXCITED TO TELL YOU A

277
00:11:12,455 --> 00:11:14,391
LITTLE BIT ABOUT WHERE WE ARE

278
00:11:14,391 --> 00:11:19,129
GOING IN THE FUTURE IN LARGE

279
00:11:19,129 --> 00:11:20,397
PART BECAUSE SOME OF THE

280
00:11:20,397 --> 00:11:22,399
PRIORITIES OF THE NEW

281
00:11:22,399 --> 00:11:23,200
ADMINISTRATION FIT REALLY WELL

282
00:11:23,200 --> 00:11:31,341
WITH THE OFFICE OF AIDS

283
00:11:31,341 --> 00:11:31,775
RESEARCH.

284
00:11:31,775 --> 00:11:34,611
I WANT TO, AGAIN, JUST STATE

285
00:11:34,611 --> 00:11:39,883
THAT AS THIS GROUP MOVES

286
00:11:39,883 --> 00:11:45,622
FORWARD, I'M VERY HOPEFUL OARAC

287
00:11:45,622 --> 00:11:47,457
WILL GUIDANCE, THIS IS A REPORT

288
00:11:47,457 --> 00:11:49,192
OUT TO YOU ABOUT DIFFERENT

289
00:11:49,192 --> 00:11:50,594
ASPECTS OF WHAT WE'RE DOING BUT

290
00:11:50,594 --> 00:11:53,296
I'M HOPING THAT AS WE MOVE

291
00:11:53,296 --> 00:11:56,499
FORWARD WE FIND WAYS TO ALSO

292
00:11:56,499 --> 00:12:00,604
BRING IN A LOT MORE COMMENTS,

293
00:12:00,604 --> 00:12:04,241
ADVICE, AND GUIDANCE AND

294
00:12:04,241 --> 00:12:06,676
RECOMMENDATIONS MOVING FORWARD.

295
00:12:06,676 --> 00:12:09,179
SO, TODAY OARAC IS BEING HOLD

296
00:12:09,179 --> 00:12:11,014
THE DAY BEFORE THE HIV --

297
00:12:11,014 --> 00:12:13,149
NATIONAL HIV TESTING DAY WHICH

298
00:12:13,149 --> 00:12:15,652
WAS FIRST OBSERVED ON JUNE

299
00:12:15,652 --> 00:12:16,753
27th IN 1995.

300
00:12:16,753 --> 00:12:18,989
IT'S A DAY TO ENCOURAGE PEOPLE

301
00:12:18,989 --> 00:12:21,558
TO GET TESTED FOR HIV, TO KNOW

302
00:12:21,558 --> 00:12:24,160
THEIR STATUS, GET LINKED TO CARE

303
00:12:24,160 --> 00:12:24,494
AND TREATMENT.

304
00:12:24,494 --> 00:12:28,698
AND THE SAME FOR THE 2025

305
00:12:28,698 --> 00:12:30,333
NATIONAL TESTING DAY IS LEVEL

306
00:12:30,333 --> 00:12:32,969
UP -- THE THEME IS LEVEL UP YOUR

307
00:12:32,969 --> 00:12:34,838
SELF LOVE, AND CHECK YOUR

308
00:12:34,838 --> 00:12:37,574
STATUS. 

309
00:12:37,574 --> 00:12:41,611
THE REAL EMPHASIS IS VALUE

310
00:12:41,611 --> 00:12:43,847
ONESELF, SHOW COMPASSION AND

311
00:12:43,847 --> 00:12:48,652
RESPECT AND HONOR OUR NEEDS WITH

312
00:12:48,652 --> 00:12:49,586
SELF-LOVE.

313
00:12:49,586 --> 00:12:50,920
NOW, BEFORE MOVING ON TO MY

314
00:12:50,920 --> 00:12:52,989
REPORT, I WANT TO ACKNOWLEDGE,

315
00:12:52,989 --> 00:12:55,225
AND I THINK MARY DID SOME OF

316
00:12:55,225 --> 00:12:57,627
THIS EARLIER, THAT THERE HAVE

317
00:12:57,627 --> 00:13:00,163
BEEN THE DELAYS AND DISRUPTIONS

318
00:13:00,163 --> 00:13:02,299
THIS YEAR POSED A NUMBER OF

319
00:13:02,299 --> 00:13:05,101
CHALLENGES WITHIN OUR RESEARCH

320
00:13:05,101 --> 00:13:06,036
COMMUNITY.

321
00:13:06,036 --> 00:13:07,904
WE CERTAINLY WANT TO ACKNOWLEDGE

322
00:13:07,904 --> 00:13:09,239
THEIR DEDICATION AND COMMITMENT

323
00:13:09,239 --> 00:13:12,142
TO THE RESEARCH EFFORT.

324
00:13:12,142 --> 00:13:15,812
WE DEEPLY APPRECIATE ALSO THE

325
00:13:15,812 --> 00:13:19,616
NIH STAFF AND GRANTEES WHO HAVE

326
00:13:19,616 --> 00:13:20,750
NAVIGATED THIS DIFFICULT

327
00:13:20,750 --> 00:13:22,052
TERRAIN.

328
00:13:22,052 --> 00:13:24,954
WITH THAT IN MIND, PLEASE NOTE

329
00:13:24,954 --> 00:13:28,258
THAT OAR CANNOT COMMENT ON THE

330
00:13:28,258 --> 00:13:30,093
FOLLOWING SPECIFIC SITUATIONS

331
00:13:30,093 --> 00:13:33,096
SUCH AS INDIVIDUAL GRANTS,

332
00:13:33,096 --> 00:13:34,631
APPLICATIONS, INSTITUTIONS, OR

333
00:13:34,631 --> 00:13:34,964
INVESTIGATORS.

334
00:13:34,964 --> 00:13:39,502
WE CANNOT COMMENT ON PENDING OR

335
00:13:39,502 --> 00:13:41,504
ONGOING LITIGATION.

336
00:13:41,504 --> 00:13:43,139
INTERNAL GUIDANCE DEVELOPED TO

337
00:13:43,139 --> 00:13:44,708
ENSURE ALIGNMENT WITH CURRENT

338
00:13:44,708 --> 00:13:46,009
PRIORITIES AND EXECUTIVE ORDERS,

339
00:13:46,009 --> 00:13:49,012
AND WE ALSO CANNOT COMMENT ON

340
00:13:49,012 --> 00:13:50,980
WHETHER OPPORTUNITIES WILL BE

341
00:13:50,980 --> 00:13:53,350
REOPENED OR REISSUED IN THE

342
00:13:53,350 --> 00:13:53,717
FUTURE.

343
00:13:53,717 --> 00:13:57,754
AND WE THANK YOU FOR YOUR

344
00:13:57,754 --> 00:13:59,823
PATIENCE IN THOSE LIMITATIONS.

345
00:13:59,823 --> 00:14:01,324
THERE ARE, HOWEVER, PUBLICLY

346
00:14:01,324 --> 00:14:03,360
AVAILABLE RESOURCES FOR YOU TO

347
00:14:03,360 --> 00:14:05,295
STAY INFORMED, AND ONE OF THESE

348
00:14:05,295 --> 00:14:08,498
IS THE NIH GRANTS AND FUNDING

349
00:14:08,498 --> 00:14:11,868
INFORMATION STATUS WEB PAGE

350
00:14:11,868 --> 00:14:13,837
WHICH INCLUDES INFORMATION ON

351
00:14:13,837 --> 00:14:15,905
LATEST CHANGES THAT AFFECT NIH

352
00:14:15,905 --> 00:14:17,173
GRANTS ADMINISTRATION AND

353
00:14:17,173 --> 00:14:17,707
FUNDING.

354
00:14:17,707 --> 00:14:20,076
THERE IS ALSO AN HHS WEBSITE

355
00:14:20,076 --> 00:14:23,680
THAT PROVIDES A LIST OF ALL

356
00:14:23,680 --> 00:14:24,214
NIH'S TERMINATED GRANTS,

357
00:14:24,214 --> 00:14:28,518
ALTHOUGH GIVEN THAT THIS IS A

358
00:14:28,518 --> 00:14:29,719
VERY EVOLVING SITUATION, YOU

359
00:14:29,719 --> 00:14:31,354
ALMOST HAVE TO CHECK BACK DAILY

360
00:14:31,354 --> 00:14:33,857
TO SEE WHAT'S LISTED AND WHAT

361
00:14:33,857 --> 00:14:34,157
ISN'T.

362
00:14:34,157 --> 00:14:36,860
BOTH OF THESE SITES CAN BE

363
00:14:36,860 --> 00:14:37,961
ACCESSED BY SCANNING THE QR CODE

364
00:14:37,961 --> 00:14:40,964
SHOWN ON THE SLIDE AND I'LL

365
00:14:40,964 --> 00:14:42,599
PAUSE SO YOU MAY TAKE A PICTURE

366
00:14:42,599 --> 00:14:52,575
OF THOSE IF YOU WANT.

367
00:14:52,575 --> 00:14:56,012
YOU'LL SEE THAT WE HAVE QUITE AN

368
00:14:56,012 --> 00:14:57,414
EXCITING AGENDA, I HOPE, FOR YOU

369
00:14:57,414 --> 00:14:57,680
TODAY.

370
00:14:57,680 --> 00:15:01,284
AND I WANT TO THANK ALL THE

371
00:15:01,284 --> 00:15:03,219
PRESENTERS FOR THEIR TIME AND

372
00:15:03,219 --> 00:15:05,922
WILLINGNESS TO PRESENT HERE.

373
00:15:05,922 --> 00:15:07,323
FOLLOWING MY OWN DIRECTOR'S

374
00:15:07,323 --> 00:15:09,959
REPORT, WE'RE EXCITED TO HEAR A

375
00:15:09,959 --> 00:15:11,361
PRESENTATION ON ADVANCED

376
00:15:11,361 --> 00:15:14,531
PLATFORMS FOR HIV VIRAL LOAD

377
00:15:14,531 --> 00:15:16,966
MONITORING AT THE POINT-OF-CARE

378
00:15:16,966 --> 00:15:20,103
FROM DR. SHAWN MULVANEY, OF

379
00:15:20,103 --> 00:15:23,139
NIH'S NATIONAL INSTITUTE OF

380
00:15:23,139 --> 00:15:24,641
BIOMEDICAL IMAGING AND

381
00:15:24,641 --> 00:15:25,008
BIOENGINEERING.

382
00:15:25,008 --> 00:15:27,110
I'LL THEN PROVIDE A STRATEGY

383
00:15:27,110 --> 00:15:28,745
UPDATE REGARDING THE HIV

384
00:15:28,745 --> 00:15:30,380
CLINICAL PRACTICE GUIDELINES

385
00:15:30,380 --> 00:15:32,882
WHICH MANY OF YOU HAVE COMMENTED

386
00:15:32,882 --> 00:15:33,283
ON.

387
00:15:33,283 --> 00:15:37,821
AND THEN THAT WILL BE FOLLOWED

388
00:15:37,821 --> 00:15:41,391
BY A PRESENTATION BY DR. JULIO

389
00:15:41,391 --> 00:15:44,694
ALBERTI ON THE OAR INNOVATION

390
00:15:44,694 --> 00:15:45,495
PROGRAM SYMPOSIUM FOLLOWED BY

391
00:15:45,495 --> 00:15:47,797
DR. DAVID CHANG WHO WILL PRESENT

392
00:15:47,797 --> 00:15:50,400
ON THE EARLY CAREER INVESTIGATOR

393
00:15:50,400 --> 00:15:51,634
ENGAGEMENT ACTIVITIES, WHICH HAS

394
00:15:51,634 --> 00:15:53,970
BEEN VERY ACTIVE AS OF LATE.

395
00:15:53,970 --> 00:15:55,738
BOTH ARE HEALTH SCIENCE

396
00:15:55,738 --> 00:15:57,407
ADMINISTRATORS HERE AT OAR, AND

397
00:15:57,407 --> 00:16:00,510
SO WE'RE PROUD TO FEATURE THEIR

398
00:16:00,510 --> 00:16:00,910
ACTIVITIES.

399
00:16:00,910 --> 00:16:04,681
WE'LL THEN HEAR UPDATES FROM THE

400
00:16:04,681 --> 00:16:05,448
NATIONAL INSTITUTES OF HEALTH,

401
00:16:05,448 --> 00:16:10,553
INSTITUTE OF MENTAL HEALTH,

402
00:16:10,553 --> 00:16:14,324
COURTESY OF DR. DIANNE RAUSCH

403
00:16:14,324 --> 00:16:15,358
AND SUMMARIZE PUBLIC COMMENTS WE

404
00:16:15,358 --> 00:16:17,794
RECEIVED IN ADVANCE OF AND

405
00:16:17,794 --> 00:16:19,395
DURING TODAY'S MEETING.

406
00:16:19,395 --> 00:16:22,332
SO, WITH THAT, I'M GOING TO MOVE

407
00:16:22,332 --> 00:16:24,033
FORWARD WITH MY DIRECTOR'S

408
00:16:24,033 --> 00:16:25,368
REPORT.

409
00:16:25,368 --> 00:16:27,370
AND I'M GOING TO COVER A NUMBER

410
00:16:27,370 --> 00:16:29,172
OF DIFFERENT TOPICS.

411
00:16:29,172 --> 00:16:30,173
FIRST THERE'S BEEN LEADERSHIP

412
00:16:30,173 --> 00:16:32,308
TRANSITIONS THAT YOU MAY OR MAY

413
00:16:32,308 --> 00:16:35,411
NOT BE AWARE OF, STARTING WITH

414
00:16:35,411 --> 00:16:39,549
OARAC AND THEN NIH AND AT THE

415
00:16:39,549 --> 00:16:41,384
DPCPSI LEVEL, DPCPSI IS THE

416
00:16:41,384 --> 00:16:44,287
DIVISION THAT OAR SITS IN, IN

417
00:16:44,287 --> 00:16:46,623
THE OFFICE OF THE DIRECTOR.

418
00:16:46,623 --> 00:16:51,427
I'LL PROVIDE UPDATES ON THE

419
00:16:51,427 --> 00:16:56,065
PROPOSED NIH REORGANIZATION AND

420
00:16:56,065 --> 00:16:58,668
RESEARCH -- AND NIH RESEARCH

421
00:16:58,668 --> 00:16:58,968
BUDGET.

422
00:16:58,968 --> 00:17:00,403
I'LL REVIEW THE PRIORITIES THAT

423
00:17:00,403 --> 00:17:02,839
HAVE BEEN SET FORTH BY THE NEW

424
00:17:02,839 --> 00:17:05,308
NIH DIRECTOR AS WELL AS

425
00:17:05,308 --> 00:17:08,478
OPPORTUNITIES FOR OAR TO HELP

426
00:17:08,478 --> 00:17:10,246
ADDRESS THESE PRIORITIES.

427
00:17:10,246 --> 00:17:12,348
I'LL UPDATE YOU ON SOME

428
00:17:12,348 --> 00:17:15,118
ENCOURAGING NEWS WHICH YOU MAY

429
00:17:15,118 --> 00:17:17,420
KNOW ABOUT REGARDING LONG-ACTING

430
00:17:17,420 --> 00:17:19,689
HIV PREVENTION, AND I'LL PROVIDE

431
00:17:19,689 --> 00:17:23,726
AN UPDATE ON THE NIH STRATEGIC

432
00:17:23,726 --> 00:17:24,661
PLAN FOR HIV AND HIV-RELATED

433
00:17:24,661 --> 00:17:29,732
RESEARCH THAT MANY OF YOU HAVE

434
00:17:29,732 --> 00:17:36,573
CONTRIBUTED HOURS AND LOTS OF

435
00:17:36,573 --> 00:17:39,242
KNOWLEDGE AND SUPPORT FOR.

436
00:17:39,242 --> 00:17:41,678
I'LL RECAP OAR'S KEY ENGAGEMENTS

437
00:17:41,678 --> 00:17:45,548
SINCE WE LAST MET WITH YOU AND

438
00:17:45,548 --> 00:17:49,319
PREVIEW UPCOMING ACTIVITIES AND

439
00:17:49,319 --> 00:17:49,752
EVENTS.

440
00:17:49,752 --> 00:17:54,724
AT THE OARAC LEVEL JOIN ME IN

441
00:17:54,724 --> 00:17:56,259
WELCOMING DR. LUIS MONTANER AS

442
00:17:56,259 --> 00:17:58,761
THE NEW CHAIRPERSON, I LOOK

443
00:17:58,761 --> 00:18:00,063
FORWARD TO YOUR LEADERSHIP AND

444
00:18:00,063 --> 00:18:00,763
CONTINUED CONTRIBUTIONS.

445
00:18:00,763 --> 00:18:02,065
MANY THINGS FOR YOUR WILLINGNESS

446
00:18:02,065 --> 00:18:04,167
TO SERVE IN THIS LEADERSHIP

447
00:18:04,167 --> 00:18:05,168
POSITION.

448
00:18:05,168 --> 00:18:09,072
AND THEN ON BEHALF OF OAR AND

449
00:18:09,072 --> 00:18:14,344
OARAC A SPECIAL THANK YOU TO DR.

450
00:18:14,344 --> 00:18:16,379
IVY TURNBULL, OARAC CHAIRPERSON

451
00:18:16,379 --> 00:18:18,281
FROM 2023 UNTIL EARLIER THIS

452
00:18:18,281 --> 00:18:19,115
YEAR.

453
00:18:19,115 --> 00:18:21,584
YOUR COMMITMENT TO THE COUNCIL,

454
00:18:21,584 --> 00:18:24,654
TO OAR, AND TO THE NIH HIV

455
00:18:24,654 --> 00:18:26,255
RESEARCH ENTERPRISE IS GREATLY

456
00:18:26,255 --> 00:18:26,756
APPRECIATED.

457
00:18:26,756 --> 00:18:32,228
AND I LOOK FORWARD TO OUR

458
00:18:32,228 --> 00:18:32,996
CONTINUED ENGAGEMENT.

459
00:18:32,996 --> 00:18:34,964
MARY DID THIS EARLIER BUT I

460
00:18:34,964 --> 00:18:37,467
WOULD LIKE TO ALSO WELCOME TWO

461
00:18:37,467 --> 00:18:41,270
NEW EX OFFICIO MEMBERS TO OARAC,

462
00:18:41,270 --> 00:18:45,408
WHICH INCLUDES CAPTAIN ROBIN

463
00:18:45,408 --> 00:18:51,481
NEBLET FANFARE, REPRESENTING

464
00:18:51,481 --> 00:18:53,716
CDC, AND HEATHER HAUCK, THANK

465
00:18:53,716 --> 00:18:56,819
YOU BOTH FOR JOINING AND IN

466
00:18:56,819 --> 00:18:59,222
ADVANCE FOR YOUR CONTRIBUTIONS.

467
00:18:59,222 --> 00:19:01,457
SO MOVING TO NIH, MANY OF YOU

468
00:19:01,457 --> 00:19:04,227
MAY KNOW ALREADY THERE HAVE BEEN

469
00:19:04,227 --> 00:19:06,896
A NUMBER OF TRANSITIONS AT THE

470
00:19:06,896 --> 00:19:08,431
ICO LEADERSHIP LEVEL SINCE WE

471
00:19:08,431 --> 00:19:09,432
LAST MET.

472
00:19:09,432 --> 00:19:12,935
AND THESE INCLUDE A NUMBER OF

473
00:19:12,935 --> 00:19:14,103
NEW ACTING DIRECTORS LISTED ON

474
00:19:14,103 --> 00:19:17,707
THIS SLIDE.

475
00:19:17,707 --> 00:19:20,276
DR. CORTI AKLIN AT NATIONAL

476
00:19:20,276 --> 00:19:24,414
INSTITUTE OF NURSING RESEARCH,

477
00:19:24,414 --> 00:19:25,715
DR. ALISON CERNICH, EUNICE

478
00:19:25,715 --> 00:19:26,449
KENNEDY SHRIVER NATIONAL

479
00:19:26,449 --> 00:19:28,584
INSTITUTE OF CHILD HEALTH AND

480
00:19:28,584 --> 00:19:29,819
HUMAN DEVELOPMENT.

481
00:19:29,819 --> 00:19:31,988
DR. MONICA WEBB HOOPER AT

482
00:19:31,988 --> 00:19:33,222
NATIONAL INSTITUTE ON MINORITY

483
00:19:33,222 --> 00:19:38,594
HEALTH AND HEALTH DISPARITIES.

484
00:19:38,594 --> 00:19:44,667
DR. ANDREA BECKEL-MITCHENER AT

485
00:19:44,667 --> 00:19:46,002
MENTAL HEALTH, DR. JEFF

486
00:19:46,002 --> 00:19:51,908
TAUBENBERGER, AND DR. CAROLYN

487
00:19:51,908 --> 00:19:53,710
HUTTER, NATIONAL HUMAN GENOME

488
00:19:53,710 --> 00:19:54,610
RESEARCH INSTITUTE AND WE THANK

489
00:19:54,610 --> 00:19:55,311
THEM FOR STEPPING INTO THESE

490
00:19:55,311 --> 00:19:57,013
ROLES AT THIS TIME.

491
00:19:57,013 --> 00:20:00,483
FINALLY THERE HAS BEEN SOME

492
00:20:00,483 --> 00:20:02,452
LEADERSHIP CHANGES IN OUR

493
00:20:02,452 --> 00:20:05,521
DIVISION, THE NIH DIVISION OF

494
00:20:05,521 --> 00:20:07,957
PROGRAM COORDINATION PLANNING

495
00:20:07,957 --> 00:20:09,859
AND STRATEGIC INITIATIVES, WE

496
00:20:09,859 --> 00:20:11,761
CALL DPCPSI, WHICH IS WITHIN THE

497
00:20:11,761 --> 00:20:14,497
NIH OFFICE OF THE DIRECTOR.

498
00:20:14,497 --> 00:20:17,734
THE NIH DIVISION WITHIN WHICH

499
00:20:17,734 --> 00:20:19,435
OAR RESIDES.

500
00:20:19,435 --> 00:20:22,405
DR. NICOLE KLEINSTREUER NAMED

501
00:20:22,405 --> 00:20:26,175
ACTING DPCPSI DIRECTOR, SHE

502
00:20:26,175 --> 00:20:27,944
REPLACES DR. TARA SCHWETZ.

503
00:20:27,944 --> 00:20:31,013
TWO ACTING DIRECTORS NAMED FOR

504
00:20:31,013 --> 00:20:33,249
OFFICES WITHIN DPCPSI, DR.

505
00:20:33,249 --> 00:20:35,752
VIVIAN OTA WANG IS THE ACTING

506
00:20:35,752 --> 00:20:38,621
DIRECTOR OF THE OFFICE OF

507
00:20:38,621 --> 00:20:41,457
STRATEGIC COORDINATION.

508
00:20:41,457 --> 00:20:48,965
AND MS. CINDY CAUGHMAN, ACTING

509
00:20:48,965 --> 00:20:51,334
DEPUTY DIRECTOR, OFFICE OF

510
00:20:51,334 --> 00:20:53,169
RESEARCH ON WOMEN'S HEALTH.

511
00:20:53,169 --> 00:20:54,804
OKAY.

512
00:20:54,804 --> 00:20:59,041
TURNING NOW TO NIH'S

513
00:20:59,041 --> 00:21:01,778
ORGANIZATION, THE HIV RESEARCH

514
00:21:01,778 --> 00:21:02,145
BUDGET.

515
00:21:02,145 --> 00:21:03,780
SO, YOU HAVE LIKELY HEARD, I

516
00:21:03,780 --> 00:21:07,283
WANT TO ALSO PUT A SHOUT OUT TO

517
00:21:07,283 --> 00:21:09,085
MY COLLEAGUE, CARL DIEFFENBACH,

518
00:21:09,085 --> 00:21:12,288
FOR SLIDES THAT I ADOPTED FROM

519
00:21:12,288 --> 00:21:15,358
HIS PRESENTATION TO THE ACTG

520
00:21:15,358 --> 00:21:15,792
NETWORK RECENTLY.

521
00:21:15,792 --> 00:21:18,261
AND THIS IS ONE OF THEM.

522
00:21:18,261 --> 00:21:21,731
YOU'VE LIKELY HEARD ABOUT THE

523
00:21:21,731 --> 00:21:23,399
PROPOSED NIH REORGANIZATION.

524
00:21:23,399 --> 00:21:25,368
THIS SLIDE DEPICTS WHAT THE NEW

525
00:21:25,368 --> 00:21:27,703
ORGANIZATION WOULD LOOK LIKE.

526
00:21:27,703 --> 00:21:31,841
IT COMES FROM THE HHS BUDGET IN

527
00:21:31,841 --> 00:21:33,810
BRIEF FOR FISCAL YEAR 2026.

528
00:21:33,810 --> 00:21:38,080
ON THE LEFT SIDE SHOWS THE 19

529
00:21:38,080 --> 00:21:40,883
NIH INSTITUTES IN THEIR CURRENT

530
00:21:40,883 --> 00:21:41,617
STRUCTURES, YOU'RE FAMILIAR

531
00:21:41,617 --> 00:21:42,652
LIKELY WITH THAT.

532
00:21:42,652 --> 00:21:45,955
ON THE RIGHT SIDE IT SHOWS THE

533
00:21:45,955 --> 00:21:47,790
PROPOSED REORGANIZATION INTO

534
00:21:47,790 --> 00:21:51,928
EIGHT INSTITUTES.

535
00:21:51,928 --> 00:21:52,562
IT PRESERVES THE NATIONAL CANCER

536
00:21:52,562 --> 00:21:53,996
INSTITUTE, NATIONAL INSTITUTE ON

537
00:21:53,996 --> 00:21:56,032
AGING, AND NATIONAL INSTITUTE OF

538
00:21:56,032 --> 00:21:57,733
ALLERGY AND INFECTIOUS DISEASES

539
00:21:57,733 --> 00:22:01,938
ON ITS OWN AS UNIQUE

540
00:22:01,938 --> 00:22:03,339
INSTITUTIONS, THE OTHERS COMBINE

541
00:22:03,339 --> 00:22:08,177
INTO THE INSTITUTES THAT YOU SEE

542
00:22:08,177 --> 00:22:08,544
HERE.

543
00:22:08,544 --> 00:22:12,849
IN TERMS OF BUDGET UPDATES, FOR

544
00:22:12,849 --> 00:22:15,585
FISCAL YEAR 2025, YOU MAY KNOW

545
00:22:15,585 --> 00:22:17,820
THAT THE FEDERAL GOVERNMENT

546
00:22:17,820 --> 00:22:19,689
CONTINUED TO OPERATE UNDER A

547
00:22:19,689 --> 00:22:21,824
FULL YEAR CONTINUING RESOLUTION.

548
00:22:21,824 --> 00:22:27,530
THE PRESIDENT'S BUDGET THAT WAS

549
00:22:27,530 --> 00:22:30,399
RELEASED FOR FISCAL YEAR 2026

550
00:22:30,399 --> 00:22:36,873
REDUCES THE NIH BUDGET FROM $48

551
00:22:36,873 --> 00:22:38,774
BILLION TO $27 BILLION.

552
00:22:38,774 --> 00:22:41,344
AND IT CONSIDERS THE

553
00:22:41,344 --> 00:22:43,045
REORGANIZATION THAT WE SHOWED ON

554
00:22:43,045 --> 00:22:44,814
THE PREVIOUS SLIDE.

555
00:22:44,814 --> 00:22:46,782
THIS LEVEL OF FUNDING WOULD

556
00:22:46,782 --> 00:22:52,521
RETURN NIH TO THE ALLOCATION IT

557
00:22:52,521 --> 00:22:54,290
RECEIVED IN FISCAL YEAR 2003.

558
00:22:54,290 --> 00:22:56,525
CONGRESS, OF COURSE, CONTINUES

559
00:22:56,525 --> 00:22:58,661
TO DEBATE AND DELIBERATE ON THE

560
00:22:58,661 --> 00:22:59,762
FISCAL YEAR 2026 BUDGET.

561
00:22:59,762 --> 00:23:02,031
SO WE DON'T KNOW WHAT THE FINAL

562
00:23:02,031 --> 00:23:03,966
BUDGET WILL BE.

563
00:23:03,966 --> 00:23:06,569
AND IT WILL BE JOINT DISCUSSION

564
00:23:06,569 --> 00:23:08,738
AMONG THEM AND I'M SURE AS WELL

565
00:23:08,738 --> 00:23:15,912
AS WITH THE PRESIDENT IN

566
00:23:15,912 --> 00:23:17,680
NEGOTIATIONS.

567
00:23:17,680 --> 00:23:24,086
EACH YEAR OAR PREPARES A

568
00:23:24,086 --> 00:23:27,790
CONGRESSIONAL BUDGET 

569
00:23:27,790 --> 00:23:28,124
JUSTIFICATION.

570
00:23:28,124 --> 00:23:31,360
WE USE THE NUMBERS THAT THE

571
00:23:31,360 --> 00:23:34,797
PRESIDENT'S BUDGET OUTLINES.

572
00:23:34,797 --> 00:23:37,733
FISCAL YEAR 26 CJ WAS RELEASED A

573
00:23:37,733 --> 00:23:39,402
FEW WEEKS AGO, AND IS AVAILABLE

574
00:23:39,402 --> 00:23:41,470
ON OUR WEBSITE.

575
00:23:41,470 --> 00:23:45,174
YOU CAN SCAN THE QR CODE FOR A

576
00:23:45,174 --> 00:23:46,609
COPY OF THE CJ.

577
00:23:46,609 --> 00:23:48,844
IT'S ALSO INCLUDED IN BRIEFING

578
00:23:48,844 --> 00:23:51,681
MATERIALS YOU RECEIVED.

579
00:23:51,681 --> 00:23:58,254
THE FISCAL YEAR 26 CJ IS

580
00:23:58,254 --> 00:23:59,255
ORGANIZED BASED ON PROPOSEED

581
00:23:59,255 --> 00:23:59,755
STRUCTURE.

582
00:23:59,755 --> 00:24:02,758
THE TABLE MAY BE DIFFICULT TO

583
00:24:02,758 --> 00:24:06,562
READ BUT IT APPEARS ON PAGE 4 OF

584
00:24:06,562 --> 00:24:08,431
THE C.J. DOCUMENT.

585
00:24:08,431 --> 00:24:13,669
THE TABLE ON THIS SLIDE SHOWS IN

586
00:24:13,669 --> 00:24:16,238
COLUMNS THE FINAL 2024

587
00:24:16,238 --> 00:24:19,809
ALLOCATION, FISCAL YEAR 2024, IT

588
00:24:19,809 --> 00:24:23,245
ALSO SHOWS THE 2025 ALLOCATION

589
00:24:23,245 --> 00:24:25,881
UNDER THE CONTINUING CURRENT

590
00:24:25,881 --> 00:24:28,084
CONTINUING RESOLUTION, AND THEN

591
00:24:28,084 --> 00:24:29,685
IT PROVIDES WHAT THE ALLOCATION

592
00:24:29,685 --> 00:24:33,956
WOULD BE UNDER THE PROPOSED 2026

593
00:24:33,956 --> 00:24:34,991
PRESIDENT'S BUDGET.

594
00:24:34,991 --> 00:24:37,960
SO THAT THE FAR RIGHT COLUMN

595
00:24:37,960 --> 00:24:40,730
SHOWS DIFFERENCE BETWEEN THE

596
00:24:40,730 --> 00:24:43,466
FISCAL YEAR 2025 FUNDED LEVELS

597
00:24:43,466 --> 00:24:45,001
AND THE PROPOSED PRESIDENT'S

598
00:24:45,001 --> 00:24:47,937
BUDGET. 

599
00:24:47,937 --> 00:24:50,973
IT SHOWS A NEARLY $1.4 BILLION,

600
00:24:50,973 --> 00:24:55,277
OR 42%, REDUCTION IN TOTAL NIH

601
00:24:55,277 --> 00:24:56,912
HIV FUNDING PROPOSED IN THE

602
00:24:56,912 --> 00:24:58,948
PRESIDENT'S BUDGET FOR THE NEXT

603
00:24:58,948 --> 00:24:59,715
FISCAL YEAR.

604
00:24:59,715 --> 00:25:01,617
AGAIN, I WANT TO REITERATE THIS

605
00:25:01,617 --> 00:25:02,918
IS A PROPOSAL.

606
00:25:02,918 --> 00:25:04,487
AND CONGRESS WILL DETERMINE THE

607
00:25:04,487 --> 00:25:09,291
FINAL BUDGET FOR THIS YEAR.

608
00:25:09,291 --> 00:25:14,030
SO WITH THAT I'M GOING TO TURN

609
00:25:14,030 --> 00:25:18,334
TO THE OVERVIEW OF THE NIH

610
00:25:18,334 --> 00:25:20,503
PRIORITIES AND THE OAR'S

611
00:25:20,503 --> 00:25:22,271
OPPORTUNITIES TO HELP ADVANCE

612
00:25:22,271 --> 00:25:23,639
THESE PRIORITIES.

613
00:25:23,639 --> 00:25:28,677
SO MANY OF YOU KNOW THAT DR. JAY

614
00:25:28,677 --> 00:25:31,881
BHATTACHARYA HAS BEEN APPOINTED

615
00:25:31,881 --> 00:25:32,448
NEW DIRECTOR OF THE NATIONAL

616
00:25:32,448 --> 00:25:34,083
INSTITUTES OF HEALTH.

617
00:25:34,083 --> 00:25:37,787
AND HE HAS OUTLINED A NUMBER OF

618
00:25:37,787 --> 00:25:41,223
PRIORITIES THAT HE WOULD LIKE TO

619
00:25:41,223 --> 00:25:46,095
SEE MOVE FURTHER IN THE NIH

620
00:25:46,095 --> 00:25:46,862
PORTFOLIO.

621
00:25:46,862 --> 00:25:49,098
ONE IS TO IMPROVE POPULATION

622
00:25:49,098 --> 00:25:49,331
HEALTH.

623
00:25:49,331 --> 00:25:52,835
NIH MUST -- AND HE DEFINES THIS

624
00:25:52,835 --> 00:25:55,004
AS ADDRESSING THE HEALTH NEEDS

625
00:25:55,004 --> 00:25:57,073
OF THE AMERICAN PEOPLE AND

626
00:25:57,073 --> 00:25:59,408
FINDING BETTER WAYS TO PREVENT,

627
00:25:59,408 --> 00:26:02,778
TREAT, AND CURE CHRONIC

628
00:26:02,778 --> 00:26:03,045
DISEASES.

629
00:26:03,045 --> 00:26:06,449
THE SECOND AREA OF PRIORITY IS

630
00:26:06,449 --> 00:26:08,517
TO ENSURE RELIABLE RESULTS, AND

631
00:26:08,517 --> 00:26:11,187
IN THAT WAY HE WANTS

632
00:26:11,187 --> 00:26:17,326
NIH-SUPPORTED SCIENCE TO BE

633
00:26:17,326 --> 00:26:17,827
REPRESENT LIABLABLE,

634
00:26:17,827 --> 00:26:19,128
REPRODUCIBLE, GENERALIZABLE.

635
00:26:19,128 --> 00:26:21,130
THIRD PRIORITY TO MAKE BIG

636
00:26:21,130 --> 00:26:24,300
ADVANCES, HE WANTS NIH TO INVEST

637
00:26:24,300 --> 00:26:26,535
IN INNOVATION, EMBRACE NEW

638
00:26:26,535 --> 00:26:30,039
TECHNOLOGIES, NEW IDEAS, AND NEW

639
00:26:30,039 --> 00:26:32,141
APPROACHES TO OLD PROBLEMS.

640
00:26:32,141 --> 00:26:36,278
THE FOURTH AREA OF PRIORITY IS

641
00:26:36,278 --> 00:26:37,813
TO MAINTAIN SAFETY AND

642
00:26:37,813 --> 00:26:38,247
TRANSPARENCY.

643
00:26:38,247 --> 00:26:39,882
AND WITH THIS HE STATES THAT THE

644
00:26:39,882 --> 00:26:42,518
RESEARCH SHOULD MEET THE HIGHEST

645
00:26:42,518 --> 00:26:45,788
ETHICAL STANDARDS AND SHOULD NOT

646
00:26:45,788 --> 00:26:48,557
ENDANGER HUMAN POPULATIONS.

647
00:26:48,557 --> 00:26:50,392
AND THEN FINALLY, HIS FIFTH

648
00:26:50,392 --> 00:26:51,760
PRIORITY IS TO ENCOURAGE

649
00:26:51,760 --> 00:26:52,695
ACADEMIC FREEDOM.

650
00:26:52,695 --> 00:26:55,564
AND IN THIS WAY, HE STATES THAT

651
00:26:55,564 --> 00:26:58,534
NIH WILL FOSTER A CULTURE IN

652
00:26:58,534 --> 00:27:04,540
WHICH SCIENTISTS CAN EXPRESS

653
00:27:04,540 --> 00:27:07,343
DISAGREEMENT RESPECTFULLY.

654
00:27:07,343 --> 00:27:09,912
WITHIN DR. BHATTACHARYA'S

655
00:27:09,912 --> 00:27:11,447
FRAMEWORK OF PRIORITIES, OAR IS

656
00:27:11,447 --> 00:27:17,386
VERY WELL POSITIONED TO OVERSEE

657
00:27:17,386 --> 00:27:19,088
AND COORDINATE COMPREHENSIVE,

658
00:27:19,088 --> 00:27:21,056
COMPLEX NIH HIV RESEARCH

659
00:27:21,056 --> 00:27:22,258
PORTFOLIO.

660
00:27:22,258 --> 00:27:25,961
WHILE AT THE SAME TIME WORKING

661
00:27:25,961 --> 00:27:29,131
TO IDENTIFY NEW RESEARCH

662
00:27:29,131 --> 00:27:31,000
OPPORTUNITIES, ADDRESS

663
00:27:31,000 --> 00:27:33,369
CHALLENGES, INCREASE EFFICIENCY,

664
00:27:33,369 --> 00:27:37,072
PROMOTE INNOVATION, FACILITATE

665
00:27:37,072 --> 00:27:40,342
COLLABORATIVE SCIENCE, ENSURE

666
00:27:40,342 --> 00:27:41,510
RIGOR AND REPRODUCIBILITY.

667
00:27:41,510 --> 00:27:43,379
I'D LIKE TO HIGHLIGHT THREE

668
00:27:43,379 --> 00:27:46,148
AREAS IN WHICH OAR SEES GREAT

669
00:27:46,148 --> 00:27:47,316
OPPORTUNITIES TO ENHANCE OUR

670
00:27:47,316 --> 00:27:49,518
EFFORTS IN WAYS THAT ALIGN WITH

671
00:27:49,518 --> 00:27:52,454
OUR UNDERSTANDING OF THE STATED

672
00:27:52,454 --> 00:27:54,657
PRIORITIES OF DR. BHATTACHARYA

673
00:27:54,657 --> 00:27:56,392
AND THE NEW ADMINISTRATION.

674
00:27:56,392 --> 00:27:58,827
FIRST, HOW BEST TO PROMOTE DATA

675
00:27:58,827 --> 00:28:01,397
HARMONIZATION, OR COMMON DATA

676
00:28:01,397 --> 00:28:02,731
ELEMENTS.

677
00:28:02,731 --> 00:28:04,400
I RECENTLY PUBLISHED A PAPER ON

678
00:28:04,400 --> 00:28:06,101
THE BENEFITS OF DATA

679
00:28:06,101 --> 00:28:08,237
HARMONIZATION, WHICH I SEE AS

680
00:28:08,237 --> 00:28:10,206
BUILDING CONSENSUS ON A SET OF

681
00:28:10,206 --> 00:28:14,243
COMMON DATA ELEMENTS THAT CAN BE

682
00:28:14,243 --> 00:28:15,978
USED TO IMPROVE COMPARISONS

683
00:28:15,978 --> 00:28:18,113
ACROSS STUDIES.

684
00:28:18,113 --> 00:28:20,883
IT WILL ALSO PERMIT SECONDARY

685
00:28:20,883 --> 00:28:22,985
DATA ANALYSES BY BOLSTERING

686
00:28:22,985 --> 00:28:24,620
RIGOR AND REPRODUCIBILITY AND

687
00:28:24,620 --> 00:28:28,224
INCREASING THE RETURN ON NIH

688
00:28:28,224 --> 00:28:28,857
INVESTMENT.

689
00:28:28,857 --> 00:28:33,629
SECOND, WE'D LIKE TO FOCUS ON

690
00:28:33,629 --> 00:28:34,396
SUSTAINING EVIDENCE-BASED

691
00:28:34,396 --> 00:28:34,997
INTERVENTIONS.

692
00:28:34,997 --> 00:28:36,398
WHEN WE FIND SOMETHING THAT

693
00:28:36,398 --> 00:28:38,801
WORKS, WE NEED TO WORK WITH OUR

694
00:28:38,801 --> 00:28:40,603
FEDERAL, STATE, AND LOCAL

695
00:28:40,603 --> 00:28:47,076
PARTNERS TO SUSTAIN IT.

696
00:28:47,076 --> 00:28:49,745
THE ENDING THE HIV EPIDEMIC WAS

697
00:28:49,745 --> 00:28:51,814
AN EXAMPLE OF WORKING WITH

698
00:28:51,814 --> 00:28:54,617
COMMUNITY PARTNERS TO ENSURE

699
00:28:54,617 --> 00:28:56,218
SUSTAINABILITY OF EFFECTIVE

700
00:28:56,218 --> 00:28:58,821
INTERVENTIONS AND TOOLS.

701
00:28:58,821 --> 00:29:04,760
LASTLY, WE'D LIKE TO EMPHASIZE

702
00:29:04,760 --> 00:29:05,761
IMPLEMENTATION RESEARCH ENSURING

703
00:29:05,761 --> 00:29:08,530
ALL AMERICANS BENEFIT FROM NIH'S

704
00:29:08,530 --> 00:29:12,735
INVESTMENTS BY CLOSING THE GAP

705
00:29:12,735 --> 00:29:13,936
BETWEEN AN INNOVATIVE DISCOVERY

706
00:29:13,936 --> 00:29:15,804
AND APPLYING IT IN THE REAL

707
00:29:15,804 --> 00:29:16,005
WORLD.

708
00:29:16,005 --> 00:29:17,773
SORRY, THERE'S LIKE A FLY THAT

709
00:29:17,773 --> 00:29:21,610
KEEPS COMING IN FRONT OF ME LIKE

710
00:29:21,610 --> 00:29:25,047
A GNAT, IF YOU SEE ME DOING

711
00:29:25,047 --> 00:29:25,447
THIS.

712
00:29:25,447 --> 00:29:27,316
THIS REQUIRES RIGOROUS STUDY OF

713
00:29:27,316 --> 00:29:34,223
FACTORS THAT WILL IMPROVE REACH,

714
00:29:34,223 --> 00:29:35,057
ACCEPTABILITY, FEASIBILITY,

715
00:29:35,057 --> 00:29:36,091
ADOPTION, FIDELITY,

716
00:29:36,091 --> 00:29:36,792
SUSTAINABILITY.

717
00:29:36,792 --> 00:29:38,827
SO TAKING ADVANTAGE OF THESE

718
00:29:38,827 --> 00:29:40,629
FUTURE OPPORTUNITIES WILL

719
00:29:40,629 --> 00:29:42,698
REQUIRE AN EMPHASIS ON

720
00:29:42,698 --> 00:29:45,601
IMPLEMENTATION SCIENCE.

721
00:29:45,601 --> 00:29:49,271
AS AN EXAMPLE, CDC SURVEILLANCE

722
00:29:49,271 --> 00:29:51,740
DATA ESTIMATES 1 IN 8 AMERICANS

723
00:29:51,740 --> 00:29:54,810
WITH HIV DO NOT KNOW THEIR

724
00:29:54,810 --> 00:29:55,978
STATUS.

725
00:29:55,978 --> 00:29:58,113
WE NEED IMPLEMENTATION SCIENCE

726
00:29:58,113 --> 00:30:00,149
TO UNDERSTAND HOW BEST TO

727
00:30:00,149 --> 00:30:02,785
IMPROVE UPTAKE AND ADOPTION OF

728
00:30:02,785 --> 00:30:04,553
EVIDENCE-BASED TESTING IN THE

729
00:30:04,553 --> 00:30:06,689
INTERVENTION TO CLOSE THIS GAP.

730
00:30:06,689 --> 00:30:10,526
IN FACT, THERE IS A

731
00:30:10,526 --> 00:30:11,160
WELL-ESTABLISHED 17-YEAR GAP

732
00:30:11,160 --> 00:30:12,828
BETWEEN DISCOVERY AND WHEN IT

733
00:30:12,828 --> 00:30:15,030
GETS USED IN PRACTICE.

734
00:30:15,030 --> 00:30:17,733
EVEN THEN, FEWER THAN HALF OF

735
00:30:17,733 --> 00:30:18,500
EVIDENCE-BASED INTERVENTIONS

736
00:30:18,500 --> 00:30:22,604
EVER MAKE IT INTO PRACTICE.

737
00:30:22,604 --> 00:30:24,907
IMPLEMENTATION SCIENCE SEEKS TO

738
00:30:24,907 --> 00:30:28,510
CLOSE THIS GAP BY SPECIFYING

739
00:30:28,510 --> 00:30:30,946
STEPS IN BETWEEN DEVELOPMENT OF

740
00:30:30,946 --> 00:30:32,448
THE INNOVATION AND ITS

741
00:30:32,448 --> 00:30:34,650
APPLICATION IN REAL LIFE.

742
00:30:34,650 --> 00:30:36,785
SO IN OTHER WORDS IMPLEMENTATION

743
00:30:36,785 --> 00:30:39,955
RESEARCH STUDIES THE WHY, WHAT,

744
00:30:39,955 --> 00:30:41,690
WHEN, WHERE, AND WHO.

745
00:30:41,690 --> 00:30:44,360
WHY AREN'T AMERICANS GETTING

746
00:30:44,360 --> 00:30:46,028
TESTED FOR HIV?

747
00:30:46,028 --> 00:30:48,430
WHAT STRATEGIES WILL OPTIMIZE

748
00:30:48,430 --> 00:30:49,965
HIV TESTING?

749
00:30:49,965 --> 00:30:52,501
WHEN SHOULD HIV TESTING BE

750
00:30:52,501 --> 00:30:54,937
OFFERED TO MAXIMIZE UPTAKE?

751
00:30:54,937 --> 00:30:57,473
WHERE SHOULD HIV TESTING BE

752
00:30:57,473 --> 00:30:59,375
PROVIDED TO STRENGTHEN UPTAKE?

753
00:30:59,375 --> 00:31:01,443
AND WHO SHOULD CONDUCT THE

754
00:31:01,443 --> 00:31:06,415
TESTING TO ACHIEVE THE GREATEST

755
00:31:06,415 --> 00:31:08,550
REACH? 

756
00:31:08,550 --> 00:31:12,321
I'M PLEASED TO LEARN THAT THE

757
00:31:12,321 --> 00:31:13,756
NIH LEADERSHIP SHARES MY

758
00:31:13,756 --> 00:31:16,024
APPRECIATION FOR THE IMPORTANCE

759
00:31:16,024 --> 00:31:16,625
OF IMPLEMENTATION SCIENCE, AND

760
00:31:16,625 --> 00:31:18,694
THEY HAVE REQUESTED A GREATER

761
00:31:18,694 --> 00:31:22,097
EMPHASIS IN THIS AREA OF

762
00:31:22,097 --> 00:31:22,865
RESEARCH.

763
00:31:22,865 --> 00:31:29,204
OAR IS ACTIVELY MEETING WITH NIH

764
00:31:29,204 --> 00:31:30,806
INSTITUTES AND CENTER DIRECTORS,

765
00:31:30,806 --> 00:31:34,109
WITH HIV RESEARCH IN THEIR

766
00:31:34,109 --> 00:31:37,446
PORTFOLIOS, TO DISCUSS THEIR

767
00:31:37,446 --> 00:31:38,647
RESPECTIVE INTERESTS, CURRENT

768
00:31:38,647 --> 00:31:40,082
ACTIVITIES, AND AVAILABLE

769
00:31:40,082 --> 00:31:42,050
EXPERTISE RELATED TO

770
00:31:42,050 --> 00:31:43,419
IMPLEMENTATION SCIENCE AND HIV.

771
00:31:43,419 --> 00:31:46,989
I WILL ALSO BE WORKING WITH THEM

772
00:31:46,989 --> 00:31:50,259
TO DEFINE AVAILABLE FUNDS FOR

773
00:31:50,259 --> 00:31:52,461
EXPANDING IMPLEMENTATION SCIENCE

774
00:31:52,461 --> 00:31:54,296
IN HIV RESEARCH.

775
00:31:54,296 --> 00:31:58,467
WORKING WITH THE INSTITUTES, WE

776
00:31:58,467 --> 00:32:00,002
WILL DEVELOP RECOMMENDATIONS,

777
00:32:00,002 --> 00:32:01,970
DEFINE LEVELS OF SUPPORT,

778
00:32:01,970 --> 00:32:07,409
IDENTIFY WAYS TO STRENGTHEN HIV

779
00:32:07,409 --> 00:32:08,911
IMPLEMENTATION SCIENCE, CONVENE

780
00:32:08,911 --> 00:32:11,246
CROSS-NIH PANELS, TO MAP

781
00:32:11,246 --> 00:32:13,348
PATHWAYS FOR FACILITATING HIV

782
00:32:13,348 --> 00:32:15,050
IMPLEMENTATION SCIENCE RESEARCH

783
00:32:15,050 --> 00:32:16,251
AND SUPPORT.

784
00:32:16,251 --> 00:32:21,056
AND THEN FINALLY WE PLAN TO

785
00:32:21,056 --> 00:32:22,691
EXPAND CROSS-ICO COLLABORATIONS

786
00:32:22,691 --> 00:32:27,763
TO DEVELOP A BROAD PROGRAM OF

787
00:32:27,763 --> 00:32:29,064
HIV IMPLEMENTATION SCIENCE,

788
00:32:29,064 --> 00:32:30,833
ENGAGING COMMUNITIES AT THE

789
00:32:30,833 --> 00:32:32,968
CENTER AND OTHER PARTNERS.

790
00:32:32,968 --> 00:32:37,940
THE GOAL IS TO CREATE INCLUSIVE

791
00:32:37,940 --> 00:32:39,241
CROSS-INSTITUTE AND CENTER

792
00:32:39,241 --> 00:32:41,610
FUNDING OPPORTUNITIES TO FOSTER

793
00:32:41,610 --> 00:32:46,648
IMPLEMENTATION SCIENCE TO END

794
00:32:46,648 --> 00:32:48,617
THE HIV EPIDEMIC.

795
00:32:48,617 --> 00:32:50,853
ANOTHER EXAMPLE OF OAR

796
00:32:50,853 --> 00:32:53,989
APPROACHES TO TAKE ADVANTAGE OF

797
00:32:53,989 --> 00:32:55,891
FUTURE OPPORTUNITIES SHOWN A FEW

798
00:32:55,891 --> 00:32:58,694
SLIDES AGO IS THROUGH NIH-WIDE

799
00:32:58,694 --> 00:33:01,296
INITIATIVES DESIGNED TO CATALYZE

800
00:33:01,296 --> 00:33:02,064
SCIENCE.

801
00:33:02,064 --> 00:33:05,901
SHOWN ON THIS SLIDE ARE OUR FIVE

802
00:33:05,901 --> 00:33:09,238
CURRENT FOCUS AREA THAT AIM TO

803
00:33:09,238 --> 00:33:10,339
STIMULATE AND SUPPORT

804
00:33:10,339 --> 00:33:10,973
INTERDISCIPLINARY RESEARCH AND

805
00:33:10,973 --> 00:33:14,009
TRAINING TO MEET THE NEEDS OF

806
00:33:14,009 --> 00:33:17,546
PEOPLE WITH AND IMPACTED BY HIV.

807
00:33:17,546 --> 00:33:22,384
EACH OF THE PROGRAMS CONVENES

808
00:33:22,384 --> 00:33:23,685
STAKEHOLDERS, PRODUCES

809
00:33:23,685 --> 00:33:25,787
SCIENTIFIC WORKSHOP AND

810
00:33:25,787 --> 00:33:26,221
DATA-DRIVEN FUNDING

811
00:33:26,221 --> 00:33:26,822
OPPORTUNITIES.

812
00:33:26,822 --> 00:33:29,658
MANY OF YOU HAVE BEEN

813
00:33:29,658 --> 00:33:30,959
PARTICIPANTS AND CONTRIBUTORS TO

814
00:33:30,959 --> 00:33:34,363
THESE PROGRAMS, AND WE'RE

815
00:33:34,363 --> 00:33:38,901
GRATEFUL FOR YOUR ENGAGEMENT.

816
00:33:38,901 --> 00:33:40,435
OAR IS CONGRESSIONALLY MANDATED

817
00:33:40,435 --> 00:33:44,640
AS YOU KNOW TO MONITOR THE HIV

818
00:33:44,640 --> 00:33:45,974
RESEARCH PORTFOLIO TO ENSURE IT

819
00:33:45,974 --> 00:33:49,811
IS ALIGNED WITH THE STRATEGIC

820
00:33:49,811 --> 00:33:50,579
PLAN.

821
00:33:50,579 --> 00:33:54,449
TO DO SO, OAR STAFF BUILT A

822
00:33:54,449 --> 00:33:58,387
ROBUST ANALYTICS PLATFORM THAT

823
00:33:58,387 --> 00:34:01,356
SYNTHESIZES EXISTING HIV PUBLIC

824
00:34:01,356 --> 00:34:01,623
DATA.

825
00:34:01,623 --> 00:34:04,493
THE NIH OAR DATA HUB IS

826
00:34:04,493 --> 00:34:07,429
AVAILABLE TO THE PUBLIC, AND

827
00:34:07,429 --> 00:34:10,332
ENABLES RESEARCHERS TO IDENTIFY

828
00:34:10,332 --> 00:34:12,901
HIV-RELATED AWARDS RELEVANT TO

829
00:34:12,901 --> 00:34:14,436
THEIR SPECIFIC INTERESTS,

830
00:34:14,436 --> 00:34:15,537
ESPECIALLY EARLY STAGE

831
00:34:15,537 --> 00:34:16,705
INVESTIGATORS.

832
00:34:16,705 --> 00:34:17,940
THE DATA HUB INCREASES

833
00:34:17,940 --> 00:34:20,976
UNDERSTANDING OF THE RESEARCH

834
00:34:20,976 --> 00:34:24,112
THAT WE DO, ENHANCES

835
00:34:24,112 --> 00:34:25,480
TRANSPARENCY AND ACCOUNTABILITY,

836
00:34:25,480 --> 00:34:28,450
HELPS DISSEMINATE HIV RESEARCH

837
00:34:28,450 --> 00:34:31,186
INFORMATION, AND IT SERVES AS

838
00:34:31,186 --> 00:34:33,922
ANOTHER EXAMPLE OF OUR EFFORTS

839
00:34:33,922 --> 00:34:38,894
TO ALIGN WITH NIH'S CURRENT

840
00:34:38,894 --> 00:34:39,394
PRIORITIES.

841
00:34:39,394 --> 00:34:42,397
TURNING NOW TO A BRIEF UPDATE ON

842
00:34:42,397 --> 00:34:44,232
LONG-ACTING HIV PREVENTION, THIS

843
00:34:44,232 --> 00:34:46,468
IS A VERY EXCITING DEVELOPMENT I

844
00:34:46,468 --> 00:34:47,502
THINK FOR ALL OF US.

845
00:34:47,502 --> 00:34:50,539
WE DID DISCUSS AT THE LAST

846
00:34:50,539 --> 00:34:52,307
MEETING HOW DECADES OF

847
00:34:52,307 --> 00:34:54,309
INVESTMENT IN NIH RESEARCH

848
00:34:54,309 --> 00:34:55,344
SUPPORTED THE FOUNDATIONAL

849
00:34:55,344 --> 00:34:58,914
DISCOVERIES THAT LED TO THE

850
00:34:58,914 --> 00:35:05,220
DEVELOPMENT OF LENACAPAVIR.

851
00:35:05,220 --> 00:35:06,088
RECENT CLINICAL TRIALS

852
00:35:06,088 --> 00:35:08,657
DEMONSTRATED IT IS REMARKABLY

853
00:35:08,657 --> 00:35:12,027
EFFECTIVE FOR HIV PREVENTION.

854
00:35:12,027 --> 00:35:16,298
IN ONE PROMISE STUDY, WOMEN WERE

855
00:35:16,298 --> 00:35:19,301
100% PROTECTED IN SOUTH AFRICA

856
00:35:19,301 --> 00:35:21,536
IN UGANDA, ADOLESCENT GIRLS AND

857
00:35:21,536 --> 00:35:24,406
YOUNG WOMEN 16-25 YEARS OLD.

858
00:35:24,406 --> 00:35:29,511
IN ANOTHER STUDY, IT WAS

859
00:35:29,511 --> 00:35:34,049
DEMONSTRATED ACROSS -- OH, OKAY.

860
00:35:34,049 --> 00:35:37,386
ACROSS SEVEN COUNTRIES, ABOUT

861
00:35:37,386 --> 00:35:39,955
96% ADHERENCE -- PROTECTION

862
00:35:39,955 --> 00:35:41,790
AGAINST HIV.

863
00:35:41,790 --> 00:35:47,195
IN OTHER WORDS, 99.9% OF

864
00:35:47,195 --> 00:35:48,797
PARTICIPANTS REMAINED HIV

865
00:35:48,797 --> 00:35:52,401
NEGATIVE FOLLOWING TWO

866
00:35:52,401 --> 00:35:54,736
INJECTIONS ANNUALLY.

867
00:35:54,736 --> 00:35:56,004
IMPRESSIVELY THE JOURNAL

868
00:35:56,004 --> 00:35:58,507
"SCIENCE" HAILED LENCAPAVIR AS

869
00:35:58,507 --> 00:36:01,777
THE 2024 BREAKTHROUGH OF THE

870
00:36:01,777 --> 00:36:02,511
YEAR.

871
00:36:02,511 --> 00:36:03,945
NOTING THAT NIH-SUPPORTED BASIC

872
00:36:03,945 --> 00:36:05,147
RESEARCH ADVANCES REGARDING THE

873
00:36:05,147 --> 00:36:08,784
STRUCTURE AND FUNCTION OF THE

874
00:36:08,784 --> 00:36:10,285
HIV CAPSID PROTEIN COULD

875
00:36:10,285 --> 00:36:12,454
INCLUDES THE UNDERSTANDING OF

876
00:36:12,454 --> 00:36:15,390
OTHER VIRAL CAPSID INHIBITORS TO

877
00:36:15,390 --> 00:36:17,659
POTENTIALLY FIGHT OTHER VIRAL

878
00:36:17,659 --> 00:36:18,226
INFECTIONS.

879
00:36:18,226 --> 00:36:21,163
AND LAST WEEK WAS A HUGE

880
00:36:21,163 --> 00:36:24,132
MILESTONE IN THAT THE FOOD AND

881
00:36:24,132 --> 00:36:25,333
DRUG ADMINISTRATION APPROVED

882
00:36:25,333 --> 00:36:29,137
LENCAPAVIR FOR HIV PREVENTION.

883
00:36:29,137 --> 00:36:30,472
THIS GROUNDBREAKING INTERVENTION

884
00:36:30,472 --> 00:36:32,274
HAS THE POTENTIAL TO CHANGE THE

885
00:36:32,274 --> 00:36:35,110
COURSE OF THE HIV PANDEMIC, AS

886
00:36:35,110 --> 00:36:40,649
LONG AS WE CAN ADDRESS ACCESS,

887
00:36:40,649 --> 00:36:43,752
ACCEPTABILITY, DELIVERY

888
00:36:43,752 --> 00:36:48,023
MESSENGERS AND OTHER

889
00:36:48,023 --> 00:36:48,924
IMPLEMENTATION-RELATED CONCERNS.

890
00:36:48,924 --> 00:36:50,492
I'M ALMOST DONE BUT I WOULD LIKE

891
00:36:50,492 --> 00:36:53,295
TO PROVIDE A LITTLE UPDATE ON

892
00:36:53,295 --> 00:36:58,200
THE STRATEGIC PLAN THAT IS

893
00:36:58,200 --> 00:37:05,173
ORGANIZED AND PRODUCED BY OAR

894
00:37:05,173 --> 00:37:06,475
FOR HIV AND HIV-RELATED

895
00:37:06,475 --> 00:37:06,742
RESEARCH.

896
00:37:06,742 --> 00:37:07,542
WE DISCUSSED IN THE LAST MEETING

897
00:37:07,542 --> 00:37:12,614
WE WERE IN THE FINAL STAGES

898
00:37:12,614 --> 00:37:14,015
DEVELOPING THE 2026-2030 NIH

899
00:37:14,015 --> 00:37:14,583
STRATEGIC PLAN.

900
00:37:14,583 --> 00:37:16,184
AND WE'LL SHARE IT WITH YOU IN

901
00:37:16,184 --> 00:37:18,253
THE COMING MONTHS.

902
00:37:18,253 --> 00:37:21,156
THE NEW PLAN HIGHLIGHTS HIV

903
00:37:21,156 --> 00:37:22,758
RESEARCH OPPORTUNITIES ACROSS

904
00:37:22,758 --> 00:37:26,561
THE RESEARCH CONTINUUM, STARTING

905
00:37:26,561 --> 00:37:27,562
WITH FUNDAMENTAL BASIC SCIENCE

906
00:37:27,562 --> 00:37:29,464
ALL THE WAY THROUGH

907
00:37:29,464 --> 00:37:30,298
IMPLEMENTATION RESEARCH.

908
00:37:30,298 --> 00:37:35,337
AND AT EACH OF THOSE PHASES,

909
00:37:35,337 --> 00:37:35,904
STRENGTHENING CAPACITY TO

910
00:37:35,904 --> 00:37:40,442
CONDUCT RESEARCH IN THESE AREAS.

911
00:37:40,442 --> 00:37:42,778
SO, JUST AS A QUICK RECAP OF THE

912
00:37:42,778 --> 00:37:45,480
STEPS THAT WENT INTO DEVELOPING

913
00:37:45,480 --> 00:37:48,250
THE PLAN, WE RECEIVED FEEDBACK

914
00:37:48,250 --> 00:37:51,253
AND INPUT FROM MULTIPLE INTERNAL

915
00:37:51,253 --> 00:37:53,321
AND EXTERNAL SOURCES, INCLUDING

916
00:37:53,321 --> 00:37:55,557
A PUBLIC REQUEST FOR INFORMATION

917
00:37:55,557 --> 00:37:58,093
THAT WAS SUMMARIZED BY OAR INTO

918
00:37:58,093 --> 00:38:00,195
A FRAMEWORK THAT WAS THEN

919
00:38:00,195 --> 00:38:04,032
REVIEWED AND DELIBERATED BY OUR

920
00:38:04,032 --> 00:38:05,600
THREE EXPERT TASK FORCES

921
00:38:05,600 --> 00:38:06,001
REPRESENTED HERE.

922
00:38:06,001 --> 00:38:08,170
AGAIN, I'D LIKE TO THANK THE

923
00:38:08,170 --> 00:38:10,472
TASK FORCE LEADERSHIP AS WELL AS

924
00:38:10,472 --> 00:38:15,076
THE TASK FORCE MEMBERS FOR ALL

925
00:38:15,076 --> 00:38:17,779
OF THEIR HARD WORK.

926
00:38:17,779 --> 00:38:20,916
AND THAT BRINGS US WHERE WE ARE

927
00:38:20,916 --> 00:38:25,020
TODAY IN THE PROCESS.

928
00:38:25,020 --> 00:38:30,425
OARAC RECEIVED REPORT-OUTS FROM

929
00:38:30,425 --> 00:38:31,626
TASK FORCES AND PUT

930
00:38:31,626 --> 00:38:32,928
RECOMMENDATIONS FORWARD TO ME.

931
00:38:32,928 --> 00:38:35,297
INSTITUTES AND CENTERS HAVE SEEN

932
00:38:35,297 --> 00:38:36,264
THESE RECOMMENDATIONS AND

933
00:38:36,264 --> 00:38:37,933
PROVIDED INPUT ON THE STRATEGIC

934
00:38:37,933 --> 00:38:39,935
PLAN AS WELL.

935
00:38:39,935 --> 00:38:41,703
I'VE GIVEN MY FINAL REVIEW OF

936
00:38:41,703 --> 00:38:46,041
THE PLAN, AND IT IS CURRENTLY

937
00:38:46,041 --> 00:38:47,442
UNDERGOING INTERNAL NIH REVIEW

938
00:38:47,442 --> 00:38:48,343
AND CLEARANCE.

939
00:38:48,343 --> 00:38:51,746
WE WILL SEND THE PLAN TO OARAC

940
00:38:51,746 --> 00:38:53,915
MEMBERS FOR NOTATIONAL VOTE

941
00:38:53,915 --> 00:38:57,419
BEFORE RELEASING IT PUBLICLY

942
00:38:57,419 --> 00:38:58,854
LATER THIS YEAR.

943
00:38:58,854 --> 00:39:00,589
SO BEFORE CONCLUDING I'LL JUST

944
00:39:00,589 --> 00:39:03,658
NOTE A FEW RECENT AND UPCOMING

945
00:39:03,658 --> 00:39:04,793
OAR ENGAGEMENTS.

946
00:39:04,793 --> 00:39:07,829
MUCH HAS HAPPENED SINCE WE MET

947
00:39:07,829 --> 00:39:08,463
LAST OCTOBER.

948
00:39:08,463 --> 00:39:10,732
AND WHILE THERE ISN'T ENOUGH

949
00:39:10,732 --> 00:39:12,734
TIME TO DISCUSS EVERY OAR

950
00:39:12,734 --> 00:39:14,302
ENGAGEMENT I'LL HIGHLIGHT AND

951
00:39:14,302 --> 00:39:17,272
TOUCH ON A FEW.

952
00:39:17,272 --> 00:39:19,975
SO, EACH YEAR OAR LEADS THE

953
00:39:19,975 --> 00:39:22,911
ANNUAL NIH OBSERVANCE OF WORLD

954
00:39:22,911 --> 00:39:31,152
AIDS DAY, AND THIS YEAR WE LED A

955
00:39:31,152 --> 00:39:34,856
VIRTUAL EVENT DECEMBER 4 THAT

956
00:39:34,856 --> 00:39:36,057
WAS VERY WELL RECEIVED.

957
00:39:36,057 --> 00:39:45,600
I WAS JOINED BY FELLOW PANELIST

958
00:39:45,600 --> 00:39:47,669
FRANCISCO RUIZ AND OTHERS.

959
00:39:47,669 --> 00:39:49,804
THIS AND RELATED EVENTS WERE

960
00:39:49,804 --> 00:39:52,040
WELL ATTENDED AND OFFERED TIME

961
00:39:52,040 --> 00:39:53,408
TO CELEBRATE BREAKTHROUGHS IN

962
00:39:53,408 --> 00:39:55,744
HIV RESEARCH AS WELL AS A CHANCE

963
00:39:55,744 --> 00:39:59,814
TO ACKNOWLEDGE THE NEED TO

964
00:39:59,814 --> 00:40:01,316
ACCELERATE SCIENTIFIC PROGRESS

965
00:40:01,316 --> 00:40:03,218
AND ENSURE THAT THOSE WITH AND

966
00:40:03,218 --> 00:40:06,187
AFFECTED BY HIV HAVE THE CHANCE

967
00:40:06,187 --> 00:40:08,957
TO INFORM AND PARTICIPATE IN

968
00:40:08,957 --> 00:40:11,359
RESEARCH AND EXPERIENCE THE

969
00:40:11,359 --> 00:40:14,029
LIFE-CHANGING IMPACT OF RESEARCH

970
00:40:14,029 --> 00:40:14,796
INNOVATIONS.

971
00:40:14,796 --> 00:40:16,665
WE ALSO VERY SADLY PAID TRIBUTE

972
00:40:16,665 --> 00:40:20,468
TO MANY HEROES IN THE HIV

973
00:40:20,468 --> 00:40:23,605
COMMUNITY WHO WERE LOST

974
00:40:23,605 --> 00:40:28,043
INCLUDING LONGTIME OAR ADVISER

975
00:40:28,043 --> 00:40:30,178
MR. CORNELIUS BAKER.

976
00:40:30,178 --> 00:40:31,980
LOOKING AHEAD, THE 13th IAS

977
00:40:31,980 --> 00:40:34,816
CONFERENCE ON HIV SCIENCE WILL

978
00:40:34,816 --> 00:40:37,018
BE HAPPENING NEXT MONTH IN JULY

979
00:40:37,018 --> 00:40:37,619
IN RWANDA.

980
00:40:37,619 --> 00:40:41,823
I WILL BE IN ATTENDANCE,

981
00:40:41,823 --> 00:40:43,625
REPRESENTING NIH OAR.

982
00:40:43,625 --> 00:40:47,696
IN ADDITION TO RESEARCH-BASED

983
00:40:47,696 --> 00:40:49,097
PRESENTATIONS IAS 2025 WILL

984
00:40:49,097 --> 00:40:50,832
ADDRESS THE CURRENT POLITICAL

985
00:40:50,832 --> 00:40:53,335
AND FINANCIAL ISSUES AFFECTING

986
00:40:53,335 --> 00:40:55,003
THE HIV RESPONSE, INCLUDING

987
00:40:55,003 --> 00:40:58,707
IMPLICATIONS FOR AFRICA AND

988
00:40:58,707 --> 00:40:59,240
GLOBALLY.

989
00:40:59,240 --> 00:41:02,644
THE 2025 U.S. CONFERENCE ON

990
00:41:02,644 --> 00:41:05,013
HIV/AIDS WILL BE HELD IN

991
00:41:05,013 --> 00:41:06,081
WASHINGTON, D.C. THIS YEAR IN

992
00:41:06,081 --> 00:41:08,350
EARLY SEPTEMBER FROM THE 4th

993
00:41:08,350 --> 00:41:11,653
TO 7th. 

994
00:41:11,653 --> 00:41:13,955
THE OVERALL THEME OF USCHA IS

995
00:41:13,955 --> 00:41:16,324
AGING WITH HIV AND OAR WILL BE

996
00:41:16,324 --> 00:41:19,594
PARTNERING WITH MULTIPLE NIH

997
00:41:19,594 --> 00:41:21,196
INSTITUTES AND CENTERS AS WELL

998
00:41:21,196 --> 00:41:24,065
AS HIV COMMUNITY LEADERS TO

999
00:41:24,065 --> 00:41:25,533
FACILITATE THREE INTERACTIVE

1000
00:41:25,533 --> 00:41:25,867
SESSIONS.

1001
00:41:25,867 --> 00:41:30,338
ONE IS FOCUSED ON COMORBIDITIES,

1002
00:41:30,338 --> 00:41:31,806
ONE FOCUSED ON MENOPAUSE AND

1003
00:41:31,806 --> 00:41:34,642
WOMEN WITH HIV, AND A THIRD IS

1004
00:41:34,642 --> 00:41:37,112
FOCUSED ON VIRAL LOAD MONITORING

1005
00:41:37,112 --> 00:41:39,080
WHICH WE'LL HEAR MORE ABOUT

1006
00:41:39,080 --> 00:41:40,448
AFTER MY REPORT.

1007
00:41:40,448 --> 00:41:42,917
YOU'LL HEAR MORE ABOUT OTHER

1008
00:41:42,917 --> 00:41:44,886
CURRENT ACTIVITIES, INCLUDING

1009
00:41:44,886 --> 00:41:47,322
OUR NEXT INNOVATION PROGRAM

1010
00:41:47,322 --> 00:41:52,427
SYMPOSIUM, AND A NUMBER OF

1011
00:41:52,427 --> 00:41:56,464
ENGAGEMENTS RELATED TO EARLY

1012
00:41:56,464 --> 00:41:58,233
CAREER INVESTIGATORS LATER IN

1013
00:41:58,233 --> 00:42:00,335
TODAY'S PROGRAM FROM DR. ALBERTI

1014
00:42:00,335 --> 00:42:02,103
AND CHANG.

1015
00:42:02,103 --> 00:42:03,972
SO BEFORE CLOSING, I'D LIKE TO

1016
00:42:03,972 --> 00:42:05,373
THANK COUNCIL MEMBERS FOR

1017
00:42:05,373 --> 00:42:07,409
LISTENING TO ME TALK FOR A VERY

1018
00:42:07,409 --> 00:42:09,444
LONG TIME.

1019
00:42:09,444 --> 00:42:11,079
AND MAKING THESE MEETINGS A

1020
00:42:11,079 --> 00:42:11,413
PRIORITY.

1021
00:42:11,413 --> 00:42:13,314
IF YOU HAVEN'T DONE SO ALREADY,

1022
00:42:13,314 --> 00:42:15,950
PLEASE MARK YOUR CALENDARS FOR

1023
00:42:15,950 --> 00:42:18,386
OUR NEXT OARAC MEETING, ON

1024
00:42:18,386 --> 00:42:19,587
SEPTEMBER 18th.

1025
00:42:19,587 --> 00:42:22,891
AND THIS DATE COINCIDES WITH THE

1026
00:42:22,891 --> 00:42:25,160
OBSERVANCE OF NATIONAL HIV/AIDS

1027
00:42:25,160 --> 00:42:27,128
AND AGING AWARENESS DAY WHICH

1028
00:42:27,128 --> 00:42:31,466
TIES IN NICELY WITH THE UPCOMING

1029
00:42:31,466 --> 00:42:34,102
THEME FOR THE MEETING.

1030
00:42:34,102 --> 00:42:36,604
AND WITH THAT, THAT CONCLUDES MY

1031
00:42:36,604 --> 00:42:37,005
DIRECTOR'S REPORT.

1032
00:42:37,005 --> 00:42:39,207
THANK YOU FOR YOUR ATTENTION.

1033
00:42:39,207 --> 00:42:42,343
LUIS, I'LL TURN IT BACK TO YOU.

1034
00:42:42,343 --> 00:42:43,878
>> THANK YOU, DR.
DONENBERG.

1035
00:42:43,878 --> 00:42:45,914
THANK YOU FOR THE OVERVIEW ON

1036
00:42:45,914 --> 00:42:47,382
THE UPCOMING OPPORTUNITIES FOR

1037
00:42:47,382 --> 00:42:49,751
THE STRATEGIC PLAN AND

1038
00:42:49,751 --> 00:42:51,953
PRIORITIES THAT OARAC MAY HAVE

1039
00:42:51,953 --> 00:42:53,288
THE OPPORTUNITY TO CONTRIBUTE

1040
00:42:53,288 --> 00:42:54,055
ADVICE ON.

1041
00:42:54,055 --> 00:42:59,060
SO, WE'RE GOING TO MOVE INTO

1042
00:42:59,060 --> 00:43:01,396
OPEN DISCUSSION NOW, TAKING ANY

1043
00:43:01,396 --> 00:43:02,263
POINTS FROM MEMBERS VIRTUALLY

1044
00:43:02,263 --> 00:43:05,133
AND PERSONS IN THE ROOM.

1045
00:43:05,133 --> 00:43:07,068
SO IF YOU'RE VIRTUAL AND VOTING

1046
00:43:07,068 --> 00:43:09,571
OR A MEMBER PLEASE RAISE YOUR

1047
00:43:09,571 --> 00:43:10,038
HAND.

1048
00:43:10,038 --> 00:43:11,973
WE'LL START WITH THE ROOM.

1049
00:43:11,973 --> 00:43:13,875
FIRST I'LL TAKE THE CHAIR'S

1050
00:43:13,875 --> 00:43:17,912
PRIORITIES AND ASK THE FIRST

1051
00:43:17,912 --> 00:43:18,446
QUESTION.

1052
00:43:18,446 --> 00:43:21,549
DR. DONENBERG, REGARDING THE

1053
00:43:21,549 --> 00:43:23,818
BUDGET THAT WAS PROPOSED BY YOUR

1054
00:43:23,818 --> 00:43:26,821
OFFICE FOR SORT OF WITHIN THE

1055
00:43:26,821 --> 00:43:29,457
PRESIDENT'S BUDGET, DO YOU

1056
00:43:29,457 --> 00:43:36,264
ANTICIPATE OR PLAN FOR KEEPING

1057
00:43:36,264 --> 00:43:37,966
PROPORTIONALLY AMOUNTS THAT

1058
00:43:37,966 --> 00:43:39,734
WOULD OTHERWISE BE CONSOLIDATED?

1059
00:43:39,734 --> 00:43:41,769
TAKE NIDA, THE BUDGET NIDA HAD,

1060
00:43:41,769 --> 00:43:44,305
IS IT LIKE MOVED INTO THE

1061
00:43:44,305 --> 00:43:47,509
CONSOLIDATED OR WERE THERE ANY

1062
00:43:47,509 --> 00:43:51,513
OTHER KIND OF CHANGES DONE ONCE

1063
00:43:51,513 --> 00:43:53,548
THAT CONSOLIDATION AND BUDGET

1064
00:43:53,548 --> 00:44:01,756
WAS MADE, TRYING TO SEE WHAT

1065
00:44:01,756 --> 00:44:06,694
POSITION YOUR OFFICE TOOK.

1066
00:44:06,694 --> 00:44:09,797
>> THE BUDGET OFFICE
INVITED

1067
00:44:09,797 --> 00:44:13,935
INSTITUTES INDIVIDUAL THROW

1068
00:44:13,935 --> 00:44:17,038
REPORT OUT HOW THEY WOULD

1069
00:44:17,038 --> 00:44:20,575
PROPORTION THE 40% CUT ACROSS

1070
00:44:20,575 --> 00:44:22,510
THEIR SPECIFIC INSTITUTES.

1071
00:44:22,510 --> 00:44:24,112
AND SO, WE DIDN'T CHANGE THAT.

1072
00:44:24,112 --> 00:44:26,848
WE JUST WORKED WITH WHAT EACH

1073
00:44:26,848 --> 00:44:27,215
INSTITUTE SAID.

1074
00:44:27,215 --> 00:44:31,419
BUT I AM VERY PROUD TO SAY THAT

1075
00:44:31,419 --> 00:44:33,755
EVERY -- THAT THEY WERE ALSO

1076
00:44:33,755 --> 00:44:35,590
ASKED TO HYPOTHESIZE, THIS IS IN

1077
00:44:35,590 --> 00:44:38,760
NO WAY FOR SURE, BUT HYPOTHESIZE

1078
00:44:38,760 --> 00:44:40,428
IF THE AIDS ALLOCATION WERE

1079
00:44:40,428 --> 00:44:47,502
INCLUDED IN THE BASE OF THEIR

1080
00:44:47,502 --> 00:44:48,870
TYPICAL NIH FUNDING HOW WOULD

1081
00:44:48,870 --> 00:44:50,138
THEY APPORTION THEIR FUNDS FOR

1082
00:44:50,138 --> 00:44:51,406
HIV?

1083
00:44:51,406 --> 00:44:54,075
AND ALL OF THE INSTITUTES

1084
00:44:54,075 --> 00:44:56,444
RETAINED A STRONG COMMITMENT TO

1085
00:44:56,444 --> 00:44:59,314
RESEARCH IN HIV, EVEN WITH THE

1086
00:44:59,314 --> 00:45:00,181
40% CUT.

1087
00:45:00,181 --> 00:45:02,450
SO, THAT'S REALLY GREAT NEWS.

1088
00:45:02,450 --> 00:45:03,451
SHOWS A REAL COMMITMENT ON THE

1089
00:45:03,451 --> 00:45:06,621
PART OF ALL THE INSTITUTES.

1090
00:45:06,621 --> 00:45:08,923
>> THANK YOU.

1091
00:45:08,923 --> 00:45:11,025
WE'LL START WITH COMMENTS IN THE

1092
00:45:11,025 --> 00:45:11,226
ROOM.

1093
00:45:11,226 --> 00:45:12,393
ARE THERE COMMENTS IN THE ROOM

1094
00:45:12,393 --> 00:45:14,095
BEFORE WE GO TO VIRTUAL?

1095
00:45:14,095 --> 00:45:15,330
>> NOT AT THIS TIME.

1096
00:45:15,330 --> 00:45:16,431
>> THANK YOU.

1097
00:45:16,431 --> 00:45:21,703
I SEE ONE HAND RAISED.

1098
00:45:21,703 --> 00:45:23,037
I BELIEVE DR. NEILAN.

1099
00:45:23,037 --> 00:45:24,272
>> THANKS SO MUCH.

1100
00:45:24,272 --> 00:45:27,775
I WANT TO START BY ACKNOWLEDGING

1101
00:45:27,775 --> 00:45:30,111
MY APPRECIATION FOR YOUR

1102
00:45:30,111 --> 00:45:31,012
ACKNOWLEDGMENT OF CURRENT

1103
00:45:31,012 --> 00:45:36,484
CHALLENGES FACING THE FIELD AND

1104
00:45:36,484 --> 00:45:37,185
HIGHLIGHTING OPPORTUNITIES TO

1105
00:45:37,185 --> 00:45:38,186
ADVANCE HIV SCIENCE.

1106
00:45:38,186 --> 00:45:41,522
I'M THINKING ABOUT THE CURRENT

1107
00:45:41,522 --> 00:45:42,156
BUDGET.

1108
00:45:42,156 --> 00:45:44,525
AND MY ROLE AS A VOTING OARAC

1109
00:45:44,525 --> 00:45:44,926
MEMBER.

1110
00:45:44,926 --> 00:45:49,197
I WONDER IF OAR HAS AN

1111
00:45:49,197 --> 00:45:50,999
OPPORTUNITY TO PROVIDE FEEDBACK

1112
00:45:50,999 --> 00:45:52,166
ON THE SUBSTANTIVE THREAT THAT

1113
00:45:52,166 --> 00:45:54,335
THE LACK OF RELEASE OF MANY OF

1114
00:45:54,335 --> 00:45:55,336
THE CURRENT FUNDS, THINKING

1115
00:45:55,336 --> 00:45:58,406
ABOUT THE CURRENT FUNDS, ARE FOR

1116
00:45:58,406 --> 00:46:00,074
DESTABILIZING THE WORKFORCE AND

1117
00:46:00,074 --> 00:46:01,909
SORT OF THE, AS YET TO MY

1118
00:46:01,909 --> 00:46:04,078
KNOWLEDGE, NO TIMELINE OR

1119
00:46:04,078 --> 00:46:04,646
GUIDANCE BEING RELEASED,

1120
00:46:04,646 --> 00:46:06,648
WONDERING HOW OAR IS ABLE TO

1121
00:46:06,648 --> 00:46:08,916
PROVIDE FEEDBACK ON THAT.

1122
00:46:08,916 --> 00:46:10,151
THANK YOU.

1123
00:46:10,151 --> 00:46:11,719
>> IT'S A GOOD QUESTION.

1124
00:46:11,719 --> 00:46:15,490
SOMETHING THAT I THINK ABOUT A

1125
00:46:15,490 --> 00:46:15,957
LOT.

1126
00:46:15,957 --> 00:46:17,425
AND I THINK ABOUT IN TERMS OF

1127
00:46:17,425 --> 00:46:19,294
WHAT AM I KIND OF ABLE TO DO AND

1128
00:46:19,294 --> 00:46:22,497
WHAT AM I NOT ABLE TO DO.

1129
00:46:22,497 --> 00:46:26,000
I CERTAINLY FOLLOW ALL OF THE

1130
00:46:26,000 --> 00:46:26,801
INFORMATION THAT'S COMING

1131
00:46:26,801 --> 00:46:28,303
FORWARD, PROBABLY AS MUCH AS YOU

1132
00:46:28,303 --> 00:46:28,469
DO.

1133
00:46:28,469 --> 00:46:33,174
AND YOU MIGHT EVEN GET THAT

1134
00:46:33,174 --> 00:46:34,309
INFORMATION BEFORE US.

1135
00:46:34,309 --> 00:46:37,011
AND TO BE HONEST I'M ALWAYS

1136
00:46:37,011 --> 00:46:37,845
CHECKING WITH MY COLLEAGUES

1137
00:46:37,845 --> 00:46:40,381
ABOUT WHAT AM I ALLOWED TO SEND

1138
00:46:40,381 --> 00:46:41,716
OUT TO SHARE.

1139
00:46:41,716 --> 00:46:43,484
AND THE TRUTH IS WE'RE NOT

1140
00:46:43,484 --> 00:46:49,857
ALLOWED TO COMMENT ON ANY OF

1141
00:46:49,857 --> 00:46:50,191
THOSE ISSUES.

1142
00:46:50,191 --> 00:46:52,994
AND, HOWEVER, WE SIT IN MEETINGS

1143
00:46:52,994 --> 00:46:54,562
AND THERE ARE DEFINITELY

1144
00:46:54,562 --> 00:46:57,165
OPPORTUNITIES WITHIN THOSE

1145
00:46:57,165 --> 00:47:00,101
MEETINGS TO EXPRESS CONCERN

1146
00:47:00,101 --> 00:47:02,270
ABOUT HOW THE VARIOUS SITUATIONS

1147
00:47:02,270 --> 00:47:06,307
ARE IMPACTING THE SCIENCE, THE

1148
00:47:06,307 --> 00:47:07,709
FUTURE OF THE SCIENCE,

1149
00:47:07,709 --> 00:47:08,476
INVESTIGATORS, AND SO FORTH.

1150
00:47:08,476 --> 00:47:13,381
WE ARE ABLE TO DO THAT

1151
00:47:13,381 --> 00:47:13,781
INTERNALLY.

1152
00:47:13,781 --> 00:47:15,950
>> THANK YOU SO MUCH.

1153
00:47:15,950 --> 00:47:18,319
>> AND WE DO.

1154
00:47:18,319 --> 00:47:23,057
SO --

1155
00:47:23,057 --> 00:47:24,359
>> ANY OTHER QUESTIONS OR

1156
00:47:24,359 --> 00:47:24,759
COMMENTS?

1157
00:47:24,759 --> 00:47:27,862
YES, I SEE ANOTHER HAND UP.

1158
00:47:27,862 --> 00:47:31,299
GO AHEAD.

1159
00:47:31,299 --> 00:47:31,532
>> HI.

1160
00:47:31,532 --> 00:47:32,800
THIS IS LISA.

1161
00:47:32,800 --> 00:47:34,335
THANKS FOR OUTLINING THE CURRENT

1162
00:47:34,335 --> 00:47:34,936
SITUATION.

1163
00:47:34,936 --> 00:47:38,239
I WAS WONDERING HOW

1164
00:47:38,239 --> 00:47:40,241
INTERNATIONALLY RESEARCH FITS

1165
00:47:40,241 --> 00:47:42,543
INTO THE PLANS AND PRIORITIES

1166
00:47:42,543 --> 00:47:43,945
FOR OFFICE OF AIDS RESEARCH

1167
00:47:43,945 --> 00:47:47,982
GOING FORWARD AND WHAT THIS

1168
00:47:47,982 --> 00:47:49,183
COMMITTEE IS RECOMMENDING.

1169
00:47:49,183 --> 00:47:50,952
>> THANK YOU.

1170
00:47:50,952 --> 00:47:53,388
AS SOMEONE WHO HAS DONE -- WHO

1171
00:47:53,388 --> 00:47:55,523
HAS MY PREVIOUS 30 YEARS OF

1172
00:47:55,523 --> 00:47:58,159
RESEARCH AS AN ACADEMIC IN

1173
00:47:58,159 --> 00:48:00,461
GLOBAL HEALTH RESEARCH, I AM

1174
00:48:00,461 --> 00:48:04,332
SYMPATHETIC TO WHAT YOU MIGHT BE

1175
00:48:04,332 --> 00:48:04,565
ASKING.

1176
00:48:04,565 --> 00:48:10,471
I KNOW THAT THERE IS AN EFFORT

1177
00:48:10,471 --> 00:48:13,508
TO FUND GLOBAL HEALTH RESEARCH,

1178
00:48:13,508 --> 00:48:15,576
BUT IT IS HALTED.

1179
00:48:15,576 --> 00:48:17,278
AND THERE IS A LOT OF DISCUSSION

1180
00:48:17,278 --> 00:48:22,850
AS FAR AS I HAVE HEARD ABOUT HOW

1181
00:48:22,850 --> 00:48:25,420
THE FOREIGN SUBCONTRACTS MAY BE

1182
00:48:25,420 --> 00:48:30,124
FUNDED OR INTEGRATED INTO THE

1183
00:48:30,124 --> 00:48:30,591
NIH SYSTEM.

1184
00:48:30,591 --> 00:48:32,827
BUT, AGAIN, YOU KNOW, IN MANY

1185
00:48:32,827 --> 00:48:35,062
WAYS YOU KNOW WHAT WE KNOW.

1186
00:48:35,062 --> 00:48:37,231
AND THERE HAS BEEN A STATEMENT

1187
00:48:37,231 --> 00:48:39,467
THAT THERE IS -- THAT THERE IS

1188
00:48:39,467 --> 00:48:42,770
VALUE IN GLOBAL HEALTH RESEARCH.

1189
00:48:42,770 --> 00:48:44,705
BUT THAT'S ABOUT THE EXTENT OF

1190
00:48:44,705 --> 00:48:46,974
WHAT I HAVE HEARD.

1191
00:48:46,974 --> 00:48:49,277
AND, AGAIN, JUST SPEAKING TO

1192
00:48:49,277 --> 00:48:51,979
ANNE'S COMMENT, WE DO HAVE AN

1193
00:48:51,979 --> 00:48:55,716
OPPORTUNITY INTERNALLY TO HAVE

1194
00:48:55,716 --> 00:48:56,717
THESE DISCUSSIONS AND VOICE WHAT

1195
00:48:56,717 --> 00:49:01,923
WE THINK IS IMPORTANT.

1196
00:49:01,923 --> 00:49:08,529
>> ANY OTHER COMMENTS OR
WEST

1197
00:49:08,529 --> 00:49:10,298
FROM THOSE ATTENDING VIRTUALLY?

1198
00:49:10,298 --> 00:49:12,667
OR BACK IN THE ROOM, DR.

1199
00:49:12,667 --> 00:49:13,334
GLENSHAW?

1200
00:49:13,334 --> 00:49:14,202
>> NOT IN THE ROOM.

1201
00:49:14,202 --> 00:49:15,503
>> ALL RIGHT.

1202
00:49:15,503 --> 00:49:19,774
THANK YOU, DR. DONENBERG, IT'S A

1203
00:49:19,774 --> 00:49:20,875
CHALLENGING TIME DETERMINING THE

1204
00:49:20,875 --> 00:49:23,778
WAY FORWARD AND BEST WAY TO

1205
00:49:23,778 --> 00:49:24,779
CONSTRUCTIVELY SORT OF ADVANCE

1206
00:49:24,779 --> 00:49:26,147
THE FIELD IN MANY WAYS.

1207
00:49:26,147 --> 00:49:29,083
SO THANK YOU FOR YOUR CANDOR AND

1208
00:49:29,083 --> 00:49:30,318
FOR PRESENTING ALL THE

1209
00:49:30,318 --> 00:49:31,886
INFORMATION THAT'S AVAILABLE AND

1210
00:49:31,886 --> 00:49:34,989
WHAT WE CAN AND CANNOT

1211
00:49:34,989 --> 00:49:36,924
POTENTIALLY CONTRIBUTE TO AT

1212
00:49:36,924 --> 00:49:37,592
THIS TIME.

1213
00:49:37,592 --> 00:49:42,096
SO, WE'LL PROCEED WITH OUR

1214
00:49:42,096 --> 00:49:42,563
AGENDA.

1215
00:49:42,563 --> 00:49:46,701
AND NOW OUR NEXT PRESENTER DR.

1216
00:49:46,701 --> 00:49:48,069
SHAWN MULVANEY, HEALTH SCIENCE

1217
00:49:48,069 --> 00:49:53,040
ADMINISTRATOR, DIVISION OF

1218
00:49:53,040 --> 00:49:53,841
HEALTH INFORMATICS TECHNOLOGIES

1219
00:49:53,841 --> 00:49:55,510
AT NATIONAL INSTITUTES OF

1220
00:49:55,510 --> 00:49:57,111
BIOMEDICAL IMAGING AND

1221
00:49:57,111 --> 00:49:58,312
BIOENGINEERING, PRESENTING ON

1222
00:49:58,312 --> 00:50:00,248
THE ADVANCED PLATFORMS FOR HIV

1223
00:50:00,248 --> 00:50:01,449
VIRAL LOAD MONITORING AT POINT

1224
00:50:01,449 --> 00:50:04,418
OF CARE, AN AREA THAT IS OF HIGH

1225
00:50:04,418 --> 00:50:06,888
INTEREST ACROSS ALL CLINICAL

1226
00:50:06,888 --> 00:50:10,925
SETTINGS, AND ONE WE'VE BEEN

1227
00:50:10,925 --> 00:50:12,927
LOOKING FORWARD TO BRINGING

1228
00:50:12,927 --> 00:50:13,728
FORT.

1229
00:50:13,728 --> 00:50:15,530
I'M PLEASED TO WELCOME DR.

1230
00:50:15,530 --> 00:50:17,365
MULVANEY TO GIVE AN UPDATE AND

1231
00:50:17,365 --> 00:50:19,000
THE WAY FORWARD.

1232
00:50:19,000 --> 00:50:20,401
DR. MULVANEY?

1233
00:50:20,401 --> 00:50:21,302
>> GOOD AFTERNOON.

1234
00:50:21,302 --> 00:50:24,238
THANK YOU VERY MUCH FOR THAT

1235
00:50:24,238 --> 00:50:25,573
KIND INTRODUCTION.

1236
00:50:25,573 --> 00:50:29,443
I'M GOING TO CALL UP SOME SLIDES

1237
00:50:29,443 --> 00:50:39,687
FOR US TO SEE.

1238
00:50:40,254 --> 00:50:41,956
CAN YOU KINDLY SAY WHETHER YOU

1239
00:50:41,956 --> 00:50:42,256
CAN --

1240
00:50:42,256 --> 00:50:43,991
>> WE CAN SEE IT WELL.

1241
00:50:43,991 --> 00:50:47,595
IT SHOWS UP WELL.

1242
00:50:47,595 --> 00:50:48,229
>> PERFECT.

1243
00:50:48,229 --> 00:50:49,864
GOOD AFTERNOON.

1244
00:50:49,864 --> 00:50:51,499
AND THANK YOU, AGAIN, FOR THE

1245
00:50:51,499 --> 00:50:53,401
OPPORTUNITY TO BE HERE TODAY.

1246
00:50:53,401 --> 00:50:56,404
THANK YOU TO OAR.

1247
00:50:56,404 --> 00:50:58,239
I'M SHAWN MULVANEY, PROGRAM

1248
00:50:58,239 --> 00:50:59,206
OFFICER, NATIONAL INSTITUTE OF

1249
00:50:59,206 --> 00:51:03,678
BIOMEDICAL  IMAGING.

1250
00:51:03,678 --> 00:51:05,046
FOR THOSE LESS FAMILIAR WITH

1251
00:51:05,046 --> 00:51:07,448
NIBIB WE'RE ONE OF THE SMALLER

1252
00:51:07,448 --> 00:51:08,849
I.C.s AT NIH.

1253
00:51:08,849 --> 00:51:11,452
WE DO NOT PARTICULARLY FOCUS ON

1254
00:51:11,452 --> 00:51:12,787
ANY DISEASE, CONDITION, OR BODY

1255
00:51:12,787 --> 00:51:13,621
PART.

1256
00:51:13,621 --> 00:51:15,389
BUT INSTEAD WE CONSIDER

1257
00:51:15,389 --> 00:51:16,123
OURSELVES TOOL BUILDERS.

1258
00:51:16,123 --> 00:51:19,226
OUR GOAL IS TO REALIZE THOSE

1259
00:51:19,226 --> 00:51:20,528
TOOLS, THAT MAKES POSSIBLE

1260
00:51:20,528 --> 00:51:23,064
SPECIFIC RESEARCH AND HEALTH

1261
00:51:23,064 --> 00:51:24,599
INTERVENTIONS NEEDED AND THEREBY

1262
00:51:24,599 --> 00:51:26,534
SHAPE THE FUTURE OF HEALTH.

1263
00:51:26,534 --> 00:51:28,603
TODAY I'D LIKE TO TAKE TIME TO

1264
00:51:28,603 --> 00:51:31,072
TALK ABOUT HIV VIRAL LOAD

1265
00:51:31,072 --> 00:51:32,640
MONITORING, AND OUR COLLECTIVE

1266
00:51:32,640 --> 00:51:35,977
DESIRE TO BRING FORTH PROJECTS

1267
00:51:35,977 --> 00:51:37,411
FOR DOMESTIC POINT-OF-CARE

1268
00:51:37,411 --> 00:51:38,479
MARKET.

1269
00:51:38,479 --> 00:51:40,748
THIS WORK IS CO-SPONSORED BY

1270
00:51:40,748 --> 00:51:42,049
OAR, NIAID, AND NIBIB.

1271
00:51:42,049 --> 00:51:44,285
BUT BEFORE WE GET TO THE HEART

1272
00:51:44,285 --> 00:51:46,320
OF THAT STORY, PLEASE LET ME

1273
00:51:46,320 --> 00:51:49,290
BEGIN BY TELLING A LITTLE BIT

1274
00:51:49,290 --> 00:51:59,000
RADx, RAPID ACCELERATION OF

1275
00:51:59,000 --> 00:52:00,401
DIAGNOSTICS PROGRAMS AND WHY WE

1276
00:52:00,401 --> 00:52:01,268
HAVE SOMETHING TO CONTRIBUTE.

1277
00:52:01,268 --> 00:52:03,571
BEFORE I GET TO THAT, A

1278
00:52:03,571 --> 00:52:04,905
DISCLAIMER TO START.

1279
00:52:04,905 --> 00:52:06,674
THE OPINIONS EXPRESSED HERE ARE

1280
00:52:06,674 --> 00:52:08,042
MY OWN.

1281
00:52:08,042 --> 00:52:09,110
THEY DO NOT NECESSARILY REFLECT

1282
00:52:09,110 --> 00:52:12,013
OPINIONS OF THE U.S. GOVERNMENT,

1283
00:52:12,013 --> 00:52:13,948
DEPARTMENT OF HEALTH AND HUMAN

1284
00:52:13,948 --> 00:52:16,283
SERVICES, NATIONAL INSTITUTES OF

1285
00:52:16,283 --> 00:52:18,819
HEALTH, NIBIB, AND ANY MENTION

1286
00:52:18,819 --> 00:52:19,920
OF RESEARCH ENTITY, COMPANY,

1287
00:52:19,920 --> 00:52:22,657
PRODUCT, OR TRADE NAME DOES NOT

1288
00:52:22,657 --> 00:52:26,894
CONSTITUTE OFFICIAL ENDORSEMENT

1289
00:52:26,894 --> 00:52:28,929
OF NOR CAUTION AGAINST.

1290
00:52:28,929 --> 00:52:30,765
RADx, WHAT WAS RADx?

1291
00:52:30,765 --> 00:52:33,267
IT WAS FORGED IN THE FIRES OF

1292
00:52:33,267 --> 00:52:35,069
THE COVID-19 PANDEMIC.

1293
00:52:35,069 --> 00:52:37,538
BY THE SPRING OF 2020, IF YOU

1294
00:52:37,538 --> 00:52:39,073
CAN TURN YOUR MIND BACK TO THEN,

1295
00:52:39,073 --> 00:52:40,508
OUR CHILDREN WERE DOING SCHOOL

1296
00:52:40,508 --> 00:52:42,777
IN THE LIVING ROOM, FOR MANY OF

1297
00:52:42,777 --> 00:52:44,211
US, ME INCLUDED, THE KITCHEN

1298
00:52:44,211 --> 00:52:46,414
TABLE WAS THE NEW OFFICE.

1299
00:52:46,414 --> 00:52:50,251
THE MOST CRITICAL PIECE OF

1300
00:52:50,251 --> 00:52:51,752
INTELLIGENCE IS WHICH STORE HAD

1301
00:52:51,752 --> 00:52:53,254
TOILET PAPER IN STOCK.

1302
00:52:53,254 --> 00:52:55,990
THOSE DAYS WERE SCARY.

1303
00:52:55,990 --> 00:52:58,225
EVERY AMERICAN NEEDED ACCESS TO

1304
00:52:58,225 --> 00:52:59,326
ACCURATE TESTING, THAT TESTING

1305
00:52:59,326 --> 00:53:01,062
DID NOT YET EXIST.

1306
00:53:01,062 --> 00:53:03,731
RADx FELT THIS TIME PRESSURE

1307
00:53:03,731 --> 00:53:04,131
ACUTELY.

1308
00:53:04,131 --> 00:53:06,500
WE VERY WELL UNDERSTOOD THAT

1309
00:53:06,500 --> 00:53:07,935
UNDER TYPICAL CIRCUMSTANCES

1310
00:53:07,935 --> 00:53:09,670
DIAGNOSTIC TESTS REQUIRE 3 TO 5

1311
00:53:09,670 --> 00:53:12,239
YEARS OF R&D, PLUS
REGULATORY

1312
00:53:12,239 --> 00:53:13,507
STUDIES TO REACH MARKET.

1313
00:53:13,507 --> 00:53:15,142
WE WERE BEING ASKED TO ACHIEVE

1314
00:53:15,142 --> 00:53:17,778
THIS FEAT IN A MATTER OF MONTHS.

1315
00:53:17,778 --> 00:53:20,314
QUITE FRANKLY FAILURE WAS NOT AN

1316
00:53:20,314 --> 00:53:20,581
OPTION.

1317
00:53:20,581 --> 00:53:22,216
AS WE AT THIS SLIDE ON THE LEFT

1318
00:53:22,216 --> 00:53:24,518
WE CAN SEE THE FUNNEL STRUCTURE

1319
00:53:24,518 --> 00:53:26,387
THAT HAS BECOME SYNONYMOUS WITH

1320
00:53:26,387 --> 00:53:28,089
THE RADx BRAND.

1321
00:53:28,089 --> 00:53:29,957
THE FUNNEL DESIGN INTEGRATED

1322
00:53:29,957 --> 00:53:32,226
BEST PRACTICES FROM INDUSTRY,

1323
00:53:32,226 --> 00:53:33,627
ACADEMIA, GOVERNMENT, WITH THE

1324
00:53:33,627 --> 00:53:35,996
GOAL OF DE-RISKING EACH AND

1325
00:53:35,996 --> 00:53:38,032
EVERY PROJECT AS SOON AS

1326
00:53:38,032 --> 00:53:41,702
POSSIBLE AND ALONG THE WAY.

1327
00:53:41,702 --> 00:53:44,638
FOLLOWING CALL FOR PROPOSAL,

1328
00:53:44,638 --> 00:53:47,708
FIRST CUT MADE BASED ON

1329
00:53:47,708 --> 00:53:48,209
APPLICATIONS.

1330
00:53:48,209 --> 00:53:51,178
ADVANCING IDEAS WERE PAIRED WITH

1331
00:53:51,178 --> 00:53:54,515
TEAMS WHO USED INTERVIEWS TO VET

1332
00:53:54,515 --> 00:53:57,318
THE TECHNOLOGY ITSELF BUT ALSO

1333
00:53:57,318 --> 00:53:58,185
ORGANIZATION, THEIR

1334
00:53:58,185 --> 00:53:59,920
INFRASTRUCTURE, AND THOSE

1335
00:53:59,920 --> 00:54:00,588
CRITICAL ELEMENTS REQUIRED FOR

1336
00:54:00,588 --> 00:54:04,291
THIS PROJECT TO BE A SUCCESS.

1337
00:54:04,291 --> 00:54:05,493
THIS IS WHERE RADx WAS

1338
00:54:05,493 --> 00:54:07,027
COMPARED TO THE TV SHOW, THE

1339
00:54:07,027 --> 00:54:07,828
SHARK TANK.

1340
00:54:07,828 --> 00:54:14,635
YOU CAN SEE OUR SHARK LOGO

1341
00:54:14,635 --> 00:54:15,035
THERE.

1342
00:54:15,035 --> 00:54:15,936
OUR HOLICKIST APPROACH, MANY

1343
00:54:15,936 --> 00:54:19,240
WORK STREAMS HAD TO WORK IN

1344
00:54:19,240 --> 00:54:21,842
PARALLEL, RADx NEEDED TO

1345
00:54:21,842 --> 00:54:24,378
QUICKLY DETERMINE WHAT WERE THE

1346
00:54:24,378 --> 00:54:25,813
LIKELY BARRIERS TO SUCCESS,

1347
00:54:25,813 --> 00:54:28,282
CRITICALLY IF THOSE BARRIERS

1348
00:54:28,282 --> 00:54:29,717
COULD BE OVERCOME.

1349
00:54:29,717 --> 00:54:31,152
AS THE PROJECT MOVED FORWARD.

1350
00:54:31,152 --> 00:54:32,386
ON THE RIGHT-HAND SIDE OF THE

1351
00:54:32,386 --> 00:54:36,524
SLIDE YOU CAN  SEE OUTCOME

1352
00:54:36,524 --> 00:54:38,025
MEASURES WHICH GREATLY EXCEED

1353
00:54:38,025 --> 00:54:40,928
OUR OWN EXPECTATIONS.

1354
00:54:40,928 --> 00:54:42,563
WE BROUGHT OVER 8 BILLION

1355
00:54:42,563 --> 00:54:43,197
POINT-OF-CARE AND OVER THE

1356
00:54:43,197 --> 00:54:45,533
COUNTER TESTS TO THE PUBLIC,

1357
00:54:45,533 --> 00:54:47,468
SHIFTING THE TESTING PARADIGM

1358
00:54:47,468 --> 00:54:49,270
AWAY FROM CENTRAL LABS.

1359
00:54:49,270 --> 00:54:51,238
IT'S WORTH REFLECTING WHILE WE

1360
00:54:51,238 --> 00:54:53,107
HAD FAITH IN THE FUNNEL

1361
00:54:53,107 --> 00:54:56,210
APPROACH, SUCCESS WAS NOT

1362
00:54:56,210 --> 00:54:56,677
PRE-DETERMINED.

1363
00:54:56,677 --> 00:54:59,246
DRAMATICALLY REDUCING TIME TO

1364
00:54:59,246 --> 00:55:01,248
MARKET FOR THESE TECHNOLOGIES

1365
00:55:01,248 --> 00:55:02,416
HAD NEVER BEEN ACHIEVED.

1366
00:55:02,416 --> 00:55:05,052
NOW ONE OF THE ADVANTAGES WE HAD

1367
00:55:05,052 --> 00:55:07,488
AND WHY NIBIB WAS POISED TO

1368
00:55:07,488 --> 00:55:09,190
ATTEMPT SUCH A FEAT WAS

1369
00:55:09,190 --> 00:55:12,459
EXISTENCE AND GROWTH OF THE

1370
00:55:12,459 --> 00:55:17,631
POINT-OF-CARE TECHNOLOGY

1371
00:55:17,631 --> 00:55:20,267
RESEARCH NETWORK, POCTRN.

1372
00:55:20,267 --> 00:55:23,237
POCTRN WAS A U54 PROGRAM LUNCHED

1373
00:55:23,237 --> 00:55:25,105
IN 2007, AND THEY HAVE SINCE

1374
00:55:25,105 --> 00:55:27,141
GAINED OVER A DECADE OF

1375
00:55:27,141 --> 00:55:28,976
EXPERIENCE IN THE TRANSLATION

1376
00:55:28,976 --> 00:55:30,644
AND DIAGNOSTIC DEVICES.

1377
00:55:30,644 --> 00:55:32,980
WITH MULTIPLE CENTERS COVERING

1378
00:55:32,980 --> 00:55:34,281
COMPLEMENTARY FOCUS AREAS,

1379
00:55:34,281 --> 00:55:36,684
POCTRN HAS BUILT KEY

1380
00:55:36,684 --> 00:55:37,751
CAPABILITIES AND EXPERTISE THAT

1381
00:55:37,751 --> 00:55:39,753
WOULD PROVE INVALUABLE TO A

1382
00:55:39,753 --> 00:55:40,788
RAPID RESPONSE EFFORT.

1383
00:55:40,788 --> 00:55:44,892
UNDER THE GUIDANCE OF THE POCTRN

1384
00:55:44,892 --> 00:55:46,493
COORDINATING CENTER THE, THE

1385
00:55:46,493 --> 00:55:47,828
WISDOM OF COLLEAGUES HELPED

1386
00:55:47,828 --> 00:55:50,364
SHAPE THE DESIGN OF THE

1387
00:55:50,364 --> 00:55:53,100
INNOVATION FUNNEL MODEL, WITH

1388
00:55:53,100 --> 00:55:54,635
KEEN EYE TO MAXIMIZING

1389
00:55:54,635 --> 00:55:54,969
ACCELERATION.

1390
00:55:54,969 --> 00:55:59,206
GIVEN THE CONSTRAINTS WE WERE

1391
00:55:59,206 --> 00:56:00,574
UNDER, PARDON ME, GIVEN

1392
00:56:00,574 --> 00:56:02,109
CONSTRAINTS THE CREATION OF THE

1393
00:56:02,109 --> 00:56:04,445
RADx PROCESS WAS NOT INVENTION

1394
00:56:04,445 --> 00:56:06,814
OF SOMETHING COMPLETELY NEW OR

1395
00:56:06,814 --> 00:56:07,281
UNIQUE.

1396
00:56:07,281 --> 00:56:09,416
RATHER, IT WAS LARGELY AN EFFORT

1397
00:56:09,416 --> 00:56:12,119
TO INTEGRATE BEST PRACTICES

1398
00:56:12,119 --> 00:56:12,853
WHILE LEVERAGING AVAILABLE

1399
00:56:12,853 --> 00:56:16,490
RESOURCES AND OF COURSE THE

1400
00:56:16,490 --> 00:56:17,825
PROFESSIONAL NETWORKS INHERENT

1401
00:56:17,825 --> 00:56:18,525
THEREIN.

1402
00:56:18,525 --> 00:56:19,927
POCTRN ALLOWED US TO EXERCISE

1403
00:56:19,927 --> 00:56:22,096
STRENGTH WE HAD BEEN BUILDING

1404
00:56:22,096 --> 00:56:25,499
AND TO PIVOT AND AMPLIFY IN A

1405
00:56:25,499 --> 00:56:26,734
TIME OF URGENCY AND GREAT

1406
00:56:26,734 --> 00:56:27,301
NATIONAL NEED.

1407
00:56:27,301 --> 00:56:29,570
AS WE'VE HAD THE OPPORTUNITY TO

1408
00:56:29,570 --> 00:56:30,537
ANALYZE THE OUTCOMES, AND

1409
00:56:30,537 --> 00:56:32,740
REFLECT ON THE STRUCTURES AND

1410
00:56:32,740 --> 00:56:33,474
WORKFLOWS IMPLEMENTED, WE'VE

1411
00:56:33,474 --> 00:56:34,909
COME TO BETTER UNDERSTAND THE

1412
00:56:34,909 --> 00:56:37,645
KEY FEATURES OF THE RADx

1413
00:56:37,645 --> 00:56:39,980
MODEL, THAT CONTRIBUTE TO

1414
00:56:39,980 --> 00:56:43,484
ACCELERATED PACE AND ACHIEVEMENT

1415
00:56:43,484 --> 00:56:44,118
OF PROJECTS.

1416
00:56:44,118 --> 00:56:46,420
HERE WE LIST A NUMBER OF PROGRAM

1417
00:56:46,420 --> 00:56:49,490
FEATURES WE THINK ARE CRITICAL.

1418
00:56:49,490 --> 00:56:51,125
THE IDEA MAY SEEM FAMILIAR, AND

1419
00:56:51,125 --> 00:56:54,528
ARE PARTS OF OUR TRANSLATIONAL

1420
00:56:54,528 --> 00:56:55,296
PROGRAMS, BUT THEIR

1421
00:56:55,296 --> 00:56:57,631
IMPLEMENTATION AS RADx IS HOW

1422
00:56:57,631 --> 00:56:59,600
WE CUSTOMIZED SUPPORT AND

1423
00:56:59,600 --> 00:57:00,434
ACCELERATED MULTIPLE PARALLEL

1424
00:57:00,434 --> 00:57:02,436
PATHWAYS TO REACH A COMMON

1425
00:57:02,436 --> 00:57:02,870
ENDPOINT.

1426
00:57:02,870 --> 00:57:04,138
DUE TO THE TIME LIMITS TODAY I'M

1427
00:57:04,138 --> 00:57:05,973
NOT GOING TO DELVE DEEPLY INTO

1428
00:57:05,973 --> 00:57:08,676
EACH BUT LET ME BRIEFLY TOUCH ON

1429
00:57:08,676 --> 00:57:09,743
SOME OF THEM.

1430
00:57:09,743 --> 00:57:11,946
EACH INNOVATOR WAS PAIRED WITH A

1431
00:57:11,946 --> 00:57:15,482
RADx TEAM THAT CONSISTED OF

1432
00:57:15,482 --> 00:57:18,052
PORTFOLIO EXECUTIVE, TEAM LEAD,

1433
00:57:18,052 --> 00:57:18,652
PROJECT FACILITATOR.

1434
00:57:18,652 --> 00:57:21,822
THE PORTFOLIO EXECUTIVE AND TEAM

1435
00:57:21,822 --> 00:57:23,757
LEAD HAVE DECADES OF INDUSTRIAL

1436
00:57:23,757 --> 00:57:25,926
EXPERIENCE BRINGING DIAGNOSTIC

1437
00:57:25,926 --> 00:57:26,894
PRODUCTS TO MARKET.

1438
00:57:26,894 --> 00:57:29,563
THEIR EXPERIENCE AND CLOSE

1439
00:57:29,563 --> 00:57:30,631
WORKING RELATIONSHIP FUELED

1440
00:57:30,631 --> 00:57:32,499
INTENSIVE RISK ASSESSMENT

1441
00:57:32,499 --> 00:57:34,802
THROUGHOUT THE PROCESS.

1442
00:57:34,802 --> 00:57:36,236
CONCURRENTLY OFFERING THESE

1443
00:57:36,236 --> 00:57:36,971
ENTREPRENEURIAL TEAMS MENTORSHIP

1444
00:57:36,971 --> 00:57:39,506
AND ADVICE THAT THEY MAY NOT

1445
00:57:39,506 --> 00:57:41,909
HAVE HAD ACCESS TO.

1446
00:57:41,909 --> 00:57:44,311
RADx THEN ESTABLISHED A

1447
00:57:44,311 --> 00:57:45,512
LIBRARY OF SUBJECT MATTER

1448
00:57:45,512 --> 00:57:47,982
EXPERTS FROM ASSAY DESIGN TO

1449
00:57:47,982 --> 00:57:49,783
SUPPLY CHAIN MANAGEMENT TO

1450
00:57:49,783 --> 00:57:50,718
COMMERCIALIZATION TO REGULATORY

1451
00:57:50,718 --> 00:57:52,987
AFFAIRS AND MUCH, MUCH MORE.

1452
00:57:52,987 --> 00:57:58,659
THESE EXPERTS COULD BE TAPPED AS

1453
00:57:58,659 --> 00:58:06,467
NEEDED, USE TO DE-RISK PROJECTS,

1454
00:58:06,467 --> 00:58:11,505
INDEPENDENT ASSESSMENT OF

1455
00:58:11,505 --> 00:58:13,807
TECHNOLOGY READINESS INNOVATORS

1456
00:58:13,807 --> 00:58:16,744
HAD CRITICAL FEELBACK AND

1457
00:58:16,744 --> 00:58:19,613
UTILIZED MILESTONE CONTRACTS TO

1458
00:58:19,613 --> 00:58:21,648
DEFINE, ESTABLISH INSTEAD, YES,

1459
00:58:21,648 --> 00:58:22,950
AGGRESSIVE SCHEDULE, BUT

1460
00:58:22,950 --> 00:58:24,518
PROVIDED ALL PARTIES CLEAR

1461
00:58:24,518 --> 00:58:26,720
CRITERIA FOR SUCCESS AT EACH

1462
00:58:26,720 --> 00:58:26,987
STEP.

1463
00:58:26,987 --> 00:58:29,189
AND WHERE WE'RE WERE GOING FROM

1464
00:58:29,189 --> 00:58:29,490
THERE.

1465
00:58:29,490 --> 00:58:30,791
CONTRACTING MAY BE THE ITEM ON

1466
00:58:30,791 --> 00:58:32,526
THE LIST YOU MAY FIND MOST

1467
00:58:32,526 --> 00:58:35,596
SURPRISING BUT WE CAN ASSURE YOU

1468
00:58:35,596 --> 00:58:39,700
IT'S CRITICAL FACTORS TO OUR

1469
00:58:39,700 --> 00:58:41,502
SUCCESS.

1470
00:58:41,502 --> 00:58:45,506
RADx DESIGNED FLEXIBLE

1471
00:58:45,506 --> 00:58:47,307
MECHANISMS APPLIED ACROSS

1472
00:58:47,307 --> 00:58:49,710
TECHNOLOGIES, LIKE RESPONDING TO

1473
00:58:49,710 --> 00:58:50,210
VIRAL PANDEMIC.

1474
00:58:50,210 --> 00:58:52,146
I'D LIKE TO PAUSE AND

1475
00:58:52,146 --> 00:58:53,580
ACKNOWLEDGE THE UNWAVERING

1476
00:58:53,580 --> 00:58:55,716
SUPPORT FROM OUR COLLEAGUES AT

1477
00:58:55,716 --> 00:58:58,185
THE NHLBI OFFICE OF ACQUISITION

1478
00:58:58,185 --> 00:59:00,487
WHO HAVE BRILLIANTLY AND

1479
00:59:00,487 --> 00:59:01,355
TIRELESSLY WORKED TO ESTABLISH

1480
00:59:01,355 --> 00:59:02,423
CORE STRUCTURES.

1481
00:59:02,423 --> 00:59:03,524
I WOULD LIKE TO ACKNOWLEDGE ALL

1482
00:59:03,524 --> 00:59:05,859
OF THE PEOPLE WHO CONTRIBUTED TO

1483
00:59:05,859 --> 00:59:08,228
RADx, FAR TOO MANY TO LIST BY

1484
00:59:08,228 --> 00:59:08,429
NAME.

1485
00:59:08,429 --> 00:59:11,265
I WON'T TRY TO DO THAT HERE.

1486
00:59:11,265 --> 00:59:12,800
I MAY BE THE FIRST TELLING YOU

1487
00:59:12,800 --> 00:59:14,435
THE STORY BUT KNOW I PLAYED A

1488
00:59:14,435 --> 00:59:15,202
SMALL PART.

1489
00:59:15,202 --> 00:59:18,005
THIS IS A STORY OF HUNDREDS

1490
00:59:18,005 --> 00:59:22,976
ROLLING UP  SLEEVES AND A BIG

1491
00:59:22,976 --> 00:59:26,613
THANK YOU IS OWED TO ALL OF

1492
00:59:26,613 --> 00:59:26,880
THEM.

1493
00:59:26,880 --> 00:59:27,981
SO THANK YOU.

1494
00:59:27,981 --> 00:59:31,718
BACK TO THE STORY. 

1495
00:59:31,718 --> 00:59:33,220
ALONG WITH THE ACCELERATING

1496
00:59:33,220 --> 00:59:34,888
ATTRIBUTES AND CAPABILITIES OF

1497
00:59:34,888 --> 00:59:37,891
POCTRN CENTER'S NETWORK THE

1498
00:59:37,891 --> 00:59:40,761
PRIMARY CHALLENGE WAS TO CODIFY

1499
00:59:40,761 --> 00:59:41,462
ORGANIZATIONAL AND FUNDING

1500
00:59:41,462 --> 00:59:44,398
STRUCTURES TO SUSTAIN OUR

1501
00:59:44,398 --> 00:59:45,065
ONGOING EFFORTS.

1502
00:59:45,065 --> 00:59:45,799
DEPICTED ON THE RIGHT-HAND SIDE

1503
00:59:45,799 --> 00:59:50,804
OF THE SLIDE YOU CAN SEE THREE

1504
00:59:50,804 --> 00:59:51,939
FOUNDATIONAL CONTRACT VEHICLES,

1505
00:59:51,939 --> 00:59:54,408
WHILE CREATING SCALABILITY AND

1506
00:59:54,408 --> 00:59:56,210
HEAD ROOM FOR FUTURE ACTIVITIES

1507
00:59:56,210 --> 00:59:57,945
INCLUDING HIV PROGRAM WE'LL TALK

1508
00:59:57,945 --> 01:00:00,481
ABOUT TODAY.

1509
01:00:00,481 --> 01:00:02,182
THREE PRIMARY CONTRACTS ARE

1510
01:00:02,182 --> 01:00:03,717
FIRST COORDINATION CENTER

1511
01:00:03,717 --> 01:00:06,386
MANAGED BY CIMIT.

1512
01:00:06,386 --> 01:00:07,020
THEIR RESPONSIBILITIES INCLUDE

1513
01:00:07,020 --> 01:00:09,356
ESTABLISHMENT OF STANDARD

1514
01:00:09,356 --> 01:00:10,290
OPERATING PROCEDURES AND

1515
01:00:10,290 --> 01:00:12,259
WORKLOAD, PROPOSAL INTAKE AND

1516
01:00:12,259 --> 01:00:16,296
PROCESSING, PROJECT RISK

1517
01:00:16,296 --> 01:00:17,064
ASSESSMENT, MANAGEMENT AND

1518
01:00:17,064 --> 01:00:19,967
ENTREPRENEURIAL TRAINING OF THE

1519
01:00:19,967 --> 01:00:20,167
TEAM.

1520
01:00:20,167 --> 01:00:20,701
SECOND, COMMERCIALIZATION

1521
01:00:20,701 --> 01:00:23,637
CENTER, THIS WAS LED BY

1522
01:00:23,637 --> 01:00:24,338
VENTUREWELL.

1523
01:00:24,338 --> 01:00:26,140
THEY OVERSAW THE CURATION OF

1524
01:00:26,140 --> 01:00:27,374
NETWORK OF PROFESSIONAL EXPERTS

1525
01:00:27,374 --> 01:00:29,776
AND DEPLOYMENT OF THOSE HUMAN

1526
01:00:29,776 --> 01:00:32,746
RESOURCES ACROSS THE VARIOUS

1527
01:00:32,746 --> 01:00:32,980
PROMISE.

1528
01:00:32,980 --> 01:00:34,648
THIRD, VALIDATION CENTER WHICH

1529
01:00:34,648 --> 01:00:36,917
WAS ANCHORED AT EMORY

1530
01:00:36,917 --> 01:00:37,317
UNIVERSITY.

1531
01:00:37,317 --> 01:00:38,318
THEY PERFORMED TESTING AND

1532
01:00:38,318 --> 01:00:40,821
EVALUATION SERVICES OF THE

1533
01:00:40,821 --> 01:00:41,955
VARIOUS TECHNOLOGIES AND

1534
01:00:41,955 --> 01:00:42,189
DEVICES.

1535
01:00:42,189 --> 01:00:43,857
AS I LIKE TO SAY, THEY JUST

1536
01:00:43,857 --> 01:00:47,461
TESTED THE TEST AND GAVE US THE

1537
01:00:47,461 --> 01:00:47,661
FACTS.

1538
01:00:47,661 --> 01:00:49,630
TOGETHER THESE THREE CENTERS

1539
01:00:49,630 --> 01:00:50,831
UNDER THE CONTRACTING STRUCTURES

1540
01:00:50,831 --> 01:00:53,433
SEEN HERE FORM A STABLE PLATFORM

1541
01:00:53,433 --> 01:00:55,135
THAT CAN PROVIDE TECHNOLOGY

1542
01:00:55,135 --> 01:01:00,607
ACCELERATION ACROSS THE

1543
01:01:00,607 --> 01:01:03,310
HEALTHCARE SPECTRUM.

1544
01:01:03,310 --> 01:01:05,345
WITH THAT VERY ABBREVIATION THE

1545
01:01:05,345 --> 01:01:08,849
INTRODUCTION LET ME TURN TO THE

1546
01:01:08,849 --> 01:01:12,319
GROWING HEALTH INITIATIVES TO

1547
01:01:12,319 --> 01:01:13,554
UTILIZE RESOURCES.

1548
01:01:13,554 --> 01:01:17,958
THERE'S A WIDE ARRAY OF

1549
01:01:17,958 --> 01:01:20,894
DECISIONS, TESTING, MATERNAL

1550
01:01:20,894 --> 01:01:22,729
HEALTH, FETAL HEALTH, AND MORE.

1551
01:01:22,729 --> 01:01:25,832
EACH OF THESE PROGRAMS CAN BE

1552
01:01:25,832 --> 01:01:27,501
TAILORED TO REACH THE

1553
01:01:27,501 --> 01:01:28,202
OPPORTUNITY AND SPONSOR FUNDS

1554
01:01:28,202 --> 01:01:31,038
THAT ARE AVAILABLE TO RUN THE

1555
01:01:31,038 --> 01:01:31,271
PROGRAM.

1556
01:01:31,271 --> 01:01:32,773
AGAIN, WE DON'T HAVE TIME TO

1557
01:01:32,773 --> 01:01:34,641
TALK ABOUT THOSE ITEMS TODAY BUT

1558
01:01:34,641 --> 01:01:41,181
I'M  HAPPY TO HAVE THOSE

1559
01:01:41,181 --> 01:01:41,882
DISCUSSIONS LATER.

1560
01:01:41,882 --> 01:01:45,018
ONE OF OUR STRONGER PARTNERS HAS

1561
01:01:45,018 --> 01:01:46,553
BEEN OFFICE OF AIDS RESEARCH.

1562
01:01:46,553 --> 01:01:49,990
LET'S FINISH WITH A DISCUSSION

1563
01:01:49,990 --> 01:01:54,728
OF ONGOING VIRAL LOAD PROGRAM.

1564
01:01:54,728 --> 01:01:57,998
IN CLOSE COLLABORATION WITH OAR

1565
01:01:57,998 --> 01:02:01,034
AND NIBIB, NIBIB IS ENGAGED IN

1566
01:02:01,034 --> 01:02:02,603
ADVANCE PLATFORMS FOR HIV VIRAL

1567
01:02:02,603 --> 01:02:04,938
LOAD AT POINT OF CARE.

1568
01:02:04,938 --> 01:02:08,375
THIS 15-MONTH PROGRAM SEEKS TO

1569
01:02:08,375 --> 01:02:09,810
ACCELERATE TECHNOLOGY TO DESIGN,

1570
01:02:09,810 --> 01:02:12,312
HAVING DE-RISKED MAJOR AREAS OF

1571
01:02:12,312 --> 01:02:14,648
EACH PROJECT, AND REACHING POINT

1572
01:02:14,648 --> 01:02:16,683
WHERE CLINICAL TRIALS IS THE

1573
01:02:16,683 --> 01:02:17,584
LOGICAL NEXT STEP.

1574
01:02:17,584 --> 01:02:22,189
WE'LL TALK A BIT MORE ABOUT THE

1575
01:02:22,189 --> 01:02:23,056
TECHNICAL PRODUCTS PROFILE, TPP,

1576
01:02:23,056 --> 01:02:26,126
IN THE COMING SLIDES BUT FIRST

1577
01:02:26,126 --> 01:02:29,429
LET'S VISIT THE OTHER AREAS OF

1578
01:02:29,429 --> 01:02:30,764
SUPPORT RADx IS OFFERING,

1579
01:02:30,764 --> 01:02:32,099
LEVERAGING STRENGTH OF POCTRN

1580
01:02:32,099 --> 01:02:35,569
CENTERS TO OFFER THIRD PARTY

1581
01:02:35,569 --> 01:02:36,770
TESTING FOR USABILITY,

1582
01:02:36,770 --> 01:02:38,939
ANALYTICAL CAPABILITIES, EVEN A

1583
01:02:38,939 --> 01:02:41,708
PRE-CLINICAL EVALUATION WITH

1584
01:02:41,708 --> 01:02:43,110
REAL WORLD SAMPLES.

1585
01:02:43,110 --> 01:02:44,311
WRAP-AROUND SUPPORT WILL INCLUDE

1586
01:02:44,311 --> 01:02:46,947
INFORMATION ABOUT BLOOD

1587
01:02:46,947 --> 01:02:49,483
COLLECTION DEVICES, A

1588
01:02:49,483 --> 01:02:51,318
MARKETPLACE LANDSCAPE ANALYSIS.

1589
01:02:51,318 --> 01:02:53,086
SO USING THE RADx MODEL THAT I

1590
01:02:53,086 --> 01:02:55,889
DESCRIBED A FEW SLIDES AGO, WE

1591
01:02:55,889 --> 01:03:01,361
PUT OUT A CALL AND CIMIT

1592
01:03:01,361 --> 01:03:03,563
RECEIVED 27 APPLICATIONS.

1593
01:03:03,563 --> 01:03:08,268
19 MET MINIMUM REQUIREMENTS. 

1594
01:03:08,268 --> 01:03:13,307
EXPERT PAN PARED DOWN FOR A DEEP

1595
01:03:13,307 --> 01:03:15,142
DIVE AND VETTING.

1596
01:03:15,142 --> 01:03:19,212
THE TEAMS HAVE INTERACTIONS WITH

1597
01:03:19,212 --> 01:03:20,881
INNOVATORS OVER SEVERAL WEEKS

1598
01:03:20,881 --> 01:03:23,617
EVALUATING STRENGTH, WEAKNESSES,

1599
01:03:23,617 --> 01:03:25,485
MOST IMPORTANTLY THE RISKS

1600
01:03:25,485 --> 01:03:25,686
AHEAD.

1601
01:03:25,686 --> 01:03:26,887
RADx INNOVATOR TEAMS PUT

1602
01:03:26,887 --> 01:03:30,957
TOGETHER A PITCH DECK THAT LAID

1603
01:03:30,957 --> 01:03:32,793
OUT TECHNICAL INFORMATION, WHAT

1604
01:03:32,793 --> 01:03:34,628
THEY FORESAW AS THE SCHEDULE AND

1605
01:03:34,628 --> 01:03:36,496
MILESTONES REQUIRED TO BE

1606
01:03:36,496 --> 01:03:39,132
SUCCESSFUL IN THE VIRAL LOAD

1607
01:03:39,132 --> 01:03:39,900
PROGRAM.

1608
01:03:39,900 --> 01:03:41,101
THOSE PRESENTATIONS WERE

1609
01:03:41,101 --> 01:03:42,402
EVALUATED BY RADx FUNDING

1610
01:03:42,402 --> 01:03:47,507
PANELS AND THREE TEAMS WERE

1611
01:03:47,507 --> 01:03:48,475
SELECTED TO ADVANCE.

1612
01:03:48,475 --> 01:03:51,545
BEFORE WE LOOK AT THOSE THREE

1613
01:03:51,545 --> 01:03:52,479
TEAMS AND TECHNOLOGIES, LET'S

1614
01:03:52,479 --> 01:03:53,747
DISCUSS HOW WE GOT HERE ON THE

1615
01:03:53,747 --> 01:03:55,782
OTHER SIDE OF THE PROGRAM, THE

1616
01:03:55,782 --> 01:03:58,452
HIV SIDE OF THE PROGRAM.

1617
01:03:58,452 --> 01:04:00,887
FOR THE PAST 3 YEARS I'VE BEEN

1618
01:04:00,887 --> 01:04:03,357
PART OF OAR'S HIV DIAGNOSTICS

1619
01:04:03,357 --> 01:04:04,524
WORKING GROUP.

1620
01:04:04,524 --> 01:04:06,860
THIS DYNAMIC GROUP HAS DONE MUCH

1621
01:04:06,860 --> 01:04:08,895
WORK BUT IN 2023 THE WORKING

1622
01:04:08,895 --> 01:04:10,630
GROUP CONTRIBUTED TO THE

1623
01:04:10,630 --> 01:04:12,399
COMMUNITY VOICES MEETING.

1624
01:04:12,399 --> 01:04:14,134
AT THAT MEETING COMMUNITIES

1625
01:04:14,134 --> 01:04:16,002
SHARED PREFERENCES FOR TESTING

1626
01:04:16,002 --> 01:04:16,603
AND CARE.

1627
01:04:16,603 --> 01:04:18,004
WE HEARD FROM PRACTITIONERS

1628
01:04:18,004 --> 01:04:19,873
ABOUT USE AND VARIOUS SETTINGS,

1629
01:04:19,873 --> 01:04:23,210
AND THE EXPERTS FROM THE POCTRN

1630
01:04:23,210 --> 01:04:24,378
COMMUNITY DESCRIBED WHAT

1631
01:04:24,378 --> 01:04:25,345
TECHNOLOGIES WERE AVAILABLE OR

1632
01:04:25,345 --> 01:04:29,416
WERE UNDER DEVELOPMENT IN THE

1633
01:04:29,416 --> 01:04:30,183
HIV SPACE.

1634
01:04:30,183 --> 01:04:33,320
DURING THIS TIME FRAME OAR ALSO

1635
01:04:33,320 --> 01:04:36,757
CEDED THE VIRAL LOAD DEVELOPMENT

1636
01:04:36,757 --> 01:04:39,393
COMMUNITY WITH -- SEEDED WITH

1637
01:04:39,393 --> 01:04:41,228
FUNDS TO NORTHWESTERN AND JOHNS

1638
01:04:41,228 --> 01:04:43,463
HOPKINS POCTRN CENTERS IN A

1639
01:04:43,463 --> 01:04:47,501
PROGRAM WE CALLED HIV VIRAL LOAD

1640
01:04:47,501 --> 01:04:48,435
MINI FUNNEL.

1641
01:04:48,435 --> 01:04:49,603
THIS PROGRAM USED RADx

1642
01:04:49,603 --> 01:04:53,440
INFRASTRUCTURE BUT AT A MODEST

1643
01:04:53,440 --> 01:04:57,344
INVESTMENT LEVEL, WE FUNDED SIX

1644
01:04:57,344 --> 01:04:59,179
TEAMS WITH NOT A MARKET READY

1645
01:04:59,179 --> 01:05:03,183
PROJECT, A BRIDGE TOO FAR, BUT

1646
01:05:03,183 --> 01:05:06,186
INSTEAD TO ACT AS ACCELERATING

1647
01:05:06,186 --> 01:05:16,663
FORCE THAT MOVED NASCENT AND

1648
01:05:19,666 --> 01:05:20,467
PROTOTYPES, THE POSSIBILITY WAS

1649
01:05:20,467 --> 01:05:22,002
THERE BUT WE HAD TO MOVE THE

1650
01:05:22,002 --> 01:05:23,503
TECHNOLOGY ALONG OF THE

1651
01:05:23,503 --> 01:05:25,405
CONTRIBUTING TO DUE DILIGENCE,

1652
01:05:25,405 --> 01:05:26,840
POCTRN CENTERS AT NORTHWESTERN

1653
01:05:26,840 --> 01:05:28,875
AND JOHNS HOPKINS REMAINED

1654
01:05:28,875 --> 01:05:30,310
ACTIVE IN THE HIV SPACE AND

1655
01:05:30,310 --> 01:05:31,311
THEIR KNOWLEDGE BASE CONTINUES

1656
01:05:31,311 --> 01:05:33,914
TO INFORM US ABOUT VIRAL LOAD

1657
01:05:33,914 --> 01:05:35,115
TESTING FOR BOTH DOMESTIC AND

1658
01:05:35,115 --> 01:05:36,082
GLOBAL MARKETS.

1659
01:05:36,082 --> 01:05:39,085
ON THE RIGHT-HAND SIDE OF THE

1660
01:05:39,085 --> 01:05:43,023
SLIDE YOU SEE A FIGURE FROM A

1661
01:05:43,023 --> 01:05:45,125
PENDING MANU SCRIPT AUTHORED BY

1662
01:05:45,125 --> 01:05:46,626
CLINICIANS AT JOHNS HOPKINS,

1663
01:05:46,626 --> 01:05:47,928
NORTHWESTERN, UNIVERSITY OF

1664
01:05:47,928 --> 01:05:48,228
WASHINGTON.

1665
01:05:48,228 --> 01:05:51,431
WHAT IS EMPHASIZED HERE IS THAT

1666
01:05:51,431 --> 01:05:52,966
THERE ARE NO FDA-APPROVED VIRAL

1667
01:05:52,966 --> 01:05:56,303
LOAD TESTS FOR THE POINT-OF-CARE

1668
01:05:56,303 --> 01:05:57,704
MARKET AVAILABLE TODAY.

1669
01:05:57,704 --> 01:06:00,006
THERE ARE A HANDFUL IN THE

1670
01:06:00,006 --> 01:06:01,174
GLOBAL MARKET BUT DOMESTIC

1671
01:06:01,174 --> 01:06:07,547
MARKET DOES NOT YET EXIST.

1672
01:06:07,547 --> 01:06:09,216
ALSO IN THAT PENDING MANUSCRIPT

1673
01:06:09,216 --> 01:06:11,718
THE AUTHORS DRILL DOWN ON USE

1674
01:06:11,718 --> 01:06:14,120
CASE SCENARIOS AND DISCUSS IN

1675
01:06:14,120 --> 01:06:15,522
DETAIL WHAT TESTING ATTRIBUTES

1676
01:06:15,522 --> 01:06:16,990
MAY BE MOST CRITICAL AND

1677
01:06:16,990 --> 01:06:17,390
DESIRABLE.

1678
01:06:17,390 --> 01:06:19,593
AS YOU CAN SEE HERE IN THEIR

1679
01:06:19,593 --> 01:06:21,294
ANALYSIS, THE WHY OR WHEN YOU'RE

1680
01:06:21,294 --> 01:06:23,463
TESTING MAY CHANGE HOW ONE

1681
01:06:23,463 --> 01:06:26,766
CHOOSES TO TEST, AND WITH WHAT

1682
01:06:26,766 --> 01:06:29,069
TYPE OF TEST.

1683
01:06:29,069 --> 01:06:30,470
AMONGST AUTHORS ARE FACULTY AT

1684
01:06:30,470 --> 01:06:32,873
NORTHWESTERN, KELLOGG SCHOOL OF

1685
01:06:32,873 --> 01:06:33,173
MANAGEMENT.

1686
01:06:33,173 --> 01:06:34,841
THEY ARE INGAUGED IN

1687
01:06:34,841 --> 01:06:37,577
UNDERSTANDING THE MARKET FOR FOR

1688
01:06:37,577 --> 01:06:41,181
HIV TESTING HELPING US ROUND OUT

1689
01:06:41,181 --> 01:06:43,483
DUE DILIGENCE.

1690
01:06:43,483 --> 01:06:45,352
THAT KELLOGG TEAM HAS EXPLORED

1691
01:06:45,352 --> 01:06:47,654
THE GLOBAL MARKETS WITH A

1692
01:06:47,654 --> 01:06:50,223
CONJOINED ANALYSIS THAT WEIGHS

1693
01:06:50,223 --> 01:06:51,424
COMBINATIONS OF TEST

1694
01:06:51,424 --> 01:06:53,426
CHARACTERISTICS TO TEASE OUT THE

1695
01:06:53,426 --> 01:06:54,594
MOST INFLUENTIAL CHARACTERISTICS

1696
01:06:54,594 --> 01:06:56,696
FOR HIV VIRAL LOAD TEST

1697
01:06:56,696 --> 01:06:57,197
SELECTION.

1698
01:06:57,197 --> 01:07:05,939
FOR THIS ANALYSIS THEY USE 14

1699
01:07:05,939 --> 01:07:06,306
LEVELS.

1700
01:07:06,306 --> 01:07:07,941
I LOVE TO PORE THROUGH THE DATA,

1701
01:07:07,941 --> 01:07:10,644
SO INTERESTING, EVEN BETTER YET

1702
01:07:10,644 --> 01:07:14,281
HAVE TARA PREVENT  -- PRESENT BT

1703
01:07:14,281 --> 01:07:18,985
LET'S LOOK AT THE BIG PICTURE. 

1704
01:07:18,985 --> 01:07:20,654
SENSITIVITY IS THE ATTRIBUTE,

1705
01:07:20,654 --> 01:07:28,862
WITH PRICE AND TIME  HAVING

1706
01:07:28,862 --> 01:07:29,195
SIGNIFICANCE.

1707
01:07:29,195 --> 01:07:30,263
THE KELLOGG TEAM IS AGAIN

1708
01:07:30,263 --> 01:07:32,299
PARTNERING WITH JOHNS HOPKINS TO

1709
01:07:32,299 --> 01:07:35,902
MAKE THIS INFORMATION KNOWN IN A

1710
01:07:35,902 --> 01:07:36,469
MANUSCRIPT IN PREPARATION,

1711
01:07:36,469 --> 01:07:37,604
SHOULD BE ABLE SOON.

1712
01:07:37,604 --> 01:07:40,907
WITHIN THE  RADx VIRAL LOAD

1713
01:07:40,907 --> 01:07:42,709
PROGRAM THAT TEAM IS NOW WORKING

1714
01:07:42,709 --> 01:07:45,312
ON A CONJOINED ANALYSIS FOR THE

1715
01:07:45,312 --> 01:07:49,916
U.S. DOMESTIC MARKET AND WE

1716
01:07:49,916 --> 01:07:51,051
EAGERLY AWAIT THOSE RESULTS.

1717
01:07:51,051 --> 01:07:53,386
LET'S MOVE ON TO THE TARGET

1718
01:07:53,386 --> 01:07:57,023
PRODUCT PROFILE OF THE TPP.

1719
01:07:57,023 --> 01:07:58,792
INTO THIS LANDSCAPE OAR, NIAID,

1720
01:07:58,792 --> 01:08:01,061
AND NIBIB OPENED THE FULL VIRAL

1721
01:08:01,061 --> 01:08:03,463
LOAD MONITORING FUNNEL.

1722
01:08:03,463 --> 01:08:05,765
THE GOAL IS ACCELERATING

1723
01:08:05,765 --> 01:08:10,470
TECHNOLOGY FOR THE POINT-OF-CARE

1724
01:08:10,470 --> 01:08:10,971
DOMESTIC MARKET.

1725
01:08:10,971 --> 01:08:15,742
WE HAD TO DEFINE TPP, STARTED

1726
01:08:15,742 --> 01:08:16,676
WITH WHAT WAS AVAILABLE, ON

1727
01:08:16,676 --> 01:08:18,745
VIRAL LOAD MORE THANKING TOKER.

1728
01:08:18,745 --> 01:08:20,947
WE LAYERED IN DESIRE TO MOVE

1729
01:08:20,947 --> 01:08:22,082
TESTING CLOSER TO PARTICIPANTS

1730
01:08:22,082 --> 01:08:25,251
AS ASKED, IN THE COMMUNITY

1731
01:08:25,251 --> 01:08:27,020
VOICES MEETING.

1732
01:08:27,020 --> 01:08:28,822
WE WANTED THOSE TESTS TO BE

1733
01:08:28,822 --> 01:08:31,224
SUITABLE FOR POINT OF CARE

1734
01:08:31,224 --> 01:08:33,026
MARKET, IDEALLY THE CLIA

1735
01:08:33,026 --> 01:08:33,693
SETTING.

1736
01:08:33,693 --> 01:08:37,030
THIS MEANT WHOLE BLOOD, MINIMUM

1737
01:08:37,030 --> 01:08:39,032
SAMPLE HANDING, TOTAL TIME UNDER

1738
01:08:39,032 --> 01:08:39,599
AN HOUR.

1739
01:08:39,599 --> 01:08:42,235
WE LIKE THE ANSWER IN 30

1740
01:08:42,235 --> 01:08:44,738
MINUTES, FOR QUANTITATIVE AND

1741
01:08:44,738 --> 01:08:46,139
VERY SENSITIVE AND WE'RE

1742
01:08:46,139 --> 01:08:51,177
SPEAKING LOWER LIMITS OF

1743
01:08:51,177 --> 01:08:52,345
QUANTITATION OF 200 COPIES.

1744
01:08:52,345 --> 01:08:54,581
THIS IS A SIGNIFICANT ASK OF

1745
01:08:54,581 --> 01:08:55,782
THESE COMPANIES.

1746
01:08:55,782 --> 01:08:57,417
WE ABSOLUTELY UNDERSTAND THAT.

1747
01:08:57,417 --> 01:09:00,587
BUT VARIOUS ASPECTS OF THE

1748
01:09:00,587 --> 01:09:01,821
TECHNOLOGICAL CHALLENGE HAVE

1749
01:09:01,821 --> 01:09:05,258
BEEN SOLVED FOR OTHER TARGETS

1750
01:09:05,258 --> 01:09:07,494
AND OTHER COMPLEX MATRICES IN

1751
01:09:07,494 --> 01:09:08,428
THE GREATER TECHNOLOGY

1752
01:09:08,428 --> 01:09:08,862
LANDSCAPE.

1753
01:09:08,862 --> 01:09:11,498
THE QUESTION IS, WHAT CAN WE GET

1754
01:09:11,498 --> 01:09:16,302
DONE HERE AND FOR HIV VIRAL LOAD

1755
01:09:16,302 --> 01:09:16,703
MONITORING.

1756
01:09:16,703 --> 01:09:17,804
ONE OF THE COMMON CHALLENGES IS

1757
01:09:17,804 --> 01:09:20,507
ALWAYS GOING TO BE THE SAMPLE

1758
01:09:20,507 --> 01:09:21,341
AND ITS VOLUME.

1759
01:09:21,341 --> 01:09:22,842
WE'RE ASKING THESE TEAMS TO

1760
01:09:22,842 --> 01:09:24,110
START WITH WHOLE BLOOD.

1761
01:09:24,110 --> 01:09:25,779
THEY CAN PROCESS THAT SAMPLE ON

1762
01:09:25,779 --> 01:09:27,280
OR OFF THE DEVICE BUT NEED TO

1763
01:09:27,280 --> 01:09:29,115
FIGURE OUT HOW MUCH SAMPLE IS

1764
01:09:29,115 --> 01:09:33,420
NEEDED, HOW THEY ARE GOING TO

1765
01:09:33,420 --> 01:09:34,788
GET TO QUANTITATIVE ASSAY, 200

1766
01:09:34,788 --> 01:09:37,557
COPIES PER ML, NEED TO

1767
01:09:37,557 --> 01:09:38,758
BACK-CALCULATE HOW MUCH BLOOD TO

1768
01:09:38,758 --> 01:09:46,332
START WITH TO DO THOSE THINGS. 

1769
01:09:46,332 --> 01:09:48,101
SUGGESTING HIGHER VOLUME THAN

1770
01:09:48,101 --> 01:09:51,671
FINGER STICK VOLUME MAY BE

1771
01:09:51,671 --> 01:09:52,072
NEEDED.

1772
01:09:52,072 --> 01:09:55,608
WE ASKED EMORY TO LOOK AT BLOOD

1773
01:09:55,608 --> 01:09:56,743
COLLECTION DEVICES, EACH HERE

1774
01:09:56,743 --> 01:09:58,645
HAS SOME FORM OF REGULATORY

1775
01:09:58,645 --> 01:09:59,079
APPROVAL.

1776
01:09:59,079 --> 01:10:01,414
BUT WHAT WE WANTED TO KNOW WAS

1777
01:10:01,414 --> 01:10:03,216
HOW WELL DID THEY WORK, WHAT

1778
01:10:03,216 --> 01:10:04,651
VOLUME DID THEY DRAW, HOW FAST

1779
01:10:04,651 --> 01:10:09,322
DID IT DRAW THAT VOLUME, HOW

1780
01:10:09,322 --> 01:10:11,591
RELIABLY DOES THAT HAPPEN,

1781
01:10:11,591 --> 01:10:14,461
PARTICIPANT TO PARTICIPANT, DOES

1782
01:10:14,461 --> 01:10:16,096
IT HURT OR LEAVE A SCAR?

1783
01:10:16,096 --> 01:10:18,665
ON A SECOND SHELF THAT A QUALITY

1784
01:10:18,665 --> 01:10:21,067
SAMPLE, SUITABLE FOR VIRAL LOAD

1785
01:10:21,067 --> 01:10:22,469
TESTING?

1786
01:10:22,469 --> 01:10:25,105
EMORY IS STARTING WITH THE

1787
01:10:25,105 --> 01:10:26,172
DEVICE HERE.

1788
01:10:26,172 --> 01:10:27,874
BUT EACH OF THE TEAMS THAT WE'LL

1789
01:10:27,874 --> 01:10:30,744
TALK ABOUT ARE DOING THEIR OWN

1790
01:10:30,744 --> 01:10:31,845
RESEARCH AS WELL.

1791
01:10:31,845 --> 01:10:34,481
BROADLY I WILL ALSO NOTE THAT A

1792
01:10:34,481 --> 01:10:36,082
MOVE TO DECENTRALIZE MEDICINE

1793
01:10:36,082 --> 01:10:38,918
THAT WE SAW THROUGHOUT THE LAST

1794
01:10:38,918 --> 01:10:40,720
FIVE YEARS IS QUICKENING, SUCH A

1795
01:10:40,720 --> 01:10:43,189
STUDY IS NOT ONLY GERMANE TO HIV

1796
01:10:43,189 --> 01:10:45,859
BUT TO ALL BLOOD-BASED

1797
01:10:45,859 --> 01:10:47,026
DIAGNOSTICS, A COMMON THEME YOU

1798
01:10:47,026 --> 01:10:48,628
CAN SEE IN THE GATES GLOBAL

1799
01:10:48,628 --> 01:10:50,530
CHALLENGE I HIGHLIGHTED AT THE

1800
01:10:50,530 --> 01:10:53,500
LOWER RIGHT OF THE GRAPH.

1801
01:10:53,500 --> 01:10:56,269
THEY WANT TO ENHANCE HIV AND

1802
01:10:56,269 --> 01:10:57,103
TUBERCULOSIS DIAGNOSTICS, AND TO

1803
01:10:57,103 --> 01:11:01,040
THAT THEY GOT A ROBUST RESPONSE.

1804
01:11:01,040 --> 01:11:07,647
I EXCITEDLY AWAIT TO SEE WHAT

1805
01:11:07,647 --> 01:11:09,048
THEY DEVELOP IF IT'S APPLICABLE

1806
01:11:09,048 --> 01:11:10,150
TO OUR PROGRAM AND PROGRAMS IN

1807
01:11:10,150 --> 01:11:10,850
THE FUTURE.

1808
01:11:10,850 --> 01:11:15,455
LET'S TAKE A CLOSER LOOK AT THE

1809
01:11:15,455 --> 01:11:17,023
THREE TEAMS WE'RE FUNDING.

1810
01:11:17,023 --> 01:11:19,325
THESE THREE TEAMS PRESENT WITH

1811
01:11:19,325 --> 01:11:23,096
UNIQUE QUALITIES AND CHALLENGES

1812
01:11:23,096 --> 01:11:27,233
ACROSS THEIR APPROACHES.

1813
01:11:27,233 --> 01:11:28,535
CEPHEID WILL BE MODIFYING WHICH

1814
01:11:28,535 --> 01:11:32,539
RUNS ON GENE EXPRESS PLATFORM.

1815
01:11:32,539 --> 01:11:35,575
BAEBIES AIMS TO ADD TO THE

1816
01:11:35,575 --> 01:11:37,877
FINDER PLATFORM, FDA APPROVED

1817
01:11:37,877 --> 01:11:40,847
FOR INFANT ANEMIA.

1818
01:11:40,847 --> 01:11:43,249
PROMPT IS DEVELOPING MAG NEED OH

1819
01:11:43,249 --> 01:11:45,985
FLUIDIC INSTRUMENT FOR THIS

1820
01:11:45,985 --> 01:11:46,252
CHALLENGE.

1821
01:11:46,252 --> 01:11:48,421
NOTE THAT BAEBIES AND PROMPT ARE

1822
01:11:48,421 --> 01:11:49,622
ALUMNI OF THE VIRAL LOAD MINI

1823
01:11:49,622 --> 01:11:52,225
FUNNEL WHICH I HOPE THEY WOULD

1824
01:11:52,225 --> 01:11:54,160
AGREE HELPED PREPARE THEM TO

1825
01:11:54,160 --> 01:11:58,264
SUCCESSFULLY COMPLETE WITHIN

1826
01:11:58,264 --> 01:12:02,769
THIS LARGER FUNNEL HERE.

1827
01:12:02,769 --> 01:12:05,538
FIRST TEAM, CEPHEID IS

1828
01:12:05,538 --> 01:12:08,474
DEVELOPING THEIR VIRAL LOAD TEST

1829
01:12:08,474 --> 01:12:10,944
FOR THE PLATFORM, 60,000 EXPERTS

1830
01:12:10,944 --> 01:12:12,278
IN THE FIELD GLOBALLY, HAVE 35

1831
01:12:12,278 --> 01:12:15,114
TESTS AVAILABLE FOR THE

1832
01:12:15,114 --> 01:12:15,748
PLATFORM.

1833
01:12:15,748 --> 01:12:17,584
THIS INCLUDES HEPATITIS C TEST

1834
01:12:17,584 --> 01:12:19,586
FOR USE AT THE POINT OF CARE

1835
01:12:19,586 --> 01:12:23,923
ALSO DEVELOPED IN COLLABORATION

1836
01:12:23,923 --> 01:12:25,859
WITH RADx.

1837
01:12:25,859 --> 01:12:27,360
AS I MENTIONED EARLIER, CEPHEID

1838
01:12:27,360 --> 01:12:29,662
DOES HAVE AN HIV VIRAL LOAD TEST

1839
01:12:29,662 --> 01:12:33,700
AVAILABLE ON THE GLOBAL MARKET.

1840
01:12:33,700 --> 01:12:37,136
IT'S CAPABLE OF 40 COPIES, LOWER

1841
01:12:37,136 --> 01:12:43,776
LIMIT OF QUANTITATION, RUN WITH

1842
01:12:43,776 --> 01:12:45,278
ONE MIL, USING CAPILLARY BLOOD,

1843
01:12:45,278 --> 01:12:48,548
FILTERED IN THE CARTRIDGE

1844
01:12:48,548 --> 01:12:48,882
ITSELF.

1845
01:12:48,882 --> 01:12:51,484
REQUIRING NO TEST BY USER.

1846
01:12:51,484 --> 01:12:52,986
DUE TO LIMITATIONS OF HOW MUCH

1847
01:12:52,986 --> 01:12:55,154
BLOOD AND THEREFORE PLASMA, ONE

1848
01:12:55,154 --> 01:12:57,190
CAN COLLECT IN CAPILLARIES, THEY

1849
01:12:57,190 --> 01:12:59,959
ARE EXPECTING HIGHER LIMIT THAN

1850
01:12:59,959 --> 01:13:00,760
40 COPIES.

1851
01:13:00,760 --> 01:13:04,530
NATIONALLY WORKING TO A GOAL OF

1852
01:13:04,530 --> 01:13:06,699
200 COPIES PER ML.

1853
01:13:06,699 --> 01:13:08,935
LESSONS LEARNED FROM THE HEP C

1854
01:13:08,935 --> 01:13:11,237
TEST ARE LEVERAGED HERE FOR THE

1855
01:13:11,237 --> 01:13:14,474
HIV VIRAL LOAD ASSAY.

1856
01:13:14,474 --> 01:13:18,778
THE  TEAM WILL BALANCE

1857
01:13:18,778 --> 01:13:19,712
COLLECTION, FILTRATION, TARGET

1858
01:13:19,712 --> 01:13:21,214
AVAILABILITY TO REACH FINAL

1859
01:13:21,214 --> 01:13:22,315
PERFORMANCE METRIC.

1860
01:13:22,315 --> 01:13:24,784
THE UNIQUE ABILITY OF THE EXPERT

1861
01:13:24,784 --> 01:13:28,755
SYSTEM TO HANDLE SUCH FLUIDIC

1862
01:13:28,755 --> 01:13:31,824
CHALLENGES PROVIDES PATHWAYS FOR

1863
01:13:31,824 --> 01:13:32,258
MEANINGFUL RESULTS.

1864
01:13:32,258 --> 01:13:33,526
HOW THE INITIAL SAMPLE IS

1865
01:13:33,526 --> 01:13:35,662
COLLECTED AND WHAT VOLUME IS

1866
01:13:35,662 --> 01:13:37,397
ROUTINELY COLLECTED ARE CLEARLY

1867
01:13:37,397 --> 01:13:44,337
CRITICAL FACTORS AS THEY MOVE

1868
01:13:44,337 --> 01:13:44,570
FORWARD.

1869
01:13:44,570 --> 01:13:45,605
INITIAL FEASIBILITY STUDIES SEEN

1870
01:13:45,605 --> 01:13:47,774
IN THE UPPER RIGHT-HAND SIDE OF

1871
01:13:47,774 --> 01:13:49,876
THIS SLIDE WITH DETECTION DOWN

1872
01:13:49,876 --> 01:13:52,812
TO 200 COPIES PER ML,

1873
01:13:52,812 --> 01:13:56,516
DEMONSTRATED IN BENCH TOP ASSAYS

1874
01:13:56,516 --> 01:13:58,384
WITH REDUCED INPUT VOLUMES.

1875
01:13:58,384 --> 01:14:02,388
CEPHEID TEAM WORKS ON

1876
01:14:02,388 --> 01:14:03,723
FILTRATION, FLUIDIC HANDLING,

1877
01:14:03,723 --> 01:14:05,458
CARTRIDGE CHANGES.

1878
01:14:05,458 --> 01:14:06,392
YET AGGRESSIVE TIMELINES WILL

1879
01:14:06,392 --> 01:14:08,761
PUSH THEM TO HAVE THIS DONE THIS

1880
01:14:08,761 --> 01:14:15,935
FALL FOR END TO END CUSTOMER

1881
01:14:15,935 --> 01:14:16,736
TESTING.

1882
01:14:16,736 --> 01:14:19,639
SECOND TEAM IS BAEBIES, A

1883
01:14:19,639 --> 01:14:22,542
DIGITAL FLUIDIC SYSTEM WITH PCR

1884
01:14:22,542 --> 01:14:29,148
READOUT, SYSTEM HAS CAPABILITY

1885
01:14:29,148 --> 01:14:30,416
FOR GENOMIC, A SINGLE SYSTEM

1886
01:14:30,416 --> 01:14:33,453
WITH A MENU OF TESTS.

1887
01:14:33,453 --> 01:14:39,158
AT PRESENT BAEBIES HAS FDA

1888
01:14:39,158 --> 01:14:49,602
APPROVED TEST FOR ANEMIA.

1889
01:14:50,670 --> 01:14:55,742
G 6 HELPS PROTECT RED BLOOD

1890
01:14:55,742 --> 01:14:58,144
CELLS FROM DAMAGE, CAUSING

1891
01:14:58,144 --> 01:14:58,611
HEMOLYTIC ANEMIA.

1892
01:14:58,611 --> 01:15:01,514
FOR THIS PROGRAM BAEBIES

1893
01:15:01,514 --> 01:15:03,416
ENVISIONS HIV AMONG MOLECULAR

1894
01:15:03,416 --> 01:15:04,951
TEST MENU.

1895
01:15:04,951 --> 01:15:06,853
FINDER PLATFORM AND CARTRIDGE IS

1896
01:15:06,853 --> 01:15:07,887
BASED ON DIGITAL FLUIDICS, SOME

1897
01:15:07,887 --> 01:15:11,324
MAY NOT BE FAMILIAR WITH.

1898
01:15:11,324 --> 01:15:14,460
DIGITAL FLUIDICS IS CONTROL OF

1899
01:15:14,460 --> 01:15:17,964
LIQUID SAMPLE AMONGST A SET OF

1900
01:15:17,964 --> 01:15:18,531
ELECTRONIC PATHS.

1901
01:15:18,531 --> 01:15:20,466
LET ME START A VIDEO FOR

1902
01:15:20,466 --> 01:15:25,872
EVERYONE TO SEE HERE.

1903
01:15:25,872 --> 01:15:28,408
THIS VIDEO WILL GIVE YOU A SENSE

1904
01:15:28,408 --> 01:15:32,245
OF FIDELITY IN WHICH LIQUID CAN

1905
01:15:32,245 --> 01:15:35,381
BE HANDLED ON SUCH CARTRIDGE,

1906
01:15:35,381 --> 01:15:36,716
HEATING ELEMENTS LOCATED AT

1907
01:15:36,716 --> 01:15:39,018
KNOWN LOCATIONS AROUND THE

1908
01:15:39,018 --> 01:15:41,621
CARTRIDGE, TOGETHER THEY MAKES

1909
01:15:41,621 --> 01:15:46,926
FOR A POWERFUL PLATFORM FOR

1910
01:15:46,926 --> 01:15:48,094
SUITABLE FOR MANY ASSAYS.

1911
01:15:48,094 --> 01:15:50,296
LIKE THE OTHER TWO TEAMS,

1912
01:15:50,296 --> 01:15:52,899
BAEBIES IS WORKING AGAINST A

1913
01:15:52,899 --> 01:15:53,800
SIGNIFICANT CHALLENGE RADx

1914
01:15:53,800 --> 01:15:54,267
POSTS.

1915
01:15:54,267 --> 01:15:56,402
THEY ARE TRYING TO UNDERSTAND

1916
01:15:56,402 --> 01:15:58,171
HOW SAMPLE COLLECTIONS, SAMPLE

1917
01:15:58,171 --> 01:15:59,839
VOLUME, AND WORKFLOW WILL PLAY

1918
01:15:59,839 --> 01:16:03,543
IN THE FINAL PRODUCT DESIGN.

1919
01:16:03,543 --> 01:16:06,279
NOTABLY THE TOTAL VOLUME USED

1920
01:16:06,279 --> 01:16:07,947
PRESENTS TRADEOFFS WITH FLUID

1921
01:16:07,947 --> 01:16:08,214
HANDLING.

1922
01:16:08,214 --> 01:16:10,616
THESE STEPS ARE A DANCE,

1923
01:16:10,616 --> 01:16:13,119
COMPLEXITY GOES UP WITH THE

1924
01:16:13,119 --> 01:16:14,087
GREATER VOLUME.

1925
01:16:14,087 --> 01:16:17,423
SO WE NEED TO FIGURE OUT HOW TO

1926
01:16:17,423 --> 01:16:21,761
PROCESS TOTAL VOLUME REQUIRED TO

1927
01:16:21,761 --> 01:16:22,628
REACH THE SENSITIVITY REQUIRED.

1928
01:16:22,628 --> 01:16:24,263
ON THE LEFT-HAND SIDE OF THIS

1929
01:16:24,263 --> 01:16:27,600
SLIDE WE CAN SEE PRELIMINARY

1930
01:16:27,600 --> 01:16:32,538
DATA FOR WET REAGENT VERSIONS OF

1931
01:16:32,538 --> 01:16:34,640
THE ASSAY, DEMONSTRATING

1932
01:16:34,640 --> 01:16:37,143
DETECTION AS LOW AS 200 COPIES

1933
01:16:37,143 --> 01:16:38,911
PER ML LEAVING ROOM FOR FURTHER

1934
01:16:38,911 --> 01:16:41,080
DEVELOPMENT AND TRADEOFFS ON THE

1935
01:16:41,080 --> 01:16:41,447
CARTRIDGE.

1936
01:16:41,447 --> 01:16:44,817
IN THE DATA SHOWN ON THE RIGHT

1937
01:16:44,817 --> 01:16:46,986
OF THE SLIDE ASSAY HAS

1938
01:16:46,986 --> 01:16:48,387
APPLICABILITY ACROSS MANY HIV

1939
01:16:48,387 --> 01:16:49,589
CLADES.

1940
01:16:49,589 --> 01:16:54,327
THIS MARKS A PROMISING START TO

1941
01:16:54,327 --> 01:16:54,594
THE TEAM.

1942
01:16:54,594 --> 01:16:56,729
OUR THIRD COMPANY IS PROMPT

1943
01:16:56,729 --> 01:16:57,029
DIAGNOSTICS.

1944
01:16:57,029 --> 01:16:59,999
PROMPT IS A SMALL COMPANY THAT

1945
01:16:59,999 --> 01:17:01,467
FORMED OUT OF JOHNS HOPKINS,

1946
01:17:01,467 --> 01:17:11,911
HAVE AT CORE MAGNITO CORE

1947
01:17:12,478 --> 01:17:13,579
FLUIDIC EXPERTISE.

1948
01:17:13,579 --> 01:17:15,047
IN THE HIV SPACE, PROMPT WAS ONE

1949
01:17:15,047 --> 01:17:17,083
OF OUR PARTICIPANTS IN THE MINI

1950
01:17:17,083 --> 01:17:17,550
FUNNEL.

1951
01:17:17,550 --> 01:17:19,018
ON THE RIGHT-HAND SIDE OF THE

1952
01:17:19,018 --> 01:17:22,255
SLIDE YOU CAN SEE EMBODIMENT OF

1953
01:17:22,255 --> 01:17:24,624
VIRAL LOAD ASSAY, IN EARLY

1954
01:17:24,624 --> 01:17:27,226
CONCEPT FOR SAMPLE HANDLING.

1955
01:17:27,226 --> 01:17:30,296
WORKING PROTOTYPE OF THE PCR

1956
01:17:30,296 --> 01:17:32,999
INSTRUMENT ON THE FAR RIGHT.

1957
01:17:32,999 --> 01:17:34,867
THE COMPACT PORTABLE INSTRUMENT

1958
01:17:34,867 --> 01:17:35,968
AND DISPOSABLE CARTRIDGE

1959
01:17:35,968 --> 01:17:37,670
DEVELOPED IN THE MINI FUNNEL

1960
01:17:37,670 --> 01:17:39,238
SERVE AS STRONG BASE FROM WHICH

1961
01:17:39,238 --> 01:17:41,274
THE CURRENT PROJECT CAN BUILD

1962
01:17:41,274 --> 01:17:44,210
AND MEET THE TPP SPECIFICATIONS

1963
01:17:44,210 --> 01:17:44,610
REQUIRED.

1964
01:17:44,610 --> 01:17:49,215
AT THE HEART OF THE PLATFORM

1965
01:17:49,215 --> 01:17:49,715
REMAINS MAGNETO SAMPLE

1966
01:17:49,715 --> 01:17:51,117
MANIPULATION THAT BINDS VIRAL

1967
01:17:51,117 --> 01:17:56,689
MATERIAL AND MOVES IT THROUGH

1968
01:17:56,689 --> 01:17:57,256
PURIFICATION, LOCATION,

1969
01:17:57,256 --> 01:17:57,523
DETECTION.

1970
01:17:57,523 --> 01:18:00,893
LIKE THE OTHER TWO TEAMS, PROMPT

1971
01:18:00,893 --> 01:18:02,195
IS ADAPTING ASSAY AND PROTOCOLS

1972
01:18:02,195 --> 01:18:05,097
TO DEAL WITH REALITY OF WHAT

1973
01:18:05,097 --> 01:18:06,499
VOLUME OF WHOLE BLOOD THEY WILL

1974
01:18:06,499 --> 01:18:11,904
UTILIZE AND TRADEOFFS FOR

1975
01:18:11,904 --> 01:18:13,472
SENSITIVITY, TIME, INSTRUMENT

1976
01:18:13,472 --> 01:18:13,940
AND CARTRIDGE DESIGN.

1977
01:18:13,940 --> 01:18:15,608
ON THE RIGHT-HAND SIDE YOU CAN

1978
01:18:15,608 --> 01:18:17,743
SEE PRELIMINARY DATA FOR THE

1979
01:18:17,743 --> 01:18:19,745
DETECTION OF 200 COPIES PER ML

1980
01:18:19,745 --> 01:18:24,483
IF ALL OF THOSE TRADEOFFS YIELD

1981
01:18:24,483 --> 01:18:28,087
100 MICROLITER PLASMA SAMPLES TO

1982
01:18:28,087 --> 01:18:28,821
BEGIN.

1983
01:18:28,821 --> 01:18:30,323
AS PROMPT WORKS TO HARDEN

1984
01:18:30,323 --> 01:18:32,558
PERFORMANCE THEY ARE LOOKING AT

1985
01:18:32,558 --> 01:18:36,028
HOW THE TPP SPECIFICATIONS PLAY

1986
01:18:36,028 --> 01:18:38,531
INTO TOTAL WORKFLOW.

1987
01:18:38,531 --> 01:18:44,870
EVE ENGAGED DESIGN PARTNERS,

1988
01:18:44,870 --> 01:18:45,504
ENVISIONING A NEW CONFIGURATION

1989
01:18:45,504 --> 01:18:50,910
FOR POINT OF CARE AND CLIA

1990
01:18:50,910 --> 01:18:51,444
SETTINGS.

1991
01:18:51,444 --> 01:18:52,545
WITH THAT INTRODUCTION TO THE

1992
01:18:52,545 --> 01:18:55,848
HIV TEAM, LET ME LEAVE YOU WITH

1993
01:18:55,848 --> 01:18:57,617
FINAL THOUGHTS.

1994
01:18:57,617 --> 01:18:59,385
STARTING WITH THE RADx VALUE.

1995
01:18:59,385 --> 01:19:08,094
WE FEEL THROUGH THE CRUCIBLE OF

1996
01:19:08,094 --> 01:19:11,897
THE PANDEMIC, RADx WAS

1997
01:19:11,897 --> 01:19:12,265
PRESSURE TESTED.

1998
01:19:12,265 --> 01:19:16,135
WE HAVE A GREAT TEAM OF PEOPLE

1999
01:19:16,135 --> 01:19:17,103
WITH TIMELINES AND SUCCESS.

2000
01:19:17,103 --> 01:19:24,143
SOME MECHANICS  -- MEMBERS HAVE

2001
01:19:24,143 --> 01:19:24,944
TESTS IN THEIR MEDICINE CABINET

2002
01:19:24,944 --> 01:19:25,778
AS WE SPEAK.

2003
01:19:25,778 --> 01:19:28,314
WE'VE COME TO UNDERSTAND AND

2004
01:19:28,314 --> 01:19:30,549
BELIEVE THAT IN-KIND SERVICES

2005
01:19:30,549 --> 01:19:31,984
CAN GENERATE MORE VALUE TO

2006
01:19:31,984 --> 01:19:34,754
PROJECTS THAN FUNDING SUPPORT

2007
01:19:34,754 --> 01:19:35,655
ALONE.

2008
01:19:35,655 --> 01:19:37,590
THE EXPERT GUIDANCE AND

2009
01:19:37,590 --> 01:19:41,427
MENTORSHIP CAN HELP TEAMS AVOID

2010
01:19:41,427 --> 01:19:43,429
COSTLY MISTAKES AND VALIDATION

2011
01:19:43,429 --> 01:19:45,865
SUPPORT CAN PROVIDE A RESOURCE

2012
01:19:45,865 --> 01:19:51,203
THAT DE-RISK DECISION MAKING,

2013
01:19:51,203 --> 01:19:52,772
ADDS CREDIBILITY IN THE INVOLVED

2014
01:19:52,772 --> 01:19:56,842
AND VC COMMUNITY AT LARGE.

2015
01:19:56,842 --> 01:19:59,078
CUSTOMIZABLE NATURE AFFORDS

2016
01:19:59,078 --> 01:20:00,212
GREAT FLEXIBILITY AS

2017
01:20:00,212 --> 01:20:03,249
DEMONSTRATED ACROSS CLINICAL AND

2018
01:20:03,249 --> 01:20:05,818
TECHNOLOGICAL AREAS IN PROCESS.

2019
01:20:05,818 --> 01:20:06,719
PARTNERSHIPS INSIDE AND OUTSIDE

2020
01:20:06,719 --> 01:20:08,754
GOVERNMENT HAVE BEEN KEY FOR

2021
01:20:08,754 --> 01:20:10,256
BUILDING A SUSTAINABLE

2022
01:20:10,256 --> 01:20:11,424
INFRASTRUCTURE FOR RADx AND

2023
01:20:11,424 --> 01:20:15,561
WILL CONTINUE TO ENABLE US TO

2024
01:20:15,561 --> 01:20:18,164
WITHSTAND THE SCOPE OF THE

2025
01:20:18,164 --> 01:20:19,999
IMPACT.

2026
01:20:19,999 --> 01:20:22,635
FOR ANYONE INTERESTED, TWO

2027
01:20:22,635 --> 01:20:23,269
COLLABORATORS PUT TOGETHER A

2028
01:20:23,269 --> 01:20:24,770
BOOK ON THE RIGHT-HAND SIDE OF

2029
01:20:24,770 --> 01:20:25,471
THE SLIDE.

2030
01:20:25,471 --> 01:20:29,241
OR YOU CAN REACH OUT TO NIBIB

2031
01:20:29,241 --> 01:20:30,576
DIRECTOR FOR MORE INFORMATION

2032
01:20:30,576 --> 01:20:32,244
ABOUT THE RADx PROGRAM.

2033
01:20:32,244 --> 01:20:34,347
FOR HIV VIRAL LOAD, WE HAVE

2034
01:20:34,347 --> 01:20:36,916
THREE PROMISING TEAMS WITH THREE

2035
01:20:36,916 --> 01:20:39,985
UNIQUE APPROACHES AND I'M BUOYED

2036
01:20:39,985 --> 01:20:41,887
BY THE EARLY RETURNS.

2037
01:20:41,887 --> 01:20:43,989
RADx ACCELERATORS ARE IN PLACE

2038
01:20:43,989 --> 01:20:48,361
TO SUSTAIN THIS MOMENT,

2039
01:20:48,361 --> 01:20:49,328
INCLUDING USABILITY, ANALYTICAL,

2040
01:20:49,328 --> 01:20:50,629
PRE-CLINICAL EVALUATION TO

2041
01:20:50,629 --> 01:20:51,664
ASSIST INNOVATORS AND SHOULD

2042
01:20:51,664 --> 01:20:53,799
INFORM IF CLINICAL TRIALS ARE

2043
01:20:53,799 --> 01:20:54,934
THE SUITABLE NEXT STEP.

2044
01:20:54,934 --> 01:20:56,769
WE HAVE HEARD THE COMMUNITY'S

2045
01:20:56,769 --> 01:20:58,437
CALL TO BRING TESTING CLOSER TO

2046
01:20:58,437 --> 01:21:00,506
THE PARTICIPANTS AND OUR FIRST

2047
01:21:00,506 --> 01:21:06,212
STEP IS TO FULFILL OPEN DOMESTIC

2048
01:21:06,212 --> 01:21:06,679
POINT-OF-CARE MARKET.

2049
01:21:06,679 --> 01:21:08,180
LET ME CLOSE BY THANKING MANY

2050
01:21:08,180 --> 01:21:10,383
PEOPLE IN RADx AND IN EACH OF

2051
01:21:10,383 --> 01:21:12,184
OUR HIV VIRAL LOAD PARTNER

2052
01:21:12,184 --> 01:21:14,387
COMPANIES FOR THEIR COMMITMENT

2053
01:21:14,387 --> 01:21:15,721
TO BETTER HEALTH OUTCOMES.

2054
01:21:15,721 --> 01:21:17,356
THESE ARE STILL VERY EARLY DAYS

2055
01:21:17,356 --> 01:21:18,791
FOR THE HIV VIRAL LOAD PROGRAM

2056
01:21:18,791 --> 01:21:19,992
AND I HOPE TO HAVE MUCH MORE TO

2057
01:21:19,992 --> 01:21:22,328
SHARE WITH YOU IN THE FUTURE.

2058
01:21:22,328 --> 01:21:24,130
LET ME THANK YOU FOR YOUR KIND

2059
01:21:24,130 --> 01:21:26,132
ATTENTION AND I'D BE HAPPY TO

2060
01:21:26,132 --> 01:21:27,666
TAKE ANY QUESTIONS AND OPEN THE

2061
01:21:27,666 --> 01:21:28,834
FLOOR FOR FURTHER DISCUSSION.

2062
01:21:28,834 --> 01:21:35,207
THANK YOU VERY MUCH. 

2063
01:21:35,207 --> 01:21:35,975
>> THANK YOU.

2064
01:21:35,975 --> 01:21:42,882
EXCITING PROGRESS ON ALL THREE

2065
01:21:42,882 --> 01:21:44,216
FRONTS AND THE PROGRAM AS A

2066
01:21:44,216 --> 01:21:45,151
WHOLE.

2067
01:21:45,151 --> 01:21:47,787
WE'LL START WITH A DISCUSSION

2068
01:21:47,787 --> 01:21:50,756
AND, AGAIN, I'LL GO WITH THE DR.

2069
01:21:50,756 --> 01:21:53,592
GLENSHAW IN THE ROOM AND

2070
01:21:53,592 --> 01:21:54,293
VIRTUALLY.

2071
01:21:54,293 --> 01:21:57,096
I'LL START SINCE IT'S REALLY

2072
01:21:57,096 --> 01:21:57,463
EXCITING.

2073
01:21:57,463 --> 01:22:02,034
JUST TO COMMENT, THREE PLATFORMS

2074
01:22:02,034 --> 01:22:04,970
ARE ON PLASMA, CORRECT?

2075
01:22:04,970 --> 01:22:11,977
NOT WHOLE BLOOD, ON THE PLASMA

2076
01:22:11,977 --> 01:22:13,412
FRACTION, AND CAN YOU COMMENT ON

2077
01:22:13,412 --> 01:22:14,713
COST, WAS THAT ADDRESSED

2078
01:22:14,713 --> 01:22:17,149
RELATIVE TO DEVELOPMENT?

2079
01:22:17,149 --> 01:22:19,585
BECAUSE THE TECHNOLOGY WOULD BE

2080
01:22:19,585 --> 01:22:22,455
AS ACCESSIBLE AS IT IS

2081
01:22:22,455 --> 01:22:23,022
AFFORDABLE.

2082
01:22:23,022 --> 01:22:25,925
SO WHAT SORT OF PRIORITIES OR

2083
01:22:25,925 --> 01:22:29,228
GUIDELINES ARE IN PLACE TO

2084
01:22:29,228 --> 01:22:30,296
ADDRESS THAT COMPONENT?

2085
01:22:30,296 --> 01:22:31,764
>> THANK YOU FOR THE TWO

2086
01:22:31,764 --> 01:22:32,097
QUESTIONS.

2087
01:22:32,097 --> 01:22:34,433
THE FIRST IS WE TOLD THE TEAM

2088
01:22:34,433 --> 01:22:35,634
THEY NEEDED TO START WITH WHOLE

2089
01:22:35,634 --> 01:22:38,737
BLOOD AND GAVE THEM THE

2090
01:22:38,737 --> 01:22:41,240
CHALLENGE OF BEING SUITABLE FOR

2091
01:22:41,240 --> 01:22:42,675
CLIA WAIVED SETTINGS.

2092
01:22:42,675 --> 01:22:44,510
WHAT THEY DID WITH THAT SAMPLE

2093
01:22:44,510 --> 01:22:46,612
AFTER COLLECTION WAS THEIR

2094
01:22:46,612 --> 01:22:46,846
CHOICE.

2095
01:22:46,846 --> 01:22:48,814
SO, YES, ALL THREE TEAMS AT THE

2096
01:22:48,814 --> 01:22:51,050
MOMENT ARE SEPARATING OUT FOR

2097
01:22:51,050 --> 01:22:53,419
THE PLASMA FRACTION, AND THAT IS

2098
01:22:53,419 --> 01:22:56,288
GUIDING THEIR VOLUME CHOICES AT

2099
01:22:56,288 --> 01:22:57,323
THE MOMENT.

2100
01:22:57,323 --> 01:23:00,059
BUT WE DID NOT PRESCRIBE FOR

2101
01:23:00,059 --> 01:23:02,962
THEM THAT THEY HAD TO START WITH

2102
01:23:02,962 --> 01:23:03,195
PLASMA.

2103
01:23:03,195 --> 01:23:04,997
WE SAID YOU'RE STARTING AT THE

2104
01:23:04,997 --> 01:23:07,166
PATIENT, GIVE ME AN ANSWER.

2105
01:23:07,166 --> 01:23:09,435
THE SECOND PART OF YOUR QUESTION

2106
01:23:09,435 --> 01:23:12,972
WAS WE DID NOT PUT ANY

2107
01:23:12,972 --> 01:23:14,306
CONSTRAINTS OR EXPECTATIONS ON

2108
01:23:14,306 --> 01:23:16,041
PRICE AT THIS POINT.

2109
01:23:16,041 --> 01:23:17,943
WE'RE ATTEMPTING TO FULFILL A

2110
01:23:17,943 --> 01:23:19,778
COMPLETELY UNMET MARKET.

2111
01:23:19,778 --> 01:23:22,248
AND WE WANTED TO GET TECHNOLOGY

2112
01:23:22,248 --> 01:23:23,816
THAT WAS SUITABLE FOR THAT

2113
01:23:23,816 --> 01:23:27,353
MARKET READY AND TO A POINT

2114
01:23:27,353 --> 01:23:30,923
WHERE REGULATORY TESTING AND

2115
01:23:30,923 --> 01:23:32,458
POTENTIAL APPROVAL MADE LOGICAL

2116
01:23:32,458 --> 01:23:32,758
SENSE.

2117
01:23:32,758 --> 01:23:33,659
>> THANK YOU.

2118
01:23:33,659 --> 01:23:34,894
DR. GLENSHAW, ARE THERE ANY

2119
01:23:34,894 --> 01:23:37,730
COMMENTS OR QUESTIONS FROM THE

2120
01:23:37,730 --> 01:23:37,930
ROOM?

2121
01:23:37,930 --> 01:23:40,165
>> NO, NOT AT THIS TIME.

2122
01:23:40,165 --> 01:23:41,133
>> THANK YOU.

2123
01:23:41,133 --> 01:23:43,502
WE HAVE A COUPLE HANDS UP.

2124
01:23:43,502 --> 01:23:51,544
I'LL START WITH DR. NEILAN.

2125
01:23:51,544 --> 01:23:53,679
>> FASCINATING
PRESENTATION HOW

2126
01:23:53,679 --> 01:23:54,580
FEDERAL SUPPORT REALLY

2127
01:23:54,580 --> 01:23:56,115
ACCELERATED THIS AREA OF

2128
01:23:56,115 --> 01:23:57,550
TREMENDOUSLY HIGH NEED, POINT OF

2129
01:23:57,550 --> 01:24:00,452
CARROLL VIRAL LOAD TESTING.

2130
01:24:00,452 --> 01:24:01,086
PATIENTS AND CLINICIANS,

2131
01:24:01,086 --> 01:24:02,688
RESEARCHERS WOULD LOVE TO HAVE

2132
01:24:02,688 --> 01:24:02,922
THIS.

2133
01:24:02,922 --> 01:24:09,094
ONE CAN SEE HOW THIS ALIGNS WITH

2134
01:24:09,094 --> 01:24:11,430
DR. DON ENBERG'S PRESENTATION,

2135
01:24:11,430 --> 01:24:13,566
THAT WOULD BE INCREDIBLY

2136
01:24:13,566 --> 01:24:15,701
POWERFUL, HOPING THE DIRECTION

2137
01:24:15,701 --> 01:24:21,173
YOU WILL CONSIDER AS DR.

2138
01:24:21,173 --> 01:24:24,677
DONENBERG BUILDS ON THAT.

2139
01:24:24,677 --> 01:24:25,744
BUILDING ON DR. MONTANER'S

2140
01:24:25,744 --> 01:24:27,880
QUESTION, TO SEE THE VALUE OF

2141
01:24:27,880 --> 01:24:29,448
FEDERAL SUPPORT HERE, TO

2142
01:24:29,448 --> 01:24:30,783
OPTIMIZE EFFICIENCY OF

2143
01:24:30,783 --> 01:24:31,951
SCIENTIFIC ADVANCES AND ENSURE

2144
01:24:31,951 --> 01:24:34,520
THE EFFICIENT USE OF TAXPAYER

2145
01:24:34,520 --> 01:24:36,722
DOLLARS, CAN YOU JUST ELABORATE

2146
01:24:36,722 --> 01:24:39,925
MORE ON THE CONTRACTING AND HOW

2147
01:24:39,925 --> 01:24:40,859
THAT RELATED TO PRICE POINT.

2148
01:24:40,859 --> 01:24:42,661
YOU SAID THAT WAS SO VALUABLE

2149
01:24:42,661 --> 01:24:45,965
BUT I'M HOPING YOU CAN CLARIFY

2150
01:24:45,965 --> 01:24:48,334
WHERE THAT VALUE IS.

2151
01:24:48,334 --> 01:24:50,636
>> SO, THE VALUE OF THE

2152
01:24:50,636 --> 01:24:55,574
CONTRACTING AS DESCRIBED HERE IS

2153
01:24:55,574 --> 01:24:58,277
THE FLEXIBILITY TO ACCELERATE

2154
01:24:58,277 --> 01:25:02,381
TECHNOLOGIES ACROSS THE

2155
01:25:02,381 --> 01:25:04,450
SPECTRUM, WHETHER THEY BE A

2156
01:25:04,450 --> 01:25:08,821
VIRAL LOAD TASK, PARTICULARLY

2157
01:25:08,821 --> 01:25:09,955
GENOMIC, OR ANTIGEN TEST IN THE

2158
01:25:09,955 --> 01:25:11,090
CASE OF THE COVID I SHOWED AT

2159
01:25:11,090 --> 01:25:11,824
THE BEGINNING.

2160
01:25:11,824 --> 01:25:16,595
WE NEEDED TO HAVE A FLEXIBLE

2161
01:25:16,595 --> 01:25:17,997
CONTRACTING STRUCTURE TO ALLOW

2162
01:25:17,997 --> 01:25:21,600
US TO ACHIEVE THOSE THINGS IN AN

2163
01:25:21,600 --> 01:25:23,402
UNCERTAIN LANDSCAPE,

2164
01:25:23,402 --> 01:25:25,971
PARTICULARLY UNCERTAIN LANDSCAPE

2165
01:25:25,971 --> 01:25:26,872
OF THE PANDEMIC.

2166
01:25:26,872 --> 01:25:29,875
THE MARKET FORCES WILL DRIVE

2167
01:25:29,875 --> 01:25:32,678
YOUR PRICE EVENTUALLY.

2168
01:25:32,678 --> 01:25:35,948
I UNDERSTAND ALL OF YOUR

2169
01:25:35,948 --> 01:25:42,521
CONCERNS WITH PRICE EQUALING

2170
01:25:42,521 --> 01:25:42,855
ACCESSIBILITY.

2171
01:25:42,855 --> 01:25:45,591
THE ACCELERATION AT THIS POINT

2172
01:25:45,591 --> 01:25:48,527
IS TO REACH A REGULATORY

2173
01:25:48,527 --> 01:25:50,429
APPROVAL, AND THEN MARKET FORCES

2174
01:25:50,429 --> 01:25:53,866
ONCE WE HAVE THAT AREA FILLED

2175
01:25:53,866 --> 01:25:55,501
TEND TO MOVE PRICE IN THE

2176
01:25:55,501 --> 01:25:56,902
DIRECTION IT CAN GO.

2177
01:25:56,902 --> 01:26:00,806
IF NOTHING IS AVAILABLE THERE IS

2178
01:26:00,806 --> 01:26:01,674
NO ACCESS.

2179
01:26:01,674 --> 01:26:04,109
>> THANK YOU.

2180
01:26:04,109 --> 01:26:11,984
DR. SAWYER? 

2181
01:26:11,984 --> 01:26:12,284
>> SORRY.

2182
01:26:12,284 --> 01:26:14,453
HI, GOOD MORNING.

2183
01:26:14,453 --> 01:26:17,356
DR. MULVANEY, THANK YOU FOR YOUR

2184
01:26:17,356 --> 01:26:17,823
PRESENTATION.

2185
01:26:17,823 --> 01:26:19,124
I'M DEFINITELY IN THE CAMP

2186
01:26:19,124 --> 01:26:20,793
HOPING FOR THE MOONSHOT.

2187
01:26:20,793 --> 01:26:23,128
I'M ROOTING FOR A HOME TEST TO

2188
01:26:23,128 --> 01:26:25,397
EMPOWER PEOPLE TO PROTECT

2189
01:26:25,397 --> 01:26:26,298
THEMSELVES AT THE MOMENT WHERE

2190
01:26:26,298 --> 01:26:28,000
THEY ARE GOING TO BE DOING

2191
01:26:28,000 --> 01:26:29,802
SOMETHING THAT THEY MIGHT GET

2192
01:26:29,802 --> 01:26:30,135
EXPOSED.

2193
01:26:30,135 --> 01:26:31,970
AND SO, YOU KNOW, WHAT I'M

2194
01:26:31,970 --> 01:26:33,372
HEARING YOU SAYING IS THAT

2195
01:26:33,372 --> 01:26:35,174
FINGER PRICK BLOOD IS JUST NOT

2196
01:26:35,174 --> 01:26:36,942
ENOUGH VOLUME, RIGHT?

2197
01:26:36,942 --> 01:26:38,677
LIKE IT'S JUST -- NOBODY IS

2198
01:26:38,677 --> 01:26:40,112
EASTBOUND COMING CLOSE TO BEING

2199
01:26:40,112 --> 01:26:42,481
ABLE TO DETECT VIRAL LOAD FROM A

2200
01:26:42,481 --> 01:26:47,019
FRINGIER  -- FINGER PRICK, NOW

2201
01:26:47,019 --> 01:26:53,258
YOU REQUIRE INSTRUMENT ICE,  --

2202
01:26:53,258 --> 01:26:55,160
INSTRUMENTATION.

2203
01:26:55,160 --> 01:26:57,362
HAVE THERE BEEN OUTSIDE-THE-BOX

2204
01:26:57,362 --> 01:26:59,431
PROPOSALS LOOKING FOR HIV DEBRIS

2205
01:26:59,431 --> 01:27:02,234
IN BIOFLUID LIKE URINE OR SALIVA

2206
01:27:02,234 --> 01:27:07,239
WHICH CAN BE COLLECTED EASILY AT

2207
01:27:07,239 --> 01:27:11,443
HIGHER VOLUMES AND CONCENTRATED?

2208
01:27:11,443 --> 01:27:12,745
>> THERE ARE TWO HALVES TO
THE

2209
01:27:12,745 --> 01:27:16,415
ANSWER I'D LIKE TO PROVIDE TO

2210
01:27:16,415 --> 01:27:16,715
YOU.

2211
01:27:16,715 --> 01:27:18,917
FIRST HALF IS WE'RE UNCERTAIN AT

2212
01:27:18,917 --> 01:27:21,453
THIS POINT WHAT THE LOWER LIMIT

2213
01:27:21,453 --> 01:27:22,988
OF QUANTITATION WILL BE.

2214
01:27:22,988 --> 01:27:26,925
WHETHER THAT IS GOING TO BE 200

2215
01:27:26,925 --> 01:27:30,095
OR SOMETHING AS LOW AS THE 40

2216
01:27:30,095 --> 01:27:31,697
THAT CEPHEID SHOWED IN THEIR

2217
01:27:31,697 --> 01:27:35,968
GLOBAL PRODUCTS, OR FANTASTIC

2218
01:27:35,968 --> 01:27:36,502
 -- FANTASTIC

2219
01:27:36,502 --> 01:27:38,504
HIGHER, 500 OR 1,000.

2220
01:27:38,504 --> 01:27:39,571
I'LL ALLOW INNOVATOR TEAMS TO

2221
01:27:39,571 --> 01:27:44,042
PUSH ON THAT PART OF IT.

2222
01:27:44,042 --> 01:27:45,077
VERY SENSITIVE ASSAYS ARE

2223
01:27:45,077 --> 01:27:49,248
POSSIBLE IN A VARIETY OF

2224
01:27:49,248 --> 01:27:49,848
LANDSCAPES.

2225
01:27:49,848 --> 01:27:50,916
WE WILL HAVE TO SEE THE

2226
01:27:50,916 --> 01:27:52,651
REALITIES OF THAT WITH THE HIV

2227
01:27:52,651 --> 01:27:55,320
VIRAL LOAD, OR OTHER ASPECTS OF

2228
01:27:55,320 --> 01:27:56,588
HIV CARE.

2229
01:27:56,588 --> 01:27:58,056
AND THIS IS SOMETHING THAT I

2230
01:27:58,056 --> 01:28:00,359
HAVE EXCITEDLY TALKED TO A

2231
01:28:00,359 --> 01:28:04,696
NUMBER OF MY COLLEAGUES AT NIAID

2232
01:28:04,696 --> 01:28:09,067
ABOUT, AND OAR ABOUT.

2233
01:28:09,067 --> 01:28:10,969
THE PROGRAM HERE WAS

2234
01:28:10,969 --> 01:28:12,070
SPECIFICALLY DESIGNED TO BRING A

2235
01:28:12,070 --> 01:28:14,439
PRODUCT TO MARKET IN THE POINT

2236
01:28:14,439 --> 01:28:16,508
OF CARE SPACE, THAT'S NOT TO SAY

2237
01:28:16,508 --> 01:28:19,778
THAT WE'RE AREN'T INTERESTED IN

2238
01:28:19,778 --> 01:28:22,915
THE AT-HOME SPACE BUT WITH

2239
01:28:22,915 --> 01:28:24,716
NEITHER BEING AVAILABLE AT THE

2240
01:28:24,716 --> 01:28:29,021
TIME, WE CHOSE THIS AS THE FOCUS

2241
01:28:29,021 --> 01:28:29,254
HEREIN.

2242
01:28:29,254 --> 01:28:30,489
WE WOULD NEED TO TALK TO

2243
01:28:30,489 --> 01:28:31,824
INNOVATORS ABOUT WHAT THEY CAN

2244
01:28:31,824 --> 01:28:33,759
DO AND WHAT IS THE MINIMUM VALUE

2245
01:28:33,759 --> 01:28:38,363
THEY CAN DO IT AT.

2246
01:28:38,363 --> 01:28:44,236
AND THEN MAP THAT TOWARDS A

2247
01:28:44,236 --> 01:28:48,373
REGULATORY PATHWAY THAT COULD

2248
01:28:48,373 --> 01:28:49,341
SEEK AN APPLICATION WITHIN THE

2249
01:28:49,341 --> 01:28:50,976
UNITED STATES OR GLOBAL MARKET.

2250
01:28:50,976 --> 01:28:53,111
SO WE'RE ARE NOT GIVING UP ON

2251
01:28:53,111 --> 01:28:54,379
THAT.

2252
01:28:54,379 --> 01:29:00,085
THAT'S NOT THE FOCUS.

2253
01:29:00,085 --> 01:29:00,419
IS.

2254
01:29:00,419 --> 01:29:02,054
>> DR. FLETCHER?

2255
01:29:02,054 --> 01:29:06,391
>> COURTNEY  FLETCHER.

2256
01:29:06,391 --> 01:29:07,492
THANKS FOR YOUR PRESENTATION AND

2257
01:29:07,492 --> 01:29:09,528
PROS SHOWN.

2258
01:29:09,528 --> 01:29:11,263
MY QUESTION IS HAS ANY

2259
01:29:11,263 --> 01:29:14,600
CONSIDERATION BEEN GIVEN TO

2260
01:29:14,600 --> 01:29:16,602
PERHAPS AN ACCOMPANYING TEST FOR

2261
01:29:16,602 --> 01:29:18,003
MEDICATION ADHERENCE?

2262
01:29:18,003 --> 01:29:19,304
I THINK IT'S PROBABLY OBVIOUS

2263
01:29:19,304 --> 01:29:20,639
THE INTERPRETATION OF HIGH VIRAL

2264
01:29:20,639 --> 01:29:23,041
LOAD IN THE PRESENCE OF NO DRUG

2265
01:29:23,041 --> 01:29:26,612
IS VERY DIFFERENT THAN HIGH

2266
01:29:26,612 --> 01:29:36,221
VIRAL LOAD IN PRESENCE OF DRUG.

2267
01:29:36,221 --> 01:29:38,390
>> I REMAIN OUT OF THE
ANSWER TO

2268
01:29:38,390 --> 01:29:39,758
THE QUESTION, I WOULD THROW OPEN

2269
01:29:39,758 --> 01:29:42,661
TO THOSE MORE EXPERT IN HIV.

2270
01:29:42,661 --> 01:29:47,799
I'M MORE OF A PHYSICAL CHEMIST,

2271
01:29:47,799 --> 01:29:48,734
AND DEVICE DEVELOPER.

2272
01:29:48,734 --> 01:29:50,502
SO MY COLLEAGUES WITHIN POCTRN,

2273
01:29:50,502 --> 01:29:53,238
I SHOWED YOU THEY ARE WRITING

2274
01:29:53,238 --> 01:29:54,539
THAT MANUSCRIPT FOR DIFFERENT

2275
01:29:54,539 --> 01:29:56,842
USE CASE SETTINGS AND THAT THOSE

2276
01:29:56,842 --> 01:30:00,279
DIFFERENT USE CASE SETTINGS MAY

2277
01:30:00,279 --> 01:30:00,946
HAVE DIFFERENT DEVICE

2278
01:30:00,946 --> 01:30:03,582
CONFIGURATIONS THAT ARE

2279
01:30:03,582 --> 01:30:04,049
INTERESTING.

2280
01:30:04,049 --> 01:30:08,887
SO, DO YOU NEED QUANTITATION,

2281
01:30:08,887 --> 01:30:10,289
WOULD QUALITATIVE TESTS BE OKAY?

2282
01:30:10,289 --> 01:30:15,360
THOSE ARE  THRESHOLD SO LOWER

2283
01:30:15,360 --> 01:30:16,762
VOLUMES WOULD BE OKAY.

2284
01:30:16,762 --> 01:30:18,030
THERE ARE CONFIGURATIONS OF

2285
01:30:18,030 --> 01:30:19,698
CAPABILITY THAT CAN MATCH

2286
01:30:19,698 --> 01:30:22,801
DIFFERENT USE SETTINGS, AND I

2287
01:30:22,801 --> 01:30:24,736
RELY ON MY HIV COLLEAGUES TO

2288
01:30:24,736 --> 01:30:27,372
TELL ME WHAT THEY WOULD LIKE TO

2289
01:30:27,372 --> 01:30:28,140
HAVE MADE.

2290
01:30:28,140 --> 01:30:30,342
SO, WHAT IS GOING ON IN THE

2291
01:30:30,342 --> 01:30:34,212
PROGRAM HERE IS FOCUSED ON ONE

2292
01:30:34,212 --> 01:30:35,981
SET OF GOALS.

2293
01:30:35,981 --> 01:30:38,984
AND A FUTURE PROGRAM,

2294
01:30:38,984 --> 01:30:39,885
PARTICULARLY WITH ENTHUSIASM AND

2295
01:30:39,885 --> 01:30:44,656
SUPPORT BEHIND IT COULD GO AFTER

2296
01:30:44,656 --> 01:30:45,924
A SECOND GOAL.

2297
01:30:45,924 --> 01:30:48,393
>> ANY OTHER COMMENTS OR

2298
01:30:48,393 --> 01:30:50,095
QUESTIONS? 

2299
01:30:50,095 --> 01:30:52,264
I THINK I'LL SORT OF JUST CHIME

2300
01:30:52,264 --> 01:30:52,431
IN.

2301
01:30:52,431 --> 01:30:54,399
THE REASON I WAS ASKING ABOUT

2302
01:30:54,399 --> 01:30:55,767
PLASMA, THERE ARE PUBLICATIONS

2303
01:30:55,767 --> 01:30:57,336
WHERE THEY HAVE SHOWN THAT THE

2304
01:30:57,336 --> 01:30:59,104
WHOLE BLOOD WILL GIVE YOU A

2305
01:30:59,104 --> 01:31:02,407
READING OF VIRAL LOAD WHEN THE

2306
01:31:02,407 --> 01:31:03,842
PLASMA WILL BE UNDETECTABLE BY

2307
01:31:03,842 --> 01:31:05,944
REGULAR TESTS SO THAT THERE IS A

2308
01:31:05,944 --> 01:31:08,080
FRACTION OF THE VIRUS, EVEN IN

2309
01:31:08,080 --> 01:31:09,247
PEOPLE ON ADJUVANT TRIAL

2310
01:31:09,247 --> 01:31:11,083
THERAPY, THAT ARE SUPPRESSED

2311
01:31:11,083 --> 01:31:11,516
OTHERWISE.

2312
01:31:11,516 --> 01:31:13,218
BUT THAT DOESN'T EXCLUDE THE

2313
01:31:13,218 --> 01:31:14,853
FACT THAT IF YOU'RE TALKING

2314
01:31:14,853 --> 01:31:16,254
ABOUT DIAGNOSIS THAT WHOLE BLOOD

2315
01:31:16,254 --> 01:31:18,023
MAY BE MORE SENSITIVE TO DETECT

2316
01:31:18,023 --> 01:31:19,257
BECAUSE OF THAT COMPONENT THAT

2317
01:31:19,257 --> 01:31:23,261
YOU COULD HAVE THE ADDITIONAL

2318
01:31:23,261 --> 01:31:26,965
SIGNAL COMING FROM

2319
01:31:26,965 --> 01:31:27,833
CELL-ASSOCIATED OR CELL-BOUND

2320
01:31:27,833 --> 01:31:28,834
PLATELETS AND WITH PARTICLES.

2321
01:31:28,834 --> 01:31:32,037
SO TO THE EXTENT THAT YOU COULD

2322
01:31:32,037 --> 01:31:35,507
I GUESS NOT ENCOURAGE BUT

2323
01:31:35,507 --> 01:31:37,075
SUGGEST THAT IF THEY ARE

2324
01:31:37,075 --> 01:31:37,976
DEVELOPING DEVICES THAT THEY

2325
01:31:37,976 --> 01:31:39,711
KIND OF HAVE THE OPTION TO RUN

2326
01:31:39,711 --> 01:31:41,580
WHOLE BLOOD OR FILTRATE IT

2327
01:31:41,580 --> 01:31:43,915
BECAUSE THERE MAY BE DIFFERENT

2328
01:31:43,915 --> 01:31:45,450
APPLICATIONS FOR EITHER ONE.

2329
01:31:45,450 --> 01:31:47,986
DEPENDING WHAT THE OBJECTIVE IS,

2330
01:31:47,986 --> 01:31:52,324
WHETHER EXPOSURE AND VIREMIA

2331
01:31:52,324 --> 01:31:54,326
VERSUS SUPPRESSION UNDER

2332
01:31:54,326 --> 01:31:56,028
ANTIRETROVIRAL THERAPY.

2333
01:31:56,028 --> 01:31:57,362
>> THOSE ARE ALL EXCELLENT

2334
01:31:57,362 --> 01:31:57,929
POINTS.

2335
01:31:57,929 --> 01:32:02,367
I WOULD NOTE THAT THE CRS, THE

2336
01:32:02,367 --> 01:32:05,170
FDA HAS PUBLISHED THAT WE'RE

2337
01:32:05,170 --> 01:32:06,271
WORKING TOWARDS, SAYS THIS IS

2338
01:32:06,271 --> 01:32:10,742
NOT FOR DIAGNOSIS, SO THIS IS A

2339
01:32:10,742 --> 01:32:12,611
VIRAL LOAD TEST FOR

2340
01:32:12,611 --> 01:32:14,346
QUANTITATION, AND THAT'S THE

2341
01:32:14,346 --> 01:32:18,650
SORT OF GUIDING THING WITHIN THE

2342
01:32:18,650 --> 01:32:21,920
PROGRAM THAT'S ONGOING, ONGOING

2343
01:32:21,920 --> 01:32:23,288
DISCUSSION CAN ATTACK DIFFERENT

2344
01:32:23,288 --> 01:32:24,156
LEVELS.

2345
01:32:24,156 --> 01:32:29,327
>> I GET IT BUT I'M SAYING

2346
01:32:29,327 --> 01:32:31,897
QUANTIFICATION WITH NO ANTIBODY

2347
01:32:31,897 --> 01:32:32,731
POSITIVITY, YOU'RE QUANTIFYING

2348
01:32:32,731 --> 01:32:35,600
VIRUS ANYWAY SO EVEN IF IT'S

2349
01:32:35,600 --> 01:32:37,869
QUANTIFICATION MY SUGGESTION WAS

2350
01:32:37,869 --> 01:32:40,639
TO MAKE THEM, ENCOURAGE THEM TO

2351
01:32:40,639 --> 01:32:44,009
RUN TESTS WITH PLASMA OR WHOLE

2352
01:32:44,009 --> 01:32:46,311
BLOOD IF POSSIBLE.

2353
01:32:46,311 --> 01:32:46,912
YOU SAID QUANTIFICATION MORE

2354
01:32:46,912 --> 01:32:47,946
MONITORING, THERE MIGHT BE OTHER

2355
01:32:47,946 --> 01:32:50,982
USES AS THEY DEVELOP THE

2356
01:32:50,982 --> 01:32:51,483
TECHNOLOGY.

2357
01:32:51,483 --> 01:32:53,218
>> PERFECT, THANK YOU.

2358
01:32:53,218 --> 01:32:55,220
>> ANY OTHER QUESTIONS OR

2359
01:32:55,220 --> 01:33:01,093
COMMENTS FROM ANYONE?

2360
01:33:01,093 --> 01:33:01,626
>> ALL RIGHT.

2361
01:33:01,626 --> 01:33:04,896
WE'RE A BIT AHEAD OF AGENDA.

2362
01:33:04,896 --> 01:33:07,099
DR. GLENSHAW, CAN WE PROCEED

2363
01:33:07,099 --> 01:33:08,533
WITH OUR EXTENDED BREAK?

2364
01:33:08,533 --> 01:33:09,067
>> YES.

2365
01:33:09,067 --> 01:33:10,235
THAT'S A GREAT IDEA.

2366
01:33:10,235 --> 01:33:11,236
>> PERFECT.

2367
01:33:11,236 --> 01:33:11,503
THANK YOU.

2368
01:33:11,503 --> 01:33:18,443
SO WE'LL NOW PROCEED TO A BREAK,

2369
01:33:18,443 --> 01:33:20,011
RECONVENING AT 2:15.

2370
01:33:20,011 --> 01:33:22,147
PLEASE COME BACK BY 2:15.

2371
01:33:22,147 --> 01:33:24,916
DO NOT LOG OUT FROM THE TEAMS

2372
01:33:24,916 --> 01:33:26,518
BUT PUT YOURSELF ON MUTE AND

2373
01:33:26,518 --> 01:33:30,288
HIDE YOUR CAMERA. 

2374
01:33:30,288 --> 01:33:32,324
THAT WAY WE CAN KEEP EVERYONE ON

2375
01:33:32,324 --> 01:33:33,291
BOARD.

2376
01:33:33,291 --> 01:33:34,175
SEE YOU BACK AT 2:15.

2377
01:33:34,175 --> 01:33:35,158
THANK YOU, EVERYONE.

2378
01:33:35,158 --> 01:33:36,927
WELCOME BACK, EVERYONE, FROM

2379
01:33:36,927 --> 01:33:37,761
OUR BREAK.

2380
01:33:37,761 --> 01:33:42,366
AND WE CAN PROCEED NOW WITH OUR

2381
01:33:42,366 --> 01:33:43,333
AGENDA FOR TODAY.

2382
01:33:43,333 --> 01:33:45,335
AS WE HAVE RECEIVED SUBSTANTIAL

2383
01:33:45,335 --> 01:33:47,037
FEEDBACK REGARDING THE SUPPORT

2384
01:33:47,037 --> 01:33:49,573
OF THE GUIDELINES, WE DISCUSSED

2385
01:33:49,573 --> 01:33:53,643
THIS BEFORE, AND THIS DISCUSSION

2386
01:33:53,643 --> 01:33:55,379
IS ONGOING, DR. DAN DONENBERG

2387
01:33:55,379 --> 01:33:57,814
WILL SHARE UPDATES AS THE PLAN

2388
01:33:57,814 --> 01:34:02,352
FORWARD AT THIS TIME.

2389
01:34:02,352 --> 01:34:03,487
DR. DONENBERG?

2390
01:34:03,487 --> 01:34:06,089
>> YES, THANK YOU.

2391
01:34:06,089 --> 01:34:07,691
I'M GOING TO ADDRESS THE

2392
01:34:07,691 --> 01:34:09,760
SUBSTANTIAL INTEREST THAT FOLKS

2393
01:34:09,760 --> 01:34:13,397
HAVE HAD IN THE GUIDELINES AND

2394
01:34:13,397 --> 01:34:17,300
OUR STRATEGY TO PLAN FOR THEIR

2395
01:34:17,300 --> 01:34:18,735
SUSTAINABILITY OVER TIME.

2396
01:34:18,735 --> 01:34:23,140
FOR ANYONE IN THE AUDIENCE WHO

2397
01:34:23,140 --> 01:34:26,009
ISN'T FAMILIAR WITH THIS, OARAC

2398
01:34:26,009 --> 01:34:27,944
COORDINATES FIVE EXPERT WORKING

2399
01:34:27,944 --> 01:34:30,213
GROUPS TO DEVELOP THE HIV

2400
01:34:30,213 --> 01:34:32,783
CLINICAL PRACTICE GUIDELINES.

2401
01:34:32,783 --> 01:34:33,617
AND THE GUIDELINES ARE

2402
01:34:33,617 --> 01:34:36,319
RECOMMENDED FOR USE BY THE U.S.

2403
01:34:36,319 --> 01:34:39,423
HEALTH CARE PRACTITIONERS AND

2404
01:34:39,423 --> 01:34:40,357
INFORM CLINICAL PRACTICE AROUND

2405
01:34:40,357 --> 01:34:43,493
THE WORLD AS WELL AS THE U.S. TO

2406
01:34:43,493 --> 01:34:45,328
IMPROVE HEALTH OF PEOPLE WITH

2407
01:34:45,328 --> 01:34:46,163
AND AFFECTED BY HIV.

2408
01:34:46,163 --> 01:34:50,033
SO FOR A LITTLE BIT OF BRIEF

2409
01:34:50,033 --> 01:34:52,069
HISTORICAL CONTEXT.

2410
01:34:52,069 --> 01:34:54,271
THE GUIDELINES PANELS BECAME THE

2411
01:34:54,271 --> 01:34:57,607
WORKING GROUPS OF OARAC IN 2005.

2412
01:34:57,607 --> 01:35:01,278
AND FOR SEVERAL YEARS, THE

2413
01:35:01,278 --> 01:35:02,179
MANAGEMENT, PUBLICATION AND

2414
01:35:02,179 --> 01:35:04,114
DISSEMINATION SUPPORT WAS

2415
01:35:04,114 --> 01:35:10,420
PROVIDED BY THE NATIONAL LIBRARY

2416
01:35:10,420 --> 01:35:12,189
OF MEDICINE, HERE IN THE FEDERAL

2417
01:35:12,189 --> 01:35:12,656
GOVERNMENT.

2418
01:35:12,656 --> 01:35:15,959
THEN IN 2020, THE NIH OFFICE OF

2419
01:35:15,959 --> 01:35:18,295
AIDS RESEARCH TOOK THEM OVER.

2420
01:35:18,295 --> 01:35:21,097
AND, YOU KNOW, HAVING ONLY BEEN

2421
01:35:21,097 --> 01:35:25,068
HERE SINCE OCTOBER, IT HAS BEEN

2422
01:35:25,068 --> 01:35:26,536
AN INCREDIBLE HONOR FOR OAR TO

2423
01:35:26,536 --> 01:35:30,307
CONTRIBUTE TO THE HEALTH OF

2424
01:35:30,307 --> 01:35:32,175
PEOPLE AFFECTED BY HIV THROUGH

2425
01:35:32,175 --> 01:35:33,410
THE GUIDELINES.

2426
01:35:33,410 --> 01:35:36,379
WE'RE INCREDIBLY GRATEFUL FOR

2427
01:35:36,379 --> 01:35:37,581
THE SUBSTANTIAL AND DEDICATED

2428
01:35:37,581 --> 01:35:39,916
WORK OF THE VOLUNTEERS EXPERTS

2429
01:35:39,916 --> 01:35:42,085
WHO DEVELOPED THEM.

2430
01:35:42,085 --> 01:35:43,854
WE ABSOLUTELY KNOW THE

2431
01:35:43,854 --> 01:35:45,388
LIFE-SUSTAINING VALUE OF THESE

2432
01:35:45,388 --> 01:35:46,857
GUIDELINES AND WHAT THEY

2433
01:35:46,857 --> 01:35:49,526
PROVIDE, AND WE ARE EAGER TO

2434
01:35:49,526 --> 01:35:51,061
ENSURE THAT THEY CONTINUE TO DO

2435
01:35:51,061 --> 01:35:51,528
SO.

2436
01:35:51,528 --> 01:35:55,065
I WANT TO MAKE THAT REALLY

2437
01:35:55,065 --> 01:35:55,699
CLEAR.

2438
01:35:55,699 --> 01:35:58,335
THIS IS WHY AMID RECENT EFFORTS

2439
01:35:58,335 --> 01:36:02,105
TO STREAMLINE THE FEDERAL

2440
01:36:02,105 --> 01:36:03,373
COORDINATION AND REDUCE

2441
01:36:03,373 --> 01:36:04,908
SPENDING, OAR FOUGHT VERY HARD

2442
01:36:04,908 --> 01:36:07,177
TO PRESERVE FUNDING FOR THE

2443
01:36:07,177 --> 01:36:07,744
GUIDELINES.

2444
01:36:07,744 --> 01:36:10,380
AND WE WERE ABLE TO SECURE

2445
01:36:10,380 --> 01:36:14,618
FUNDING FOR THE NEXT 12 MONTHS.

2446
01:36:14,618 --> 01:36:16,086
AFTER THAT TIME WE ANTICIPATE

2447
01:36:16,086 --> 01:36:19,356
THAT A MORE LIMITED BUDGET IN

2448
01:36:19,356 --> 01:36:22,926
OAR MAY FORCE US TO REALLOCATE

2449
01:36:22,926 --> 01:36:26,696
RESOURCES FROM THE GUIDELINES

2450
01:36:26,696 --> 01:36:28,098
MANAGEMENT TOWARD ACTIVITIES

2451
01:36:28,098 --> 01:36:33,003
DIRECTLY RELATED TO OUR PRIMARY

2452
01:36:33,003 --> 01:36:37,674
COORDINATING ROLE OF THE NIH HIV

2453
01:36:37,674 --> 01:36:38,475
RESEARCH PROGRAM.

2454
01:36:38,475 --> 01:36:45,081
WE SEE THE NEXT YEAR AS A

2455
01:36:45,081 --> 01:36:46,349
CRITICAL AND IMPORTANT

2456
01:36:46,349 --> 01:36:47,450
OPPORTUNITY TO PLAN FOR

2457
01:36:47,450 --> 01:36:48,518
POTENTIAL TRANSITION.

2458
01:36:48,518 --> 01:36:50,887
TO THAT END, WE HAD PLANNED TO

2459
01:36:50,887 --> 01:36:54,057
CONVENE A DISCUSSION ON THIS

2460
01:36:54,057 --> 01:36:55,625
TOPIC TODAY BUT WE WANT YOU TO

2461
01:36:55,625 --> 01:36:58,595
KNOW THAT AFTER OUR INITIAL

2462
01:36:58,595 --> 01:37:03,366
OUTREACH TO THE GUIDELINE

2463
01:37:03,366 --> 01:37:06,770
PANELS, WE RECEIVED SWIFT AND

2464
01:37:06,770 --> 01:37:09,239
PASSIONATE RESPONSES, EXPRESSING

2465
01:37:09,239 --> 01:37:12,242
CONCERN ABOUT THIS DIRECTION.

2466
01:37:12,242 --> 01:37:14,344
AS A RESULT, WE DEEPLY

2467
01:37:14,344 --> 01:37:16,212
APPRECIATE THE FEEDBACK WE

2468
01:37:16,212 --> 01:37:17,914
RECEIVED FROM PANEL MEMBERS AND

2469
01:37:17,914 --> 01:37:20,884
THE THE BROADER COMMUNITY

2470
01:37:20,884 --> 01:37:23,486
REFLECTING BOTH INDIVIDUALS AND

2471
01:37:23,486 --> 01:37:25,755
ORGANIZATIONS' DEEP DEDICATION

2472
01:37:25,755 --> 01:37:27,557
AND EXPERTISE.

2473
01:37:27,557 --> 01:37:28,658
AND THE FEEDBACK DROVE TO US

2474
01:37:28,658 --> 01:37:29,993
SHIFT PLANS.

2475
01:37:29,993 --> 01:37:32,395
THIS WAS NOT MEANT TO ELIMINATE

2476
01:37:32,395 --> 01:37:32,762
PUBLIC COMMENT.

2477
01:37:32,762 --> 01:37:36,399
IT'S ACTUALLY TO RECEIVE IT IN A

2478
01:37:36,399 --> 01:37:38,602
MORE COORDINATED AND THOUGHTFUL

2479
01:37:38,602 --> 01:37:39,803
WAY.

2480
01:37:39,803 --> 01:37:42,072
SO IN CONSULTATION WITH THE NIH

2481
01:37:42,072 --> 01:37:43,607
EXECUTIVE SECRETARIES AND

2482
01:37:43,607 --> 01:37:47,544
LEADERS OF THE GUIDELINES, WE

2483
01:37:47,544 --> 01:37:49,412
DECIDED TO CREATE ADDITIONAL NEW

2484
01:37:49,412 --> 01:37:52,449
OPPORTUNITIES FOR INPUT AND MORE

2485
01:37:52,449 --> 01:37:53,950
IN-DEPTH DISCUSSIONS.

2486
01:37:53,950 --> 01:37:57,153
SO, WE DECIDED THAT RATHER THAN

2487
01:37:57,153 --> 01:37:58,188
FACILITATING AN EXTENDED

2488
01:37:58,188 --> 01:37:59,689
DISCUSSION TODAY, BECAUSE TIME

2489
01:37:59,689 --> 01:38:01,925
IS REALLY LIMITED IN THIS

2490
01:38:01,925 --> 01:38:04,594
MEETING, I'M GOING TO SPEAK

2491
01:38:04,594 --> 01:38:07,264
BRIEFLY ABOUT OUR PLANS FOR THE

2492
01:38:07,264 --> 01:38:09,866
NEXT STEPS AND THEN ASK

2493
01:38:09,866 --> 01:38:11,901
SPECIFICALLY FOR FEEDBACK ABOUT

2494
01:38:11,901 --> 01:38:14,738
THOSE PLANS.

2495
01:38:14,738 --> 01:38:16,706
WE WILL THEN PRIORITIZE MORE

2496
01:38:16,706 --> 01:38:19,175
DISCUSSION WITH SMALLER GROUPS

2497
01:38:19,175 --> 01:38:24,114
OF PANEL MEMBERS AND FULLY

2498
01:38:24,114 --> 01:38:25,882
EXPLORE TRANSITION OPPORTUNITIES

2499
01:38:25,882 --> 01:38:27,851
WITHIN HHS BEFORE BRINGING THE

2500
01:38:27,851 --> 01:38:33,423
TOPIC TO THE LARGER OARAC FORUM.

2501
01:38:33,423 --> 01:38:36,459
SO, ON THE SCREEN YOU'LL SEE OUR

2502
01:38:36,459 --> 01:38:39,696
PLANNED NEXT STEPS TO ENSURE

2503
01:38:39,696 --> 01:38:42,499
THAT ANY TRANSITION IS

2504
01:38:42,499 --> 01:38:46,036
ABSOLUTELY INFORMED BY INPUT

2505
01:38:46,036 --> 01:38:48,371
FROM FEDERAL PARTNERS, GUIDELINE

2506
01:38:48,371 --> 01:38:52,409
PANEL MEMBERS, AND THE BROADER

2507
01:38:52,409 --> 01:38:53,643
COMMUNITY.

2508
01:38:53,643 --> 01:38:55,612
FIRST, WE PLAN TO CONVENE SMALL

2509
01:38:55,612 --> 01:38:58,715
GROUP DISCUSSIONS WITH EACH OF

2510
01:38:58,715 --> 01:39:00,383
THE GUIDELINE PANELS ABOUT

2511
01:39:00,383 --> 01:39:02,686
OPPORTUNITIES TO IMPROVE THE

2512
01:39:02,686 --> 01:39:05,689
GUIDELINES AND THE PROCESS TO

2513
01:39:05,689 --> 01:39:06,556
DEVELOP THEM.

2514
01:39:06,556 --> 01:39:08,425
WE'LL ASK THE LEADERSHIP OF EACH

2515
01:39:08,425 --> 01:39:11,594
PANEL TO DRIVE THESE DISCUSSIONS

2516
01:39:11,594 --> 01:39:13,897
AND OAR IS ABSOLUTELY AVAILABLE

2517
01:39:13,897 --> 01:39:17,033
TO HELP SUPPORT THAT EFFORT.

2518
01:39:17,033 --> 01:39:19,936
ULTIMATELY, WE'RE HOPING TO GET

2519
01:39:19,936 --> 01:39:21,805
FEEDBACK AND INPUT ON THE

2520
01:39:21,805 --> 01:39:23,273
ELEMENTS OF THE GUIDELINES THAT

2521
01:39:23,273 --> 01:39:27,444
WE REALLY NEED TO MAINTAIN OR

2522
01:39:27,444 --> 01:39:29,045
CHANGE OR MAYBE INITIATE TO

2523
01:39:29,045 --> 01:39:32,248
ENSURE THAT THEY REMAIN RELEVANT

2524
01:39:32,248 --> 01:39:33,950
ACROSS SETTINGS.

2525
01:39:33,950 --> 01:39:36,953
WE WANT INPUT ON OPPORTUNITIES

2526
01:39:36,953 --> 01:39:39,522
TO ENHANCE THE ROLE OF THE

2527
01:39:39,522 --> 01:39:40,890
COMMUNITY IN THE PROCESS.

2528
01:39:40,890 --> 01:39:43,827
WE WOULD LIKE INPUT ON ANY WAYS

2529
01:39:43,827 --> 01:39:48,031
TO STREAMLINE AND IMPROVE THE

2530
01:39:48,031 --> 01:39:49,199
GUIDELINES MANAGEMENT AND

2531
01:39:49,199 --> 01:39:52,302
PRODUCTION AND WE'RE SEEKING

2532
01:39:52,302 --> 01:39:55,105
INPUT ON RECOMMENDATIONS FOR

2533
01:39:55,105 --> 01:39:55,572
PROCESS ENHANCEMENTS.

2534
01:39:55,572 --> 01:39:57,073
FOR EXAMPLE, WHAT'S THE

2535
01:39:57,073 --> 01:40:01,678
FREQUENCY OF THE UPDATE AND

2536
01:40:01,678 --> 01:40:03,713
MEMBERSHIP STRUCTURE?

2537
01:40:03,713 --> 01:40:06,883
WE ALSO WELCOME ANY INPUT ON A

2538
01:40:06,883 --> 01:40:09,352
POTENTIAL TRANSITION OF OAR'S

2539
01:40:09,352 --> 01:40:13,490
ROLE IN MANAGING AND PRODUCING

2540
01:40:13,490 --> 01:40:16,726
THE GUIDELINES.

2541
01:40:16,726 --> 01:40:27,270
SIMULTANEOUSLY, WE INVITE PUBLIC

2542
01:40:29,038 --> 01:40:32,041
INPUT AT OARACINFO@NIH.GOV.

2543
01:40:32,041 --> 01:40:33,710
WE'RE CURRENTLY WORKING TO

2544
01:40:33,710 --> 01:40:36,079
DISCUSS THE FUTURE OF THE

2545
01:40:36,079 --> 01:40:39,682
GUIDELINES WITH HHS AND OTHER

2546
01:40:39,682 --> 01:40:41,718
FEDERAL PARTNERS.

2547
01:40:41,718 --> 01:40:43,153
FINALLY, WE'LL REPORT BACK

2548
01:40:43,153 --> 01:40:46,256
PUBLICLY AND TO OARAC AT FUTURE

2549
01:40:46,256 --> 01:40:50,693
OARAC MEETINGS ON OUR PROGRESS.

2550
01:40:50,693 --> 01:40:54,531
I WANT TO EMPHASIZE WE NEVER

2551
01:40:54,531 --> 01:40:55,765
INTENDED TO ELIMINATE THE

2552
01:40:55,765 --> 01:40:56,266
GUIDELINES.

2553
01:40:56,266 --> 01:40:58,234
THAT WAS NEVER THE INTENT.

2554
01:40:58,234 --> 01:41:01,337
SO I JUST WANT TO BE CLEAR.

2555
01:41:01,337 --> 01:41:04,207
I'M GOING TO STOP HERE TO INVITE

2556
01:41:04,207 --> 01:41:05,909
BRIEF COMMENTS ON THESE SPECIFIC

2557
01:41:05,909 --> 01:41:10,280
NEXT STEPS FROM OARAC MEMBERS

2558
01:41:10,280 --> 01:41:12,515
AND GUIDELINE LEADERSHIP, AND

2559
01:41:12,515 --> 01:41:15,819
TO -- SO WE CAN KNOW BEST HOW TO

2560
01:41:15,819 --> 01:41:17,821
MOVE FORWARD AND AGAIN I'M GOING

2561
01:41:17,821 --> 01:41:19,789
TO ASK EVERYONE TO HOLD ON

2562
01:41:19,789 --> 01:41:21,090
ADDITIONAL FEEDBACK FOR THE

2563
01:41:21,090 --> 01:41:22,525
SMALLER GROUP MEETINGS WHEN WE

2564
01:41:22,525 --> 01:41:28,231
HAVE A MORE IN-DEPTH DISCUSSION.

2565
01:41:28,231 --> 01:41:29,899
>> THANK YOU, DR.
DONENBERG.

2566
01:41:29,899 --> 01:41:30,466
>> SURE.

2567
01:41:30,466 --> 01:41:32,869
>> AND IT'S -- YEAH, I
MEAN, I

2568
01:41:32,869 --> 01:41:34,571
THINK IT'S A VERY GOOD IDEA TO

2569
01:41:34,571 --> 01:41:37,507
HAVE THE SMALLER GROUPS BECAUSE

2570
01:41:37,507 --> 01:41:40,844
THERE'S A LOT TO DISCUSS AND

2571
01:41:40,844 --> 01:41:42,879
IMPLICATIONS OF A TRANSITION AND

2572
01:41:42,879 --> 01:41:44,814
HOW TO STREAMLINE IT IS --

2573
01:41:44,814 --> 01:41:46,015
SHOULD HAVE A FULL DISCUSSION ON

2574
01:41:46,015 --> 01:41:48,651
EACH ONE OF THE WORKING GROUPS.

2575
01:41:48,651 --> 01:41:51,054
SO THANK YOU FOR TAKING THE

2576
01:41:51,054 --> 01:41:53,890
LEADERSHIP TO MAKE THAT

2577
01:41:53,890 --> 01:41:55,825
POSSIBLE, MOVING FORWARD WITH

2578
01:41:55,825 --> 01:41:58,294
OAR SUPPORT.

2579
01:41:58,294 --> 01:42:00,396
SO, WE'LL START WITH A BRIEF

2580
01:42:00,396 --> 01:42:02,699
CLARIFICATION AND DISCUSSION ON

2581
01:42:02,699 --> 01:42:05,068
THE PROPOSED PLAN.

2582
01:42:05,068 --> 01:42:07,237
SO IS THERE ANY FEEDBACK FROM

2583
01:42:07,237 --> 01:42:09,806
THE ROOM AS WE START FIRST?

2584
01:42:09,806 --> 01:42:11,040
 

2585
01:42:11,040 --> 01:42:11,541
>> NOT AT THIS TIME.

2586
01:42:11,541 --> 01:42:13,009
>> THANK YOU.

2587
01:42:13,009 --> 01:42:20,850
WE HAVE ONE ARM, DR. FLETCHER?

2588
01:42:20,850 --> 01:42:23,152
>> YEAH, THANKS FOR SOME
HELPFUL

2589
01:42:23,152 --> 01:42:24,387
CLARIFYING COMMENTS.

2590
01:42:24,387 --> 01:42:26,523
I GUESS I DO -- I MAY NOT BE

2591
01:42:26,523 --> 01:42:28,391
EXACTLY DOING WHAT YOU WANT ME

2592
01:42:28,391 --> 01:42:34,464
TO BUT YOU'RE GOING TO HAVE TO

2593
01:42:34,464 --> 01:42:36,165
BEAR WITH ME.

2594
01:42:36,165 --> 01:42:38,968
I DON'T HOW OAR VIEWS THIS MAY

2595
01:42:38,968 --> 01:42:41,070
BE DIRECTLY RELATED --

2596
01:42:41,070 --> 01:42:42,739
>> WE LOST YOU FOR A
SECOND.

2597
01:42:42,739 --> 01:42:43,806
START OVER.

2598
01:42:43,806 --> 01:42:44,807
THAT WASN'T INTENTIONAL.

2599
01:42:44,807 --> 01:42:46,776
I HAVE NO CONTROL.

2600
01:42:46,776 --> 01:42:49,078
IF YOU COULD START AND SAY THAT

2601
01:42:49,078 --> 01:42:50,079
OVER AGAIN PLEASE.

2602
01:42:50,079 --> 01:42:52,916
>> I GUESS MY FIRST
QUESTION IS

2603
01:42:52,916 --> 01:42:54,617
I DON'T UNDERSTAND THE VIEW THAT

2604
01:42:54,617 --> 01:42:56,519
OAR SEEMS TO HAVE THAT THIS IS

2605
01:42:56,519 --> 01:43:01,691
NOT CENTRAL TO THE MISSION OF

2606
01:43:01,691 --> 01:43:04,227
COORDINATING THE HIV RESEARCH

2607
01:43:04,227 --> 01:43:04,460
PROGRAM.

2608
01:43:04,460 --> 01:43:06,563
IN MY READING, YOU KNOW, THE

2609
01:43:06,563 --> 01:43:07,997
MISSION OF THE NIH, YOU KNOW,

2610
01:43:07,997 --> 01:43:13,903
THE VERY FIRST BULLET IS TO

2611
01:43:13,903 --> 01:43:14,737
FOSTER FUNDAMENTAL DISCOVERIES

2612
01:43:14,737 --> 01:43:15,705
AND THEIR APPLICATIONS.

2613
01:43:15,705 --> 01:43:18,608
TO ME, THIS IS EXACTLY WHAT THE

2614
01:43:18,608 --> 01:43:20,443
GUIDELINES DO.

2615
01:43:20,443 --> 01:43:24,347
IN FULL DISCLOSURE, I WAS ON THE

2616
01:43:24,347 --> 01:43:26,249
HIV GUIDELINES PANEL FROM 2001

2617
01:43:26,249 --> 01:43:26,983
TO 2013.

2618
01:43:26,983 --> 01:43:30,219
AND, YOU KNOW, HAVE FIRSTHAND

2619
01:43:30,219 --> 01:43:33,990
EXPERIENCE IN THE PANEL TAKING

2620
01:43:33,990 --> 01:43:35,591
NIH DISCOVERIES AND TRANSLATING

2621
01:43:35,591 --> 01:43:38,328
THEM INTO, YOU KNOW, HOW TO USE

2622
01:43:38,328 --> 01:43:39,128
THEM.

2623
01:43:39,128 --> 01:43:42,332
SO MEETING THAT, YOU KNOW,

2624
01:43:42,332 --> 01:43:45,768
APPLICATION OF DISCOVERY INTO

2625
01:43:45,768 --> 01:43:46,302
PRACTICE.

2626
01:43:46,302 --> 01:43:49,305
AND SO, YOU KNOW, I'M GOING TO I

2627
01:43:49,305 --> 01:43:51,641
THINK STOP THERE, BUT MY CONCERN

2628
01:43:51,641 --> 01:43:53,810
IS WITH WHAT IS BEING GIVEN AS

2629
01:43:53,810 --> 01:43:55,612
THE PREMISE OF THAT, THAT IT

2630
01:43:55,612 --> 01:44:00,049
DOESN'T SEEM TO BE CENTRAL TO

2631
01:44:00,049 --> 01:44:03,152
THE OARAC OAR MISSION OF

2632
01:44:03,152 --> 01:44:05,688
COORDINATING THE NIH RESEARCH

2633
01:44:05,688 --> 01:44:06,356
PROGRAM.

2634
01:44:06,356 --> 01:44:07,490
>> THANK YOU.

2635
01:44:07,490 --> 01:44:08,992
I APPRECIATE THAT COMMENT.

2636
01:44:08,992 --> 01:44:12,328
AND I -- YOU KNOW, I CERTAINLY

2637
01:44:12,328 --> 01:44:13,830
UNDERSTAND THAT PERSPECTIVE.

2638
01:44:13,830 --> 01:44:15,865
AND WE'RE GOING TO WORK REALLY

2639
01:44:15,865 --> 01:44:18,601
HARD TO FIGURE OUT HOW TO MAKE

2640
01:44:18,601 --> 01:44:23,506
SURE THAT THEY ARE SUSTAINED,

2641
01:44:23,506 --> 01:44:25,108
AND WE CAN DISCUSS THAT FURTHER

2642
01:44:25,108 --> 01:44:32,448
AS WE MOVE FORWARD, YOUR

2643
01:44:32,448 --> 01:44:39,555
PERSPECTIVE, CERTAINLY.

2644
01:44:39,555 --> 01:44:43,793
THANK YOU.

2645
01:44:43,793 --> 01:44:45,661
>> LISA BORGI, I
APPRECIATE THAT

2646
01:44:45,661 --> 01:44:48,398
WILL BE MORE OPPORTUNITY FOR THE

2647
01:44:48,398 --> 01:44:49,665
LARGER COMMUNITIES THAT GIVE

2648
01:44:49,665 --> 01:44:51,634
FEED BANK REGARDING THIS

2649
01:44:51,634 --> 01:44:52,201
PROPOSED TRANSITION.

2650
01:44:52,201 --> 01:44:55,838
I THINK THAT'S REALLY IMPORTANT.

2651
01:44:55,838 --> 01:44:58,107
I ECHO DR. FLETCHER'S COMMENTS,

2652
01:44:58,107 --> 01:45:00,910
I THINK THIS IS CENTRAL TO OAR

2653
01:45:00,910 --> 01:45:03,212
AND HAVING OUTLINED THAT

2654
01:45:03,212 --> 01:45:09,419
IMPLEMENTATION SCIENCE IS PART

2655
01:45:09,419 --> 01:45:10,987
OF WHAT WANTS TO DO GOING

2656
01:45:10,987 --> 01:45:11,421
FORWARD.

2657
01:45:11,421 --> 01:45:14,323
THEY DO THAT RIGOROUSLY AND I

2658
01:45:14,323 --> 01:45:15,625
THINK IT SITS BROADLY.

2659
01:45:15,625 --> 01:45:21,931
THERE ARE WAYS TO ENHANCE

2660
01:45:21,931 --> 01:45:23,332
EFFICIENCY AND REDUCE COST, I

2661
01:45:23,332 --> 01:45:25,835
THINK AS PART OF YOUR PLAN TO

2662
01:45:25,835 --> 01:45:30,940
EXPLORE TRANSITION OPPORTUNITIES

2663
01:45:30,940 --> 01:45:33,709
WITHIN HHS YOU MAY WANT TO HEAR

2664
01:45:33,709 --> 01:45:35,912
HOW DIFFICULT IT IS OUTSIDE HHS.

2665
01:45:35,912 --> 01:45:38,081
WE'VE EXPLORED THAT AND THERE'S

2666
01:45:38,081 --> 01:45:43,152
NO GOOD FIT THAT WILL MAINTAIN

2667
01:45:43,152 --> 01:45:44,220
RIGOROUSNESS, TIMELINESS, AND

2668
01:45:44,220 --> 01:45:46,956
ACCESSIBILITY AS WELL AS THE

2669
01:45:46,956 --> 01:45:49,158
TRUST AND REPUTATION OF WHAT OAR

2670
01:45:49,158 --> 01:45:54,430
IS ABLE TO BRING NOW.

2671
01:45:54,430 --> 01:45:54,964
WHICH WILL DE-EMPHASIZE

2672
01:45:54,964 --> 01:45:56,099
IMPORTANCE OF HIV IN THE UNITED

2673
01:45:56,099 --> 01:45:59,368
STATES OVERALL, WHICH IS NOT THE

2674
01:45:59,368 --> 01:45:59,669
GOAL.

2675
01:45:59,669 --> 01:46:01,771
IF YOU MOVE THIS TO A SMALLER

2676
01:46:01,771 --> 01:46:02,839
ORGANIZATION THAT DOESN'T HAVE

2677
01:46:02,839 --> 01:46:07,443
THE REPUTATION OR ABILITY TO

2678
01:46:07,443 --> 01:46:08,711
PROVIDE WIDE ACCESS, AGAIN WE'RE

2679
01:46:08,711 --> 01:46:10,813
FALLING INTO THE TRAP OF SAYING

2680
01:46:10,813 --> 01:46:11,614
SHIV NO LONGER IMPORTANT IN THE

2681
01:46:11,614 --> 01:46:12,949
UNITED STATES AND I DID NOT

2682
01:46:12,949 --> 01:46:14,750
THINK THAT'S THE MESSAGE THAT

2683
01:46:14,750 --> 01:46:25,328
THIS PANEL WANTS TO SEND.

2684
01:46:25,328 --> 01:46:26,195
THANK YOU.

2685
01:46:26,195 --> 01:46:27,497
>> WE DO NATURAL WANT TO

2686
01:46:27,497 --> 01:46:29,265
COMMUNICATE HIV IS NO LONGER

2687
01:46:29,265 --> 01:46:29,565
IMPORTANT.

2688
01:46:29,565 --> 01:46:31,033
I APPRECIATE THAT.

2689
01:46:31,033 --> 01:46:32,235
>> THANK YOU.

2690
01:46:32,235 --> 01:46:34,871
DR. GULICK?

2691
01:46:34,871 --> 01:46:37,640
>> THANKS FOR BRINGING
THIS TO

2692
01:46:37,640 --> 01:46:41,043
THE FOREFRONT AND ALLOWING US TO

2693
01:46:41,043 --> 01:46:41,477
COMMENT.

2694
01:46:41,477 --> 01:46:46,749
I'M THE ACTION CO-CHAIR OF THE

2695
01:46:46,749 --> 01:46:48,718
ADULT ADOLESCENT ART GUIDELINES.

2696
01:46:48,718 --> 01:46:53,556
THESE GUIDELINES HAVE BEEN IN

2697
01:46:53,556 --> 01:46:55,224
POSITION FOR SEVERAL DECADES,

2698
01:46:55,224 --> 01:46:58,794
AND PROVIDE AS YOU POINTED OUT

2699
01:46:58,794 --> 01:47:01,998
NOT JUST HELPFUL INFORMATION AND

2700
01:47:01,998 --> 01:47:04,700
GUIDANCE FOR U.S. PROVIDERS BUT

2701
01:47:04,700 --> 01:47:07,603
ACCESSED BY PEOPLE AROUND THE

2702
01:47:07,603 --> 01:47:08,004
WORLD.

2703
01:47:08,004 --> 01:47:09,105
AT INTERNATIONAL HIV CONFERENCES

2704
01:47:09,105 --> 01:47:11,073
PEOPLE WILL REFER TO OUR

2705
01:47:11,073 --> 01:47:13,376
GUIDELINES AS BEING THE STANDARD

2706
01:47:13,376 --> 01:47:16,445
OF CARE REALLY FOR THE WORLD.

2707
01:47:16,445 --> 01:47:18,648
SO THE IMPORTANCE OF THEM, I

2708
01:47:18,648 --> 01:47:20,883
ECHO THE PREVIOUS TWO SPEAKERS'

2709
01:47:20,883 --> 01:47:21,817
COMMENTS ABOUT HOW IMPORTANT

2710
01:47:21,817 --> 01:47:22,518
THEY ARE.

2711
01:47:22,518 --> 01:47:30,893
I'D LIKE YOU TO SAY MORE ABOUT

2712
01:47:30,893 --> 01:47:32,528
WHAT'S MOTIVATING THIS CHANGE.

2713
01:47:32,528 --> 01:47:33,830
THERE ARE TWO THINGS, IF I

2714
01:47:33,830 --> 01:47:34,130
UNDERSTAND.

2715
01:47:34,130 --> 01:47:36,165
ONE IS THE MISSION OF US.

2716
01:47:36,165 --> 01:47:38,267
SECONDLY, IS THIS A FINANCIAL

2717
01:47:38,267 --> 01:47:39,168
DECISION HERE?

2718
01:47:39,168 --> 01:47:42,038
AND OBVIOUSLY WE ALL LIVE IN THE

2719
01:47:42,038 --> 01:47:43,072
CURRENT ENVIRONMENT WHERE

2720
01:47:43,072 --> 01:47:44,440
FINANCIAL ISSUES HAVE RISEN TO

2721
01:47:44,440 --> 01:47:46,676
THE TOP OF THE LIST.

2722
01:47:46,676 --> 01:47:48,177
BUT I WOULD BE INTERESTED TO

2723
01:47:48,177 --> 01:47:52,515
HEAR YOU COMMENT MORE WHAT'S

2724
01:47:52,515 --> 01:47:54,817
REALLY MOTIVATING THIS BIG

2725
01:47:54,817 --> 01:47:55,051
CHANGE.

2726
01:47:55,051 --> 01:47:58,221
>> THANK YOU.

2727
01:47:58,221 --> 01:48:00,456
IT WAS INITIALLY MOTIVATED BY

2728
01:48:00,456 --> 01:48:03,259
THE FINANCIAL CONCERNS THAT HAVE

2729
01:48:03,259 --> 01:48:05,161
BEEN RAISED.

2730
01:48:05,161 --> 01:48:07,496
AND THAT, YOU KNOW, WITH THESE

2731
01:48:07,496 --> 01:48:12,001
BUDGET CUTS AMID ALL OF THESE

2732
01:48:12,001 --> 01:48:17,139
BUDGET CUTS WE HAVE TO THINK

2733
01:48:17,139 --> 01:48:17,607
ABOUT BOTH SUSTAINING

2734
01:48:17,607 --> 01:48:19,375
GUIDELINES, AND SO WE FOUGHT TO

2735
01:48:19,375 --> 01:48:21,611
PRESERVE THE FUNDING, BUT WE

2736
01:48:21,611 --> 01:48:23,312
ANTICIPATE THAT HAVING THIS MORE

2737
01:48:23,312 --> 01:48:27,583
LIMITED BUDGET IS GOING TO FORCE

2738
01:48:27,583 --> 01:48:29,318
US TO REALLOCATE THE RESOURCES

2739
01:48:29,318 --> 01:48:32,855
FOR THE GUIDELINES TOWARDS

2740
01:48:32,855 --> 01:48:34,257
ACTIVITIES MORE DIRECTLY RELATED

2741
01:48:34,257 --> 01:48:36,859
TO OUR COORDINATING ROLE.

2742
01:48:36,859 --> 01:48:38,728
WHICH IS TO, YOU KNOW, AROUND

2743
01:48:38,728 --> 01:48:40,429
THE HIV RESEARCH PROGRAM.

2744
01:48:40,429 --> 01:48:43,566
SO THE KINDS OF FUNDS THAT WE

2745
01:48:43,566 --> 01:48:46,602
MAKE DECISIONS ABOUT OR THAT WE

2746
01:48:46,602 --> 01:48:48,804
ALLOCATE FOR RESEARCH STUDIES

2747
01:48:48,804 --> 01:48:50,873
AND PROJECTS LIKE THAT.

2748
01:48:50,873 --> 01:48:54,343
BUT, YOU KNOW, WE CERTAINLY HAVE

2749
01:48:54,343 --> 01:48:56,779
TO BE RESPONSIVE TO, FOR

2750
01:48:56,779 --> 01:48:58,581
EXAMPLE, THE 40% CUT IN THE

2751
01:48:58,581 --> 01:49:02,118
BUDGET THAT WAS PROPOSED.

2752
01:49:02,118 --> 01:49:06,022
AND ACTUALLY IT WAS NOT 40%

2753
01:49:06,022 --> 01:49:10,359
ACROSS THE ENTIRE NIH AND THE

2754
01:49:10,359 --> 01:49:11,327
ENTIRE OFFICES.

2755
01:49:11,327 --> 01:49:14,096
SOME WERE HIGHER, SOME WERE

2756
01:49:14,096 --> 01:49:14,297
LOWER.

2757
01:49:14,297 --> 01:49:16,198
SO ...

2758
01:49:16,198 --> 01:49:17,566
>> WELL, LISA, IF IT'S
OKAY IF I

2759
01:49:17,566 --> 01:49:19,802
COULD DO A FOLLOW-UP TO THAT.

2760
01:49:19,802 --> 01:49:21,404
I THINK IF YOU LOOK AT THE

2761
01:49:21,404 --> 01:49:23,472
BUDGET FOR THOSE GUIDELINES YOU

2762
01:49:23,472 --> 01:49:26,942
WILL FIND THAT THERE IS AN

2763
01:49:26,942 --> 01:49:28,311
ENORMOUS AMOUNT OF VOLUNTEER

2764
01:49:28,311 --> 01:49:31,247
EFFORT THAT HAS BEEN CONTRIBUTED

2765
01:49:31,247 --> 01:49:32,982
TO THIS.

2766
01:49:32,982 --> 01:49:35,318
ACADEMICS FROM ACROSS THE NATION

2767
01:49:35,318 --> 01:49:37,887
WHO VOLUNTEER THEIR TIME TO PUT

2768
01:49:37,887 --> 01:49:39,021
INTO THIS.

2769
01:49:39,021 --> 01:49:42,959
AND AS I UNDERSTAND IT, THE

2770
01:49:42,959 --> 01:49:45,761
SUPPORT FOR THE GUIDELINES

2771
01:49:45,761 --> 01:49:49,098
REALLY BOILS DOWN TO THE

2772
01:49:49,098 --> 01:49:51,834
ADMINISTRATION AND TO THE

2773
01:49:51,834 --> 01:49:53,035
COMMUNICATION OF THE GUIDELINES,

2774
01:49:53,035 --> 01:49:56,806
AND I'LL JUST VOLUNTEER THAT I

2775
01:49:56,806 --> 01:49:58,240
THINK WE'RE REMARKABLY

2776
01:49:58,240 --> 01:49:59,608
STREAMLINED AND EFFECTIVE, COST

2777
01:49:59,608 --> 01:50:01,711
EFFECTIVE, IN TERMS OF WHAT

2778
01:50:01,711 --> 01:50:03,145
WE'RE DOING.

2779
01:50:03,145 --> 01:50:04,447
IF COST WAS MOTIVATING FACTOR

2780
01:50:04,447 --> 01:50:06,148
HERE, I WOULD ASK THAT YOU TAKE

2781
01:50:06,148 --> 01:50:10,252
A VERY GOOD LOOK AT THAT AND SEE

2782
01:50:10,252 --> 01:50:11,387
THE EFFECTIVENESS OF WHAT'S COME

2783
01:50:11,387 --> 01:50:15,124
OUT OF THESE FIVE PANELS AND HOW

2784
01:50:15,124 --> 01:50:16,292
MUCH MONETARY SUPPORT'S REALLY

2785
01:50:16,292 --> 01:50:17,693
GONE INTO IT.

2786
01:50:17,693 --> 01:50:18,894
IF IT'S MISSION, THAT'S

2787
01:50:18,894 --> 01:50:19,462
IMPORTANT TOO.

2788
01:50:19,462 --> 01:50:21,063
BUT MAYBE THOSE TWO THINGS COULD

2789
01:50:21,063 --> 01:50:25,935
BE SPLIT WHEN WE TALK ABOUT IT.

2790
01:50:25,935 --> 01:50:27,636
AND AS COURTNEY FLETCHER POINTED

2791
01:50:27,636 --> 01:50:30,473
OUT ALREADY MUCH OF WHAT WE DO

2792
01:50:30,473 --> 01:50:33,042
ON THE GUIDELINES IS ACTUALLY

2793
01:50:33,042 --> 01:50:34,777
MISSION DRIVEN HERE.

2794
01:50:34,777 --> 01:50:36,512
SO, AGAIN, I LOOK FORWARD TO

2795
01:50:36,512 --> 01:50:38,247
FURTHER CONVERSATIONS BUT IF

2796
01:50:38,247 --> 01:50:40,816
WE'RE TALKING ABOUT MONEY VERSUS

2797
01:50:40,816 --> 01:50:42,651
MISSION, PERHAPS WE COULD FOCUS

2798
01:50:42,651 --> 01:50:47,356
ON THOSE TWO ISSUES CAREFULLY.

2799
01:50:47,356 --> 01:50:48,824
>> I APPRECIATE THAT.

2800
01:50:48,824 --> 01:50:52,461
I THINK DISTINGUISHING THOSE IS

2801
01:50:52,461 --> 01:50:54,597
DEFINITELY IMPORTANT.

2802
01:50:54,597 --> 01:50:55,831
WE RECOGNIZE ABSOLUTELY AMAZING

2803
01:50:55,831 --> 01:51:01,270
VOLUNTEER EFFORT THAT GOES INTO

2804
01:51:01,270 --> 01:51:02,338
THESE GUIDELINES.

2805
01:51:02,338 --> 01:51:03,672
WE AGREE THEY NEED TO BE

2806
01:51:03,672 --> 01:51:08,077
SUSTAINED, THAT THEY ARE VERY

2807
01:51:08,077 --> 01:51:08,577
IMPORTANT.

2808
01:51:08,577 --> 01:51:09,779
SO THANK YOU.

2809
01:51:09,779 --> 01:51:13,182
>> I THINK IT'S CLEAR
BASED ON

2810
01:51:13,182 --> 01:51:15,050
EVERYONE THAT HAS SPOKEN, THE

2811
01:51:15,050 --> 01:51:16,585
COMMITMENT TO MAINTAIN AS YOU

2812
01:51:16,585 --> 01:51:18,087
ALREADY HAVE INDICATED THAT IS

2813
01:51:18,087 --> 01:51:22,691
ALSO THE COMMITMENT OF OAR TO

2814
01:51:22,691 --> 01:51:25,027
MAINTAIN THE GUIDELINES.

2815
01:51:25,027 --> 01:51:29,065
THE ISSUES RAISED IS REGARDING,

2816
01:51:29,065 --> 01:51:31,434
DR. GULICK JUST STATED, THE

2817
01:51:31,434 --> 01:51:35,271
COMMUNICATION AND PERHAPS THE

2818
01:51:35,271 --> 01:51:38,641
DISCUSSIONS MOVING FORWARD

2819
01:51:38,641 --> 01:51:42,278
SHOULD CLARIFY WHETHER THE

2820
01:51:42,278 --> 01:51:44,346
DISCUSSIONS NEED TO INCLUDE THE

2821
01:51:44,346 --> 01:51:46,816
ADAPTING WITHIN THE FISCAL

2822
01:51:46,816 --> 01:51:48,217
REALITY, THE GUIDELINES WITHIN

2823
01:51:48,217 --> 01:51:55,524
OAR OR IS IT REALLY ABOUT THE

2824
01:51:55,524 --> 01:51:57,893
TRANSITION OUT AS AN

2825
01:51:57,893 --> 01:51:59,662
ALREADY-MADE DETERMINATION.

2826
01:51:59,662 --> 01:52:02,264
I THINK THAT MAY CLARIFY THE WAY

2827
01:52:02,264 --> 01:52:02,598
FORWARD.

2828
01:52:02,598 --> 01:52:05,668
BUT THE CLEAR FROM THE FEEDBACK

2829
01:52:05,668 --> 01:52:08,037
THAT OARAC IS PROVIDING YOUR

2830
01:52:08,037 --> 01:52:09,171
OFFICE, THE ADVISORY COMMITTEE

2831
01:52:09,171 --> 01:52:12,641
IS PROVIDING YOUR OFFICE, THAT

2832
01:52:12,641 --> 01:52:16,278
THERE'S STILL SOME SORT OF

2833
01:52:16,278 --> 01:52:17,079
ADVOCACY OR CONCERN OR

2834
01:52:17,079 --> 01:52:18,547
RECOMMENDATION THAT THE BENEFITS

2835
01:52:18,547 --> 01:52:22,418
OF MAINTAINING IT WITHIN YOUR

2836
01:52:22,418 --> 01:52:25,054
OFFICE MAY STILL BE WORTH

2837
01:52:25,054 --> 01:52:26,155
CONSIDERING RELATIVE TO HOW THEY

2838
01:52:26,155 --> 01:52:27,823
WOULD BE MAINTAINED WHICH COULD

2839
01:52:27,823 --> 01:52:29,692
BE STREAMLINED EVEN WITHIN THE

2840
01:52:29,692 --> 01:52:31,293
EXISTING OFFICE.

2841
01:52:31,293 --> 01:52:33,095
SO PROVIDING SOME GUIDANCE ON

2842
01:52:33,095 --> 01:52:35,030
THAT TOWARDS THE WORKING GROUPS

2843
01:52:35,030 --> 01:52:38,534
WOULD BE REALLY HELPFUL BECAUSE

2844
01:52:38,534 --> 01:52:41,237
IT SEEMS THE COMMENTS ARE STILL

2845
01:52:41,237 --> 01:52:43,205
SORT OF ARTICULATING THIS

2846
01:52:43,205 --> 01:52:47,543
QUESTION AS BEING PERHAPS STILL

2847
01:52:47,543 --> 01:52:49,845
OPEN FOR DISCUSSION.

2848
01:52:49,845 --> 01:52:51,514
BUT IF THERE'S AN ADDITIONAL

2849
01:52:51,514 --> 01:52:52,214
POINT --

2850
01:52:52,214 --> 01:52:54,383
>> MAY I RESPOND?

2851
01:52:54,383 --> 01:52:55,117
>> PLEASE.

2852
01:52:55,117 --> 01:52:56,018
>> I WANT TO REITERATE NO
FINAL

2853
01:52:56,018 --> 01:52:57,119
DECISION HAS BEEN MADE.

2854
01:52:57,119 --> 01:52:58,854
I WANT TO MAKE THAT REALLY

2855
01:52:58,854 --> 01:52:59,088
CLEAR.

2856
01:52:59,088 --> 01:53:02,591
THERE'S NO FINAL DECISION THAT

2857
01:53:02,591 --> 01:53:04,093
HAS BEEN MADE ABOUT WHERE THE

2858
01:53:04,093 --> 01:53:05,194
GUIDELINES ARE GOING TO BE.

2859
01:53:05,194 --> 01:53:10,199
THE SECOND POINT I WOULD MAKE IS

2860
01:53:10,199 --> 01:53:12,301
LOOKING AT OUR PLANS, THE REASON

2861
01:53:12,301 --> 01:53:16,872
WE HAVE THOSE STEPS IN PLACE IS

2862
01:53:16,872 --> 01:53:18,941
TO BASICALLY ADDRESS HOW WE --

2863
01:53:18,941 --> 01:53:22,945
IF THE PERCEPTION OR IF THE

2864
01:53:22,945 --> 01:53:24,547
ISSUES ARE FINANCIAL, WHERE CAN

2865
01:53:24,547 --> 01:53:26,015
THERE BE STREAMLINING OF SOME OF

2866
01:53:26,015 --> 01:53:28,651
THESE PROCESSES AND SOME OF

2867
01:53:28,651 --> 01:53:30,719
THESE SUPPORTS SO THAT THEY --

2868
01:53:30,719 --> 01:53:33,856
SO THEY ARE MORE MANAGEABLE AND

2869
01:53:33,856 --> 01:53:36,759
MORE EFFICIENTLY PRODUCED AND

2870
01:53:36,759 --> 01:53:38,427
MORE EFFICIENTLY DISSEMINATED.

2871
01:53:38,427 --> 01:53:40,596
SO, JUST WANTED TO PUT THAT OUT

2872
01:53:40,596 --> 01:53:42,598
THAT OUR HOPE IS THAT SOME OF

2873
01:53:42,598 --> 01:53:45,935
THE STEPS WE'VE LAID OUT WILL

2874
01:53:45,935 --> 01:53:46,769
ACCOMPLISH THAT.

2875
01:53:46,769 --> 01:53:48,170
AND PROVIDE THAT KIND OF

2876
01:53:48,170 --> 01:53:48,571
DIRECTION.

2877
01:53:48,571 --> 01:53:52,441
I HEAR YOU AND JUST WANT TO MAKE

2878
01:53:52,441 --> 01:53:55,978
CLEAR NO FINAL DECISION HAS BEEN

2879
01:53:55,978 --> 01:54:01,283
MADE ABOUT WHERE THE GUIDELINES

2880
01:54:01,283 --> 01:54:01,951
WOULD LIVE.

2881
01:54:01,951 --> 01:54:03,085
>> IS IT CORRECT TO
INTERPRET

2882
01:54:03,085 --> 01:54:05,321
THAT OARAC COULD BE ONE OF THOSE

2883
01:54:05,321 --> 01:54:08,791
LOCATIONS STILL IN THE FUTURE?

2884
01:54:08,791 --> 01:54:09,458
>> YES.

2885
01:54:09,458 --> 01:54:10,092
>> OKAY.

2886
01:54:10,092 --> 01:54:12,027
SO GETTING THE FINANCIAL ASPECT

2887
01:54:12,027 --> 01:54:13,462
ADDRESSED WITHIN THE CONTEXT OF

2888
01:54:13,462 --> 01:54:14,430
STAYING WITHIN THE EXISTING

2889
01:54:14,430 --> 01:54:15,998
STRUCTURE IS STILL AN OPTION?

2890
01:54:15,998 --> 01:54:21,136
>> IT IS STILL AN OPTION.

2891
01:54:21,136 --> 01:54:22,371
>> THANK YOU.

2892
01:54:22,371 --> 01:54:27,343
I'M SORRY TO MISPRONOUNCE  YOUR

2893
01:54:27,343 --> 01:54:28,410
PEOPLE IN.

2894
01:54:28,410 --> 01:54:30,346
>> LISA IS FINE.

2895
01:54:30,346 --> 01:54:33,515
A FINAL POINT, EVEN AS CO-PANEL

2896
01:54:33,515 --> 01:54:35,451
LEADERSHIP, I'M NOT CLEAR ON THE

2897
01:54:35,451 --> 01:54:35,818
BUDGET.

2898
01:54:35,818 --> 01:54:38,554
AND SO IF WE'RE GOING HAVE

2899
01:54:38,554 --> 01:54:39,955
DISCUSSIONS THAT ARE PRIMARILY

2900
01:54:39,955 --> 01:54:41,991
FINANCIALLY DRIVEN, THERE NEEDS

2901
01:54:41,991 --> 01:54:43,492
TO BE SOME TRANSPARENCY ABOUT

2902
01:54:43,492 --> 01:54:45,761
WHAT IS THE BUDGET, WHERE DOES

2903
01:54:45,761 --> 01:54:47,463
IT GO TO, BECAUSE WE CAN'T TELL

2904
01:54:47,463 --> 01:54:50,733
YOU HOW WE CAN ENHANCE

2905
01:54:50,733 --> 01:54:52,001
EFFICIENCY IF WE DON'T KNOW

2906
01:54:52,001 --> 01:54:53,669
WHERE THE MONEY IS SPENT OR WHAT

2907
01:54:53,669 --> 01:54:54,937
PROPORTION OF OAR IT IS TAKING

2908
01:54:54,937 --> 01:54:56,238
SO I THINK THAT WOULD BE AN

2909
01:54:56,238 --> 01:54:57,306
IMPORTANT PIECE OF THIS

2910
01:54:57,306 --> 01:54:57,640
DISCUSSION.

2911
01:54:57,640 --> 01:55:02,044
>> THANK YOU. 

2912
01:55:02,044 --> 01:55:05,281
AND I COMPLETELY AGREE.

2913
01:55:05,281 --> 01:55:05,981
>> THANK YOU.

2914
01:55:05,981 --> 01:55:08,417
WE'VE REACHED THE END OF THE

2915
01:55:08,417 --> 01:55:09,551
ALLOTTED TIME.

2916
01:55:09,551 --> 01:55:10,386
THANK YOU, EVERYONE, FOR YOUR

2917
01:55:10,386 --> 01:55:14,390
COMMITMENT TO THE FIELD AND TO

2918
01:55:14,390 --> 01:55:15,758
EVERYONE THAT IS BENEFITING AND

2919
01:55:15,758 --> 01:55:16,592
DEPENDS ON THE GUIDELINES.

2920
01:55:16,592 --> 01:55:19,194
THE COMMITMENT FROM THE PANEL

2921
01:55:19,194 --> 01:55:23,532
AND WORKING GROUPS AND OAR IS

2922
01:55:23,532 --> 01:55:24,266
REALLY WITHOUT QUESTION.

2923
01:55:24,266 --> 01:55:27,136
THE QUESTION IS HOW TO PRESERVE

2924
01:55:27,136 --> 01:55:29,872
THE BENEFIT FOR EVERYONE WITHIN

2925
01:55:29,872 --> 01:55:30,639
THE CURRENT ENVIRONMENT.

2926
01:55:30,639 --> 01:55:33,609
THANK YOU TO PANEL LEADERS AND

2927
01:55:33,609 --> 01:55:35,010
OARAC MEMBERS AND EVERYONE FOR

2928
01:55:35,010 --> 01:55:37,279
YOUR INPUT AND WE LOOK FORWARD

2929
01:55:37,279 --> 01:55:39,048
TO WORKING GROUPS BEING A

2930
01:55:39,048 --> 01:55:41,750
PRODUCTIVE DIRECTION TO MAINTAIN

2931
01:55:41,750 --> 01:55:44,253
THE GUIDELINES.

2932
01:55:44,253 --> 01:55:46,388
AND THE IMPORTANT ROLE THEY PLAY

2933
01:55:46,388 --> 01:55:48,590
FOR PEOPLE LIVING WITH HIV.

2934
01:55:48,590 --> 01:55:52,027
WITH THIS WE'LL PROCEED TO OAR

2935
01:55:52,027 --> 01:55:55,698
UPDATES, SO WE'LL NOW HEAR BRIEF

2936
01:55:55,698 --> 01:55:58,500
UPDATES SO DR. JULIO ALBERTI,

2937
01:55:58,500 --> 01:56:00,636
ACTING SCIENCE TEAM LEAD, AND

2938
01:56:00,636 --> 01:56:02,071
DR. DAVID CHANG, HEALTH

2939
01:56:02,071 --> 01:56:03,439
SCIENTIST ADMINISTRATOR, OFFICE

2940
01:56:03,439 --> 01:56:05,674
OF AIDS RESEARCH, WILL PROVIDE

2941
01:56:05,674 --> 01:56:08,277
UPDATES ON RECENT ENGAGEMENTS

2942
01:56:08,277 --> 01:56:09,945
FROM OAR INNOVATION AND EARLY

2943
01:56:09,945 --> 01:56:12,581
CAREER INVESTIGATORS PROGRAM.

2944
01:56:12,581 --> 01:56:16,385
SO DR. ALBERTI FIRST, PLEASE,

2945
01:56:16,385 --> 01:56:18,987
AND THEN WE'LL MOVE ON TO DR.

2946
01:56:18,987 --> 01:56:19,188
CHANG.

2947
01:56:19,188 --> 01:56:21,190
>> GOOD AFTERNOON.

2948
01:56:21,190 --> 01:56:26,328
I'M JULIO ALBERTI, SENIOR

2949
01:56:26,328 --> 01:56:33,836
SCIENCE  ADVISER, INNOVATION IN

2950
01:56:33,836 --> 01:56:36,271
HIV RESEARCH SYMPOSIUM.

2951
01:56:36,271 --> 01:56:39,641
EVERY YEAR OAR DEVELOPED THIS

2952
01:56:39,641 --> 01:56:42,344
PROCESS TO AWARD MERITORIOUS

2953
01:56:42,344 --> 01:56:44,813
PROJECTS THAT BRING INNOVATIVE

2954
01:56:44,813 --> 01:56:48,417
APPROACHES TO ADDRESS HIGH

2955
01:56:48,417 --> 01:56:50,719
PRIORITY OPPORTUNITIES IN

2956
01:56:50,719 --> 01:56:52,421
HIV/AIDS RESEARCH.

2957
01:56:52,421 --> 01:56:55,724
THESE ARE CONSIDERED HIGH RISK,

2958
01:56:55,724 --> 01:56:56,725
HIGH REWARD APPLICATIONS.

2959
01:56:56,725 --> 01:56:58,594
AND THEY ARE PROVIDED TO US,

2960
01:56:58,594 --> 01:57:01,663
THEY ARE SUBMITTED TO US BY

2961
01:57:01,663 --> 01:57:03,031
INSTITUTES, CENTERS, AND

2962
01:57:03,031 --> 01:57:04,867
OFFICES, AND WE CONSIDER THEM

2963
01:57:04,867 --> 01:57:05,768
FOR FUNDING.

2964
01:57:05,768 --> 01:57:07,169
TO BE CONSIDERED FOR FUNDING

2965
01:57:07,169 --> 01:57:08,804
THESE APPLICATIONS NEED TO BE

2966
01:57:08,804 --> 01:57:11,940
ALIGNED WITH THE HIV/AIDS

2967
01:57:11,940 --> 01:57:15,010
RESEARCH PRIORITIES.

2968
01:57:15,010 --> 01:57:17,379
AND WHICH ALSO INCLUDE STRATEGIC

2969
01:57:17,379 --> 01:57:21,483
PLAN AND PROFESSIONAL JUDGMENT

2970
01:57:21,483 --> 01:57:21,850
BUDGET.

2971
01:57:21,850 --> 01:57:25,687
SEVERAL TYPES OF APPLICATIONS

2972
01:57:25,687 --> 01:57:27,256
CAN BE BROUGHT UP FOR

2973
01:57:27,256 --> 01:57:32,761
CONSIDERATION UNDER THE

2974
01:57:32,761 --> 01:57:33,929
INNOVATION PROGRAM.

2975
01:57:33,929 --> 01:57:38,300
I WILL SPEAK SPECIFICALLY ABOUT

2976
01:57:38,300 --> 01:57:40,702
INTRAMURAL PROJECTS.

2977
01:57:40,702 --> 01:57:42,738
TOTAL HIV RESEARCH IN INTRAMURAL

2978
01:57:42,738 --> 01:57:45,307
PROGRAM IS 12% OF THE --

2979
01:57:45,307 --> 01:57:48,410
APPROXIMATELY 12% OF THE NIH HIV

2980
01:57:48,410 --> 01:57:50,879
RESEARCH BUDGET.

2981
01:57:50,879 --> 01:57:54,583
AND UNDER THE INNOVATION

2982
01:57:54,583 --> 01:57:59,021
PROGRAM, WE HAVE BEEN AWARDING

2983
01:57:59,021 --> 01:58:02,791
SOMEWHERE BETWEEN 19 AND 25

2984
01:58:02,791 --> 01:58:04,660
INTRAMURAL PROJECTS SINCE FISCAL

2985
01:58:04,660 --> 01:58:05,294
YEAR 22.

2986
01:58:05,294 --> 01:58:07,462
TOTAL AMOUNT OF FUNDING FOR

2987
01:58:07,462 --> 01:58:11,600
THESE INTRAMURAL PROJECTS RANGE

2988
01:58:11,600 --> 01:58:15,170
FROM 11 TO $14 MILLION, FROM 22

2989
01:58:15,170 --> 01:58:17,272
TO 24.

2990
01:58:17,272 --> 01:58:19,374
AND SEVERAL INSTITUTES

2991
01:58:19,374 --> 01:58:21,677
PARTICIPATE IN THIS EFFORT.

2992
01:58:21,677 --> 01:58:25,981
AND THESE ARE LISTED HERE,

2993
01:58:25,981 --> 01:58:29,284
NIAID, NCI, NIDDC, NINDS, NIEHS,

2994
01:58:29,284 --> 01:58:39,094
AND NATIONAL LIBRARY OF

2995
01:58:39,094 --> 01:58:40,562
MEDICINE.

2996
01:58:40,562 --> 01:58:42,331
EXTRAMURAL AWARDS AND CONTRACTS

2997
01:58:42,331 --> 01:58:45,734
ARE EXTENSIVELY FOLLOWED UP AND

2998
01:58:45,734 --> 01:58:48,737
DOCUMENTED.

2999
01:58:48,737 --> 01:58:52,975
THIS IS NOT TRUE, NOT OBVIOUS

3000
01:58:52,975 --> 01:58:55,043
FOR INTRAMURAL PROJECTS.

3001
01:58:55,043 --> 01:58:58,680
AND ONCE INTRAMURAL AWARDS ARE

3002
01:58:58,680 --> 01:59:00,582
MADE, UNDER THE INNOVATION

3003
01:59:00,582 --> 01:59:03,619
PROGRAM, WHAT HAPPENS IS THEY

3004
01:59:03,619 --> 01:59:04,887
GET DILUTED IN THE ENTIRE

3005
01:59:04,887 --> 01:59:06,922
PRODUCTION OF THESE LABS.

3006
01:59:06,922 --> 01:59:08,991
INTRAMURAL LABS ARE HIGHLY

3007
01:59:08,991 --> 01:59:12,628
PRODUCTIVE, AND SO, YOU KNOW,

3008
01:59:12,628 --> 01:59:13,962
OUR CONTRIBUTION SOMETIMES GETS

3009
01:59:13,962 --> 01:59:18,267
DILUTED AND WE CANNOT PINPOINT

3010
01:59:18,267 --> 01:59:22,504
THE IMPACT OF OUR PROGRAM,

3011
01:59:22,504 --> 01:59:24,006
INTRAMURAL PROGRAM.

3012
01:59:24,006 --> 01:59:25,507
ONE SOLUTION PROPOSED WAS CREATE

3013
01:59:25,507 --> 01:59:27,843
SYMPOSIUM WHERE WE BRING

3014
01:59:27,843 --> 01:59:29,645
AWARDEES FOR THE PAST YEAR TO

3015
01:59:29,645 --> 01:59:32,347
PRESENT THE SCIENTIFIC PROGRESS

3016
01:59:32,347 --> 01:59:35,918
OF THEIR WORK PROPOSED.

3017
01:59:35,918 --> 01:59:37,519
THIS SYMPOSIUM IS AN OPPORTUNITY

3018
01:59:37,519 --> 01:59:41,490
NOT JUST TO PRESENT THEIR

3019
01:59:41,490 --> 01:59:44,092
RESEARCH ADVANCES BUT ALSO TO

3020
01:59:44,092 --> 01:59:47,062
COALESCE CRITICAL MISS AMONG THE

3021
01:59:47,062 --> 01:59:49,097
INTRAMURAL HIV INVESTIGATORS.

3022
01:59:49,097 --> 01:59:54,236
AND NEW COLLABORATIONS HAVE

3023
01:59:54,236 --> 01:59:56,471
FLOURISHED SINCE WE STARTED THE

3024
01:59:56,471 --> 01:59:57,372
SYMPOSIA.

3025
01:59:57,372 --> 01:59:59,274
WE HAVE A GREATER FOCUS ON THE

3026
01:59:59,274 --> 02:00:01,810
IMPACT OF THESE RESEARCH

3027
02:00:01,810 --> 02:00:04,613
FINDINGS WHEN THEY ARE PRESENTED

3028
02:00:04,613 --> 02:00:08,617
IN THE SYMPOSIUM FORMAT.

3029
02:00:08,617 --> 02:00:12,788
AND HIV RESEARCH AS WE'VE SEEN,

3030
02:00:12,788 --> 02:00:20,629
EVER SINCE THE '80s, IT HAS A

3031
02:00:20,629 --> 02:00:23,632
VERY BROAD, FROM CELLS TO

3032
02:00:23,632 --> 02:00:24,099
COMMUNITIES.

3033
02:00:24,099 --> 02:00:26,468
WE CAN SEE INAUGURAL SYMPOSIUM

3034
02:00:26,468 --> 02:00:28,303
THAT WE STARTED IN 2023, AS YOU

3035
02:00:28,303 --> 02:00:30,906
CAN SEE HERE FOR AGENDA OF THE

3036
02:00:30,906 --> 02:00:36,645
PROGRAM IT HAS A WIDE RANGE OF

3037
02:00:36,645 --> 02:00:44,419
TOPICS THAT WERE COVERED FROM

3038
02:00:44,419 --> 02:00:50,192
TESTING TO VACCINES TO CANCER TO

3039
02:00:50,192 --> 02:00:53,095
BASIC CELL BIOLOGY AND VIROLOGY,

3040
02:00:53,095 --> 02:00:55,430
INVASION OF CELLS AND SO FORTH.

3041
02:00:55,430 --> 02:00:57,332
THE SAME WAS TRUE IN THE SECOND

3042
02:00:57,332 --> 02:01:00,535
YEAR, THE SECOND YEAR WE HAD A

3043
02:01:00,535 --> 02:01:03,171
BIGGER PROGRAM.

3044
02:01:03,171 --> 02:01:05,841
THESE ARE SEVERAL -- ALL THE

3045
02:01:05,841 --> 02:01:07,209
AWARDEES.

3046
02:01:07,209 --> 02:01:08,243
SOMETIMES THEY SEND THEIR JUNIOR

3047
02:01:08,243 --> 02:01:08,944
INVESTIGATORS THAT ARE ACTUALLY

3048
02:01:08,944 --> 02:01:10,045
DOING THE WORK TO PRESENT THE

3049
02:01:10,045 --> 02:01:14,750
WORK TO US SO IT'S AN

3050
02:01:14,750 --> 02:01:20,155
OPPORTUNITY FOR EXPOSURE AND

3051
02:01:20,155 --> 02:01:20,889
LEARNING FOR YOUNG

3052
02:01:20,889 --> 02:01:21,356
INVESTIGATORS.

3053
02:01:21,356 --> 02:01:22,691
AND WHEN YOU PUT IT ALL TOGETHER

3054
02:01:22,691 --> 02:01:26,161
YOU CAN SEE THE RANGE OF TOPICS

3055
02:01:26,161 --> 02:01:29,297
THAT HAVE BEEN COVERED IN THESE

3056
02:01:29,297 --> 02:01:34,236
TWO YEARS OF THE INNOVATION AND

3057
02:01:34,236 --> 02:01:37,472
HIV RESEARCH SYMPOSIUM.

3058
02:01:37,472 --> 02:01:44,146
YOU CAN SEE HERE MICROBIOME,

3059
02:01:44,146 --> 02:01:44,913
CANCER, KAPOSI SARCOMA,

3060
02:01:44,913 --> 02:01:46,348
VACCINES, AND SEVERAL OTHER

3061
02:01:46,348 --> 02:01:55,991
TOPICS ARE ALL COVERED IN THIS

3062
02:01:55,991 --> 02:01:56,725
WORD CLOUD.

3063
02:01:56,725 --> 02:02:00,996
AND WE COME TO THE CURRENT

3064
02:02:00,996 --> 02:02:04,399
VERSION OF THE INNOVATION IN HIV

3065
02:02:04,399 --> 02:02:05,400
RESEARCH SYMPOSIUM.

3066
02:02:05,400 --> 02:02:08,904
SO WE TRY TO MATCH THE PERIOD

3067
02:02:08,904 --> 02:02:10,439
WHERE THE NIH RESEARCH FESTIVAL

3068
02:02:10,439 --> 02:02:11,440
HAPPENS.

3069
02:02:11,440 --> 02:02:13,008
SO DURING THE DAYS WHERE

3070
02:02:13,008 --> 02:02:14,309
RESEARCH FESTIVAL IS HAPPENING,

3071
02:02:14,309 --> 02:02:15,911
WE TRY TO BRING THE

3072
02:02:15,911 --> 02:02:16,678
INVESTIGATORS TOGETHER AND

3073
02:02:16,678 --> 02:02:19,047
PRESENT THEIR WORK.

3074
02:02:19,047 --> 02:02:21,416
WE HAVE FOR THIS YEAR IT'S GOING

3075
02:02:21,416 --> 02:02:23,585
TO BE ON SEPTEMBER 10, FROM 9:30

3076
02:02:23,585 --> 02:02:25,120
TO 4:30.

3077
02:02:25,120 --> 02:02:28,156
IT'S A HYBRID EVENT SO PEOPLE

3078
02:02:28,156 --> 02:02:29,291
CAN ATTEND ONLINE.

3079
02:02:29,291 --> 02:02:31,893
AND THEY CAN COME HERE IN

3080
02:02:31,893 --> 02:02:35,097
FISHERS LANE TO SEE IN PERSON IF

3081
02:02:35,097 --> 02:02:36,298
THEY WANT TO.

3082
02:02:36,298 --> 02:02:39,267
THE AGENDA IS BEING FINALIZED,

3083
02:02:39,267 --> 02:02:40,869
CALENDAR INVITATIONS WILL BE

3084
02:02:40,869 --> 02:02:44,372
SENT SOON TO ALL PARTICIPANTS OF

3085
02:02:44,372 --> 02:02:44,573
OARAC.

3086
02:02:44,573 --> 02:02:48,510
WE HAVE ABOUT 18 PRESENTATIONS

3087
02:02:48,510 --> 02:02:50,078
FROM INTRAMURAL INVESTIGATORS

3088
02:02:50,078 --> 02:02:54,382
AND THEY ARE SHOWCASING THE

3089
02:02:54,382 --> 02:02:58,887
RESULTS THAT THEY GATHERED SINCE

3090
02:02:58,887 --> 02:03:03,125
THEY WERE AWARDED IN 2024.

3091
02:03:03,125 --> 02:03:07,796
SO WE WOULD LIKE TO ASK OARAC

3092
02:03:07,796 --> 02:03:09,331
MEMBERS' INPUT.

3093
02:03:09,331 --> 02:03:12,000
WE WOULD LIKE TO SEE YOUR

3094
02:03:12,000 --> 02:03:13,401
RECOMMENDATIONS FOR WHAT METRICS

3095
02:03:13,401 --> 02:03:16,404
SHOULD WE USE TO EVALUATE

3096
02:03:16,404 --> 02:03:18,673
LONG-TERM IMPACT OF THE

3097
02:03:18,673 --> 02:03:20,075
INNOVATION PROGRAM FUNDING.

3098
02:03:20,075 --> 02:03:23,845
HOW CAN THE INNOVATION PROGRAM

3099
02:03:23,845 --> 02:03:25,247
BETTER SUPPORT

3100
02:03:25,247 --> 02:03:29,284
CROSS-DISCIPLINARY TEAMS AND

3101
02:03:29,284 --> 02:03:31,486
WHOLE-PERSON RESEARCH

3102
02:03:31,486 --> 02:03:32,921
APPROACHES, INTEGRATING MENTAL

3103
02:03:32,921 --> 02:03:34,523
HEALTH, STIGMA, HOUSING.

3104
02:03:34,523 --> 02:03:36,925
WHAT ARE YOUR RECOMMENDATIONS TO

3105
02:03:36,925 --> 02:03:38,360
ENHANCE VISIBILITY,

3106
02:03:38,360 --> 02:03:39,528
COLLABORATION, OR POLICY IMPACT

3107
02:03:39,528 --> 02:03:42,697
OF THE ANNUAL INNOVATION IN HIV

3108
02:03:42,697 --> 02:03:43,999
RESEARCH SYMPOSIUM?

3109
02:03:43,999 --> 02:03:46,968
AND FINALLY WHAT ARE THE

3110
02:03:46,968 --> 02:03:49,037
EMERGING SCIENTIFIC OR POLICY

3111
02:03:49,037 --> 02:03:50,972
TRENDS THAT OAR SHOULD PREPARE

3112
02:03:50,972 --> 02:03:54,376
FOR WITHIN THE INNOVATION

3113
02:03:54,376 --> 02:03:56,411
PROGRAM FRAMEWORK?

3114
02:03:56,411 --> 02:04:01,082
THANK YOU.

3115
02:04:01,082 --> 02:04:02,217
>> DR. CHANG, YOU CAN
PROCEED,

3116
02:04:02,217 --> 02:04:05,387
AND THEN WE'LL HAVE DISCUSSION

3117
02:04:05,387 --> 02:04:13,695
AFTERWARDS.

3118
02:04:13,695 --> 02:04:15,330
>> HELLO, I'M DAVID CHANG,

3119
02:04:15,330 --> 02:04:16,832
SENIOR SCIENCE ADVISER, OFFICE

3120
02:04:16,832 --> 02:04:19,868
OF AIDS RESEARCH, I LEAD THE

3121
02:04:19,868 --> 02:04:20,635
EARLY CAREER INVESTIGATORS

3122
02:04:20,635 --> 02:04:21,703
SIGNATURE PROGRAM.

3123
02:04:21,703 --> 02:04:23,905
TODAY I'M EXCITED TO SHARE SOME

3124
02:04:23,905 --> 02:04:25,640
UPDATES ON OUR EFFORTS TO

3125
02:04:25,640 --> 02:04:27,375
SUPPORT EARLY CAREER

3126
02:04:27,375 --> 02:04:28,810
INVESTIGATORS IN HIV.

3127
02:04:28,810 --> 02:04:30,812
THIS INITIATIVE IS A

3128
02:04:30,812 --> 02:04:32,280
COLLABORATIVE EFFORT ACROSS

3129
02:04:32,280 --> 02:04:33,949
MULTIPLE NIH INSTITUTES,

3130
02:04:33,949 --> 02:04:35,083
CENTERS, OFFICES, AND IT'S TRULY

3131
02:04:35,083 --> 02:04:38,787
A LABOR OF LOVE THAT WE ALL

3132
02:04:38,787 --> 02:04:39,321
PRIORITIZE.

3133
02:04:39,321 --> 02:04:43,391
I'LL SPEAK ON BEHALF OF OUR ECI

3134
02:04:43,391 --> 02:04:46,795
WORKING GROUPS AT OAR, AND THE

3135
02:04:46,795 --> 02:04:49,231
NIH AIDS EXECUTIVE COMMITTEE.

3136
02:04:49,231 --> 02:04:52,167
I WANT TO ACKNOWLEDGE MY

3137
02:04:52,167 --> 02:04:52,901
COLLEAGUE LIZ KAYLOR FOR

3138
02:04:52,901 --> 02:04:54,236
STANDING UP THE PROGRAM AND

3139
02:04:54,236 --> 02:04:57,772
BUILDING IT TO WHAT IT IS TODAY.

3140
02:04:57,772 --> 02:05:02,143
SO IN MY PRESENTATION I'LL

3141
02:05:02,143 --> 02:05:04,179
EXPLAIN WHY SUPPORTING ECI,

3142
02:05:04,179 --> 02:05:05,747
EARLY CAREER INVESTIGATORS, IS

3143
02:05:05,747 --> 02:05:06,081
CRUCIAL.

3144
02:05:06,081 --> 02:05:09,384
WE'LL REVIEW PROGRESS AND

3145
02:05:09,384 --> 02:05:10,151
HIGHLIGHTS FROM 2024, DISCUSS

3146
02:05:10,151 --> 02:05:12,787
EFFORTS TO EXPAND SUPPORT AND

3147
02:05:12,787 --> 02:05:14,623
OUTREACH AND OUTLINE HOW WE'RE

3148
02:05:14,623 --> 02:05:16,424
LISTENING TO THE ECI COMMUNITY

3149
02:05:16,424 --> 02:05:22,831
IN 2025 TO PLAN FOR THE FUTURE.

3150
02:05:22,831 --> 02:05:24,199
FIRST LET'S CLARIFY TERM

3151
02:05:24,199 --> 02:05:26,601
FOLLOWING.

3152
02:05:26,601 --> 02:05:31,473
WE USE THE EARLY ECI, EARLY

3153
02:05:31,473 --> 02:05:37,545
CAREER INVESTIGATORS,  PURSUING

3154
02:05:37,545 --> 02:05:40,148
FIRST RESEARCH AWARD, R01 OR

3155
02:05:40,148 --> 02:05:40,682
EQUIVALENT.

3156
02:05:40,682 --> 02:05:43,952
TWO YEARS POST-RECEIPT OF FIRST

3157
02:05:43,952 --> 02:05:47,589
INDEPENDENT AWARD, BROADER THAN

3158
02:05:47,589 --> 02:05:50,725
THE NIH DEFINITION OF ESI WHICH

3159
02:05:50,725 --> 02:05:53,828
INCLUDES RESEARCHERS WITHIN TEN

3160
02:05:53,828 --> 02:05:55,697
YEARS POST COMPLETION OF

3161
02:05:55,697 --> 02:05:57,165
TERMINAL RESEARCH DEGREE OR

3162
02:05:57,165 --> 02:05:59,367
CLINICAL TRAINING.

3163
02:05:59,367 --> 02:06:01,603
ESI DEFINED BY NIH, APPLICATIONS

3164
02:06:01,603 --> 02:06:04,306
OR CLUSTERED IN PEER REVIEW,

3165
02:06:04,306 --> 02:06:11,546
PRIORITIZED FOR FUNDING IF

3166
02:06:11,546 --> 02:06:21,790
MERITORIOUS. 

3167
02:06:29,864 --> 02:06:39,741
>>  GIVE US ONE MINUTE,
FOLKS. 

3168
02:06:39,741 --> 02:06:41,109
>> WE'RE BACK.

3169
02:06:41,109 --> 02:06:42,043
ECI, PRIORITY ACROSS NIH,

3170
02:06:42,043 --> 02:06:45,180
SUPPORTING THEM IS NOT JUST

3171
02:06:45,180 --> 02:06:46,915
ABOUT GROWING THE PIPELINE; IT'S

3172
02:06:46,915 --> 02:06:49,484
ABOUT ENSURING THE FUTURE OF HIV

3173
02:06:49,484 --> 02:06:52,387
RESEARCH AS DIVERSE, INNOVATIVE,

3174
02:06:52,387 --> 02:06:53,154
SUSTAINABLE ACROSS MULTIPLE

3175
02:06:53,154 --> 02:06:53,855
DISCIPLINES THAT COLLABORATE TO

3176
02:06:53,855 --> 02:06:55,991
ADVANCE HEALTH OF PEOPLE LIVING

3177
02:06:55,991 --> 02:07:00,161
WITH HIV OR IMPACTED BY HIV.

3178
02:07:00,161 --> 02:07:03,031
NOW, GOAL WITHIN THE CURRENT

3179
02:07:03,031 --> 02:07:06,468
STRATEGIC PLAN FOR HIV AND

3180
02:07:06,468 --> 02:07:07,569
RELATED RESEARCH PERSISTING IS

3181
02:07:07,569 --> 02:07:09,137
COMMITMENT TO BUILD AND

3182
02:07:09,137 --> 02:07:10,638
STRENGTHEN CAPACITY TO DEVELOP

3183
02:07:10,638 --> 02:07:14,142
THE NEXT GENERATION OF HIV

3184
02:07:14,142 --> 02:07:15,043
RESEARCHERS.

3185
02:07:15,043 --> 02:07:17,479
OUR CURRENT APPROACH IS INFORMED

3186
02:07:17,479 --> 02:07:20,115
THROUGH LISTENING SESSIONS FOR

3187
02:07:20,115 --> 02:07:23,518
PARTNER OUTREACH AND ENGAGEMENT,

3188
02:07:23,518 --> 02:07:25,220
IN 2021 AND 22 OAR HELD

3189
02:07:25,220 --> 02:07:27,422
LISTENING SESSIONS ON A VARIETY

3190
02:07:27,422 --> 02:07:29,924
OF TOPICS WHICH INCLUDED ONE ON

3191
02:07:29,924 --> 02:07:31,993
SUPPORTING ECIs, AND LED TO

3192
02:07:31,993 --> 02:07:34,162
THE DEVELOPMENT OF SEVERAL

3193
02:07:34,162 --> 02:07:35,296
ACTION STEPS.

3194
02:07:35,296 --> 02:07:39,768
ANALYZING ECI AWARDS AND

3195
02:07:39,768 --> 02:07:42,504
TRAJECTORIES, ENGAGING WITH

3196
02:07:42,504 --> 02:07:43,938
WORKING GROUP, ORGANIZING

3197
02:07:43,938 --> 02:07:45,140
WORKSHOPS, INTEGRATING PARTNER

3198
02:07:45,140 --> 02:07:46,674
FEEDBACK AND MAINTAINING

3199
02:07:46,674 --> 02:07:48,710
PARTNERSHIPS WITH ICOS TO

3200
02:07:48,710 --> 02:07:52,046
SUPPORT DIVERSE DISCIPLINES AND

3201
02:07:52,046 --> 02:07:52,414
INSTITUTIONS.

3202
02:07:52,414 --> 02:07:54,349
HERE WE HAVE A BAR CHART SHOWING

3203
02:07:54,349 --> 02:07:57,619
THE NUMBER OF R01 OR EQUIVALENT

3204
02:07:57,619 --> 02:08:01,523
AWARDS TO ESI BY FISCAL YEAR.

3205
02:08:01,523 --> 02:08:04,192
RED BARS REPRESENT ESI IN HIV

3206
02:08:04,192 --> 02:08:06,728
RESEARCH AND BLUE BARS REPRESENT

3207
02:08:06,728 --> 02:08:08,530
ESI ACROSS ALL NIH RESEARCH.

3208
02:08:08,530 --> 02:08:12,834
OF THE NUMBER OF THE AWARDS

3209
02:08:12,834 --> 02:08:14,002
FLUCTUATES YEARLY AVERAGING 57

3210
02:08:14,002 --> 02:08:16,971
OVER THE PAST SEVEN YEARS.

3211
02:08:16,971 --> 02:08:20,975
FUNDING FOR ESI IN HIV IS 5

3212
02:08:20,975 --> 02:08:25,346
PERCENT OF THE HIV BUDGET.

3213
02:08:25,346 --> 02:08:26,448
SIMILAR TO NIH-WIDE TRENDS.

3214
02:08:26,448 --> 02:08:29,751
IF YOU THINK ABOUT THE RELATIVE

3215
02:08:29,751 --> 02:08:32,787
NUMBER OF NEWLY AWARDED ESI IN

3216
02:08:32,787 --> 02:08:34,289
HIV, IT'S SMALL.

3217
02:08:34,289 --> 02:08:35,723
IT'S MODEST.

3218
02:08:35,723 --> 02:08:39,627
SO RETENTION AND SUPPORT FOR

3219
02:08:39,627 --> 02:08:42,197
THESE INVESTIGATORS ARE CRUCIAL.

3220
02:08:42,197 --> 02:08:45,733
SO WHAT MAKES ECI SUCCESSFUL?

3221
02:08:45,733 --> 02:08:49,070
IN 2024 OAR ORGANIZED DIRECTOR'S

3222
02:08:49,070 --> 02:08:50,672
SEMINAR TO SHOWCASE IMPACTFUL

3223
02:08:50,672 --> 02:08:55,009
RESEARCH CONDUCTED BY AN ESI,

3224
02:08:55,009 --> 02:08:56,878
HIGHLIGHTING THEIR INCREDIBLE

3225
02:08:56,878 --> 02:08:57,579
POTENTIAL OFFERING INSIGHTS FOR

3226
02:08:57,579 --> 02:08:59,147
THE NIH.

3227
02:08:59,147 --> 02:09:01,683
WE FEATURED DR. SARAH WEIBEL

3228
02:09:01,683 --> 02:09:05,553
FROM UCSD WHO BEGAN WITH THREE

3229
02:09:05,553 --> 02:09:14,729
SMALL AWARDS IN 201  7 AND 2018

3230
02:09:14,729 --> 02:09:16,131
AND HER CAREER TOOK OFF.

3231
02:09:16,131 --> 02:09:18,933
OVER THE NEXT FOUR YEARS SECURED

3232
02:09:18,933 --> 02:09:22,737
TWO R01s AS P.I., ONE P30 AS

3233
02:09:22,737 --> 02:09:27,375
CO-P.I., ONE P01 AS PROJECT

3234
02:09:27,375 --> 02:09:31,212
P.I., MENTOR FOR ONE T32.

3235
02:09:31,212 --> 02:09:33,448
DESPITE THE CHALLENGES OF THE

3236
02:09:33,448 --> 02:09:38,753
COVID-19 PANDEMIC, SHE

3237
02:09:38,753 --> 02:09:39,220
SUCCESSFULLY OBTAINED

3238
02:09:39,220 --> 02:09:41,122
$9.88 MILLION IN NIH FUNDING,

3239
02:09:41,122 --> 02:09:43,157
DIRECT COSTS.

3240
02:09:43,157 --> 02:09:45,293
DR. GIANELLA HOLDS SEVERAL

3241
02:09:45,293 --> 02:09:47,262
APPOINTMENTS, DIRECT CORES AND

3242
02:09:47,262 --> 02:09:51,399
LACKS IN CFAR AND ATG AND

3243
02:09:51,399 --> 02:09:59,607
CO-DIRECTS LAST GIFT STUDY, AND

3244
02:09:59,607 --> 02:10:00,975
SHE'S ORIGINALLY FROM

3245
02:10:00,975 --> 02:10:02,010
SWITZERLAND, SHE COMPLETED HER

3246
02:10:02,010 --> 02:10:03,811
MEDICAL GRIEF IN ZURICH BEFORE

3247
02:10:03,811 --> 02:10:08,917
MOVING TO THE UNITED STATES FOR

3248
02:10:08,917 --> 02:10:12,420
POSTDOCTORAL POSITION AT UCSD.

3249
02:10:12,420 --> 02:10:14,155
DIRECTOR SEMINAR PRECEDED ANNUAL

3250
02:10:14,155 --> 02:10:18,493
OAR WORKSHOP FOR ECI IN HIV, WE

3251
02:10:18,493 --> 02:10:21,930
STARTED IN 2022.

3252
02:10:21,930 --> 02:10:27,068
ATTENDANCE HAS GROWN FROM 145

3253
02:10:27,068 --> 02:10:31,573
REGISTRANTS IN 2022 TO 1168 IN

3254
02:10:31,573 --> 02:10:32,407
2024.

3255
02:10:32,407 --> 02:10:33,575
WE CONTINUOUSLY COLLECT FEEDBACK

3256
02:10:33,575 --> 02:10:36,311
TO EVOLVE THE PROGRAM TO MEET

3257
02:10:36,311 --> 02:10:37,178
ECI NEEDS.

3258
02:10:37,178 --> 02:10:40,214
WHICH FOLLOWING THE END OF THE

3259
02:10:40,214 --> 02:10:43,151
2023 ECI WORKSHOP WAS FOR MORE

3260
02:10:43,151 --> 02:10:47,121
ACCESS TO NIH INFORMATION,

3261
02:10:47,121 --> 02:10:49,123
RESOURCES AND STAFF

3262
02:10:49,123 --> 02:10:49,691
INTERACTIONS.

3263
02:10:49,691 --> 02:10:52,527
THE 2024 WORKSHOP INVOLVED

3264
02:10:52,527 --> 02:10:55,697
COLLABORATION WITH 18 NIH ICOS,

3265
02:10:55,697 --> 02:10:59,801
FEATURED 9 NIH PRESENTATIONS ON

3266
02:10:59,801 --> 02:11:02,637
NIH BASICS, OAR, DEMYSTIFYING

3267
02:11:02,637 --> 02:11:04,772
PROGRAM AND PEER REVIEW.

3268
02:11:04,772 --> 02:11:10,044
WE INTRODUCED BREAKOUT ROOMS

3269
02:11:10,044 --> 02:11:11,646
WITH 40 STAFF LEADING

3270
02:11:11,646 --> 02:11:15,016
DISCUSSIONS AND FIELDING
Q&A.

3271
02:11:15,016 --> 02:11:17,018
WE INVITED SIX EXTRAMURAL

3272
02:11:17,018 --> 02:11:19,020
INVESTIGATORS TO SHARE MENTORING

3273
02:11:19,020 --> 02:11:21,189
EXPERIENCES ACROSS CAREER STAGES

3274
02:11:21,189 --> 02:11:23,524
FROM ECI TO MID-CAREER TO

3275
02:11:23,524 --> 02:11:27,562
ESTABLISHED P.I.s.

3276
02:11:27,562 --> 02:11:28,529
WE INTENTIONALLY INCLUDED

3277
02:11:28,529 --> 02:11:36,404
INVESTIGATORS FROM DIVERSE

3278
02:11:36,404 --> 02:11:40,041
FIELDS, BASIC, CLINICAL,

3279
02:11:40,041 --> 02:11:41,209
DOMESTIC AND INTERNATIONAL,

3280
02:11:41,209 --> 02:11:45,146
BACKGROUNDS INCLUDING ONE FIRST

3281
02:11:45,146 --> 02:11:46,247
GENERATION SCHOLAR.

3282
02:11:46,247 --> 02:11:49,450
INTEREST IN THE 2024 WORKSHOP

3283
02:11:49,450 --> 02:11:59,961
WAS STRONG WITH, AGAIN,  42.9

3284
02:12:00,328 --> 02:12:04,098
DOMESTIC, 35 U.S. STATES, PLUS

3285
02:12:04,098 --> 02:12:09,737
D.C. AND PUERTO RICO.

3286
02:12:09,737 --> 02:12:10,171
56.8% INTERNATIONAL.

3287
02:12:10,171 --> 02:12:14,575
SPANNING 48 COUNTRIES ACROSS ALL

3288
02:12:14,575 --> 02:12:16,377
THE CONTINENTS EXCEPT

3289
02:12:16,377 --> 02:12:17,378
ANTARCTICA.

3290
02:12:17,378 --> 02:12:18,813
NOW, FEEDBACK SURVEYS REVEALED

3291
02:12:18,813 --> 02:12:21,683
PARTICIPANTS FIELDS OF INTEREST

3292
02:12:21,683 --> 02:12:24,886
AND NIH APPLICATION HISTORY, TOP

3293
02:12:24,886 --> 02:12:27,221
FIELDS INCLUDED HIV-ASSOCIATED

3294
02:12:27,221 --> 02:12:28,890
COMORBIDITIES, CO-INFECTIONS,

3295
02:12:28,890 --> 02:12:29,724
COMPLICATIONS.

3296
02:12:29,724 --> 02:12:32,226
HEALTH DISPARITIES, HIV CURE,

3297
02:12:32,226 --> 02:12:33,961
AGING, WOMEN'S HEALTH, VACCINES,

3298
02:12:33,961 --> 02:12:37,565
RESERVOIR AND LATENCY, AND NEXT

3299
02:12:37,565 --> 02:12:39,934
GENERATION THERAPIES.

3300
02:12:39,934 --> 02:12:43,838
ABOUT 27% HAD EVER APPLIED FOR

3301
02:12:43,838 --> 02:12:47,275
AND INDEPENDENT AWARD SUCH AS

3302
02:12:47,275 --> 02:12:50,411
R01, 18% RECEIVED NIH FUNDING

3303
02:12:50,411 --> 02:12:52,313
FOR ANY AWARD.

3304
02:12:52,313 --> 02:12:53,715
ATTENDEES RATED SATISFACTION

3305
02:12:53,715 --> 02:12:57,351
WITH THE WORKSHOP COMPONENTS

3306
02:12:57,351 --> 02:13:00,822
HIGHLY, 100% LEARNED NEW

3307
02:13:00,822 --> 02:13:01,322
INFORMATION.

3308
02:13:01,322 --> 02:13:04,392
97% WOULD RECOMMEND TO A

3309
02:13:04,392 --> 02:13:04,726
COLLEAGUE.

3310
02:13:04,726 --> 02:13:07,195
WE RECEIVED SUGGESTIONS FOR

3311
02:13:07,195 --> 02:13:07,829
FUTURE TOPICS.

3312
02:13:07,829 --> 02:13:11,332
I'D LIKE TO POINT OUT MATERIALS

3313
02:13:11,332 --> 02:13:12,533
FROM LAST YEAR INCLUDING

3314
02:13:12,533 --> 02:13:13,568
EXECUTIVE SUMMARY AND VIDEO

3315
02:13:13,568 --> 02:13:15,670
CLIPS ARE AVAILABLE ON THE OAR

3316
02:13:15,670 --> 02:13:19,874
WEBSITE AND THROUGH THE QR CODE

3317
02:13:19,874 --> 02:13:22,410
AND LINK ON THE SCREEN.

3318
02:13:22,410 --> 02:13:24,846
IN 2024 THE OAR IN COLLABORATION

3319
02:13:24,846 --> 02:13:27,915
WITH ICO PARTNERS MADE CONCERTED

3320
02:13:27,915 --> 02:13:30,985
EFFORT TO PRIORITIZE ECI

3321
02:13:30,985 --> 02:13:33,020
OUTREACH AT EVERY NIH

3322
02:13:33,020 --> 02:13:34,589
PARTICIPATING MEETING AND

3323
02:13:34,589 --> 02:13:35,556
CONFERENCE.

3324
02:13:35,556 --> 02:13:37,258
AT THE INTERNATIONAL WORKSHOP ON

3325
02:13:37,258 --> 02:13:40,461
AGING AND HIV HELD ON OCTOBER 24

3326
02:13:40,461 --> 02:13:44,732
IN WASHINGTON, D.C., THE OAR AND

3327
02:13:44,732 --> 02:13:48,136
NIMH ORGANIZED ECI SPOTLIGHT

3328
02:13:48,136 --> 02:13:50,605
SYMPOSIUM AND THIS FEATURED FOUR

3329
02:13:50,605 --> 02:13:52,306
ECIs FROM DIVERSE RESEARCH

3330
02:13:52,306 --> 02:13:55,810
BACKGROUNDS, GAVE THEM A

3331
02:13:55,810 --> 02:13:57,745
PLATFORM TO SHOWCASE ECI-LED

3332
02:13:57,745 --> 02:13:58,513
RESEARCH, SIGNIFICANT CHALLENGES

3333
02:13:58,513 --> 02:14:03,451
RELATED TO HIV AND AGING.

3334
02:14:03,451 --> 02:14:08,089
IN COLLABORATION WITH 13 ICO

3335
02:14:08,089 --> 02:14:08,623
PARTNERS, OAR PRODUCED

3336
02:14:08,623 --> 02:14:10,458
CUSTOMIZABLE INFO GRAPHICS FOR

3337
02:14:10,458 --> 02:14:14,629
THE ECI SYMPOSIUM AT AGING IN

3338
02:14:14,629 --> 02:14:16,164
HIV AND OTHER EVENTS.

3339
02:14:16,164 --> 02:14:19,400
THESE ARE DESIGNED TO HELP ECI

3340
02:14:19,400 --> 02:14:22,470
AND INVESTIGATORS NEW TO HIV

3341
02:14:22,470 --> 02:14:25,072
NAVIGATE NIH HIV RESEARCH

3342
02:14:25,072 --> 02:14:25,540
PROGRAM.

3343
02:14:25,540 --> 02:14:34,782
HERE ARE EXAMPLES FOR NICHD,

3344
02:14:34,782 --> 02:14:35,783
NIDA, ORWH, AND NIAAA.

3345
02:14:35,783 --> 02:14:38,352
INFORMATION WAS GATHERED FROM

3346
02:14:38,352 --> 02:14:41,222
THE ICOS, DESIGNING LAYOUT AND

3347
02:14:41,222 --> 02:14:41,656
GRAPHICS.

3348
02:14:41,656 --> 02:14:42,623
EACH INFOGRAPHIC INCLUDES

3349
02:14:42,623 --> 02:14:45,726
DETAILS ON THE ICO MISSION,

3350
02:14:45,726 --> 02:14:49,130
HIV/AIDS PROGRAM, TRAINING AND

3351
02:14:49,130 --> 02:14:50,398
FUNDING OPPORTUNITIES FOR

3352
02:14:50,398 --> 02:14:55,403
ECIs, AND ALWAYS A POINT OF

3353
02:14:55,403 --> 02:14:56,537
CONTACT E-MAIL.

3354
02:14:56,537 --> 02:14:59,073
THROUGHOUT 2024 AND CONTINUING

3355
02:14:59,073 --> 02:15:01,542
INTO RECENT MONTHS IN 2025, OAR

3356
02:15:01,542 --> 02:15:04,011
STAFF HAS TAKEN ECI OUTREACH ON

3357
02:15:04,011 --> 02:15:06,981
THE ROAD, VIRTUALLY AND IN

3358
02:15:06,981 --> 02:15:09,917
PERSON, TO MULTIPLE AUDIENCES.

3359
02:15:09,917 --> 02:15:11,385
MY COLLEAGUES HAVE BROUGHT

3360
02:15:11,385 --> 02:15:12,920
RESOURCES WITHIN SETTINGS

3361
02:15:12,920 --> 02:15:15,790
THROUGH FOCUSED TALKS AND WITHIN

3362
02:15:15,790 --> 02:15:16,958
BROADER PRESENTATIONS, AND HERE

3363
02:15:16,958 --> 02:15:19,360
YOU CAN SEE THE TITLES AND

3364
02:15:19,360 --> 02:15:22,096
LOCATIONS, THEY HAVE MET WITH

3365
02:15:22,096 --> 02:15:26,634
WOMEN'S HEALTH SCHOLARS, MIAMI

3366
02:15:26,634 --> 02:15:29,370
CFAR, JOHNS HOPKINS

3367
02:15:29,370 --> 02:15:31,339
IMPLEMENTATION SCIENCE

3368
02:15:31,339 --> 02:15:35,543
FELLOWSHIP, AND INTERNATIONAL

3369
02:15:35,543 --> 02:15:38,045
SYMPOSIUM ON NEUROVIROLOGY.

3370
02:15:38,045 --> 02:15:40,548
PLANNING FOR THIS YEAR BEGAN IN

3371
02:15:40,548 --> 02:15:42,717
JANUARY, PAUSED DUE TO

3372
02:15:42,717 --> 02:15:43,718
COMMUNICATIONS HALT AT NIH.

3373
02:15:43,718 --> 02:15:46,454
WHICH WAS ONE OF MANY

3374
02:15:46,454 --> 02:15:49,624
DISRUPTIONS AND UNCERTAINTIES WE

3375
02:15:49,624 --> 02:15:50,691
FACED.

3376
02:15:50,691 --> 02:15:55,897
IN RESPONSE TO WORKING GROUP,

3377
02:15:55,897 --> 02:15:57,865
DEVISED TWO-PART ENGAGEMENT

3378
02:15:57,865 --> 02:15:58,366
STRATEGY.

3379
02:15:58,366 --> 02:16:00,067
FIRST LISTENING SESSIONS WITH

3380
02:16:00,067 --> 02:16:01,969
ECI AND HIV RESEARCH THAT GATHER

3381
02:16:01,969 --> 02:16:03,504
INSIGHTS INTO NEEDS AND

3382
02:16:03,504 --> 02:16:06,340
CHALLENGES IN THE CURRENT

3383
02:16:06,340 --> 02:16:06,874
CLIMATE.

3384
02:16:06,874 --> 02:16:09,277
SECOND, ECI WORKSHOP TAILORED TO

3385
02:16:09,277 --> 02:16:10,411
ADDRESS FEEDBACK RECEIVED

3386
02:16:10,411 --> 02:16:13,080
PROVIDING MORE RELEVANT AND

3387
02:16:13,080 --> 02:16:14,248
TIMELY GUIDANCE.

3388
02:16:14,248 --> 02:16:16,417
THE LISTENING SESSIONS WERE

3389
02:16:16,417 --> 02:16:18,219
DESIGNED TO INFORM

3390
02:16:18,219 --> 02:16:20,021
RECOMMENDATIONS FOR FUTURE

3391
02:16:20,021 --> 02:16:21,289
WORKSHOPS, RESOURCES, TRAINING,

3392
02:16:21,289 --> 02:16:23,291
FUNDING OPPORTUNITIES.

3393
02:16:23,291 --> 02:16:24,492
WE INVITED ECIs WHO APPLIED

3394
02:16:24,492 --> 02:16:29,230
FOR NIH AWARDS IN THE PAST TWO

3395
02:16:29,230 --> 02:16:29,630
YEARS.

3396
02:16:29,630 --> 02:16:32,166
WITHIN DAYS, 170 PARTICIPANTS

3397
02:16:32,166 --> 02:16:35,269
CONFIRMED ATTENDANCE.

3398
02:16:35,269 --> 02:16:37,772
WE ORGANIZED SIX 90-MINUTE

3399
02:16:37,772 --> 02:16:39,907
LISTENING SESSIONS, AND WE SENT

3400
02:16:39,907 --> 02:16:40,641
THEM ESSENTIAL DISCUSSION

3401
02:16:40,641 --> 02:16:44,378
PROMISE ON THE SCREEN IN

3402
02:16:44,378 --> 02:16:44,612
ADVANCE.

3403
02:16:44,612 --> 02:16:45,780
THE SESSIONS FEATURED OPEN-ENDED

3404
02:16:45,780 --> 02:16:47,548
QUESTIONS, TO EXPLORE AREAS

3405
02:16:47,548 --> 02:16:50,718
WHERE NIH COULD OFFER

3406
02:16:50,718 --> 02:16:51,018
ASSISTANCE.

3407
02:16:51,018 --> 02:16:52,153
WE'VE ALREADY HELD THREE

3408
02:16:52,153 --> 02:16:53,254
SESSIONS THIS WEEK.

3409
02:16:53,254 --> 02:16:55,856
AND WILL CONDUCT THREE MORE NEXT

3410
02:16:55,856 --> 02:16:56,157
WEEK.

3411
02:16:56,157 --> 02:16:58,225
OUR FEEDBACK THAT WE COLLECT

3412
02:16:58,225 --> 02:17:00,928
WILL BE AGGREGATED INTO

3413
02:17:00,928 --> 02:17:04,231
COMPREHENSIVE SUMMARY, AND WE'VE

3414
02:17:04,231 --> 02:17:06,000
ALSO INCLUDED A INFORMATION ON

3415
02:17:06,000 --> 02:17:07,401
PARTICIPANTS BACKGROUNDS AND

3416
02:17:07,401 --> 02:17:11,605
LOOK FORWARD TO SHARING RESULTS

3417
02:17:11,605 --> 02:17:12,573
SOON.

3418
02:17:12,573 --> 02:17:15,109
WE'RE EXCITED FOR THE 2025 ECI

3419
02:17:15,109 --> 02:17:18,279
WORKSHOP, INVITE YOU TO SAVE THE

3420
02:17:18,279 --> 02:17:19,947
DATE FOR FRIDAY, SEPTEMBER 26.

3421
02:17:19,947 --> 02:17:22,650
PLANNING IS WELL UNDERWAY.

3422
02:17:22,650 --> 02:17:25,453
WE'RE LOOKING FORWARD TO

3423
02:17:25,453 --> 02:17:26,253
CONNECTING WITH ECIs AGAIN

3424
02:17:26,253 --> 02:17:27,855
SOON.

3425
02:17:27,855 --> 02:17:30,558
IN THE TIME REMAINING I HAVE

3426
02:17:30,558 --> 02:17:33,561
SOME QUESTIONS FOR OARAC INPUT.

3427
02:17:33,561 --> 02:17:36,497
WE'RE EAGER TO EXPAND OUR

3428
02:17:36,497 --> 02:17:39,867
OUTREACH BUT RECENT CHANGES HAVE

3429
02:17:39,867 --> 02:17:43,404
REQUIRED US TO ADAPT.

3430
02:17:43,404 --> 02:17:45,239
SIGNIFICANT CHALLENGE WE FACE IS

3431
02:17:45,239 --> 02:17:47,174
IN THE PROMOTION AND

3432
02:17:47,174 --> 02:17:48,576
CROSS-PROMOTION OF EVENTS, AS

3433
02:17:48,576 --> 02:17:50,478
OUR COMMUNICATION SUPPORT IS

3434
02:17:50,478 --> 02:17:54,482
LIMITED AND OUR SOCIAL MEDIA

3435
02:17:54,482 --> 02:17:55,583
ENGAGEMENT HAS BEEN CENTRALIZED

3436
02:17:55,583 --> 02:17:56,784
IN NIH.

3437
02:17:56,784 --> 02:17:57,985
WITHOUT OUR COMMUNICATIONS

3438
02:17:57,985 --> 02:18:00,654
APPARATUS WE NEED TO EXPLORE

3439
02:18:00,654 --> 02:18:01,455
ALTERNATIVE STRATEGIES.

3440
02:18:01,455 --> 02:18:03,224
PROMPT NUMBER 1 IS WHAT ARE

3441
02:18:03,224 --> 02:18:04,925
EFFECTIVE WAYS TO PROMOTE AND

3442
02:18:04,925 --> 02:18:07,828
CROSS-PROMOTE EVENTS AND

3443
02:18:07,828 --> 02:18:09,163
RESOURCES FOR ECI?

3444
02:18:09,163 --> 02:18:10,564
ADDITIONALLY WE SEEK NEW

3445
02:18:10,564 --> 02:18:13,401
OPPORTUNITIES FOR NIH TO ENGAGE

3446
02:18:13,401 --> 02:18:14,902
WITH ECIs VIRTUALLY AND IN

3447
02:18:14,902 --> 02:18:15,336
PERSON.

3448
02:18:15,336 --> 02:18:19,006
WE AIM TO REACH GROUPS THAT ARE

3449
02:18:19,006 --> 02:18:21,275
NOT NECESSARILY LOCATED IN MAJOR

3450
02:18:21,275 --> 02:18:24,078
HIV RESEARCH HUBS OR AFFILIATED

3451
02:18:24,078 --> 02:18:26,747
WITH CFARs OR ARTs.

3452
02:18:26,747 --> 02:18:29,316
TO INVITE ATTENDEES TO THE ECI

3453
02:18:29,316 --> 02:18:31,886
LISTENING SESSIONS, WE PUT THAT

3454
02:18:31,886 --> 02:18:33,020
THROUGH THE CFARs TO

3455
02:18:33,020 --> 02:18:36,557
DISTRIBUTE, AGAIN BECAUSE WE

3456
02:18:36,557 --> 02:18:38,025
HAVE LIMITED COMMUNICATIONS

3457
02:18:38,025 --> 02:18:39,760
ABILITY RIGHT NOW.

3458
02:18:39,760 --> 02:18:41,162
NUMBER 2 HERE, WHAT ARE OTHER

3459
02:18:41,162 --> 02:18:43,230
OPPORTUNITIES FOR NIH TO ENGAGE

3460
02:18:43,230 --> 02:18:46,400
WITH ECI, VIRTUALLY OR IN

3461
02:18:46,400 --> 02:18:46,967
PERSON.

3462
02:18:46,967 --> 02:18:49,904
I'LL STOP THERE. 

3463
02:18:49,904 --> 02:18:53,107
THANK YOU VERY MUCH.

3464
02:18:53,107 --> 02:18:54,175
>> THANK YOU BOTH.

3465
02:18:54,175 --> 02:18:55,676
I THINK YOU OBVIOUSLY ARE

3466
02:18:55,676 --> 02:18:57,645
ADDRESSING CRITICAL AREAS TO THE

3467
02:18:57,645 --> 02:18:59,747
PIPELINE AND TO THE

3468
02:18:59,747 --> 02:19:01,348
SUSTAINABILITY OF OUR EARLY

3469
02:19:01,348 --> 02:19:02,316
STAGE INVESTIGATORS, WHICH WE

3470
02:19:02,316 --> 02:19:05,419
ALL WANT TO RETAIN AND FOSTER

3471
02:19:05,419 --> 02:19:06,554
AND WITHIN THE CURRENT

3472
02:19:06,554 --> 02:19:07,822
ENVIRONMENT I THINK WE NEED TO

3473
02:19:07,822 --> 02:19:12,660
MAKE SURE TO MAKE AN EXTRA

3474
02:19:12,660 --> 02:19:15,062
EFFORT TO TAKE CARE AND SUPPORT

3475
02:19:15,062 --> 02:19:15,896
THEM.

3476
02:19:15,896 --> 02:19:19,667
WE HAD BOTH PRESENTATIONS TO ASK

3477
02:19:19,667 --> 02:19:21,969
FOR FEEDBACK, MULTIPLE AREAS.

3478
02:19:21,969 --> 02:19:25,172
SO I WILL OPEN THIS UP FOR

3479
02:19:25,172 --> 02:19:26,640
INPUT.

3480
02:19:26,640 --> 02:19:29,043
WE CAN START WITH THE ROOM.

3481
02:19:29,043 --> 02:19:34,648
IS THERE ANYONE IN THE ROOM THAT

3482
02:19:34,648 --> 02:19:36,550
WANTS TO CHIME IN?

3483
02:19:36,550 --> 02:19:37,485
>> NOT AT THIS TIME.

3484
02:19:37,485 --> 02:19:39,320
>> ALL RIGHT.

3485
02:19:39,320 --> 02:19:49,864
SO WE'LL GO FOR OARAC MEMBERS. 

3486
02:19:53,767 --> 02:19:54,301
WE CAN START;

3487
02:19:54,301 --> 02:19:54,768
[CROSSTALK]

3488
02:19:54,768 --> 02:19:56,170
>> WE HAVE SOMEBODY THAT
NEEDS

3489
02:19:56,170 --> 02:20:01,375
TO GO ON MUTE. 

3490
02:20:01,375 --> 02:20:06,480
I DON'T CONTROL IT.

3491
02:20:06,480 --> 02:20:09,016
>> I APPRECIATED BOTH
TALKS.

3492
02:20:09,016 --> 02:20:11,952
AND SOMEONE WHO HAS DIRECTED

3493
02:20:11,952 --> 02:20:13,687
PIPELINE PROGRAMS FOR MORE THAN

3494
02:20:13,687 --> 02:20:15,923
30 YEARS, UNFORTUNATELY THEY

3495
02:20:15,923 --> 02:20:17,024
HAVE ALL BEEN TERMINATED.

3496
02:20:17,024 --> 02:20:19,527
I'M ALSO A P.I. ON A T32 THAT'S

3497
02:20:19,527 --> 02:20:20,861
ON PAUSE.

3498
02:20:20,861 --> 02:20:23,631
I MEAN, HOW CAN YOU GIVE US

3499
02:20:23,631 --> 02:20:25,533
ASSURANCES THAT THOSE WILL BE

3500
02:20:25,533 --> 02:20:26,233
RESTORED?

3501
02:20:26,233 --> 02:20:30,704
THEY WILL BE THE PIPELINE TO

3502
02:20:30,704 --> 02:20:31,605
THIS EARLY CAREER INVESTIGATORS,

3503
02:20:31,605 --> 02:20:34,508
SO DO YOU HAVE ANY ADVICE WHAT

3504
02:20:34,508 --> 02:20:37,244
WE SHOULD DO?

3505
02:20:37,244 --> 02:20:40,281
YOU JUST HOLD TIGHT AND LOSE A

3506
02:20:40,281 --> 02:20:41,615
GENERATION OF TRAINEES?

3507
02:20:41,615 --> 02:20:44,718
I MEAN, THIS IS PROBABLY THE BIG

3508
02:20:44,718 --> 02:20:46,820
ELEPHANT IN THE ROOM BUT AS

3509
02:20:46,820 --> 02:20:51,392
SOMEONE WHO HAS HAD ALL OF MY

3510
02:20:51,392 --> 02:20:55,329
TRAINING GRANTS SUSPENDED, I

3511
02:20:55,329 --> 02:20:56,997
WORRY VERY MUCH ABOUT LOSING THE

3512
02:20:56,997 --> 02:21:03,070
PIPELINE THAT WILL FEED INTO THE

3513
02:21:03,070 --> 02:21:04,805
EARLY CAREER INVESTIGATORS.

3514
02:21:04,805 --> 02:21:06,707
>> ARE YOU DIRECTING THIS

3515
02:21:06,707 --> 02:21:08,542
QUESTION TO DR. ALBERTI OR DR.

3516
02:21:08,542 --> 02:21:08,842
CHANG?

3517
02:21:08,842 --> 02:21:15,349
WE CAN'T COMMENT ON FUNDING. 

3518
02:21:15,349 --> 02:21:20,054
>> NO, NO, I KNOW.

3519
02:21:20,054 --> 02:21:21,956
>> AGAIN, IN FEEDING THE

3520
02:21:21,956 --> 02:21:25,593
PIPELINE, BUILDING A PIPELINE

3521
02:21:25,593 --> 02:21:29,263
FOR EARLY CAREER INVESTIGATORS,

3522
02:21:29,263 --> 02:21:31,098
HOW SHOULD WE APPROACH THE

3523
02:21:31,098 --> 02:21:31,398
FUNDING?

3524
02:21:31,398 --> 02:21:34,001
AGAIN, I'M NOT ASKING ABOUT

3525
02:21:34,001 --> 02:21:36,570
FUNDING, I'M ASKING ABOUT MAYBE

3526
02:21:36,570 --> 02:21:43,177
GUIDELINES OR ADVICE HOW SHOULD

3527
02:21:43,177 --> 02:21:43,644
WE PROCEED.

3528
02:21:43,644 --> 02:21:45,246
>> I THINK IT'S A VERY
IMPORTANT

3529
02:21:45,246 --> 02:21:47,081
CONCERN IF WE LOSE OUR ECI RIGHT

3530
02:21:47,081 --> 02:21:49,416
NOW WHO IS LEFT TO TRAIN THE

3531
02:21:49,416 --> 02:21:50,918
NEXT GENERATION AFTER THEM?

3532
02:21:50,918 --> 02:21:52,887
WE'RE STARTING WITH ECI IN THE

3533
02:21:52,887 --> 02:21:53,587
LISTENING SESSION BECAUSE WE

3534
02:21:53,587 --> 02:21:55,789
FEEL THEY ARE AT THE CUSP OF

3535
02:21:55,789 --> 02:21:56,390
LEADING.

3536
02:21:56,390 --> 02:21:58,125
WE CAN READ THAT ALL OVER THE

3537
02:21:58,125 --> 02:21:59,660
PLACE AND WRITE IT IN OTHER

3538
02:21:59,660 --> 02:21:59,994
FORMS.

3539
02:21:59,994 --> 02:22:03,530
WE HEAR IT IN THE LABS, IN

3540
02:22:03,530 --> 02:22:04,398
DIFFERENT CONFERENCES.

3541
02:22:04,398 --> 02:22:05,633
WHAT WE'RE DOING WITH LISTENING

3542
02:22:05,633 --> 02:22:07,434
SESSIONS WILL HOPEFULLY HELP US

3543
02:22:07,434 --> 02:22:10,004
INFORM WHAT TO DO NEXT.

3544
02:22:10,004 --> 02:22:11,939
AND PERHAPS VOICES RAISED WILL

3545
02:22:11,939 --> 02:22:15,109
EMPHASIZE THE NEED FOR SUSTAINED

3546
02:22:15,109 --> 02:22:15,643
FUNDING.

3547
02:22:15,643 --> 02:22:18,412
BUT ADVICE WE HAVE NOW IS FOR

3548
02:22:18,412 --> 02:22:19,480
INVESTIGATORS TO TALK WITH

3549
02:22:19,480 --> 02:22:22,483
PROGRAM OFFICERS TO SEE WHAT IS

3550
02:22:22,483 --> 02:22:23,784
AVAILABLE AND PERHAPS FIND

3551
02:22:23,784 --> 02:22:27,388
CREATIVE WAYS FOR THE TRAINING

3552
02:22:27,388 --> 02:22:28,656
TO HAPPEN.

3553
02:22:28,656 --> 02:22:29,990
PERHAPS WITH OTHER MECHANISMS.

3554
02:22:29,990 --> 02:22:33,093
WE LOOK FORWARD TO PUTTING OUT

3555
02:22:33,093 --> 02:22:34,428
THIS COMPREHENSIVE SUMMARY OF

3556
02:22:34,428 --> 02:22:35,396
THE LISTENING SESSIONS.

3557
02:22:35,396 --> 02:22:37,865
I THINK IT'S OUR FIRST CHANCE TO

3558
02:22:37,865 --> 02:22:41,835
DOCUMENT ALL OF THE DIFFERENT

3559
02:22:41,835 --> 02:22:43,470
CHALLENGES OCCURRING RIGHT NOW.

3560
02:22:43,470 --> 02:22:45,172
AND WE HOPE TO JUST PUT IT OUT

3561
02:22:45,172 --> 02:22:52,513
THERE, SO THAT WE CAN LOOK AT IT

3562
02:22:52,513 --> 02:22:57,584
FROM ALL ANGLES.

3563
02:22:57,584 --> 02:22:59,486
>> THANK YOU.

3564
02:22:59,486 --> 02:23:01,455
>> THANKS SO MUCH.

3565
02:23:01,455 --> 02:23:04,758
AND THIS IS A COMMENT FOR DAVID,

3566
02:23:04,758 --> 02:23:06,260
INTERESTED IN YOUR THOUGHTS

3567
02:23:06,260 --> 02:23:07,161
THERE.

3568
02:23:07,161 --> 02:23:09,096
YOU KNOW, WE HAVE A CONCERN JUST

3569
02:23:09,096 --> 02:23:13,701
IN TERMS OF THE OVERALL LEVEL OF

3570
02:23:13,701 --> 02:23:15,269
INTEREST IN INFECTIOUS DISEASES,

3571
02:23:15,269 --> 02:23:19,340
AMONG PEOPLE WHO ARE BECOMING

3572
02:23:19,340 --> 02:23:19,640
PHYSICIANS.

3573
02:23:19,640 --> 02:23:25,279
AND THEN THAT HAS IMPLICATIONS

3574
02:23:25,279 --> 02:23:26,513
FOR ADDRESSING HIV.

3575
02:23:26,513 --> 02:23:28,349
AND, YOU KNOW, LIMITATIONS IN

3576
02:23:28,349 --> 02:23:32,453
THE PIPELINE MAY START MUCH

3577
02:23:32,453 --> 02:23:36,357
FURTHER UPSTREAM THAN EARLY

3578
02:23:36,357 --> 02:23:37,091
STAGE INVESTIGATORS.

3579
02:23:37,091 --> 02:23:43,964
AND SO ONE QUESTION I'VE HAD,

3580
02:23:43,964 --> 02:23:45,265
HAS OAR CONSIDERED HAVING A

3581
02:23:45,265 --> 02:23:46,300
PRESENCE AT MEDICAL SCHOOL

3582
02:23:46,300 --> 02:23:48,535
RESEARCH DAYS WHERE MEDICAL

3583
02:23:48,535 --> 02:23:53,440
STUDENTS ARE PRESENTING THEIR

3584
02:23:53,440 --> 02:23:56,310
RESEARCH AND ENHANCING THE

3585
02:23:56,310 --> 02:23:59,113
VISIBILITY AND TELLING THE

3586
02:23:59,113 --> 02:24:01,715
REALLY IMPACTFUL STORY OF HIV

3587
02:24:01,715 --> 02:24:03,617
RESEARCH IN THE FIELD OF

3588
02:24:03,617 --> 02:24:07,588
MEDICINE AT THAT EARLIER LEVEL?

3589
02:24:07,588 --> 02:24:07,855
THANKS.

3590
02:24:07,855 --> 02:24:08,756
>> ACTUALLY, THANK YOU
VERY

3591
02:24:08,756 --> 02:24:09,923
MUCH, A GREAT ASKINGS.

3592
02:24:09,923 --> 02:24:13,627
I THINK WE CAN LOOK INTO THAT

3593
02:24:13,627 --> 02:24:14,194
FURTHER.

3594
02:24:14,194 --> 02:24:16,363
THERE'S ONE IDEA THAT WE HAD

3595
02:24:16,363 --> 02:24:19,433
STARTED TO GAIN SOME MOMENTUM ON

3596
02:24:19,433 --> 02:24:22,236
LAST YEAR WAS TO HAVE NIH HIV

3597
02:24:22,236 --> 02:24:25,339
RESEARCH PROGRAMS BECOME A

3598
02:24:25,339 --> 02:24:27,441
PRESENCE AT NON-HIV SETTINGS.

3599
02:24:27,441 --> 02:24:30,044
FOR EXAMPLE, THERE ARE LARGE

3600
02:24:30,044 --> 02:24:32,513
AGING CONFERENCES THAT HAVE

3601
02:24:32,513 --> 02:24:33,981
HAPPEN TWO OR THREE TIMES A

3602
02:24:33,981 --> 02:24:36,917
YEAR, VERY FEW HIV RESEARCHERS

3603
02:24:36,917 --> 02:24:37,718
ATTEND.

3604
02:24:37,718 --> 02:24:40,654
AND SOME OF THESE ARE VERY

3605
02:24:40,654 --> 02:24:42,890
INEXPENSIVE, TO HOST A BOOTH.

3606
02:24:42,890 --> 02:24:46,260
I THINK IF WE CAN DISPLAY THE

3607
02:24:46,260 --> 02:24:47,061
OPPORTUNITIES FOR AGING

3608
02:24:47,061 --> 02:24:49,163
RESEARCHERS TO COME TO HIV,

3609
02:24:49,163 --> 02:24:51,832
THAT'S ANOTHER WAY WE CAN BRING

3610
02:24:51,832 --> 02:24:55,235
WORKFORCE IN.

3611
02:24:55,235 --> 02:24:56,837
IN DIFFERENT PERSPECTIVES,

3612
02:24:56,837 --> 02:24:59,940
INNOVATIVE IDEAS. 

3613
02:24:59,940 --> 02:25:03,377
>> THANKS SO MUCH. 

3614
02:25:03,377 --> 02:25:06,146
>> ANY OTHER COMMENTS?

3615
02:25:06,146 --> 02:25:08,382
OR ISSUES?

3616
02:25:08,382 --> 02:25:10,684
I'LL ADD MY TWO CENTS FOR DR.

3617
02:25:10,684 --> 02:25:11,084
ALBERTI.

3618
02:25:11,084 --> 02:25:12,186
SOME CRITERIA TO EVALUATE IMPACT

3619
02:25:12,186 --> 02:25:14,154
OF THE INNOVATION YOU LISTED A

3620
02:25:14,154 --> 02:25:16,924
LOT OF OBVIOUS THINGS,

3621
02:25:16,924 --> 02:25:17,524
PUBLICATIONS, COLLABORATIONS.

3622
02:25:17,524 --> 02:25:20,494
BUT ONE OF THE THINGS I DIDN'T

3623
02:25:20,494 --> 02:25:23,063
SEE SPECIFICALLY STATED WAS IF

3624
02:25:23,063 --> 02:25:24,231
INTENDED TO BE KIND OF A

3625
02:25:24,231 --> 02:25:26,099
COLLABORATION IS THERE ANY KIND

3626
02:25:26,099 --> 02:25:28,735
OF METRIC WITHIN THE INTRAMURAL

3627
02:25:28,735 --> 02:25:30,771
THAT MEASURES THE OUTPUT

3628
02:25:30,771 --> 02:25:32,806
RELATIVE TO THESE, IS IT

3629
02:25:32,806 --> 02:25:36,543
PRIMARILY COLLABORATION? 

3630
02:25:36,543 --> 02:25:39,913
FOR YOUNG PEOPLE K AWARDS,

3631
02:25:39,913 --> 02:25:44,084
ALLOWING THEM TO TRANSITION OUT

3632
02:25:44,084 --> 02:25:45,686
FROM NIH, IS ONE OF THE LISTED

3633
02:25:45,686 --> 02:25:46,987
FUNDING STREAMS I'M FAMILIAR

3634
02:25:46,987 --> 02:25:50,090
WITH, A LOT OF INTRAMURAL

3635
02:25:50,090 --> 02:25:52,292
TRAINEES LOOK FORWARD TO DOING.

3636
02:25:52,292 --> 02:25:55,762
SO IS THERE ANY OBJECTIVE WITHIN

3637
02:25:55,762 --> 02:25:58,332
THE INNOVATION TO KIND OF

3638
02:25:58,332 --> 02:26:00,067
MEASURE IMPACT BY TRANSITIONS OR

3639
02:26:00,067 --> 02:26:04,238
IS IT PRIMARILY THROUGH INTERNAL

3640
02:26:04,238 --> 02:26:05,639
COLLABORATIONS, OR BOTH?

3641
02:26:05,639 --> 02:26:09,209
>> THAT IS ACTUALLY A
GREAT

3642
02:26:09,209 --> 02:26:10,677
IDEA.

3643
02:26:10,677 --> 02:26:13,247
WE HAVEN'T APPROACHED THE

3644
02:26:13,247 --> 02:26:14,348
COLLABORATION AND TRANSITION OUT

3645
02:26:14,348 --> 02:26:15,682
OF -- FOR THE YOUNG

3646
02:26:15,682 --> 02:26:17,451
INVESTIGATORS WHEN THEY

3647
02:26:17,451 --> 02:26:21,321
TRANSITION OUT OF THEIR JUNIOR

3648
02:26:21,321 --> 02:26:22,890
POSITION TO INDEPENDENT.

3649
02:26:22,890 --> 02:26:28,161
BUT THAT'S DEFINITELY AN ANGLE

3650
02:26:28,161 --> 02:26:31,198
THAT WE CAN EXPLORE FURTHER, TO

3651
02:26:31,198 --> 02:26:32,332
DOCUMENT THAT.

3652
02:26:32,332 --> 02:26:37,771
>> ALMOST SOUND LIKE WE
DEAL

3653
02:26:37,771 --> 02:26:38,939
WITH THAT WITH CFARS, EVALUATING

3654
02:26:38,939 --> 02:26:40,974
IMPACT, DID THEY PUBLISH, WRITE

3655
02:26:40,974 --> 02:26:43,377
AN R21, TRANSITION TO FACULTY

3656
02:26:43,377 --> 02:26:43,777
APPOINTMENT?

3657
02:26:43,777 --> 02:26:45,846
IT SOUNDS LIKE YOU'RE KIND OF IN

3658
02:26:45,846 --> 02:26:47,714
SIMILAR LANE AS FAR AS --

3659
02:26:47,714 --> 02:26:48,815
>> YEAH.

3660
02:26:48,815 --> 02:26:49,850
>> IN THAT REGARD.

3661
02:26:49,850 --> 02:26:51,885
FOR I GUESS DR. CHANG MY ONLY

3662
02:26:51,885 --> 02:26:54,855
COMMENT WOULD BE IF YOUR

3663
02:26:54,855 --> 02:26:58,025
ADVERTISING BUDGET IS LIMIT TO

3664
02:26:58,025 --> 02:26:59,259
TRY TO ENCOURAGE PREVIOUS

3665
02:26:59,259 --> 02:27:00,594
ATTENDEES TO NETWORK FOR YOU.

3666
02:27:00,594 --> 02:27:02,129
THEY ARE YOUNG INVESTIGATORS,

3667
02:27:02,129 --> 02:27:04,197
THEY HAVE ACCESS TO SOCIAL MEDIA

3668
02:27:04,197 --> 02:27:04,565
PLATFORM.

3669
02:27:04,565 --> 02:27:07,834
IF YOU CAN EMPOWER THEM WITH

3670
02:27:07,834 --> 02:27:09,836
POSTS THAT THEY CAN MOVE WITHIN

3671
02:27:09,836 --> 02:27:11,071
THEIR SOCIAL NETWORKS AND SAY

3672
02:27:11,071 --> 02:27:12,506
YOU'VE BEEN TO ONE OF OUR

3673
02:27:12,506 --> 02:27:14,341
CONFERENCES, SO TELL A FRIEND, A

3674
02:27:14,341 --> 02:27:16,176
LOT OF EARLY PEOPLE KNOW OTHER

3675
02:27:16,176 --> 02:27:17,244
EARLY PEOPLE OR PEOPLE COMING

3676
02:27:17,244 --> 02:27:17,878
BEHIND THEM.

3677
02:27:17,878 --> 02:27:23,250
SO I WOULD TRY TO TAP YOUR

3678
02:27:23,250 --> 02:27:26,720
ALUMNI FOR SORT OF FURTHER

3679
02:27:26,720 --> 02:27:27,621
ADVERTISING YOUR PROGRAM.

3680
02:27:27,621 --> 02:27:30,090
>> YEAH, THANK YOU FOR
THAT

3681
02:27:30,090 --> 02:27:30,424
SUGGESTION.

3682
02:27:30,424 --> 02:27:33,160
WE'RE ALSO TRYING TO TRACK THE

3683
02:27:33,160 --> 02:27:34,828
TRAJECTORIES OF OUR WORKSHOP

3684
02:27:34,828 --> 02:27:36,930
ATTENDEES TO SEE IF THEY ARE

3685
02:27:36,930 --> 02:27:39,666
SUCCESSFUL IN FUTURE YEARS IN

3686
02:27:39,666 --> 02:27:42,069
OBTAINING NIH FUNDING.

3687
02:27:42,069 --> 02:27:47,474
>> DR. FLETCHER?

3688
02:27:47,474 --> 02:27:47,841
>> THANKS.

3689
02:27:47,841 --> 02:27:49,676
THANKING BOTH PRESENTERS FOR THE

3690
02:27:49,676 --> 02:27:50,644
PRESENTATIONS, DR. CHANG, TO

3691
02:27:50,644 --> 02:27:53,246
YOUR LAST COMMENT ON YOUR SLIDE

3692
02:27:53,246 --> 02:27:54,615
ABOUT HOW TO PROMOTE, I EXPECT

3693
02:27:54,615 --> 02:27:56,950
THESE ARE ALREADY ON YOUR LIST

3694
02:27:56,950 --> 02:28:02,990
BUT I'LL MENTION THEM ANYWAY.

3695
02:28:02,990 --> 02:28:04,524
ONE I THINK UNIVERSITY RESEARCH

3696
02:28:04,524 --> 02:28:06,627
OFFICES, WHETHER THAT'S YOUR

3697
02:28:06,627 --> 02:28:09,229
VICE CHANCELLOR, VICE PRESIDENT,

3698
02:28:09,229 --> 02:28:13,033
VICE WHATEVER OF RESEARCH

3699
02:28:13,033 --> 02:28:13,834
SPONSORED PROGRAMS,

3700
02:28:13,834 --> 02:28:14,835
ADMINISTRATION, AND THE SECOND

3701
02:28:14,835 --> 02:28:19,172
THAT I THINK IS MISSED A LOT IS

3702
02:28:19,172 --> 02:28:22,109
UNIVERSITY'S BIOMEDICAL LIBRARY.

3703
02:28:22,109 --> 02:28:25,445
AT LEAST SEARCHING WITHIN THE

3704
02:28:25,445 --> 02:28:26,847
BIG TEN INSTITUTION WHERE IS WE

3705
02:28:26,847 --> 02:28:31,752
ARE BOTH OFFICES, EVEN BEFORE

3706
02:28:31,752 --> 02:28:32,853
THE CURRENT DISRUPTIONS, HAVE

3707
02:28:32,853 --> 02:28:35,622
UPPED THEIR GAME IN TERMS OF

3708
02:28:35,622 --> 02:28:38,125
BEING A RESOURCE FOR INFORMATION

3709
02:28:38,125 --> 02:28:40,594
FOR ALL INVESTIGATORS, BUT IN

3710
02:28:40,594 --> 02:28:42,129
PARTICULAR FOR EARLY CAREER,

3711
02:28:42,129 --> 02:28:42,996
EARLY STAGE INVESTIGATORS.

3712
02:28:42,996 --> 02:28:46,433
SO IF THEY ARE NOT ON YOUR RADAR

3713
02:28:46,433 --> 02:28:48,035
SCREEN I THINK PUMPING

3714
02:28:48,035 --> 02:28:50,404
INFORMATION TO UNIVERSITY

3715
02:28:50,404 --> 02:28:54,675
RESEARCH OFFICES AND THE

3716
02:28:54,675 --> 02:28:56,209
BIOMEDICAL LIBRARIES OF THOSE

3717
02:28:56,209 --> 02:28:57,577
UNIVERSITIES COULD BE TWO USEFUL

3718
02:28:57,577 --> 02:28:58,645
STRATEGIES FOR YOU.

3719
02:28:58,645 --> 02:28:58,945
>> GREAT.

3720
02:28:58,945 --> 02:29:07,854
THANK YOU FOR THOSE SUGGESTIONS 

3721
02:29:07,854 --> 02:29:08,989
>> DR. GULICK?

3722
02:29:08,989 --> 02:29:09,923
>> THANKS, LUIS.

3723
02:29:09,923 --> 02:29:12,059
I THOUGHT I WOULD CHIME IN, DR.

3724
02:29:12,059 --> 02:29:14,995
CHANG, AND GIVE YOU THE

3725
02:29:14,995 --> 02:29:16,363
SUGGESTION OR QUESTION, HAVE YOU

3726
02:29:16,363 --> 02:29:20,634
TALKED TO THE HIV MEDICAL

3727
02:29:20,634 --> 02:29:22,536
ASSOCIATION AND IDSA SINCE THEY

3728
02:29:22,536 --> 02:29:24,404
SHARE THE GOAL OF NOT ONLY

3729
02:29:24,404 --> 02:29:26,573
TRYING TO INCREASE THE PIPELINE

3730
02:29:26,573 --> 02:29:28,642
GOING INTO INFECTIOUS DISEASE

3731
02:29:28,642 --> 02:29:29,342
BUT ALSO HIV?

3732
02:29:29,342 --> 02:29:33,080
AND THEY ARE VERY GOOD AT

3733
02:29:33,080 --> 02:29:33,580
COMMUNICATION.

3734
02:29:33,580 --> 02:29:35,916
THAT WOULD BE A NICE PARTNERSHIP

3735
02:29:35,916 --> 02:29:37,317
TO EXPLORE IF THAT'S A

3736
02:29:37,317 --> 02:29:37,617
POSSIBILITY.

3737
02:29:37,617 --> 02:29:38,051
>> THANK YOU.

3738
02:29:38,051 --> 02:29:41,288
THAT'S EXACTLY WHAT WE NEEDED TO

3739
02:29:41,288 --> 02:29:46,193
HEAR.

3740
02:29:46,193 --> 02:29:48,061
>> YES, DR. SANTA MARIA?

3741
02:29:48,061 --> 02:29:50,964
>> ONE OTHER SUGGESTION
WOULD BE

3742
02:29:50,964 --> 02:29:52,566
TO BE ABLE TO DIVERSIFY ACROSS

3743
02:29:52,566 --> 02:29:53,867
DISCIPLINES AND PERHAPS WORK

3744
02:29:53,867 --> 02:29:55,535
WITH THE ASSOCIATION OF NURSES

3745
02:29:55,535 --> 02:29:59,940
AND AIDS CARE.

3746
02:29:59,940 --> 02:30:00,307
>> THANK YOU.

3747
02:30:00,307 --> 02:30:02,909
I THINK WE HAVE A PLAN

3748
02:30:02,909 --> 02:30:06,513
ENGAGEMENT WITH THEM TOO.

3749
02:30:06,513 --> 02:30:07,848
>> GREAT.

3750
02:30:07,848 --> 02:30:11,118
>> ANY OTHER COMMENTS?

3751
02:30:11,118 --> 02:30:16,022
>> WE MIGHT HAVE --  DR.
DANEN

3752
02:30:16,022 --> 02:30:17,190
BERG WOULD LIKE TO SAY

3753
02:30:17,190 --> 02:30:17,791
SOMETHING.

3754
02:30:17,791 --> 02:30:21,561
>> ONE OF THE ISSUES WE
STRUGGLE

3755
02:30:21,561 --> 02:30:24,364
WITH IS HOW TO EVALUATE THE

3756
02:30:24,364 --> 02:30:25,398
IMPACT OF LET'S SAY PROGRAMS

3757
02:30:25,398 --> 02:30:27,567
LIKE THIS AND WHAT ARE THE

3758
02:30:27,567 --> 02:30:29,069
METRICS OF SUCCESS?

3759
02:30:29,069 --> 02:30:35,275
AND THE TYPICAL ONES WE KNOW,

3760
02:30:35,275 --> 02:30:35,542
RIGHT?

3761
02:30:35,542 --> 02:30:36,243
PUBLICATIONS, GRANTS, MAYBE

3762
02:30:36,243 --> 02:30:37,410
GETTING A FACULTY POSITION.

3763
02:30:37,410 --> 02:30:42,349
I'D LOVE TO HEAR WHAT OTHER

3764
02:30:42,349 --> 02:30:47,754
METRICS YOU MIGHT PROPOSE AS

3765
02:30:47,754 --> 02:30:49,756
METRICS OF SUCCESS, COULD BE

3766
02:30:49,756 --> 02:30:52,392
TAKING A LEADERSHIP POSITION IN

3767
02:30:52,392 --> 02:30:54,127
A PUBLIC HEALTH DEPARTMENT,

3768
02:30:54,127 --> 02:30:56,396
COULD BE, YOU KNOW, I GUESS I

3769
02:30:56,396 --> 02:30:58,899
WOULD BE VERY INTERESTED TO HEAR

3770
02:30:58,899 --> 02:31:04,571
ANY SUGGESTIONS OF METRICS OF

3771
02:31:04,571 --> 02:31:09,042
SUCCESS THAT WE CAN TRACK.

3772
02:31:09,042 --> 02:31:10,510
>> I'LL ASK A
CLARIFICATION

3773
02:31:10,510 --> 02:31:10,911
PROGRAM.

3774
02:31:10,911 --> 02:31:12,179
WHEN THE PROGRAM WAS INITIATED

3775
02:31:12,179 --> 02:31:13,280
WHAT WAS THE INTENDED PURPOSE?

3776
02:31:13,280 --> 02:31:15,382
IN OTHER WORDS, WHAT DID YOU

3777
02:31:15,382 --> 02:31:16,683
ENVISION THIS PROGRAM TO

3778
02:31:16,683 --> 02:31:17,017
ACCOMPLISH?

3779
02:31:17,017 --> 02:31:20,220
WAS IT TO GENERATE LEADERS IN

3780
02:31:20,220 --> 02:31:22,055
SCIENCE AND IMPACTFUL OR

3781
02:31:22,055 --> 02:31:22,722
INDEPENDENT INVESTIGATORS,

3782
02:31:22,722 --> 02:31:28,395
COLLABORATION, OR ALL OF THE

3783
02:31:28,395 --> 02:31:29,162
ABOVE?

3784
02:31:29,162 --> 02:31:30,597
>> ARE YOU ASKING
REGARDING

3785
02:31:30,597 --> 02:31:37,037
INNOVATION PROGRAM OR ECI

3786
02:31:37,037 --> 02:31:37,771
PROGRAM?

3787
02:31:37,771 --> 02:31:38,805
>> REGARDING THE POINT HOW
BEST

3788
02:31:38,805 --> 02:31:40,507
TO EVALUATE IT I THINK THE

3789
02:31:40,507 --> 02:31:42,075
INTENDED MISSION OF THE PROGRAM,

3790
02:31:42,075 --> 02:31:45,846
SOME EXTENT, WOULD  GUIDE THAT

3791
02:31:45,846 --> 02:31:46,079
ANSWER.

3792
02:31:46,079 --> 02:31:47,380
ONE COULD WEIGH DIFFERENT

3793
02:31:47,380 --> 02:31:49,049
OUTCOMES DEPENDING WHAT THE

3794
02:31:49,049 --> 02:31:50,717
OBJECTIVE WAS, AND THAT'S WHY

3795
02:31:50,717 --> 02:31:52,986
I'M KIND OF ASKING CAN WE

3796
02:31:52,986 --> 02:31:54,221
RECONFIRM OBJECTIVES AND SAY,

3797
02:31:54,221 --> 02:31:57,791
WELL, BASED ON THAT THIS IS WHAT

3798
02:31:57,791 --> 02:32:02,162
WE WOULD SUGGEST, IF IT'S NOT

3799
02:32:02,162 --> 02:32:04,097
ALREADY THERE.

3800
02:32:04,097 --> 02:32:06,466
>> WELL, FOR THE
INNOVATION

3801
02:32:06,466 --> 02:32:09,603
PROGRAM IT'S FAIRLY SIMPLE, HIGH

3802
02:32:09,603 --> 02:32:12,305
RISK, HIGH REWARD SEED PROJECTS.

3803
02:32:12,305 --> 02:32:15,308
WE WANT TO HAVE THESE IDEAS TO

3804
02:32:15,308 --> 02:32:16,409
FLOURISH AND GROW BIGGER THAN

3805
02:32:16,409 --> 02:32:20,113
WHEN THEY COME TO US.

3806
02:32:20,113 --> 02:32:23,850
THAT'S IN A VERY BIG PICTURE.

3807
02:32:23,850 --> 02:32:24,251
>> OKAY.

3808
02:32:24,251 --> 02:32:26,887
IT'S ABOUT THE RESEARCH

3809
02:32:26,887 --> 02:32:28,054
INNOVATION ITSELF, NOT ABOUT THE

3810
02:32:28,054 --> 02:32:30,390
CANDIDATES OR TRAJECTORY OF THE

3811
02:32:30,390 --> 02:32:32,192
CANDIDATES ITSELF, FOR EXAMPLE

3812
02:32:32,192 --> 02:32:33,660
THE OTHER PROGRAM IS MORE

3813
02:32:33,660 --> 02:32:34,961
TARGETED FOR THE EARLY

3814
02:32:34,961 --> 02:32:35,295
INVESTIGATORS.

3815
02:32:35,295 --> 02:32:38,565
THIS IS FOR THE SCIENCE AND THE

3816
02:32:38,565 --> 02:32:43,169
VALUE OF THE IMPACT OF THE

3817
02:32:43,169 --> 02:32:46,139
SCIENCE.

3818
02:32:46,139 --> 02:32:46,940
DR. SANTA MARIA?

3819
02:32:46,940 --> 02:32:50,343
ONE SUGGESTION FOR A METRIC,

3820
02:32:50,343 --> 02:32:52,512
WHETHER THAT INDIVIDUAL BECOMES

3821
02:32:52,512 --> 02:32:55,248
A FELLOW IN THEIR DISCIPLINE, IF

3822
02:32:55,248 --> 02:32:57,017
THEY GET INDUCTED INTO AN

3823
02:32:57,017 --> 02:33:01,788
ACADEMY, IF THEY GET A PECASE

3824
02:33:01,788 --> 02:33:04,090
AWARD BASED ON STRATEGIES IN

3825
02:33:04,090 --> 02:33:05,959
HIV, GET INTO HONOR SOCIETIES,

3826
02:33:05,959 --> 02:33:11,565
HALL OF FAMES FOR RESEARCHES, SO

3827
02:33:11,565 --> 02:33:11,898
FORTH.

3828
02:33:11,898 --> 02:33:14,234
>> THANKS YOU.

3829
02:33:14,234 --> 02:33:15,435
THAT'S REALLY HELPFUL.

3830
02:33:15,435 --> 02:33:17,837
>> AS YOU BECOME MORE
MATURE IN

3831
02:33:17,837 --> 02:33:19,272
THE PROGRAM, IT ALMOST SOUNDS

3832
02:33:19,272 --> 02:33:21,875
LIKE IN JOURNALS WHEN THE

3833
02:33:21,875 --> 02:33:24,477
JOURNALS OFFER THE CUTTING EDGE

3834
02:33:24,477 --> 02:33:27,981
OF IMKNOWLEDGE, FOR EXAMPLE, OR

3835
02:33:27,981 --> 02:33:28,815
OTHER SUCH PREMIER COMPONENTS,

3836
02:33:28,815 --> 02:33:31,318
ONE WAY THAT THEY GET EVALUATED

3837
02:33:31,318 --> 02:33:33,520
IS TO WHAT EXTENT IS CITATION

3838
02:33:33,520 --> 02:33:38,525
RATE, WITHIN ONE YEAR, NOT

3839
02:33:38,525 --> 02:33:41,328
NECESSARILY IMPACT FACTOR BUT

3840
02:33:41,328 --> 02:33:44,864
IMMEDIACY OF ITS IMPACT IS ONE

3841
02:33:44,864 --> 02:33:48,335
POTENTIAL METRIC THAT IS USED TO

3842
02:33:48,335 --> 02:33:54,374
SEE IT CAME OUT TO A

3843
02:33:54,374 --> 02:33:55,342
PUBLICATION, DIDN'T MAKE AN

3844
02:33:55,342 --> 02:33:56,643
IMPACT WITHIN AN INTENDED GOAL,

3845
02:33:56,643 --> 02:33:58,745
THAT WOULD BE ONE POTENTIAL

3846
02:33:58,745 --> 02:34:00,280
METRIC YOU COULD POTENTIALLY

3847
02:34:00,280 --> 02:34:03,316
CONSIDER AS YOU MOVE THE PROGRAM

3848
02:34:03,316 --> 02:34:04,384
FORWARD.

3849
02:34:04,384 --> 02:34:07,587
THE OTHER IS TO WHAT EXTENT DID

3850
02:34:07,587 --> 02:34:10,957
THIS WORK SEED ADDITIONAL

3851
02:34:10,957 --> 02:34:12,392
PROPOSALS OR INITIATIVES WITHIN

3852
02:34:12,392 --> 02:34:14,561
THE PARENT GRANT OR THAT WAS

3853
02:34:14,561 --> 02:34:15,595
PICKED UP BY SOMEBODY ELSE THAT

3854
02:34:15,595 --> 02:34:16,997
WAS IN THE NETWORK.

3855
02:34:16,997 --> 02:34:20,300
IF YOU KIND OF DO -- IF YOU'RE

3856
02:34:20,300 --> 02:34:22,769
LOOKING FOR WHETHER IT TRULY

3857
02:34:22,769 --> 02:34:24,337
SEEDED SOMETHING NEW THEN OTHER

3858
02:34:24,337 --> 02:34:27,307
PEOPLE SHOULD BE WORKING ON THIS

3859
02:34:27,307 --> 02:34:29,976
SUBSEQUENTLY WITHIN THE SAME

3860
02:34:29,976 --> 02:34:30,510
DOMAIN.

3861
02:34:30,510 --> 02:34:32,645
BUT IT'S A HARDER METRIC BECAUSE

3862
02:34:32,645 --> 02:34:34,547
OBVIOUSLY WE ALL THINK WE'RE

3863
02:34:34,547 --> 02:34:35,448
DOING INNOVATION WITHIN OUR

3864
02:34:35,448 --> 02:34:38,718
LABS, SO TO COME BACK AND SAY

3865
02:34:38,718 --> 02:34:43,757
THAT YOU HAVE SOMETHING UNIQUE,

3866
02:34:43,757 --> 02:34:44,991
METRICS WOULD NEED TO WAIT IN

3867
02:34:44,991 --> 02:34:49,129
ORDER TO SEE THE IMPACT OF THAT

3868
02:34:49,129 --> 02:34:50,296
AS OPPOSED TO EARLY

3869
02:34:50,296 --> 02:34:51,965
INVESTIGATOR, I SUPPORTED AND

3870
02:34:51,965 --> 02:34:52,832
THEY TRANSITIONED WITHIN, YOU

3871
02:34:52,832 --> 02:34:58,938
KNOW, A YEAR OR TWO AS A HARD

3872
02:34:58,938 --> 02:34:59,339
METRIC AVAILABLE.

3873
02:34:59,339 --> 02:35:01,474
SO --

3874
02:35:01,474 --> 02:35:02,475
>> THANK YOU.

3875
02:35:02,475 --> 02:35:05,311
>> ANY OTHER COMMENTS OR

3876
02:35:05,311 --> 02:35:05,812
FEEDBACK?

3877
02:35:05,812 --> 02:35:07,514
>> I THINK IT'S A VERY

3878
02:35:07,514 --> 02:35:08,481
INTERESTING DISCUSSION BUT WE DO

3879
02:35:08,481 --> 02:35:10,550
NEED TO MOVE ON FOR THE SAKE OF

3880
02:35:10,550 --> 02:35:11,151
TIME.

3881
02:35:11,151 --> 02:35:12,185
>> PERFECT.

3882
02:35:12,185 --> 02:35:17,123
SO WE WILL MOVE TO THE ADVISORY

3883
02:35:17,123 --> 02:35:18,258
COUNCIL REPRESENTATIVES.

3884
02:35:18,258 --> 02:35:26,499
WE WILL GET AN UPDATE, NATIONAL

3885
02:35:26,499 --> 02:35:28,535
ADVISORY MENTAL HEALTH COUNCIL,

3886
02:35:28,535 --> 02:35:30,503
DR. DIANNE RAUSCH WILL PROVIDE A

3887
02:35:30,503 --> 02:35:31,204
SUMMARY.

3888
02:35:31,204 --> 02:35:32,939
>> THANKS FOR THE
OPPORTUNITY TO

3889
02:35:32,939 --> 02:35:36,009
PRESENT TODAY.

3890
02:35:36,009 --> 02:35:39,813
I'M GOING TO -- SINCE GERI

3891
02:35:39,813 --> 02:35:40,647
INTRODUCED NEW LEADERSHIP I'LL

3892
02:35:40,647 --> 02:35:43,149
SKIP THIS AND GO TO AN

3893
02:35:43,149 --> 02:35:45,285
INITIATIVE THAT WE ACTUALLY

3894
02:35:45,285 --> 02:35:47,787
PRESENTED THIS AT THE SEPTEMBER

3895
02:35:47,787 --> 02:35:49,756
2024 OPEN COUNCIL.

3896
02:35:49,756 --> 02:35:51,858
WE NORMALLY -- PROGRAM NORMALLY

3897
02:35:51,858 --> 02:35:53,927
DOES PRESENT THEIR INITIATIVES

3898
02:35:53,927 --> 02:35:54,794
AT THE OARAC.

3899
02:35:54,794 --> 02:35:59,165
I'M THE ONLY ONE RIGHT NOW.

3900
02:35:59,165 --> 02:36:00,333
THIS IS THE FIRST OPPORTUNITY

3901
02:36:00,333 --> 02:36:02,702
I'VE HAD TO DO THIS AT OARAC

3902
02:36:02,702 --> 02:36:04,571
SINCE WE HAVEN'T HAD AN OPEN

3903
02:36:04,571 --> 02:36:07,006
MEETING IN A WHILE.

3904
02:36:07,006 --> 02:36:08,741
THIS INITIATIVE IS -- HOLD ON.

3905
02:36:08,741 --> 02:36:13,913
I'LL GET MY COMPUTER BACK UP. 

3906
02:36:13,913 --> 02:36:16,983
ONE SECOND. 

3907
02:36:16,983 --> 02:36:24,557
IT WENT TO SLEEP.

3908
02:36:24,557 --> 02:36:25,058
OKAY.

3909
02:36:25,058 --> 02:36:27,594
SO, THIS INITIATIVE IS

3910
02:36:27,594 --> 02:36:33,299
ADDRESSING AN ISSUE IN THE

3911
02:36:33,299 --> 02:36:34,400
NEURO-HIV AREA.

3912
02:36:34,400 --> 02:36:38,204
WE KNOW HIV ENTERS THE CNS EARLY

3913
02:36:38,204 --> 02:36:41,741
AFTER INFECTION, WITHIN MAYBE 8

3914
02:36:41,741 --> 02:36:42,275
DAYS.

3915
02:36:42,275 --> 02:36:43,877
AND THERE ARE COMPLICATIONS IN

3916
02:36:43,877 --> 02:36:48,414
THE CNS FROM HAVING HIV THERE.

3917
02:36:48,414 --> 02:36:51,584
OVER THE YEARS WE'VE SPENT

3918
02:36:51,584 --> 02:36:52,685
EFFORT TRYING TO UNDERSTAND WHAT

3919
02:36:52,685 --> 02:36:54,654
CAUSES OF THESE ARE AND THERE

3920
02:36:54,654 --> 02:36:57,991
ARE A NUMBER OF COMPLEXITIES AND

3921
02:36:57,991 --> 02:36:59,692
A NUMBER OF PATHOGENESISES, BUT

3922
02:36:59,692 --> 02:37:00,393
WE'VE DONE MULTIPLE CLINICAL

3923
02:37:00,393 --> 02:37:01,828
TRIALS AND NONE OF THEM HAVE

3924
02:37:01,828 --> 02:37:06,900
EVER REALLY HAD A POSITIVE

3925
02:37:06,900 --> 02:37:07,200
EFFECT.

3926
02:37:07,200 --> 02:37:07,967
ALTHOUGH ANTIRETROVIRALS

3927
02:37:07,967 --> 02:37:11,771
DECREASE SEVER ITY THERE'S A

3928
02:37:11,771 --> 02:37:13,373
NUMBER OF PROBLEMS THAT PEOPLE

3929
02:37:13,373 --> 02:37:16,142
LIVING WITH HIV LONG TERM HAVE.

3930
02:37:16,142 --> 02:37:17,143
MULTIPLE CLINICAL TRIALS THAT

3931
02:37:17,143 --> 02:37:21,181
WE'VE TRIED TO DO OVER THE YEARS

3932
02:37:21,181 --> 02:37:22,649
HAVE NOT IDENTIFIED ANY

3933
02:37:22,649 --> 02:37:26,953
PARTICULAR POSITIVE OUTCOMES.

3934
02:37:26,953 --> 02:37:29,088
SO, OVER THE YEARS 21-22 WE

3935
02:37:29,088 --> 02:37:31,391
CONVENED A NUMBER OF WORK

3936
02:37:31,391 --> 02:37:32,559
GROUPS, AND BROUGHT TOGETHER

3937
02:37:32,559 --> 02:37:34,260
WIDE RANGE OF EXPERTISE TO TRY

3938
02:37:34,260 --> 02:37:36,796
TO UNDERSTAND WHAT THE PROBLEMS

3939
02:37:36,796 --> 02:37:39,666
WERE AND WHY WE CAN'T SEEM TO

3940
02:37:39,666 --> 02:37:42,168
GET A BETTER UNDERSTANDING OF

3941
02:37:42,168 --> 02:37:46,005
HOW TO TREAT THESE

3942
02:37:46,005 --> 02:37:46,372
COMPLICATIONS.

3943
02:37:46,372 --> 02:37:48,041
A LOT OF THE REASONS FOR THAT

3944
02:37:48,041 --> 02:37:53,613
ARE LISTED HERE ON THE RIGHT.

3945
02:37:53,613 --> 02:37:57,183
PARTICULARLY THE HIV AND CNS AS

3946
02:37:57,183 --> 02:37:57,750
MULTI-FACTORIAL PROCESS.

3947
02:37:57,750 --> 02:38:02,055
SO ONE OF THE GOALS OF THIS HOW

3948
02:38:02,055 --> 02:38:03,990
WE MIGHT UNDERSTAND HOW WE MIGHT

3949
02:38:03,990 --> 02:38:05,158
BETTER ADDRESS THIS.

3950
02:38:05,158 --> 02:38:07,560
IF YOU -- WE DECIDED WE WOULD

3951
02:38:07,560 --> 02:38:10,730
TRY TO TAKE A COMPUTATIONAL

3952
02:38:10,730 --> 02:38:14,400
PSYCHIATRY APPROACH, AND DEVELOP

3953
02:38:14,400 --> 02:38:15,902
SOME PERSONAL MEDICINE IDEAS TO

3954
02:38:15,902 --> 02:38:17,237
ADDRESS THIS.

3955
02:38:17,237 --> 02:38:20,974
THERE'S A NUMBER OF DIFFERENT

3956
02:38:20,974 --> 02:38:22,642
OBVIOUSLY POTENTIAL CONTRIBUTORS

3957
02:38:22,642 --> 02:38:23,810
TO THE PATHOGENESIS, BUT WHAT

3958
02:38:23,810 --> 02:38:26,012
THE MECHANISMS AND HOW TO TARGET

3959
02:38:26,012 --> 02:38:31,251
THESE HAVE NOT BEEN WELL

3960
02:38:31,251 --> 02:38:31,551
UNDERSTOOD.

3961
02:38:31,551 --> 02:38:33,286
SO, THIS IS KIND OF AN OUTLINE

3962
02:38:33,286 --> 02:38:35,688
OF WHAT WE'RE LOOKING AT, SOME

3963
02:38:35,688 --> 02:38:37,657
OF THE REASONS THAT WE HAVEN'T

3964
02:38:37,657 --> 02:38:42,729
BEEN ABLE TO COME UP WITH A GOOD

3965
02:38:42,729 --> 02:38:46,666
CONCEPT FOR TREATING IT IS THAT

3966
02:38:46,666 --> 02:38:49,669
WE'VE FOCUSED MOSTLY ON GLOBAL

3967
02:38:49,669 --> 02:38:51,437
OUTCOMES THAT WERE BROAD, NOT

3968
02:38:51,437 --> 02:38:52,272
SPECIFICALLY TARGETED.

3969
02:38:52,272 --> 02:39:02,148
AND SO WE WANTED TO TRY TO LOOK

3970
02:39:02,148 --> 02:39:04,150
AT MORE WORKING MEMORY,

3971
02:39:04,150 --> 02:39:05,051
EXECUTIVE FUNCTION, DEPRESSION,

3972
02:39:05,051 --> 02:39:06,286
ANXIETY, TRY TO SEPARATE THESE

3973
02:39:06,286 --> 02:39:11,991
THINGS OUT SO WE COULD TARGET

3974
02:39:11,991 --> 02:39:13,726
INDIVIDUAL COMPONENTS,

3975
02:39:13,726 --> 02:39:16,029
INDIVIDUAL TOXICITIES, AND

3976
02:39:16,029 --> 02:39:16,529
INDIVIDUAL PATHOGENESIS.

3977
02:39:16,529 --> 02:39:18,364
AND SO ONE OF THE MAJOR PROBLEMS

3978
02:39:18,364 --> 02:39:21,167
THAT WE'VE HAD IS THAT WE

3979
02:39:21,167 --> 02:39:24,904
HAVEN'T HAD -- BEEN ABLE TO HAVE

3980
02:39:24,904 --> 02:39:29,075
A REALLY GOOD RECRUITMENT

3981
02:39:29,075 --> 02:39:31,311
CRITERIA BECAUSE PATIENTS WERE

3982
02:39:31,311 --> 02:39:31,711
DIVERSE.

3983
02:39:31,711 --> 02:39:33,946
AND THERE'S A LOT OF

3984
02:39:33,946 --> 02:39:34,514
COMORBIDITIES, INTERPERSONAL

3985
02:39:34,514 --> 02:39:35,915
FACTORS THAT COME INTO PLAY.

3986
02:39:35,915 --> 02:39:39,385
SO AT THESE MEETINGS THAT WE

3987
02:39:39,385 --> 02:39:41,688
HAD, WE BROUGHT TOGETHER SOME

3988
02:39:41,688 --> 02:39:42,488
DATA SCIENTISTS, WE HAVE A LOT

3989
02:39:42,488 --> 02:39:43,890
OF DATA THAT WE'VE COLLECTED

3990
02:39:43,890 --> 02:39:44,524
OVER THE YEARS.

3991
02:39:44,524 --> 02:39:46,859
AND THEY ARE TRYING TO USE DATA

3992
02:39:46,859 --> 02:39:48,528
SCIENCE AND MACHINE LEARNING TO

3993
02:39:48,528 --> 02:39:53,533
TRY TO SEPARATE OUT SOME OF THE

3994
02:39:53,533 --> 02:39:54,801
COMPONENTS THAT MIGHT BE

3995
02:39:54,801 --> 02:39:57,537
RESPONSIBLE FOR SOME OF THESE

3996
02:39:57,537 --> 02:39:59,872
CNS COMPLICATIONS AND MAYBE

3997
02:39:59,872 --> 02:40:04,777
SEPARATE THOSE OUT INTO

3998
02:40:04,777 --> 02:40:07,013
INDIVIDUAL TARGETS AND

3999
02:40:07,013 --> 02:40:10,116
INDIVIDUAL POTENTIAL APPROACHES.

4000
02:40:10,116 --> 02:40:11,884
SO, THE WAY WE'RE TRYING TO DO

4001
02:40:11,884 --> 02:40:16,589
THIS IS TO USE A BIPHASIC

4002
02:40:16,589 --> 02:40:17,790
APPROACH, TO IDENTIFY STUDIES,

4003
02:40:17,790 --> 02:40:19,625
DEVELOP STUDIES, THESE ARE THE

4004
02:40:19,625 --> 02:40:20,760
FIRST PART WOULD BE

4005
02:40:20,760 --> 02:40:22,962
DEVELOPMENTAL STUDIES THAT WOULD

4006
02:40:22,962 --> 02:40:25,264
TRY TO IDENTIFY SPECIFIC PATIENT

4007
02:40:25,264 --> 02:40:26,466
GROUPS WITH TREATABLE TRAITS,

4008
02:40:26,466 --> 02:40:31,270
FOLLOWED BY STUDIES OF TARGET

4009
02:40:31,270 --> 02:40:32,438
ENGAGEMENT.

4010
02:40:32,438 --> 02:40:35,808
THEN EVALUATE THESE FOR THE

4011
02:40:35,808 --> 02:40:37,643
EFFECTS OF THE SPECIFIC

4012
02:40:37,643 --> 02:40:38,711
RECRUITMENT, RETENTION, AND

4013
02:40:38,711 --> 02:40:39,212
ASSESSMENTS.

4014
02:40:39,212 --> 02:40:42,048
AND THEN EXAMINE THE IMPACT OF

4015
02:40:42,048 --> 02:40:45,885
THE TARGET MODIFICATIONS ON

4016
02:40:45,885 --> 02:40:46,586
NEUROTRANSMITTERS, BRAIN

4017
02:40:46,586 --> 02:40:48,388
CIRCUITS AND NETWORK THAT MIGHT

4018
02:40:48,388 --> 02:40:53,393
REGULATE MOOD, COGNITION AND

4019
02:40:53,393 --> 02:40:55,094
BEHAVIOR AND PILOTS THAT COULD

4020
02:40:55,094 --> 02:41:01,501
LEAD TO LARGER STUDIES TO

4021
02:41:01,501 --> 02:41:02,502
CONFIRM TARGET ENGAGEMENT AND

4022
02:41:02,502 --> 02:41:03,269
TEST EFFICACY OF THESE

4023
02:41:03,269 --> 02:41:05,037
STRATEGIES AND MOVE TO A LARGER

4024
02:41:05,037 --> 02:41:09,442
TRIAL SEE IF WE COULD ACTUALLY

4025
02:41:09,442 --> 02:41:11,511
IDENTIFY THESE ETIOLOGIES AND

4026
02:41:11,511 --> 02:41:12,979
TARGET SPECIFIC ONES.

4027
02:41:12,979 --> 02:41:18,151
SO, THE PURPOSE OF THIS IS TO

4028
02:41:18,151 --> 02:41:24,490
IDENTIFY MODIFIABLE TARGETS AND

4029
02:41:24,490 --> 02:41:25,491
EMPLOYEE PERSONALIZED MEDICINE

4030
02:41:25,491 --> 02:41:27,460
APPROACH TO ADDRESS TREATABLE

4031
02:41:27,460 --> 02:41:29,495
TRAITS TO DESIGN COMPREHENSIVE

4032
02:41:29,495 --> 02:41:30,997
AND VALIDATED TREATMENT

4033
02:41:30,997 --> 02:41:34,033
STRATEGIES, TO DEVELOP TREATMENT

4034
02:41:34,033 --> 02:41:39,172
STRATEGIES USING EXPERIMENTAL

4035
02:41:39,172 --> 02:41:40,406
THERAPEUTICS APPROACH,

4036
02:41:40,406 --> 02:41:41,007
THERAPEUTICS-BASED APPROACHES,

4037
02:41:41,007 --> 02:41:42,642
IDENTIFICATION OF MODIFIABLE OR

4038
02:41:42,642 --> 02:41:45,011
POTENTIAL MODIFIABLE TARGETS

4039
02:41:45,011 --> 02:41:46,479
THAT MIGHT TRANSLATE INTO

4040
02:41:46,479 --> 02:41:53,820
CLINICAL  HYPOTHESES AND TEST

4041
02:41:53,820 --> 02:41:56,556
APPROACHES AND MONITOR OUTCOMES.

4042
02:41:56,556 --> 02:42:00,493
THE ULTIMATE GOAL IS TO ENHANCE

4043
02:42:00,493 --> 02:42:02,795
QUALITY OF LIFE, REDUCING

4044
02:42:02,795 --> 02:42:03,996
SYMPTOM SEVERITY, MAXIMIZING

4045
02:42:03,996 --> 02:42:05,765
ADEQUATE FUNCTIONING OF PEOPLE

4046
02:42:05,765 --> 02:42:09,135
WITH HIV EXPERIENCING SOME OF

4047
02:42:09,135 --> 02:42:10,136
THESE CNS COMPLICATIONS.

4048
02:42:10,136 --> 02:42:16,008
SO I'M HAPPY TO ANSWER QUESTIONS

4049
02:42:16,008 --> 02:42:20,847
IF THERE ARE ANY.

4050
02:42:20,847 --> 02:42:22,648
>> THANK YOU, WE'LL
PROCEED INTO

4051
02:42:22,648 --> 02:42:24,016
THE QUESTIONS OR COMMENTS.

4052
02:42:24,016 --> 02:42:26,819
FIRST WE'LL START WITH THE ROOM.

4053
02:42:26,819 --> 02:42:28,621
DR. GLENSHAW, ANY COMMENTS FROM

4054
02:42:28,621 --> 02:42:29,822
THE ROOM?

4055
02:42:29,822 --> 02:42:32,425
>> NOT AT THIS TIME.

4056
02:42:32,425 --> 02:42:35,061
>> THANK YOU.

4057
02:42:35,061 --> 02:42:39,031
ANY COMMENTS ONLINE, OR

4058
02:42:39,031 --> 02:42:42,401
CLARIFICATIONS? 

4059
02:42:42,401 --> 02:42:43,536
ALL RIGHT.

4060
02:42:43,536 --> 02:42:45,505
THANK YOU, EVERYONE.

4061
02:42:45,505 --> 02:42:46,939
THANK YOU, DR. RAUSCH, FOR THE

4062
02:42:46,939 --> 02:42:47,173
UPDATE.

4063
02:42:47,173 --> 02:42:49,876
WE'LL PROCEED AS WE BEGIN TO

4064
02:42:49,876 --> 02:42:50,376
CLOSE.

4065
02:42:50,376 --> 02:42:51,978
REMINDER, WE HAVE ALLOTTED TIME

4066
02:42:51,978 --> 02:42:53,646
FOR PUBLIC COMMENTS.

4067
02:42:53,646 --> 02:42:54,680
DR. GLENSHAW YOU HAVE COMMENTS

4068
02:42:54,680 --> 02:42:56,983
SO I'LL HAND OFF TO YOU.

4069
02:42:56,983 --> 02:43:00,253
>> THANK YOU.

4070
02:43:00,253 --> 02:43:03,656
YES, WE HAVE I BELIEVE 37 PUBLIC

4071
02:43:03,656 --> 02:43:03,923
COMMENTS.

4072
02:43:03,923 --> 02:43:06,826
THE FIRST THREE ARE REGARDING

4073
02:43:06,826 --> 02:43:08,194
HIV RESEARCH.

4074
02:43:08,194 --> 02:43:11,464
AND THE REST ARE REGARDING

4075
02:43:11,464 --> 02:43:11,931
GUIDELINES.

4076
02:43:11,931 --> 02:43:15,535
THE THIRD ONE IS A HYBRID.

4077
02:43:15,535 --> 02:43:18,004
WE'RE DOING OUR BEST TO BE

4078
02:43:18,004 --> 02:43:20,039
RESPONSIVE AND VOICE ALL OF

4079
02:43:20,039 --> 02:43:21,541
THESE COMMENTS, EVEN THOSE THAT

4080
02:43:21,541 --> 02:43:22,975
WERE RECEIVED DURING THE

4081
02:43:22,975 --> 02:43:23,209
MEETING.

4082
02:43:23,209 --> 02:43:26,212
SO PLEASE BEAR WITH ME IF I'M

4083
02:43:26,212 --> 02:43:28,481
STUMBLING A LITTLE BIT.

4084
02:43:28,481 --> 02:43:32,318
THE FIRST PUBLIC COMMENT FROM

4085
02:43:32,318 --> 02:43:35,721
LAUREN KLEIN FROM PHYLLIS FRANK

4086
02:43:35,721 --> 02:43:37,223
CENTER OF ROCKLAND COUNTY,

4087
02:43:37,223 --> 02:43:39,225
STATING CUTTING FUNDING FOR HIV

4088
02:43:39,225 --> 02:43:41,561
RESEARCH IS EXTREMELY SHORT

4089
02:43:41,561 --> 02:43:42,628
SIGHTED AND POLITICALLY

4090
02:43:42,628 --> 02:43:42,895
MOTIVATED.

4091
02:43:42,895 --> 02:43:45,531
THE WORLD IS ON THE BRINK OF

4092
02:43:45,531 --> 02:43:47,567
BEING ABLE TO PREVENT HIV VIA

4093
02:43:47,567 --> 02:43:50,369
VACCINE AND CURE THROUGH

4094
02:43:50,369 --> 02:43:52,838
GLOBALLY COORDINATED RESEARCH.

4095
02:43:52,838 --> 02:43:53,873
MULTIPLE CANDIDATE VACCINES MOVE

4096
02:43:53,873 --> 02:43:55,341
THROUGH THE PIPELINE EACH YEAR.

4097
02:43:55,341 --> 02:43:57,577
IT WILL TAKE ONLY ONE TO

4098
02:43:57,577 --> 02:43:57,810
SUCCEED.

4099
02:43:57,810 --> 02:44:01,314
EACH YEAR MORE PEOPLE ARE

4100
02:44:01,314 --> 02:44:03,249
FUNCTIONALLY CURED VIA STEM CELL

4101
02:44:03,249 --> 02:44:04,150
TRANSPLANT.

4102
02:44:04,150 --> 02:44:04,717
THESE TRANSPLANTS ARE ONLY

4103
02:44:04,717 --> 02:44:08,387
INDICATED FOR USE IN PEOPLE WITH

4104
02:44:08,387 --> 02:44:09,388
ADVANCED CANCERS, EACH CASE

4105
02:44:09,388 --> 02:44:11,591
TEACHES SCIENTISTS MORE ABOUT

4106
02:44:11,591 --> 02:44:14,060
THE BIOLOGICAL MECHANISMS AT

4107
02:44:14,060 --> 02:44:15,595
PLAY, GETTING CLOSER TO

4108
02:44:15,595 --> 02:44:18,631
FUNCTIONAL CURE FOR GENERAL

4109
02:44:18,631 --> 02:44:18,931
POPULATION.

4110
02:44:18,931 --> 02:44:21,100
PRETENDING NIH EXPECTS TO BE

4111
02:44:21,100 --> 02:44:23,069
SHIFTING FOCUS TOWARDS USING

4112
02:44:23,069 --> 02:44:25,204
CURRENTLY AVAILABLE APPROACHES

4113
02:44:25,204 --> 02:44:26,906
TO ELIMINATE HIV, MEANS NIH IS

4114
02:44:26,906 --> 02:44:29,175
CONTENT TO HAVE AMERICANS

4115
02:44:29,175 --> 02:44:31,344
CONTINUE TO CONTRACT HIV.

4116
02:44:31,344 --> 02:44:33,479
BECOME SICK AND DIE.

4117
02:44:33,479 --> 02:44:34,880
CURRENT APPROACHES TO PREVENT

4118
02:44:34,880 --> 02:44:35,915
HIV ARE NOT PERFECT.

4119
02:44:35,915 --> 02:44:37,450
THEY ARE MADE LESS EFFECTIVE

4120
02:44:37,450 --> 02:44:39,251
WHEN THE FEDERAL GOVERNMENT CUTS

4121
02:44:39,251 --> 02:44:40,252
FUNDING SUPPORT TO THEM.

4122
02:44:40,252 --> 02:44:42,989
IT IS ALSO MADE LESS EFFECTIVE

4123
02:44:42,989 --> 02:44:49,495
WHEN THERE'S A SUPREME COURT

4124
02:44:49,495 --> 02:44:51,364
CASE, BECAUSE IT, QUOTE,

4125
02:44:51,364 --> 02:44:53,032
PROMOTES HOMOSEXUAL BEHAVIOR.

4126
02:44:53,032 --> 02:44:56,936
THE NIH DOES NOT EXPECT THAT

4127
02:44:56,936 --> 02:44:59,138
CURRENTLY AVAILABLE APPROACHES

4128
02:44:59,138 --> 02:45:02,008
TO IN FACT -- WILL ELIMINATE

4129
02:45:02,008 --> 02:45:02,942
HIV/AIDS.

4130
02:45:02,942 --> 02:45:04,377
PERHAPS IT EXPECTS UNDESIRABLE

4131
02:45:04,377 --> 02:45:06,312
AMERICANS TO DIE OF AIDS.

4132
02:45:06,312 --> 02:45:11,917
THE DECISION TO CUT NIH FUNDING

4133
02:45:11,917 --> 02:45:13,953
IS SHORT SIGHTED, NOT POPULAR

4134
02:45:13,953 --> 02:45:15,621
WITH THE AMERICAN PEOPLE, NOR

4135
02:45:15,621 --> 02:45:22,795
ETHICAL NOR IN LINE WITH

4136
02:45:22,795 --> 02:45:24,830
CHRISTIAN VALUES.

4137
02:45:24,830 --> 02:45:32,071
>> NEXT JOHN MEADE,
KENDALL

4138
02:45:32,071 --> 02:45:35,675
WRIGHT, THEY STATE TODAY WE

4139
02:45:35,675 --> 02:45:36,609
WRITE WITH DEEP CONCERN ABOUT

4140
02:45:36,609 --> 02:45:38,377
THE INFRASTRUCTURE AND CALL TO

4141
02:45:38,377 --> 02:45:41,514
ACTION FOR THIS BODY SAFEGUARD

4142
02:45:41,514 --> 02:45:43,249
VALUES OF EQUITY, EVIDENCE,

4143
02:45:43,249 --> 02:45:45,718
ACCOUNTABLE THAT MUST GUIDE OUR

4144
02:45:45,718 --> 02:45:45,985
WORK.

4145
02:45:45,985 --> 02:45:51,624
FY 26 PRESIDENT'S BUDGET

4146
02:45:51,624 --> 02:45:54,994
PROPOSED 36.4% CUT TO NIAID, AND

4147
02:45:54,994 --> 02:45:58,798
49% TO OAR, NOT JUST BUDGET LINE

4148
02:45:58,798 --> 02:45:59,832
ITEMS AND THESE REPRESENT

4149
02:45:59,832 --> 02:46:01,901
SIGNIFICANT SETBACK FOR

4150
02:46:01,901 --> 02:46:03,369
THOUSANDS OF RESEARCHERS,

4151
02:46:03,369 --> 02:46:05,071
PROVIDERS, MOST IMPORTANTLY

4152
02:46:05,071 --> 02:46:07,073
COMMUNITIES WHO RELY ON HIV, I'M

4153
02:46:07,073 --> 02:46:09,809
SORRY, ON NIH SUPPORTED SCIENCE

4154
02:46:09,809 --> 02:46:11,343
TO STAY ALIVE.

4155
02:46:11,343 --> 02:46:14,814
JEOPARDIZING U.S. STANDING AS A

4156
02:46:14,814 --> 02:46:15,781
SCIENTIFIC SUPERPOWER, PUBLICLY

4157
02:46:15,781 --> 02:46:19,318
FUNDED RESEARCH HAS BEEN A CORE

4158
02:46:19,318 --> 02:46:20,186
DIPLOMATIC STRATEGY, BY

4159
02:46:20,186 --> 02:46:21,220
IMPROVING LIVES OF MILLIONS

4160
02:46:21,220 --> 02:46:24,056
WORLDWIDE AND IN THE U.S. THAT

4161
02:46:24,056 --> 02:46:26,859
SUFFER FROM HEALTH CONDITIONS

4162
02:46:26,859 --> 02:46:30,663
LIKE HIV, TB, HEPATITIS, STI,

4163
02:46:30,663 --> 02:46:32,031
OTHER INFECTIOUS DISEASES.

4164
02:46:32,031 --> 02:46:34,500
THESE CUTS WOULD HALT PROMISING

4165
02:46:34,500 --> 02:46:37,536
RESEARCH ON LONG ACTING PrEP,

4166
02:46:37,536 --> 02:46:38,671
CURE STRATEGIES, COMORBID

4167
02:46:38,671 --> 02:46:40,306
CONDITIONS SUCH AS CANCER,

4168
02:46:40,306 --> 02:46:42,541
MENTAL HEALTH, SUBSTANCE ABUSE.

4169
02:46:42,541 --> 02:46:45,644
ALL OF WHICH IMPACT BROWN,

4170
02:46:45,644 --> 02:46:48,080
BLACK, LGBTQ COMMUNITIES HERE

4171
02:46:48,080 --> 02:46:50,383
AND ABROAD DISPROPORTIONATELY.

4172
02:46:50,383 --> 02:46:55,221
THEY THREATEN TO ERASE GAINS

4173
02:46:55,221 --> 02:46:58,257
ESPECIALLY AMONG POPULATIONS

4174
02:46:58,257 --> 02:47:00,092
HISTORICALLY EXCLUDED FROM

4175
02:47:00,092 --> 02:47:01,093
CLINICAL TRIALS.

4176
02:47:01,093 --> 02:47:02,161
THEIR PARTICIPATION AND

4177
02:47:02,161 --> 02:47:04,897
LEADERSHIP HAVE BEEN CRITICAL TO

4178
02:47:04,897 --> 02:47:07,099
INFORMING AND IMPLEMENTING NEXT

4179
02:47:07,099 --> 02:47:08,667
GENERATION OF PREVENTION AND

4180
02:47:08,667 --> 02:47:09,735
THERAPEUTICS TAILORED TO

4181
02:47:09,735 --> 02:47:17,042
COMMUNITY NEEDS, BRIDGING GAPS.

4182
02:47:17,042 --> 02:47:19,445
THEY STRESS THE IMPORTANCE OF

4183
02:47:19,445 --> 02:47:21,380
BIOMEDICAL INNOVATION AND

4184
02:47:21,380 --> 02:47:22,214
EQUITABLE IMPLEMENTATION.

4185
02:47:22,214 --> 02:47:24,383
THEY STATE WE NEED MORE FUNDING

4186
02:47:24,383 --> 02:47:27,119
FOR RESEARCH THAT EXAMINES HOW

4187
02:47:27,119 --> 02:47:28,821
TO BUILD TRUST, ADDRESS STIGMA,

4188
02:47:28,821 --> 02:47:33,492
OVERCOME BEARERS TO ACCESS.

4189
02:47:33,492 --> 02:47:35,361
THEY URGE THE OARAC TO PUBLICLY

4190
02:47:35,361 --> 02:47:39,365
OPPOSE THE PROPOSED CUTS IN FY

4191
02:47:39,365 --> 02:47:41,534
26 PROPOSAL AND DEFEND

4192
02:47:41,534 --> 02:47:47,206
COORDINATING ROLE ACROSS NIH.

4193
02:47:47,206 --> 02:47:47,673
ADVOCATE FOR AT LEAST

4194
02:47:47,673 --> 02:47:49,942
$3.9 BILLION FOR HIV DEFINED IN

4195
02:47:49,942 --> 02:47:51,544
THE PROFESSIONAL JUDGMENT

4196
02:47:51,544 --> 02:47:52,545
BUDGET.

4197
02:47:52,545 --> 02:47:54,513
REINFORCE IMPORTANCE OF

4198
02:47:54,513 --> 02:47:57,249
COMMUNITY-LED RESEARCH AND

4199
02:47:57,249 --> 02:47:58,884
INVESTMENTS IN IMPLEMENTATION

4200
02:47:58,884 --> 02:48:01,954
SCIENCE AND THOSE OUTLINED IN

4201
02:48:01,954 --> 02:48:03,823
THE RESEARCH AGENDA.

4202
02:48:03,823 --> 02:48:05,391
PUSH FOR TRANSPARENCY AND

4203
02:48:05,391 --> 02:48:06,392
ACCOUNTABILITY REGARDING HOW NIH

4204
02:48:06,392 --> 02:48:15,234
GRANT  TERMINATIONS ARE HANDLED.

4205
02:48:15,234 --> 02:48:16,702
COMMUNITY ENGAGEMENT AND

4206
02:48:16,702 --> 02:48:17,303
SUSTAINED FEDERAL INVESTMENT

4207
02:48:17,303 --> 02:48:20,339
WILL DETERMINE WHETHER WE END

4208
02:48:20,339 --> 02:48:21,907
THE EPIDEMIC OR REGRESS.

4209
02:48:21,907 --> 02:48:28,047
SCALE UP ENTER INVESTIGATORS  IS

4210
02:48:28,047 --> 02:48:28,948
REQUIRED FOR SUSTAINABILITY IN

4211
02:48:28,948 --> 02:48:30,716
THE EPIDEMIC AND BRING US CLOSER

4212
02:48:30,716 --> 02:48:39,158
TO AN END TO HIV EVERYWHERE.

4213
02:48:39,158 --> 02:48:42,995
NEXT IS LENGTHY SO I'LL SUMMIT

4214
02:48:42,995 --> 02:48:43,329
UP.

4215
02:48:43,329 --> 02:48:48,200
FROM RICHARD JEFFRIES, TREATMENT

4216
02:48:48,200 --> 02:48:49,001
ACTION GROUP.

4217
02:48:49,001 --> 02:48:57,009
HE STATES  THE TO END REVERSAL F

4218
02:48:57,009 --> 02:49:00,045
GUIDELINES THAT SERVE IN KEEPING

4219
02:49:00,045 --> 02:49:01,947
CLINICIANS, CAREGIVERS, PEOPLE

4220
02:49:01,947 --> 02:49:04,383
WITH HIV AND ADVOCATES UP TO

4221
02:49:04,383 --> 02:49:06,352
DATE AS NEW INTERVENTIONS ARE

4222
02:49:06,352 --> 02:49:10,523
APPROVED AND/OR IMPORTANT NEW

4223
02:49:10,523 --> 02:49:11,423
DATA BECOME AVAILABLE.

4224
02:49:11,423 --> 02:49:13,993
THEY STATE THERE'S NO EVIDENCE

4225
02:49:13,993 --> 02:49:15,828
THAT ANY ANALYSIS WAS CONDUCTED

4226
02:49:15,828 --> 02:49:19,598
TO JUSTIFY DECISION TO END NIH

4227
02:49:19,598 --> 02:49:22,768
SUPPORT FOR THE GUIDELINES,

4228
02:49:22,768 --> 02:49:27,273
SUGGESTION ARE VAGUE AND

4229
02:49:27,273 --> 02:49:29,241
UNCONVINCING.

4230
02:49:29,241 --> 02:49:34,980
THEY DISCUSS THEIR OPPOSITION TO

4231
02:49:34,980 --> 02:49:37,283
GRANTS, AWARD TERMINATIONS,

4232
02:49:37,283 --> 02:49:41,820
REFERRING TO DISPROPORTIONATE

4233
02:49:41,820 --> 02:49:42,821
TERMINATIONS AFFECTING LGBTQ+

4234
02:49:42,821 --> 02:49:45,891
COMMUNITIES AND D.E.I.-RELATED

4235
02:49:45,891 --> 02:49:46,125
AWARDS.

4236
02:49:46,125 --> 02:49:53,032
THEY INCLUDE A STATEMENT THAT

4237
02:49:53,032 --> 02:50:01,640
HOMOGENEITY AND INACCESSIBILITY

4238
02:50:01,640 --> 02:50:12,151
ARE ANATHEMA TO NIH RESEARCH.

4239
02:50:23,162 --> 02:50:25,097
OARAC SHOULD QUESTION HOW

4240
02:50:25,097 --> 02:50:31,103
TERMINATION OCCURRED AND WHY

4241
02:50:31,103 --> 02:50:33,472
PROCEDURES WEREN'T FOLLOWED.

4242
02:50:33,472 --> 02:50:37,376
PAY ATTENTION TO THE PLIGHT OF

4243
02:50:37,376 --> 02:50:40,946
THE NETWORKS, NETWORKS HAVE BEEN

4244
02:50:40,946 --> 02:50:42,047
IMPACTED BY UNJUSTIFIABLE

4245
02:50:42,047 --> 02:50:43,248
DECISION TO PREVENT FUNDING TO

4246
02:50:43,248 --> 02:50:44,717
SOUTH AFRICA AND SUBSEQUENT

4247
02:50:44,717 --> 02:50:47,419
PAUSE ON FUNDING FOR ALL

4248
02:50:47,419 --> 02:50:48,487
INTERNATIONAL SUB-AWARDEES

4249
02:50:48,487 --> 02:50:49,688
INCLUDING CLINICAL TRIAL UNITS.

4250
02:50:49,688 --> 02:50:52,691
NIH HAS A LEGAL ONLY GAPINGS TO

4251
02:50:52,691 --> 02:50:53,993
ENSURE APPROPRIATE CARE AND

4252
02:50:53,993 --> 02:51:00,366
SAFETY MONITORING FOR TRIAL

4253
02:51:00,366 --> 02:51:01,433
PARTICIPANTS.

4254
02:51:01,433 --> 02:51:11,977
THESE NETWORKS WERE INTEGRAL TO

4255
02:51:12,411 --> 02:51:13,445
PrEP.

4256
02:51:13,445 --> 02:51:17,383
I'LL MOVE TO ABOUT 34 COMMENTS

4257
02:51:17,383 --> 02:51:19,184
REGARDING CLINICAL PRACTICE

4258
02:51:19,184 --> 02:51:19,718
GUIDELINES.

4259
02:51:19,718 --> 02:51:23,222
FIRST IS FROM SARAH MACBETH,

4260
02:51:23,222 --> 02:51:25,324
INFECTIOUS DISEASE PHYSICIAN AND

4261
02:51:25,324 --> 02:51:27,693
HIV SPECIALIST IN PITTSBURGH.

4262
02:51:27,693 --> 02:51:29,528
SHE FREQUENTLY USES GUIDELINES

4263
02:51:29,528 --> 02:51:31,730
AS IMPORTANT SOURCE OF

4264
02:51:31,730 --> 02:51:32,765
INFORMATION REGARDING NUANCES IN

4265
02:51:32,765 --> 02:51:34,633
CARING FOR PEOPLE WITH HIV.

4266
02:51:34,633 --> 02:51:35,901
SHE FINDS THEM ESPECIALLY

4267
02:51:35,901 --> 02:51:38,337
CRITICAL IN THE CARE OF PEOPLE

4268
02:51:38,337 --> 02:51:41,407
WITH INFREQUENTLY SEEN

4269
02:51:41,407 --> 02:51:47,780
OPPORTUNISTIC INFECTION  INFECTA

4270
02:51:47,780 --> 02:51:51,450
TOOL FOR TEACHING, URGES TO

4271
02:51:51,450 --> 02:51:55,721
MAINTAIN ONLINE, ACCESSIBLE TO

4272
02:51:55,721 --> 02:51:56,055
ALL.

4273
02:51:56,055 --> 02:52:00,993
NEXT FROM DR. PHILIP BULLDOK WHO

4274
02:52:00,993 --> 02:52:02,361
HAS FOUR AFFILIATIONS, FAMILY

4275
02:52:02,361 --> 02:52:05,064
HEALTH CENTER OF THE WORCESTER,

4276
02:52:05,064 --> 02:52:07,699
MASS; UMass CHAN MEDICAL

4277
02:52:07,699 --> 02:52:08,967
SCHOOL; NEW ENGLAND AIDS

4278
02:52:08,967 --> 02:52:12,738
EDUCATION AND TRAINING CENTER;

4279
02:52:12,738 --> 02:52:13,839
VICE CHAIR OF HIV.

4280
02:52:13,839 --> 02:52:15,507
SOMEONE WHO SPENT A CAREER

4281
02:52:15,507 --> 02:52:17,709
PROMOTING HIV CARE AND PRIMARY

4282
02:52:17,709 --> 02:52:20,379
CARE SETTINGS, ALARMED BY THIS

4283
02:52:20,379 --> 02:52:21,113
WEEK'S ANNOUNCEMENT INDICATING

4284
02:52:21,113 --> 02:52:23,649
NIH'S DECISION TO STEP AWAY FROM

4285
02:52:23,649 --> 02:52:24,950
PRODUCING THE GUIDELINES.

4286
02:52:24,950 --> 02:52:26,318
THIS RESOURCE IS ABSOLUTELY

4287
02:52:26,318 --> 02:52:28,153
ESSENTIAL FOR PEOPLE LIKE MYSELF

4288
02:52:28,153 --> 02:52:30,856
ON THE GROUND DELIVERING CARE

4289
02:52:30,856 --> 02:52:31,623
AND EDUCATING COLLEAGUES,

4290
02:52:31,623 --> 02:52:33,792
TRAINEES, STUDENTS IN THE

4291
02:52:33,792 --> 02:52:35,961
STANDARDS OF HIV CARE.

4292
02:52:35,961 --> 02:52:39,565
ALONG WITH NATIONAL HIV

4293
02:52:39,565 --> 02:52:43,969
CURRICULUM, NATIONAL CLINICIAN

4294
02:52:43,969 --> 02:52:45,170
CONSULTATION CENTER, GUIDELINES

4295
02:52:45,170 --> 02:52:47,005
FORM A TRIFECTA ENSURING PEOPLE

4296
02:52:47,005 --> 02:52:51,844
WITH HIV RECEIVE APPROPRIATE BUT

4297
02:52:51,844 --> 02:52:52,277
COST EFFECTIVE CARE.

4298
02:52:52,277 --> 02:52:55,080
  OARAC TO WORK ON FINDING

4299
02:52:55,080 --> 02:52:56,381
ALTERNATIVE DIVISION AND FUNDING

4300
02:52:56,381 --> 02:52:58,851
FOR CONTINUED PRODUCTION OF THE

4301
02:52:58,851 --> 02:53:01,186
GUIDELINES, PERHAPS WITHIN THE

4302
02:53:01,186 --> 02:53:02,254
HIV/AIDS BUREAU.

4303
02:53:02,254 --> 02:53:03,822
NOTES THAT ESPECIALLY WITH

4304
02:53:03,822 --> 02:53:06,091
PROPOSED CUTS TO PART F OF THE

4305
02:53:06,091 --> 02:53:08,494
RYAN WHITE PROGRAM WHICH COULD

4306
02:53:08,494 --> 02:53:11,763
ELIMINATE AIDS EDUCATION AND

4307
02:53:11,763 --> 02:53:12,931
TRAINING CENTERS, PRESERVATION

4308
02:53:12,931 --> 02:53:19,104
OF THREE KEY NATIONAL RESOURCES

4309
02:53:19,104 --> 02:53:20,606
IS ESSENTIAL.

4310
02:53:20,606 --> 02:53:30,215
THE NEXT IS FROM DR. LISA

4311
02:53:30,215 --> 02:53:31,316
KENSINGER, PROVIDER AT A NEW

4312
02:53:31,316 --> 02:53:32,784
YORK CITY HOSPITAL, REFERS TO

4313
02:53:32,784 --> 02:53:34,586
THE GUIDELINES ON A WEEKLY BASIS

4314
02:53:34,586 --> 02:53:37,523
TO TREAT PATIENTS, GUIDED HER IN

4315
02:53:37,523 --> 02:53:39,792
TREATING ILL PATIENTS, PREGNANT

4316
02:53:39,792 --> 02:53:49,835
WOMEN WITH HIV, AND TREATING AND

4317
02:53:49,835 --> 02:53:52,905
SHE IMPLORES OARAC TO KEEP THE

4318
02:53:52,905 --> 02:53:54,840
GUIDELINES.

4319
02:53:54,840 --> 02:53:55,541
NEXT FROM PETER McKELLAR,

4320
02:53:55,541 --> 02:53:57,743
STATES I'VE BEEN A TEACHER AND

4321
02:53:57,743 --> 02:54:00,412
CLINICIAN IN INTERNAL MEDICINE

4322
02:54:00,412 --> 02:54:02,781
AND INFECTIOUS DISEASES FOR 50

4323
02:54:02,781 --> 02:54:03,782
YEARS, FEDERAL HIV GUIDELINES

4324
02:54:03,782 --> 02:54:05,651
ARE ESSENTIAL TO TEACHING AND

4325
02:54:05,651 --> 02:54:07,553
PRACTICE OF HIV MEDICINE.

4326
02:54:07,553 --> 02:54:10,989
FOR OUR GOVERNMENT TO CURTAIL

4327
02:54:10,989 --> 02:54:13,158
PRODUCTION AND USE IS

4328
02:54:13,158 --> 02:54:14,126
UNCONSCIONABLE.

4329
02:54:14,126 --> 02:54:16,762
ASKS OARAC TO PROMPTLY

4330
02:54:16,762 --> 02:54:20,566
RECONSIDER THIS RECKLESS

4331
02:54:20,566 --> 02:54:21,200
DECISION.

4332
02:54:21,200 --> 02:54:22,634
AND RECONSIDER CONTINUANCE OF

4333
02:54:22,634 --> 02:54:23,502
THE GUIDELINES.

4334
02:54:23,502 --> 02:54:29,007
NEXT FROM DAVID BULLWARE, HIV

4335
02:54:29,007 --> 02:54:30,542
GUIDELINES ARE VALUABLE RESEARCH

4336
02:54:30,542 --> 02:54:32,678
FOR THE HIV COMMUNITY IN THE

4337
02:54:32,678 --> 02:54:35,347
U.S. AND GLOBALLY.

4338
02:54:35,347 --> 02:54:37,983
STATED RATIONALE FOR

4339
02:54:37,983 --> 02:54:39,051
DISCONTINUING GUIDANCE,

4340
02:54:39,051 --> 02:54:40,619
GUIDELINES, BASED ON FINANCES,

4341
02:54:40,619 --> 02:54:42,054
SEEMS REMARKABLE THAT VAST

4342
02:54:42,054 --> 02:54:45,657
MAJORITY OF GUIDELINES MEMBERS

4343
02:54:45,657 --> 02:54:47,926
ARE UNPAID VOLUNTEERS AND MEET

4344
02:54:47,926 --> 02:54:49,661
VIA ZOOM OR TEAMS.

4345
02:54:49,661 --> 02:54:51,496
VOLUNTEERS WRITE THE GUIDELINES.

4346
02:54:51,496 --> 02:54:53,599
INCREASED TRANSPARENCY WOULD BE

4347
02:54:53,599 --> 02:54:54,399
IDEAL TO SHARE

4348
02:54:54,399 --> 02:54:56,835
WHAT IS THE BUDGET FOR THE

4349
02:54:56,835 --> 02:54:57,169
GUIDELINES?

4350
02:54:57,169 --> 02:54:58,036
REEVALUATING THE COST WOULD BE

4351
02:54:58,036 --> 02:55:03,242
THE FIRST STEP INSTEAD OF ENDING

4352
02:55:03,242 --> 02:55:05,077
ALL SUPPORT.

4353
02:55:05,077 --> 02:55:09,548
THIS NEXT ONE FROM LYNN, A

4354
02:55:09,548 --> 02:55:12,117
FORMER NICHD LEADER AND OARAC

4355
02:55:12,117 --> 02:55:15,687
MEMBER, AND CURRENTLY WITH THE

4356
02:55:15,687 --> 02:55:16,321
GLASER PEDIATRIC AIDS

4357
02:55:16,321 --> 02:55:21,660
FOUNDATION, WAS CLAIRE  -- CHAIR

4358
02:55:21,660 --> 02:55:24,696
OF GUIDELINES WHEN SHE WORKED AT

4359
02:55:24,696 --> 02:55:25,831
NIH.

4360
02:55:25,831 --> 02:55:27,466
THIS IS A LENGTHY COMMENT.

4361
02:55:27,466 --> 02:55:29,101
SIDE NOTE WE'LL BE SHARING ALL

4362
02:55:29,101 --> 02:55:30,736
OF THE COMMENTS IN THEIR FULL

4363
02:55:30,736 --> 02:55:32,738
FORM IN THE MINUTES OF THIS

4364
02:55:32,738 --> 02:55:33,138
MEETING.

4365
02:55:33,138 --> 02:55:36,642
SO I'M DOING MY BEST TO

4366
02:55:36,642 --> 02:55:38,010
SUMMARIZE LONGER ONES TODAY.

4367
02:55:38,010 --> 02:55:41,680
SHE GIVES A LONG HISTORY OF THE

4368
02:55:41,680 --> 02:55:42,848
GUIDELINES, ONE HIGHLIGHT TO

4369
02:55:42,848 --> 02:55:47,152
NOTE IS THAT THE INITIAL

4370
02:55:47,152 --> 02:55:51,523
GUIDANCE WAS RAPIDLY PUBLISHED

4371
02:55:51,523 --> 02:55:53,592
IN MMWR IN 1994, DETAILED

4372
02:55:53,592 --> 02:55:55,761
VERSION IN AUGUST OF 1994, AND

4373
02:55:55,761 --> 02:55:58,630
THESE WERE CRITICAL IN PROVIDING

4374
02:55:58,630 --> 02:56:05,837
GUIDANCE TO CLINICIANS CARING

4375
02:56:05,837 --> 02:56:09,941
FOR WOMEN WHO APPROVED AZT AND

4376
02:56:09,941 --> 02:56:11,376
COVERAGE OF AZT WHICH OCCURRED

4377
02:56:11,376 --> 02:56:13,912
IN DECEMBER OF THAT SAME YEAR.

4378
02:56:13,912 --> 02:56:14,846
WITHIN THREE YEARS OF THIS

4379
02:56:14,846 --> 02:56:18,817
DECISION THE U.S. HAD A 65%

4380
02:56:18,817 --> 02:56:21,253
REDUCTION IN NEW PERINATAL

4381
02:56:21,253 --> 02:56:22,921
INFECTION.

4382
02:56:22,921 --> 02:56:26,058
SHE GOES ON TO DISCUSS PEDIATRIC

4383
02:56:26,058 --> 02:56:27,859
GUIDELINES AND THAT THEY WERE

4384
02:56:27,859 --> 02:56:35,634
ESTABLISHED AS A SEPARATE PANEL

4385
02:56:35,634 --> 02:56:36,368
IN 1988.

4386
02:56:36,368 --> 02:56:39,371
ONE HIGHLIGHT SHE NOTES IS THAT

4387
02:56:39,371 --> 02:56:40,505
IN 1989, 50% OF CHILDREN WITH

4388
02:56:40,505 --> 02:56:42,641
HIV IN THE UNITED STATES DIED BY

4389
02:56:42,641 --> 02:56:52,084
AGE 2. 

4390
02:56:52,084 --> 02:56:53,819
THANKS TO THE GUIDELINES, SOME

4391
02:56:53,819 --> 02:56:56,054
HAD CHILDREN OF THEIR OWN

4392
02:56:56,054 --> 02:56:58,657
WITHOUT HIV, PANELS INCLUDE

4393
02:56:58,657 --> 02:57:01,093
REPRESENTATIVES FROM CANADA AND

4394
02:57:01,093 --> 02:57:04,396
AUSTRALIA WHO ADAPT'S GUIDANCE

4395
02:57:04,396 --> 02:57:06,431
TO THEIR COUNTRIES.

4396
02:57:06,431 --> 02:57:08,400
SHE MENTIONS UNIQUE FACETS OF

4397
02:57:08,400 --> 02:57:10,535
THE GUIDELINES PANELS INCLUDE

4398
02:57:10,535 --> 02:57:13,638
MEMBERSHIP OF SPECIFIC EXPERTS

4399
02:57:13,638 --> 02:57:15,540
IN THE FIELD, MULTIPLE HHS

4400
02:57:15,540 --> 02:57:17,042
AGENCIES, REPRESENTATIVES FROM

4401
02:57:17,042 --> 02:57:18,877
OTHER COUNTRIES, AS WELL AS

4402
02:57:18,877 --> 02:57:19,945
COMMUNITY MEMBERS AFFECTED BY

4403
02:57:19,945 --> 02:57:23,048
HIV TO ENSURE THE GUIDELINES ARE

4404
02:57:23,048 --> 02:57:24,282
UNDERSTANDABLE, TO BOTH

4405
02:57:24,282 --> 02:57:25,917
COMMUNITY MEMBERS AND

4406
02:57:25,917 --> 02:57:26,218
CLINICIANS.

4407
02:57:26,218 --> 02:57:30,288
ALL OF WHOM DONATE TIME TO

4408
02:57:30,288 --> 02:57:32,491
PROVIDE THIS GUIDANCE.

4409
02:57:32,491 --> 02:57:35,227
SHE NOTES THAT HHS GOVERNANCE OF

4410
02:57:35,227 --> 02:57:38,263
THE GUIDANCE TO BE USED BY

4411
02:57:38,263 --> 02:57:39,765
PEDIATRIC AND OBSTETRIC

4412
02:57:39,765 --> 02:57:41,700
SPECIALTY ORGANIZATIONS AND FOR

4413
02:57:41,700 --> 02:57:46,838
REIMBURSEMENT THROUGH MEDICAID

4414
02:57:46,838 --> 02:57:49,775
AND HRSA.

4415
02:57:49,775 --> 02:57:52,511
NEXT COMMENT FROM SARAH BARES

4416
02:57:52,511 --> 02:57:55,781
FROM UNIVERSITY OF NEBRASKA

4417
02:57:55,781 --> 02:58:04,256
MEDICAL CENTER. 

4418
02:58:04,256 --> 02:58:06,425
CONCERN ABOUT THE PHASEOUT, HAS

4419
02:58:06,425 --> 02:58:07,759
RELIED ON THE GUIDELINES TO

4420
02:58:07,759 --> 02:58:09,628
PROVIDE HIGH QUALITY

4421
02:58:09,628 --> 02:58:10,896
EVIDENCE-BASED CARE AND

4422
02:58:10,896 --> 02:58:11,663
POTENTIAL DISCONTINUATION

4423
02:58:11,663 --> 02:58:14,533
REPRESENTS SIGNIFICANT THREAT TO

4424
02:58:14,533 --> 02:58:17,569
PROVIDERS AND PATIENTS

4425
02:58:17,569 --> 02:58:18,236
NATIONWIDE.

4426
02:58:18,236 --> 02:58:19,137
GUIDELINES ARE THE GOLD STANDARD

4427
02:58:19,137 --> 02:58:22,274
IN THE U.S., AND ARE

4428
02:58:22,274 --> 02:58:23,675
DISTINGUISHED BY SCIENTIFIC

4429
02:58:23,675 --> 02:58:25,277
RIGOR, CLINICAL RELEVANCE,

4430
02:58:25,277 --> 02:58:26,945
TIMELY RESPONSIVENESS TO

4431
02:58:26,945 --> 02:58:29,080
EMERGING EVIDENCE.

4432
02:58:29,080 --> 02:58:30,315
FROM THE FIRST PROPHYLAXIS

4433
02:58:30,315 --> 02:58:33,718
RECOMMENDATIONS TO MOST RECENT

4434
02:58:33,718 --> 02:58:34,953
UPDATES, GUIDELINES ARE

4435
02:58:34,953 --> 02:58:38,457
CONSISTENT IN THEIR HIGH IMPACT

4436
02:58:38,457 --> 02:58:39,357
AND PRACTICAL GUIDANCE.

4437
02:58:39,357 --> 02:58:42,127
SHE NOTES THEY ARE COLLABORATIVE

4438
02:58:42,127 --> 02:58:43,261
AND MULTI-DISCIPLINE GLARE

4439
02:58:43,261 --> 02:58:46,164
PROCESSES LED BY EXPERT

4440
02:58:46,164 --> 02:58:48,099
VOLUNTEER PANELS, HIGHLY SKILLED

4441
02:58:48,099 --> 02:58:49,134
NIH STAFF.

4442
02:58:49,134 --> 02:58:51,303
UNMATCHED IN INTEGRITY AND

4443
02:58:51,303 --> 02:58:51,803
SCOPE.

4444
02:58:51,803 --> 02:58:57,142
MODEL HAS  ENHANCED CREDIBILITY

4445
02:58:57,142 --> 02:59:00,178
AND CONTRIBUTED TO EQUITY AND

4446
02:59:00,178 --> 02:59:03,014
AND STANDARDIZED CARE

4447
02:59:03,014 --> 02:59:04,616
NATIONWIDE.

4448
02:59:04,616 --> 02:59:06,017
SHE NOTES THAT SUGGESTION OF

4449
02:59:06,017 --> 02:59:08,487
ANOTHER AGENCY WITHIN HHS MIGHT

4450
02:59:08,487 --> 02:59:11,389
ASSUME RESPONSIBILITY IS DEEPLY

4451
02:59:11,389 --> 02:59:12,257
CONCERNING.

4452
02:59:12,257 --> 02:59:13,992
OUR AGENCY HAS INFRASTRUCTURE,

4453
02:59:13,992 --> 02:59:15,260
EXPERTISE, ESTABLISHED PROCESS

4454
02:59:15,260 --> 02:59:17,596
TO MAINTAIN THE SAME LEVEL OF

4455
02:59:17,596 --> 02:59:19,231
QUALITY AND TIMELINESS.

4456
02:59:19,231 --> 02:59:20,665
WITHOUT CONTINUED NIH SUPPORT

4457
02:59:20,665 --> 02:59:24,336
SHE FEARS GUIDANCE WILL BECOME

4458
02:59:24,336 --> 02:59:25,137
STATIC, FRAGMENTS, AND

4459
02:59:25,137 --> 02:59:25,570
INACCESSIBLE.

4460
02:59:25,570 --> 02:59:28,740
ALL OF WHICH WOULD BE PROFOUNDLY

4461
02:59:28,740 --> 02:59:30,308
DETRIMENTAL TO PATIENT CARE.

4462
02:59:30,308 --> 02:59:33,645
SHE NOTES AT A TIME THAT WE'RE

4463
02:59:33,645 --> 02:59:35,947
STRIVING TO END THE HIV EPIDEMIC

4464
02:59:35,947 --> 02:59:40,051
IS NOT THE MOMENT TO WEAKEN A

4465
02:59:40,051 --> 02:59:40,519
TOOL.

4466
02:59:40,519 --> 02:59:44,222
URGES OAR AND NIH LEADERSHIP TO

4467
02:59:44,222 --> 02:59:45,190
RECONSIDER, CONTINUE PROVIDING

4468
02:59:45,190 --> 02:59:47,158
NECESSARY RESOURCES TO SUPPORT

4469
02:59:47,158 --> 02:59:51,930
ONGOING DEVELOPMENT AND

4470
02:59:51,930 --> 02:59:56,368
DISSEMINATION OF GUIDELINES.

4471
02:59:56,368 --> 02:59:58,837
DR. ANDREW TROTTER, UNIVERSITY

4472
02:59:58,837 --> 03:00:00,438
OF ILLINOIS COLLEGE OF MEDICINE.

4473
03:00:00,438 --> 03:00:02,374
HE NOTES THAT HIS COMMENTS ARE

4474
03:00:02,374 --> 03:00:06,177
HIS OWN, AS A PROVIDER,

4475
03:00:06,177 --> 03:00:08,813
EDUCATOR, MEMBER OF HIV M.A. AND

4476
03:00:08,813 --> 03:00:10,048
NOT HIS INSTITUTION.

4477
03:00:10,048 --> 03:00:12,717
HE'S AN HIV CLINICIAN WITH OVER

4478
03:00:12,717 --> 03:00:15,887
15 YEARS OF CLINICAL EXPERIENCE,

4479
03:00:15,887 --> 03:00:17,055
ASSOCIATE PROFESSOR, MEDICAL

4480
03:00:17,055 --> 03:00:19,624
DIRECTOR OF THE RYAN WHITE

4481
03:00:19,624 --> 03:00:21,393
PROGRAM AND STEERING COMMITTEE

4482
03:00:21,393 --> 03:00:24,362
MEMBER OF THE RYAN WHITE MEDICAL

4483
03:00:24,362 --> 03:00:25,630
PROVIDER COALITION.

4484
03:00:25,630 --> 03:00:27,899
HE STATES THE GUIDELINES ARE

4485
03:00:27,899 --> 03:00:28,500
CRITICAL RESOURCE FOR ANYONE

4486
03:00:28,500 --> 03:00:30,001
TAKING CARE OF PEOPLE WITH HIV

4487
03:00:30,001 --> 03:00:32,804
IN THE U.S.

4488
03:00:32,804 --> 03:00:34,839
PERSONALLY UTILIZES THEM AND

4489
03:00:34,839 --> 03:00:38,677
REFERS TO THEM ALMOST EVERY DAY.

4490
03:00:38,677 --> 03:00:40,979
THEY SERVE AS MOST COMPREHENSIVE

4491
03:00:40,979 --> 03:00:41,680
UP-TO-DATE EVIDENCE-BASED

4492
03:00:41,680 --> 03:00:43,515
GUIDANCE ON THE MANAGEMENT AND

4493
03:00:43,515 --> 03:00:47,218
TREATMENT OF HIV AND

4494
03:00:47,218 --> 03:00:49,087
OPPORTUNISTIC INFECTION AND

4495
03:00:49,087 --> 03:00:53,425
PERINATAL CARE, STANDARD OF CARE

4496
03:00:53,425 --> 03:00:54,526
FOR FINANCIAL AND INSURANCE

4497
03:00:54,526 --> 03:00:56,561
REIMBURSEMENT AND ENSURE HIV

4498
03:00:56,561 --> 03:00:58,496
WILL BE COVERED FOR COST OF --

4499
03:00:58,496 --> 03:01:01,266
COST OF CURE WILL BE

4500
03:01:01,266 --> 03:01:02,167
APPROPRIATELY COVERED.

4501
03:01:02,167 --> 03:01:04,603
AND THEY ARE ACCESSIBLE AT THE

4502
03:01:04,603 --> 03:01:06,037
POINT OF CARE.

4503
03:01:06,037 --> 03:01:10,542
HE UNDERSTANDS BUDGETARY

4504
03:01:10,542 --> 03:01:12,510
CONSTRAINTS BUT THEY MUST BE

4505
03:01:12,510 --> 03:01:13,612
MAINTAINED AS NATIONAL STANDARD

4506
03:01:13,612 --> 03:01:15,080
OF CARE FOR PEOPLE WITH HIV.

4507
03:01:15,080 --> 03:01:17,549
IF THEY NEED TO BE SHIFTED TO

4508
03:01:17,549 --> 03:01:19,217
ANOTHER AGENCY IN HHS, IT MUST

4509
03:01:19,217 --> 03:01:23,388
BE DONE IN A WAY GUIDELINE

4510
03:01:23,388 --> 03:01:25,390
REVIEW AND REVISION PROCESS AND

4511
03:01:25,390 --> 03:01:26,758
SUPPORT WILL BE MAINTAINED.

4512
03:01:26,758 --> 03:01:29,995
HE NOTES HIV CARE IS RAPIDLY

4513
03:01:29,995 --> 03:01:30,862
CHANGING, AND FEDERAL HIV

4514
03:01:30,862 --> 03:01:33,231
GUIDELINES ARE THE MOST

4515
03:01:33,231 --> 03:01:36,635
UP-TO-DATE RESOURCE WITH READILY

4516
03:01:36,635 --> 03:01:38,203
AVAILABLE UPDATES REGARDING THE

4517
03:01:38,203 --> 03:01:47,479
MOST RECENT SCIENTIFIC AND

4518
03:01:47,479 --> 03:01:50,215
CLINICAL DEVELOPMENT.

4519
03:01:50,215 --> 03:01:52,817
NEXT FROM DR. SUSANA QUICHEN.

4520
03:01:52,817 --> 03:01:54,753
I'M NOT CERTAIN OF HER

4521
03:01:54,753 --> 03:01:57,422
AFFILIATION BUT SHE NOTES SHE

4522
03:01:57,422 --> 03:01:59,057
WORKS IN UTAH.

4523
03:01:59,057 --> 03:02:00,959
SHE'S AN ADULT AND PEDIATRIC

4524
03:02:00,959 --> 03:02:04,362
I.D. PHYSICIAN WHO WORKS IN A

4525
03:02:04,362 --> 03:02:06,531
RELATIVELY LOW HIV INCIDENCE

4526
03:02:06,531 --> 03:02:07,666
STATE, UTAH.

4527
03:02:07,666 --> 03:02:09,267
THE GUIDELINES ARE THE MOST

4528
03:02:09,267 --> 03:02:10,602
IMPORTANT FOR HER FELLOW

4529
03:02:10,602 --> 03:02:11,970
COLLEAGUES AND FAMILY PRACTICE

4530
03:02:11,970 --> 03:02:14,406
PEDIATRICS AND INTERNAL MEDICINE

4531
03:02:14,406 --> 03:02:15,540
IN THE U.S.

4532
03:02:15,540 --> 03:02:18,610
SHE PROVIDES A LIST OF WHY THEY

4533
03:02:18,610 --> 03:02:19,844
SHOULD BE CONTINUED.

4534
03:02:19,844 --> 03:02:22,447
AS A RURAL STATE PERINATAL

4535
03:02:22,447 --> 03:02:23,348
GUIDELINES OFFER ON DEMAND

4536
03:02:23,348 --> 03:02:27,352
SUPPORT 24 HOURS A DAY FOR WOMEN

4537
03:02:27,352 --> 03:02:29,554
AND INFANTS AFFECTED BY HIV IN

4538
03:02:29,554 --> 03:02:31,756
THE INTERMOUNTAIN WEST, ONLY ONE

4539
03:02:31,756 --> 03:02:32,657
PEDIATRIC INFECTIOUS DISEASE

4540
03:02:32,657 --> 03:02:36,461
GROUP THAT SERVES ALL OF UTAH,

4541
03:02:36,461 --> 03:02:39,230
IDAHO, PARTS OF NEVADA, MONTANA,

4542
03:02:39,230 --> 03:02:41,466
WESTERN COLORADO.

4543
03:02:41,466 --> 03:02:43,401
NEARLY IMPOSSIBLE FOR US TO TAKE

4544
03:02:43,401 --> 03:02:45,804
CONSULTS AND BY PHONE AND

4545
03:02:45,804 --> 03:02:47,605
TELEMEDICINE BY PHONE FOR

4546
03:02:47,605 --> 03:02:50,141
INFANTS BORN TO A MOTHER WITH

4547
03:02:50,141 --> 03:02:50,875
HIV.

4548
03:02:50,875 --> 03:02:52,110
GUIDELINES HELP PHYSICIANS AND

4549
03:02:52,110 --> 03:02:53,545
PRACTITIONERS, THEY SERVE AS A

4550
03:02:53,545 --> 03:02:55,914
TOOL FOR MEDICAL STUDENTS,

4551
03:02:55,914 --> 03:02:57,282
RESIDENTS, FELLOWS.

4552
03:02:57,282 --> 03:03:01,119
WHICH ARE EVIDENCE-BASED AND

4553
03:03:01,119 --> 03:03:02,554
UPDATED REGULARLY.

4554
03:03:02,554 --> 03:03:04,489
HIV CHANGES WITH NEW MEDICATION

4555
03:03:04,489 --> 03:03:06,891
AND THOUSANDS OF STUDIES

4556
03:03:06,891 --> 03:03:07,992
PUBLISHED ANNUALLY.

4557
03:03:07,992 --> 03:03:09,961
GUIDELINES OFFER A PLACE NO

4558
03:03:09,961 --> 03:03:12,297
OTHER SOURCE CONSOLIDATES AND

4559
03:03:12,297 --> 03:03:13,732
REVIEWS PERTINENT INFORMATION.

4560
03:03:13,732 --> 03:03:16,267
PEOPLE LIVING WITH HIV HAVE

4561
03:03:16,267 --> 03:03:20,872
ACTIVE ROLE ON EACH GUIDELINE

4562
03:03:20,872 --> 03:03:22,373
COMMITTEE, ALLOW -- ONE OF THE

4563
03:03:22,373 --> 03:03:29,914
FEW CASE VOICES CAN BE HEARD FOR

4564
03:03:29,914 --> 03:03:32,751
A MORE PATIENT-CENTERED

4565
03:03:32,751 --> 03:03:38,356
APPROACH, IMPROVE OUTCOMES,

4566
03:03:38,356 --> 03:03:39,324
REDUCE MORBIDITY, MORTALITY,

4567
03:03:39,324 --> 03:03:41,159
GUIDELINES IDENTIFY AREAS OF

4568
03:03:41,159 --> 03:03:42,293
RESEARCH THAT NEED

4569
03:03:42,293 --> 03:03:43,862
INVESTIGATION, THUS DRIVING

4570
03:03:43,862 --> 03:03:45,930
INNOVATION AND DIAGNOSIS,

4571
03:03:45,930 --> 03:03:47,599
TREATMENT, PREVENTION.

4572
03:03:47,599 --> 03:03:50,368
THEY ARE THE SOURCE THAT GUIDE

4573
03:03:50,368 --> 03:03:54,072
INSURANCE COVERAGE IN A TIMELY

4574
03:03:54,072 --> 03:03:56,307
MANNER AND ARE RESPECTED AND

4575
03:03:56,307 --> 03:04:00,879
THEIR VALIDITY IS UNMATCHED BY

4576
03:04:00,879 --> 03:04:02,914
ANY OTHER SOURCE.

4577
03:04:02,914 --> 03:04:08,553
NEXT FROM DR. KIRK FETTERS,

4578
03:04:08,553 --> 03:04:10,221
UNIVERSITY OF COLORADO.

4579
03:04:10,221 --> 03:04:11,823
HE DISAPPROVES OF THE PLAN TO

4580
03:04:11,823 --> 03:04:13,792
REMOVE SUPPORT FROM THE

4581
03:04:13,792 --> 03:04:14,292
GUIDELINES.

4582
03:04:14,292 --> 03:04:21,966
THEY ARE ESSENTIAL RESOURCES FOR

4583
03:04:21,966 --> 03:04:24,669
BOTH PHYSICIANS AND PATIENTS.

4584
03:04:24,669 --> 03:04:24,869
SORRY.

4585
03:04:24,869 --> 03:04:26,337
THEY ARE INVALUABLE FOR

4586
03:04:26,337 --> 03:04:29,407
TREATMENT OF HIV AND SEQUELAE OF

4587
03:04:29,407 --> 03:04:31,509
HIV IN UNCOMMON SCENARIOS AND

4588
03:04:31,509 --> 03:04:33,011
MANY CLINICIANS INCLUDING I.D.

4589
03:04:33,011 --> 03:04:34,646
SPECIALISTS MAY NOT HAVE MUCH

4590
03:04:34,646 --> 03:04:35,647
EXPERIENCE IN TREATING.

4591
03:04:35,647 --> 03:04:38,850
HARD WORK PUT INTO THESE

4592
03:04:38,850 --> 03:04:41,052
GUIDELINES BY MANY CLINICIANS

4593
03:04:41,052 --> 03:04:43,988
OVER THE YEARS HAVE IMPROVED AND

4594
03:04:43,988 --> 03:04:45,356
STANDARDIZED HIV CARE AROUND THE

4595
03:04:45,356 --> 03:04:45,590
COUNTRY.

4596
03:04:45,590 --> 03:04:50,128
HE NOTES  ALTERNATIVE GUIDELINES

4597
03:04:50,128 --> 03:04:53,565
EXIST BUT ARE NOT TAILORED TO

4598
03:04:53,565 --> 03:04:58,937
LIVED  REALITY IN THE U.S.

4599
03:04:58,937 --> 03:05:00,772
DOES NOT SUPPORT TRANSITIONING

4600
03:05:00,772 --> 03:05:03,041
TO ANOTHER AGENCY.

4601
03:05:03,041 --> 03:05:05,476
OAR DEVELOPED RELATIONSHIPS AND

4602
03:05:05,476 --> 03:05:09,247
EXPERTISE UNMATCHED IN THE REST

4603
03:05:09,247 --> 03:05:09,480
OF HHS.

4604
03:05:09,480 --> 03:05:13,451
PROPOSED CHANGES COMES IN THE

4605
03:05:13,451 --> 03:05:15,253
CONTEXT OF UNPRECEDENTED REMOVAL

4606
03:05:15,253 --> 03:05:18,857
OF THE CDC STI GUIDELINES,

4607
03:05:18,857 --> 03:05:22,327
NATIONAL HIV DATASETS, CURRENT

4608
03:05:22,327 --> 03:05:24,329
ACI TEAM MEMBERS PLUS VACCINE

4609
03:05:24,329 --> 03:05:30,869
SKEPTICISM AT FDA,  CANCELLATION

4610
03:05:30,869 --> 03:05:36,307
OF RESEARCH GRANTS CREATING THE

4611
03:05:36,307 --> 03:05:37,141
APPEARANCE NO LONGER SUPPORTING,

4612
03:05:37,141 --> 03:05:39,344
THIS WOULD BE A SHORT-SIGHTED

4613
03:05:39,344 --> 03:05:40,879
POLICY GOAL THAT WOULD RESULT IN

4614
03:05:40,879 --> 03:05:46,384
MANY MORE PEOPLE DYING OF

4615
03:05:46,384 --> 03:05:47,852
PREVENTIBLE OR TREATABLE

4616
03:05:47,852 --> 03:05:48,586
DISEASES.

4617
03:05:48,586 --> 03:05:52,123
NEXT IS FROM DR. TERRY CHRISTINE

4618
03:05:52,123 --> 03:05:56,427
PHILLIPS AND COLLEAGUES FROM

4619
03:05:56,427 --> 03:05:57,529
PEDIATRIC INFECTIOUS DISEASES

4620
03:05:57,529 --> 03:05:58,763
SOCIETY.

4621
03:05:58,763 --> 03:06:00,665
THEY ARE WRITING TO EXPRESS

4622
03:06:00,665 --> 03:06:02,634
CONCERN ABOUT NIH DECISION TO

4623
03:06:02,634 --> 03:06:06,604
PHASE OUT SUPPORT OF THE

4624
03:06:06,604 --> 03:06:08,072
CLINICAL PRACTICE GUIDELINES,

4625
03:06:08,072 --> 03:06:10,041
PROFESSIONAL SOCIETY REPRESENTS

4626
03:06:10,041 --> 03:06:11,743
PEDIATRIC I.D. SPECIALISTS AND

4627
03:06:11,743 --> 03:06:14,479
RESEARCHERS, MANY ARE INVOLVED

4628
03:06:14,479 --> 03:06:16,948
WITH DIRECT PATIENT CARE,

4629
03:06:16,948 --> 03:06:17,849
INFANTS, CHILDREN, ADOLESCENTS

4630
03:06:17,849 --> 03:06:22,353
WITH HIV OR AT RISK OF HIV.

4631
03:06:22,353 --> 03:06:25,490
URGES OARAC TO RECONSIDER AND

4632
03:06:25,490 --> 03:06:26,991
ADVOCATE FOR FEDERAL LEADERSHIP

4633
03:06:26,991 --> 03:06:32,096
IN DEVELOPMENT AND DISSEMINATION

4634
03:06:32,096 --> 03:06:33,531
OF GUIDELINES.

4635
03:06:33,531 --> 03:06:35,533
SHE SAYS GUIDELINES ARE

4636
03:06:35,533 --> 03:06:36,734
FOUNDATIONAL TO DELIVERY OF HIGH

4637
03:06:36,734 --> 03:06:37,669
QUALITY EVIDENCE-BASED CARE FOR

4638
03:06:37,669 --> 03:06:39,370
OVER ONE MILLION PEOPLE LIVING

4639
03:06:39,370 --> 03:06:45,076
WITH HIV IN THE U.S., PROVIDE

4640
03:06:45,076 --> 03:06:48,179
CRITICAL INFORMATION FOR

4641
03:06:48,179 --> 03:06:50,148
CLINICIANS, OF ALL POPULATIONS,

4642
03:06:50,148 --> 03:06:51,950
AND THAT PEDIATRIC GUIDELINES

4643
03:06:51,950 --> 03:06:53,518
ARE ESPECIALLY VITAL AS THEY

4644
03:06:53,518 --> 03:06:55,653
ADDRESS UNIQUE CHALLENGES SUCH

4645
03:06:55,653 --> 03:06:59,624
AS EARLY INFANT DIAGNOSIS AND

4646
03:06:59,624 --> 03:07:05,897
TREATMENT, PREVENTION OF

4647
03:07:05,897 --> 03:07:06,364
PERINATAL TRANSITION.

4648
03:07:06,364 --> 03:07:08,366
STATES A FEW STATISTICS WHICH I

4649
03:07:08,366 --> 03:07:15,707
WON'T READ AT THIS MOMENT.

4650
03:07:15,707 --> 03:07:19,444
SHE NOTES THE GUIDELINES ARE A

4651
03:07:19,444 --> 03:07:21,713
LIVING DOCUMENT WITH UPDATES,

4652
03:07:21,713 --> 03:07:29,320
THEY ARE RESPONSIVE, HAVE A

4653
03:07:29,320 --> 03:07:34,325
LEVEL OF RESPONSIVENESS JOURNALS

4654
03:07:34,325 --> 03:07:36,861
CAN'T MATCH, ENSURE PATIENTS

4655
03:07:36,861 --> 03:07:38,563
RECEIVE CARE INFORMED BY BEST

4656
03:07:38,563 --> 03:07:42,166
PRACTICES AND SHAPE INSURANCE

4657
03:07:42,166 --> 03:07:44,736
COVERAGE DECISIONS AND DIRECTLY

4658
03:07:44,736 --> 03:07:48,373
ALLOW ACCESS TO LIFESAVING

4659
03:07:48,373 --> 03:07:50,074
DIAGNOSTICS TREATMENT,

4660
03:07:50,074 --> 03:07:51,376
PREVENTION SERVICES.

4661
03:07:51,376 --> 03:07:54,779
THEIR LOSS WOULD CREATE

4662
03:07:54,779 --> 03:07:58,650
UNCERTAINTY, POTENTIALLY LEADING

4663
03:07:58,650 --> 03:08:03,354
TO FRAGMENTED CARE AND

4664
03:08:03,354 --> 03:08:07,358
DISPARITIES, URGE MAINTENANCE OF

4665
03:08:07,358 --> 03:08:12,597
SUPPORT UNDER THE STEWARDSHIP OF

4666
03:08:12,597 --> 03:08:15,466
A BODY WITH EXPERTISE RATHER

4667
03:08:15,466 --> 03:08:17,935
THAN DISCARDING DECADE OF

4668
03:08:17,935 --> 03:08:20,171
FEDERAL INVESTMENT NIH SHOULD

4669
03:08:20,171 --> 03:08:22,507
COLLABORATE TO PRIORITIZE KEY

4670
03:08:22,507 --> 03:08:24,075
ELEMENTS, STREAMLINE PROCESSES,

4671
03:08:24,075 --> 03:08:25,777
REDUCE COST.

4672
03:08:25,777 --> 03:08:27,011
PUBLIC INPUT FROM GUIDELINES

4673
03:08:27,011 --> 03:08:29,614
USERS AND BROADER HIV COMMUNITY

4674
03:08:29,614 --> 03:08:31,783
SHOULD ALSO BE SOLICITED.

4675
03:08:31,783 --> 03:08:34,952
SUSTAINING THEM IS CRITICAL AMID

4676
03:08:34,952 --> 03:08:38,222
ONGOING WORKFORCE SHORTAGES AND

4677
03:08:38,222 --> 03:08:40,458
EROSION OF PUBLIC HEALTH

4678
03:08:40,458 --> 03:08:43,694
INFRASTRUCTURE. 

4679
03:08:43,694 --> 03:08:47,765
PEDIATRIC I.D. SOCIETY IS READY

4680
03:08:47,765 --> 03:08:48,866
TO COLLABORATE TO SAFEGUARD THE

4681
03:08:48,866 --> 03:08:50,601
HEALTH AND WELL-BEING OF

4682
03:08:50,601 --> 03:08:55,239
CHILDREN AND ADOLESCENTS

4683
03:08:55,239 --> 03:08:57,809
AFFECTED BY HIV.

4684
03:08:57,809 --> 03:09:07,151
NEXT IS FROM PETER SALBERG, HOPE

4685
03:09:07,151 --> 03:09:08,720
THAT NIH WILL RECONSIDER ANY

4686
03:09:08,720 --> 03:09:12,523
THOUGHT THEY SHOULD NOT BE A TOP

4687
03:09:12,523 --> 03:09:15,593
FUNDING PRIORITY UNDER NIH

4688
03:09:15,593 --> 03:09:16,694
SPECIFIC HIGH-QUALITY

4689
03:09:16,694 --> 03:09:17,328
SUPERVISION.

4690
03:09:17,328 --> 03:09:19,564
AS A CLINICIAN IN RURAL NEW

4691
03:09:19,564 --> 03:09:21,632
HAMPSHIRE HE CANNOT UNDERSTATE

4692
03:09:21,632 --> 03:09:24,035
HOW MUCH GUIDELINES PROVIDE KEY

4693
03:09:24,035 --> 03:09:25,369
ROLE IN DISSEMINATING BEST

4694
03:09:25,369 --> 03:09:27,638
PRACTICES IN THE COUNTRY TO

4695
03:09:27,638 --> 03:09:28,739
CLINICIANS IN BIG POPULATION

4696
03:09:28,739 --> 03:09:29,073
CENTERS.

4697
03:09:29,073 --> 03:09:35,947
HE STATES MORE AND MORE WE RELY

4698
03:09:35,947 --> 03:09:37,014
ON INEXPERIENCED WORKFORCE,

4699
03:09:37,014 --> 03:09:39,951
THERE'S NO SUBSTITUTE FOR CLEAR

4700
03:09:39,951 --> 03:09:40,685
EVIDENCE-BASED SUPER PRACTICAL

4701
03:09:40,685 --> 03:09:47,191
STRATEGIES THAT THE GUIDELINES

4702
03:09:47,191 --> 03:09:48,526
HAVE ALWAYS OFFERED.

4703
03:09:48,526 --> 03:09:50,595
THE NOTION THE GUIDELINES ARE IN

4704
03:09:50,595 --> 03:09:53,297
FACT COST EFFECTIVE AND BEST USE

4705
03:09:53,297 --> 03:09:54,765
OF LIMITED TAXPAYER DOLLARS

4706
03:09:54,765 --> 03:09:56,567
RATHER THAN SOMETHING THE

4707
03:09:56,567 --> 03:10:02,306
COUNTRY CAN AFFORD TO

4708
03:10:02,306 --> 03:10:02,874
DEPRIORITIZE.

4709
03:10:02,874 --> 03:10:09,013
NEXT IS FROM SARAH WEIBEL,

4710
03:10:09,013 --> 03:10:11,749
CONCERNING ABOUT REPORTED

4711
03:10:11,749 --> 03:10:13,050
DECISION TO CUT GUIDELINES.

4712
03:10:13,050 --> 03:10:15,286
DECISION IS NOT ONLY SHORT

4713
03:10:15,286 --> 03:10:16,487
SIGHTED, IT'S COUNTERPRODUCTIVE

4714
03:10:16,487 --> 03:10:18,456
TO PUBLIC HEALTH.

4715
03:10:18,456 --> 03:10:23,127
PANEL HAS BEEN A CORNERSTONE IN

4716
03:10:23,127 --> 03:10:25,263
ENSURING CLINICIANS, RESEARCHERS

4717
03:10:25,263 --> 03:10:28,399
AND STAKEHOLDERS HAVE ACCESS TO

4718
03:10:28,399 --> 03:10:29,467
CLEAR EVIDENCE-BASED AND

4719
03:10:29,467 --> 03:10:30,201
UP-TO-DATE TREATMENT GUIDELINES

4720
03:10:30,201 --> 03:10:30,968
FOR CARE.

4721
03:10:30,968 --> 03:10:33,471
THEY ARE CONSULTED BY THOUSANDS

4722
03:10:33,471 --> 03:10:34,438
OF PRACTITIONERS AND

4723
03:10:34,438 --> 03:10:36,974
INSTITUTIONS AND ARE REGARDED

4724
03:10:36,974 --> 03:10:38,176
GLOBALLY AS GOLD STANDARD.

4725
03:10:38,176 --> 03:10:39,677
WHAT MAKES THE DECISION EVEN

4726
03:10:39,677 --> 03:10:41,546
MORE DIFFICULT TO UNDERSTAND IS

4727
03:10:41,546 --> 03:10:44,415
THAT PANEL MEMBERS MOSTLY SEARCH

4728
03:10:44,415 --> 03:10:46,017
VOLUNTARILY, DONATING TIME AND

4729
03:10:46,017 --> 03:10:47,885
EXPERTISE WITHOUT COMPENSATION.

4730
03:10:47,885 --> 03:10:49,720
TO ELIMINATE SUCH A HIGH IMPACT

4731
03:10:49,720 --> 03:10:51,088
LOW COST INITIATIVE SEND THE

4732
03:10:51,088 --> 03:10:54,058
WRONG MESSAGE AT A TIME WHEN

4733
03:10:54,058 --> 03:10:58,095
CONSISTENCY, CLARITY, AND TRUST

4734
03:10:58,095 --> 03:11:03,267
IN PUBLIC HEALTH LEADERSHIP ARE

4735
03:11:03,267 --> 03:11:07,004
MORE VITAL THAN EVER AND WILL

4736
03:11:07,004 --> 03:11:08,873
CREATE CONFUSION, WIDEN GAPS IN

4737
03:11:08,873 --> 03:11:16,147
CARE AND UNDERMINE DECADES OF

4738
03:11:16,147 --> 03:11:16,414
TREATMENT.

4739
03:11:16,414 --> 03:11:17,682
URGES OARAC TO REAFFIRM THE

4740
03:11:17,682 --> 03:11:22,453
FEDERAL GOVERNMENT'S COMMITMENT

4741
03:11:22,453 --> 03:11:23,454
TO THE GUIDELINES.

4742
03:11:23,454 --> 03:11:28,092
NEXT IS FROM A FORMER OARAC

4743
03:11:28,092 --> 03:11:32,096
MEMBER, LINDA DEAN, AIDS ACTION

4744
03:11:32,096 --> 03:11:33,464
BALTIMORE, DISAPPOINTED THAT THE

4745
03:11:33,464 --> 03:11:34,498
DISCUSSION SCHEDULED FOR TODAY'S

4746
03:11:34,498 --> 03:11:36,601
PUBLIC SESSION WAS REMOVED,

4747
03:11:36,601 --> 03:11:40,404
ESSENTIALLY REMOVED FROM THE

4748
03:11:40,404 --> 03:11:42,506
AGENDA AND RESPECTFULLY URGES

4749
03:11:42,506 --> 03:11:44,408
NIH TO ENSURE DECISIONS ARE MADE

4750
03:11:44,408 --> 03:11:50,948
IN A PUBLIC AND TRANSPARENT

4751
03:11:50,948 --> 03:11:52,617
MANNER WITH FOR INPUT FROM THE

4752
03:11:52,617 --> 03:11:53,284
COMMUNITY PARTICULARLY

4753
03:11:53,284 --> 03:11:54,952
INDIVIDUALS WHOSE LIVES ARE

4754
03:11:54,952 --> 03:11:56,787
IMPACTED BY THEIR AVAILABILITY.

4755
03:11:56,787 --> 03:11:58,689
SHE STRONGLY URGES NIH NOT TO

4756
03:11:58,689 --> 03:12:00,891
ABANDON SUPPORT FOR THE

4757
03:12:00,891 --> 03:12:02,159
GUIDELINES THAT SET THE STANDARD

4758
03:12:02,159 --> 03:12:05,196
OF CARE FOR THREE DECADES.

4759
03:12:05,196 --> 03:12:07,498
NOTES THE GUIDELINES HAVE

4760
03:12:07,498 --> 03:12:09,133
IMPROVED LIVES OF COUNTLESS

4761
03:12:09,133 --> 03:12:11,435
PEOPLE THROUGH INCLUSIVE AND

4762
03:12:11,435 --> 03:12:12,003
COMMUNITY-DRIVEN PROCESS AND

4763
03:12:12,003 --> 03:12:14,171
THAT THEY ARE THE MODEL FOR

4764
03:12:14,171 --> 03:12:17,508
GUIDELINES DEVELOPMENT AND

4765
03:12:17,508 --> 03:12:18,843
COMMUNITY ENGAGEMENT.

4766
03:12:18,843 --> 03:12:20,711
SHE STATES SHE RECOGNIZES NIH IS

4767
03:12:20,711 --> 03:12:23,314
NOT IN THE BUSINESS OF

4768
03:12:23,314 --> 03:12:24,148
GUIDELINES INVESTMENT AND

4769
03:12:24,148 --> 03:12:27,518
INSTITUTIONS TOOK A BOLD AND

4770
03:12:27,518 --> 03:12:29,887
LIFE SAVING STEP TO DEVELOP

4771
03:12:29,887 --> 03:12:31,923
GUIDELINES TO ENSURE RAPID

4772
03:12:31,923 --> 03:12:33,424
ADVANCES IN THE FIELD, REACHING

4773
03:12:33,424 --> 03:12:36,227
THOSE WHO NEED THEM, NOT BEING

4774
03:12:36,227 --> 03:12:42,833
PRESENTED AT CONFERENCES OR

4775
03:12:42,833 --> 03:12:45,269
JOURNAL, PEOPLE LIVING WITH HIV

4776
03:12:45,269 --> 03:12:48,172
OUTSIDE OF AREAS WITH I.D.

4777
03:12:48,172 --> 03:12:49,907
EXPERTISE WHICH ARE MANY CAN

4778
03:12:49,907 --> 03:12:51,575
BENEFIT FROM THE HIGHLY

4779
03:12:51,575 --> 03:12:52,777
EFFECTIVE TREATMENT DEVELOPED

4780
03:12:52,777 --> 03:12:56,347
WITH SUPPORT FROM THE NIH.

4781
03:12:56,347 --> 03:12:57,815
GUIDELINES HELP AND CONTINUE TO

4782
03:12:57,815 --> 03:13:02,987
HELP TO  ERODE STIGMA IN

4783
03:13:02,987 --> 03:13:06,357
ACCESSING TREATMENT DUE TO

4784
03:13:06,357 --> 03:13:08,326
PROVIDER RESISTANCE AND

4785
03:13:08,326 --> 03:13:08,626
INSECURITY.

4786
03:13:08,626 --> 03:13:10,895
SHE SAYS THIS DECISION COULD NOT

4787
03:13:10,895 --> 03:13:12,530
BE MORE ILL TIMED AND FEARS IT

4788
03:13:12,530 --> 03:13:16,167
IS PART OF A BROADER STRATEGY TO

4789
03:13:16,167 --> 03:13:18,135
ABANDON COMMUNITY AND COUNTRY'S

4790
03:13:18,135 --> 03:13:22,707
EFFORTS TO END THE HIV EPIDEMIC.

4791
03:13:22,707 --> 03:13:24,408
SHE NOTES PUBLIC HEALTH PROGRAMS

4792
03:13:24,408 --> 03:13:29,113
AND PEOPLE WITH HIV AND

4793
03:13:29,113 --> 03:13:31,015
PROVIDERS ARE ALL UNDER ATTACK.

4794
03:13:31,015 --> 03:13:37,355
LOSS OF THE EXPERT UNBIASED

4795
03:13:37,355 --> 03:13:39,457
GUIDELINES SET THE GOLD

4796
03:13:39,457 --> 03:13:41,425
STANDARD, A MAJOR BLOW, PUTTING

4797
03:13:41,425 --> 03:13:43,894
LIVES AT RISK, URGES NIH TO

4798
03:13:43,894 --> 03:13:46,897
RECONSIDER THIS DECISION AND

4799
03:13:46,897 --> 03:13:48,165
INSTEAD WORK WITH THE WORKING

4800
03:13:48,165 --> 03:13:49,467
GROUP LEADERS AND COMMUNITY TO

4801
03:13:49,467 --> 03:13:52,403
DEVELOP A STRATEGY FOR REDUCING

4802
03:13:52,403 --> 03:13:55,072
BUDGETARY COSTS AND MAINTAINING

4803
03:13:55,072 --> 03:13:57,341
THEM, GUIDELINES, WITHOUT

4804
03:13:57,341 --> 03:14:00,177
COMPROMISING ACCESSIBILITY,

4805
03:14:00,177 --> 03:14:02,213
TIMELINESS, SCIENTIFIC RIGOR.

4806
03:14:02,213 --> 03:14:12,156
NEXT FROM DR. PABLO TEVS,

4807
03:14:12,156 --> 03:14:13,624
UNIVERSITY OF PENNSYLVANIA, HE

4808
03:14:13,624 --> 03:14:16,894
SAYS FOR MORE THAN 25 YEARS

4809
03:14:16,894 --> 03:14:19,230
GUIDELINES HAVE BEEN A RESOURCE

4810
03:14:19,230 --> 03:14:21,399
OFFERING TIMELY EVIDENCE-BASED

4811
03:14:21,399 --> 03:14:22,933
AND PRACTICAL RECOMMENDATIONS

4812
03:14:22,933 --> 03:14:24,869
THAT HAVE DIRECTLY IMPROVED

4813
03:14:24,869 --> 03:14:26,804
CLINICAL OUTCOMES FOR PEOPLE

4814
03:14:26,804 --> 03:14:30,508
WITH HIV, SERVED AS MODEL FOR

4815
03:14:30,508 --> 03:14:32,109
TRANSLATING CLINICAL RESEARCH

4816
03:14:32,109 --> 03:14:39,350
INTO MEANINGFUL IMPACT .

4817
03:14:39,350 --> 03:14:41,318
THESE GUIDELINES HAVE

4818
03:14:41,318 --> 03:14:42,219
CONSISTENTLY ENABLED RAPID

4819
03:14:42,219 --> 03:14:46,424
ADOPTION OF MORE EFFECTIVE AND

4820
03:14:46,424 --> 03:14:50,461
LESS TOXIC REGIMENS, CLINICAL

4821
03:14:50,461 --> 03:14:53,230
EXPERTISE AND CONSENSUS RATHER

4822
03:14:53,230 --> 03:14:54,965
THAN BUREAUCRATIC INERTIA.

4823
03:14:54,965 --> 03:14:57,067
FREQUENT UPDATES, RESPONSIVENESS

4824
03:14:57,067 --> 03:14:59,336
AND GUIDANCE DISTINGUISHED THEM

4825
03:14:59,336 --> 03:15:00,471
FROM TRADITIONAL SOCIETY

4826
03:15:00,471 --> 03:15:02,440
GUIDELINES OFTEN LESS NIMBLE AND

4827
03:15:02,440 --> 03:15:06,811
MORE CONSUMED BY PROCESS THAN

4828
03:15:06,811 --> 03:15:07,111
UTILITY.

4829
03:15:07,111 --> 03:15:09,013
HE NOTES LEADERSHIP OF DOCTORS

4830
03:15:09,013 --> 03:15:14,251
CLIFF LANE AND ALICE PAU HAVE

4831
03:15:14,251 --> 03:15:15,352
ENSURED INTEGRITY, RIGOR, AND

4832
03:15:15,352 --> 03:15:18,889
INDEPENDENCE OF THE EFFORT.

4833
03:15:18,889 --> 03:15:19,924
GUIDELINES ARE TRANSPARENT,

4834
03:15:19,924 --> 03:15:21,759
CONFLICT OF INTEREST MANAGED,

4835
03:15:21,759 --> 03:15:25,262
MOST IMPORTANTLY THEY ARE

4836
03:15:25,262 --> 03:15:25,996
INDEPENDENT FROM INDUSTRY

4837
03:15:25,996 --> 03:15:29,600
INFLUENCE, A FEATURE THAT HAS

4838
03:15:29,600 --> 03:15:30,701
GIVEN THEM UNMATCHED

4839
03:15:30,701 --> 03:15:31,001
CREDIBILITY.

4840
03:15:31,001 --> 03:15:34,038
THEY ARE A MODEL FOR HIV

4841
03:15:34,038 --> 03:15:36,006
TREATMENT POLICY WORLDWIDE,

4842
03:15:36,006 --> 03:15:37,842
REFERENCED WIDELY, ADAPTED

4843
03:15:37,842 --> 03:15:38,375
INTERNATIONALLY.

4844
03:15:38,375 --> 03:15:40,678
MODEST INVESTMENT REQUIRED TO

4845
03:15:40,678 --> 03:15:43,414
SUSTAIN THEM IS NEGLIGIBLE

4846
03:15:43,414 --> 03:15:45,483
COMPARED TO LIVES SAVED.

4847
03:15:45,483 --> 03:15:48,219
HE URGES OARAC AND NIH

4848
03:15:48,219 --> 03:15:49,086
LEADERSHIP TO PRESERVE

4849
03:15:49,086 --> 03:15:51,822
GUIDELINES PROGRAM IN CURRENT

4850
03:15:51,822 --> 03:15:54,959
FORM AND CONTINUE TO SUPPORT AS

4851
03:15:54,959 --> 03:16:00,631
A VITAL PUBLIC HEALTH TOOL.

4852
03:16:00,631 --> 03:16:02,666
NEXT FROM CADEN ANDREWS, I DON'T

4853
03:16:02,666 --> 03:16:05,503
HAVE AN AFFILIATION FOR THIS

4854
03:16:05,503 --> 03:16:05,736
PERSON.

4855
03:16:05,736 --> 03:16:07,605
THEY ARE A PHYSICIAN CARING FOR

4856
03:16:07,605 --> 03:16:10,841
PEOPLE WITH HIV IN DALLAS,

4857
03:16:10,841 --> 03:16:13,210
TEXAS, USES THE GUIDELINES AT

4858
03:16:13,210 --> 03:16:15,913
LEAST ONCE A WEEK, TO HELP WITH

4859
03:16:15,913 --> 03:16:16,380
CHALLENGING CASES.

4860
03:16:16,380 --> 03:16:20,551
THEY HAVE COME TO TRUST THEM, AS

4861
03:16:20,551 --> 03:16:22,253
AUTHORITATIVE SOURCE OF

4862
03:16:22,253 --> 03:16:23,954
INFORMATION GIVEN RIGOROUS

4863
03:16:23,954 --> 03:16:27,591
VETTING OF SCIENCE AND CAREFULLY

4864
03:16:27,591 --> 03:16:28,993
SELECTED MEMBERS OF THE PANEL.

4865
03:16:28,993 --> 03:16:30,961
THEY ARE DISTRESSED TO LEARN OF

4866
03:16:30,961 --> 03:16:32,796
THE PLAN TO PHASE OUT

4867
03:16:32,796 --> 03:16:34,532
GUIDELINES, HARD TO IMAGINE

4868
03:16:34,532 --> 03:16:35,599
ANOTHER BODY BEING ABLE TO TAKE

4869
03:16:35,599 --> 03:16:40,938
ON THIS EFFORT IN A SIMILARLY

4870
03:16:40,938 --> 03:16:42,006
EFFECTIVE WAY.

4871
03:16:42,006 --> 03:16:43,674
GUIDELINES FROM PROFESSIONAL

4872
03:16:43,674 --> 03:16:50,748
ORGANIZATIONS LIKE IDSA ARE

4873
03:16:50,748 --> 03:16:52,216
UPDATED EVERY FIVE YEARS, MAJOR

4874
03:16:52,216 --> 03:16:54,385
PROBLEM TO STAY CURRENT, URGE

4875
03:16:54,385 --> 03:16:56,020
LEADERSHIP TO RECONSIDER AND

4876
03:16:56,020 --> 03:17:03,761
CONTINUE THE PANELS IN CURRENT

4877
03:17:03,761 --> 03:17:03,961
FORM.

4878
03:17:03,961 --> 03:17:09,700
NEXT THOMAS MARTIN FROM UC-SAN

4879
03:17:09,700 --> 03:17:12,102
DIEGO, SAN DIEGO V.A., CONCERN

4880
03:17:12,102 --> 03:17:13,704
AS A PROVIDER, ASTONISHED THIS

4881
03:17:13,704 --> 03:17:17,675
INVALUABLE COMMITTEE COULD BE

4882
03:17:17,675 --> 03:17:18,309
DISBANDED, THOUSANDS OF

4883
03:17:18,309 --> 03:17:19,410
PROVIDERS LIKE THEMSELVES IN THE

4884
03:17:19,410 --> 03:17:23,614
U.S. AND AROUND THE WORLD DEPEND

4885
03:17:23,614 --> 03:17:25,349
ON THE GUIDANCE, AND UP-TO-DATE

4886
03:17:25,349 --> 03:17:26,050
RECOMMENDATIONS FOR OPTIMAL

4887
03:17:26,050 --> 03:17:28,152
TREATMENT OF HIV.

4888
03:17:28,152 --> 03:17:30,287
TO BELIEVE INDIVIDUAL PROVIDERS

4889
03:17:30,287 --> 03:17:32,990
WOULD HAVE TIME REVIEW

4890
03:17:32,990 --> 03:17:34,858
LITERATURE, MAKE COMPLEX

4891
03:17:34,858 --> 03:17:39,530
EFFICACY ANALYSES AND EVALUATE

4892
03:17:39,530 --> 03:17:41,031
COMPLEX DRUG-DRUG INTERACTIONS

4893
03:17:41,031 --> 03:17:42,066
INCLUDING PHARMACOKINETIC

4894
03:17:42,066 --> 03:17:45,536
EVALUATION IS RIDICULOUS AND

4895
03:17:45,536 --> 03:17:45,970
DANGEROUS.

4896
03:17:45,970 --> 03:17:49,773
IF WE HAVE INTEREST IN IMPROVING

4897
03:17:49,773 --> 03:17:50,708
COST EFFECTIVENESS THEY WOULD BE

4898
03:17:50,708 --> 03:17:55,579
MORE THAN HAPPY TO DISCUSS THIS

4899
03:17:55,579 --> 03:17:58,382
AND LIKELY MILLIONS AND MILLIONS

4900
03:17:58,382 --> 03:18:00,451
IN HEALTHCARE SAVINGS THAT

4901
03:18:00,451 --> 03:18:03,487
DON'T -- THAT COULD BE MADE THAT

4902
03:18:03,487 --> 03:18:09,059
DON'T REQUIRE THOUGHTLESS

4903
03:18:09,059 --> 03:18:14,098
CUTTING OF UNVOLUNTEER

4904
03:18:14,098 --> 03:18:15,366
ACADEMICS.

4905
03:18:15,366 --> 03:18:17,201
NEXT FRANCESCA TORIANA, UC-SAN

4906
03:18:17,201 --> 03:18:20,404
DIEGO, DEEP CONCERN OVER THE

4907
03:18:20,404 --> 03:18:23,307
REPORTED DECISION TO CUT THE

4908
03:18:23,307 --> 03:18:27,311
PANEL. 

4909
03:18:27,311 --> 03:18:29,413
THIS DECISION IS TROUBLING, GOES

4910
03:18:29,413 --> 03:18:31,248
AGAINST CORE PRINCIPLES, DOES

4911
03:18:31,248 --> 03:18:33,584
NOT SUPPORT IMPROVEMENT AND

4912
03:18:33,584 --> 03:18:35,319
EDUCATION OF PROFESSION,

4913
03:18:35,319 --> 03:18:36,286
COUNTERPRODUCTIVE TO PUBLIC

4914
03:18:36,286 --> 03:18:36,787
HEALTH.

4915
03:18:36,787 --> 03:18:40,324
HAS BEEN A CORNERSTONE ENSURING

4916
03:18:40,324 --> 03:18:40,891
CLINICIANS, RESEARCHERS, AND

4917
03:18:40,891 --> 03:18:42,993
STAKEHOLDERS ACROSS THE U.S. AND

4918
03:18:42,993 --> 03:18:45,229
BEYOND HAVE ACCESS TO CLEAR

4919
03:18:45,229 --> 03:18:46,530
EVIDENCE-BASED AND UP-TO-DATE

4920
03:18:46,530 --> 03:18:48,399
TREATMENT GUIDELINES FOR HIV

4921
03:18:48,399 --> 03:18:48,599
CARE.

4922
03:18:48,599 --> 03:18:50,868
THEY ARE CONSULTED BY THOUSANDS

4923
03:18:50,868 --> 03:18:53,137
OF PRACTITIONERS AND

4924
03:18:53,137 --> 03:18:56,974
INSTITUTION, REGARDED GLOBALLY

4925
03:18:56,974 --> 03:19:00,844
AS GOLD STANDARD.

4926
03:19:00,844 --> 03:19:03,180
NOTES MEMBERS ARE VOLUNTEER, AND

4927
03:19:03,180 --> 03:19:05,249
TO ELIMINATE HIGH IMPACT LOW

4928
03:19:05,249 --> 03:19:06,483
COST INITIATIVE WOULD SEND THE

4929
03:19:06,483 --> 03:19:12,022
WRONG MESSAGE AT A TIME WHEN

4930
03:19:12,022 --> 03:19:15,592
CONSISTENTLY CLARITY ARE MORE

4931
03:19:15,592 --> 03:19:18,295
VITAL THAN EVER.

4932
03:19:18,295 --> 03:19:20,364
SHE'S CONCERNED THIS DECISION

4933
03:19:20,364 --> 03:19:24,334
COULD CREATE CONFUSION IN

4934
03:19:24,334 --> 03:19:25,736
CLINICAL PRACTICE AND URGES

4935
03:19:25,736 --> 03:19:30,374
OARAC TO RECONSIDER THIS

4936
03:19:30,374 --> 03:19:31,141
DECISION.

4937
03:19:31,141 --> 03:19:34,445
NEXT FROM WILLIAM CONNORS FROM

4938
03:19:34,445 --> 03:19:37,081
UNIVERSITY OF BRITISH COLUMBIA,

4939
03:19:37,081 --> 03:19:37,681
ST. PAUL'S HOSPITAL.

4940
03:19:37,681 --> 03:19:44,488
EXPRESSING DEEP CONCERN AS AN

4941
03:19:44,488 --> 03:19:46,590
HIV PROVIDER, EDUCATOR,

4942
03:19:46,590 --> 03:19:48,192
ROUTINELY USES THE GUIDELINES TO

4943
03:19:48,192 --> 03:19:50,027
INFORM CARE AND EDUCATE STUDENTS

4944
03:19:50,027 --> 03:19:51,328
AND COLLEAGUES.

4945
03:19:51,328 --> 03:19:53,030
COULD THINK OF NO OTHER CLINICAL

4946
03:19:53,030 --> 03:19:56,533
RESOURCE THAT HE HOLDS IN SUCH

4947
03:19:56,533 --> 03:19:58,936
HIGH REGARD, BELIEVES ANY

4948
03:19:58,936 --> 03:20:00,738
DISRUPTION IN THE UPDATING

4949
03:20:00,738 --> 03:20:03,107
PROCESS AND LOSS OF HIGH

4950
03:20:03,107 --> 03:20:04,341
EVIDENCE-BASED STANDARDS AND

4951
03:20:04,341 --> 03:20:12,249
EXCEPTIONAL QUALITY WILL BE AT

4952
03:20:12,249 --> 03:20:14,184
AN A COST.

4953
03:20:14,184 --> 03:20:17,521
THIS IS FROM JOSE MIRA,

4954
03:20:17,521 --> 03:20:19,022
UNIVERSITY OF BARCELONA.

4955
03:20:19,022 --> 03:20:20,424
INTERNATIONAL MEMBER OF THE

4956
03:20:20,424 --> 03:20:21,592
EXPERT PANEL FOR MORE THAN 20

4957
03:20:21,592 --> 03:20:25,028
YEARS, I WANT TO LET YOU KNOW

4958
03:20:25,028 --> 03:20:27,030
THE GUIDELINES ARE A GLOBAL

4959
03:20:27,030 --> 03:20:29,867
BENCH MARK, PERFECTLY UP THE

4960
03:20:29,867 --> 03:20:31,869
DATE HELPING PHYSICIANS AROUND

4961
03:20:31,869 --> 03:20:33,604
THE WORLD TREAT HIV INFECTED

4962
03:20:33,604 --> 03:20:36,406
PATIENT WITH O.I.

4963
03:20:36,406 --> 03:20:38,876
THEY ARE SAVING LIVES.

4964
03:20:38,876 --> 03:20:41,078
EDUCATION AND HEALTH CARE WORK

4965
03:20:41,078 --> 03:20:41,745
IS INVALUABLE AND STRONGLY

4966
03:20:41,745 --> 03:20:43,313
BELIEVES ROLE SHOULD NOT BE

4967
03:20:43,313 --> 03:20:47,985
CHANGED IN THE FUTURE, IF

4968
03:20:47,985 --> 03:20:49,853
ANYTHING SHOULD BE STRENGTHENED.

4969
03:20:49,853 --> 03:20:54,525
THIS IS FROM ELIZABETH LAIDLAW,

4970
03:20:54,525 --> 03:20:56,393
PHYSICIAN ASSISTANT, WORKING AT

4971
03:20:56,393 --> 03:20:58,529
THE NIH IN INFECTIOUS DISEASE

4972
03:20:58,529 --> 03:20:59,329
CLINICAL RESEARCH.

4973
03:20:59,329 --> 03:21:01,532
VOICING SUPPORT FOR THE NEED TO

4974
03:21:01,532 --> 03:21:05,469
CONTINUE THE FEDERAL GUIDELINES,

4975
03:21:05,469 --> 03:21:07,371
REFERENCES FREQUENTLY TO PROVIDE

4976
03:21:07,371 --> 03:21:08,639
BEST MEDICAL CARE, KNOWS THEY

4977
03:21:08,639 --> 03:21:11,308
ARE RELIABLE, UP TO DATE, CAN BE

4978
03:21:11,308 --> 03:21:12,609
REFERENCED QUICKLY, OR READ IN

4979
03:21:12,609 --> 03:21:13,677
DEPTH AS NEEDED.

4980
03:21:13,677 --> 03:21:16,146
SHE'S REFERRED MANY P.A. AND

4981
03:21:16,146 --> 03:21:17,714
MEDICAL STUDENT TO THEM OVER THE

4982
03:21:17,714 --> 03:21:21,418
YEARS AS THEY ARE EDUCATIONAL

4983
03:21:21,418 --> 03:21:22,986
AND PRACTICAL SOURCE OF

4984
03:21:22,986 --> 03:21:24,321
INFORMATION TO MANAGE MEDICAL

4985
03:21:24,321 --> 03:21:28,926
CARE FOR PEOPLE WITH HIV.

4986
03:21:28,926 --> 03:21:36,967
THIS IS FROM DR. BRIAN EPPLIN

4987
03:21:36,967 --> 03:21:38,869
FROM NIAID, BOTH A PROVIDER AND

4988
03:21:38,869 --> 03:21:42,773
RESEARCH AT NIH HAS TURNED TO

4989
03:21:42,773 --> 03:21:44,474
THE GUIDELINES COUNTLESS TIMES,

4990
03:21:44,474 --> 03:21:45,776
IMMENSE SOURCE OF INFORMATION,

4991
03:21:45,776 --> 03:21:49,613
SYNTHESIS OF A VAST FIELD OF

4992
03:21:49,613 --> 03:21:49,880
RESEARCH.

4993
03:21:49,880 --> 03:21:51,148
FURTHERMORE THEY IDENTIFY GAPS

4994
03:21:51,148 --> 03:21:52,683
IN KNOWLEDGE, FURTHER RESEARCH

4995
03:21:52,683 --> 03:21:54,518
IS NEEDED.

4996
03:21:54,518 --> 03:21:56,820
THIS IS AN INVALUABLE WAY TO

4997
03:21:56,820 --> 03:21:57,921
GENERATE IDEAS AND DISCUSSION.

4998
03:21:57,921 --> 03:21:59,690
IN AN ENVIRONMENT WHERE THE CARE

4999
03:21:59,690 --> 03:22:02,993
OF PEOPLE WITH HIV WORLDWIDE HAS

5000
03:22:02,993 --> 03:22:06,730
BEEN CURTAILED AND HIV RESEARCH

5001
03:22:06,730 --> 03:22:10,167
COME UNDER THREAT, SHOULD BE

5002
03:22:10,167 --> 03:22:14,338
OAR'S DUTY TO BE AN ADVOCATE.

5003
03:22:14,338 --> 03:22:17,975
WOULD BE SENDING A MESSAGE TO

5004
03:22:17,975 --> 03:22:23,647
THE ENTIRE HIV COMMUNITY IT DOTS

5005
03:22:23,647 --> 03:22:33,323
NOT -- DOES NOT CONSIDER THE

5006
03:22:33,323 --> 03:22:35,659
INFORMATION GENERATED WORTH

5007
03:22:35,659 --> 03:22:36,026
ADVANCING.

5008
03:22:36,026 --> 03:22:38,462
WE'RE GETTING THERE.

5009
03:22:38,462 --> 03:22:47,504
THIS IS FROM AARON READY,

5010
03:22:47,504 --> 03:22:48,138
CANADIAN NETWORK.

5011
03:22:48,138 --> 03:22:49,773
EXPRESSING DEEP CONCERN.

5012
03:22:49,773 --> 03:22:51,441
HER ORGANIZATION IS A NATIONAL

5013
03:22:51,441 --> 03:22:53,544
NETWORK OF PHARMACISTS ACROSS

5014
03:22:53,544 --> 03:22:57,848
CANADA, THAT WAS FORMED IN 1997,

5015
03:22:57,848 --> 03:23:00,050
COLLABORATING ON CLINICAL

5016
03:23:00,050 --> 03:23:01,451
PRACTICE, RESEARCH, EDUCATION,

5017
03:23:01,451 --> 03:23:04,354
AND MEMBERS RELY HEAVILY ON THE

5018
03:23:04,354 --> 03:23:08,358
HHS HIV GUIDELINES AS TRUSTED

5019
03:23:08,358 --> 03:23:09,226
EVIDENCE-BASED RESOURCE

5020
03:23:09,226 --> 03:23:10,827
INFORMING CLINICAL DECISIONS AND

5021
03:23:10,827 --> 03:23:13,597
CONSISTENCY IN CARE IN

5022
03:23:13,597 --> 03:23:14,031
HEALTHCARE SETTINGS.

5023
03:23:14,031 --> 03:23:16,667
NOTES THEY ARE A LONGTIME GOLD

5024
03:23:16,667 --> 03:23:18,602
STANDARD OFFERING TIMELY

5025
03:23:18,602 --> 03:23:19,803
RIGOROUSLY REVIEWED AND

5026
03:23:19,803 --> 03:23:24,541
ACCESSIBLE RECOMMENDATIONS

5027
03:23:24,541 --> 03:23:26,610
INVALUABLE TO CLINICIANS

5028
03:23:26,610 --> 03:23:27,678
WORLDWIDE.

5029
03:23:27,678 --> 03:23:29,646
DEEPLY CONCERNED ABOUT

5030
03:23:29,646 --> 03:23:32,616
DISCONTINUING NIH SUPPORT, WOULD

5031
03:23:32,616 --> 03:23:34,584
JEOPARDIZE QUALITY, CREDIBILITY,

5032
03:23:34,584 --> 03:23:36,219
ACCESSIBILITY OF GUIDELINES,

5033
03:23:36,219 --> 03:23:38,288
PROPOSED TRANSFER OF

5034
03:23:38,288 --> 03:23:42,993
RESPONSIBILITY TO  ANOTHER AGENY

5035
03:23:42,993 --> 03:23:45,295
RAISES QUESTIONS ABOUT

5036
03:23:45,295 --> 03:23:46,863
PRESERVATION OF HIGH STANDARD.

5037
03:23:46,863 --> 03:23:49,399
LOSS OF NIH STEWARDSHIP WOULD BE

5038
03:23:49,399 --> 03:23:52,836
SIGNIFICANT SETBACK FOR

5039
03:23:52,836 --> 03:23:53,937
CLINICIANS AND PATIENTS, THEY

5040
03:23:53,937 --> 03:23:57,774
URGE NIH AND OAR TO RECONSIDER

5041
03:23:57,774 --> 03:23:59,409
THIS DECISION.

5042
03:23:59,409 --> 03:24:01,311
AND RECOGNIZE IRREPLACEABLE

5043
03:24:01,311 --> 03:24:04,047
VALUE OF THE GUIDELINES.

5044
03:24:04,047 --> 03:24:06,416
AND NIH SUPPORT SPECIFICALLY IS

5045
03:24:06,416 --> 03:24:08,418
ESSENTIAL TO MAINTAIN INTEGRITY

5046
03:24:08,418 --> 03:24:18,929
AND UTILITY OF THIS RESOURCE.

5047
03:24:22,432 --> 03:24:30,307
THIS IS FROM SCOTT BURTONI,

5048
03:24:30,307 --> 03:24:33,310
HEALTH HIV.ORG.

5049
03:24:33,310 --> 03:24:35,679
THERE'S A GROWING DISQUIET HOW

5050
03:24:35,679 --> 03:24:38,548
THIS WOULD BE MANAGED AND MAY

5051
03:24:38,548 --> 03:24:42,052
SIGNAL MORE BROADLY.

5052
03:24:42,052 --> 03:24:45,422
DEDICATED SESSION, HE'S GOT SOME

5053
03:24:45,422 --> 03:24:47,090
CONCERNS ABOUT TODAY'S AGENDA.

5054
03:24:47,090 --> 03:24:49,693
AND NOT JUST TECHNICAL DOCUMENTS

5055
03:24:49,693 --> 03:24:52,029
BUT ANCHORING, PRESCRIBING

5056
03:24:52,029 --> 03:24:55,399
PRACTICES, SHAPING POLICIES, IN

5057
03:24:55,399 --> 03:24:57,167
RYAN WHITE AND MEDICAID.

5058
03:24:57,167 --> 03:25:01,204
IN THE CURRENT CLIMATE SHIFTING

5059
03:25:01,204 --> 03:25:02,439
OVERSIGHT RAISES QUESTIONS FOR

5060
03:25:02,439 --> 03:25:04,608
THE FELD AND QUESTIONS WHETHER

5061
03:25:04,608 --> 03:25:06,510
GUIDELINES SCOPE, FREQUENCY OF

5062
03:25:06,510 --> 03:25:07,544
UPDATES AND LANGUAGE

5063
03:25:07,544 --> 03:25:09,980
PARTICULARLY AS RELATES TO

5064
03:25:09,980 --> 03:25:12,015
BLACK, BROWN, TRANSGENDER AND

5065
03:25:12,015 --> 03:25:12,983
DISPROPORTIONATELY AFFECTED

5066
03:25:12,983 --> 03:25:14,351
POPULATIONS WILL REMAIN

5067
03:25:14,351 --> 03:25:14,751
PROTECTED.

5068
03:25:14,751 --> 03:25:18,555
HE LOOKS FORWARD TO OARAC

5069
03:25:18,555 --> 03:25:20,757
AFFIRMING COMMITMENT TO THE

5070
03:25:20,757 --> 03:25:22,659
GUIDELINES, OUTLINING HOW

5071
03:25:22,659 --> 03:25:24,528
STAKEHOLDER VOICES WILL BE

5072
03:25:24,528 --> 03:25:34,037
MEANINGFULLY INCLUDED IN ANY

5073
03:25:34,037 --> 03:25:35,906
TRANSITION.

5074
03:25:35,906 --> 03:25:38,175
THIS IS FROM IDSA.

5075
03:25:38,175 --> 03:25:41,011
AUTHORED BY ANDREA WETEL, TINA

5076
03:25:41,011 --> 03:25:43,880
TAN, COLLEEN KELLY.

5077
03:25:43,880 --> 03:25:48,919
IT'S VERY LENGTHILY, I'LL SUM

5078
03:25:48,919 --> 03:25:49,086
UP.

5079
03:25:49,086 --> 03:25:51,655
MAIN PREMISE TO ENCOURAGE --

5080
03:25:51,655 --> 03:25:54,424
URGE NIH TO RECONSIDER THE

5081
03:25:54,424 --> 03:25:55,659
DECISION TO DISCONTINUE SUPPORT,

5082
03:25:55,659 --> 03:25:58,395
GIVEN IMMENSE VALUE TO HIV

5083
03:25:58,395 --> 03:26:01,298
CLINICAL CARE AND CRITICAL ROLE

5084
03:26:01,298 --> 03:26:02,599
IN PROMOTING A RESPONSE TO THE

5085
03:26:02,599 --> 03:26:05,802
EPIDEMIC IN THE U.S.

5086
03:26:05,802 --> 03:26:09,005
THEY URGE ALL DISCUSSIONS

5087
03:26:09,005 --> 03:26:12,642
REGARDING THE FUTURE TO THE

5088
03:26:12,642 --> 03:26:15,245
TRANSPARENT SO THE COMMUNITY,

5089
03:26:15,245 --> 03:26:16,413
PEDIATRICIANS, AND PEOPLE WITH

5090
03:26:16,413 --> 03:26:18,582
HIV WHO COUNT ON GUIDELINES CAN

5091
03:26:18,582 --> 03:26:22,853
FOLLOW AND INFORM THE PROCESS.

5092
03:26:22,853 --> 03:26:25,021
THEY MAKE SEVERAL POINTS WHICH

5093
03:26:25,021 --> 03:26:32,662
WE'LL PUBLISH WITH OUR MINUTES

5094
03:26:32,662 --> 03:26:33,930
REGARDING IMPLEMENTATION

5095
03:26:33,930 --> 03:26:34,564
SCIENCE.

5096
03:26:34,564 --> 03:26:37,434
REGARDING HEALTH OUTCOME AND

5097
03:26:37,434 --> 03:26:39,002
COST IMPACT.

5098
03:26:39,002 --> 03:26:40,570
INCREASED DEMAND FOR GUIDELINES,

5099
03:26:40,570 --> 03:26:43,073
UNIQUE NIH ROLE IN THE

5100
03:26:43,073 --> 03:26:43,740
GUIDELINES.

5101
03:26:43,740 --> 03:26:51,214
AND HOW THE GUIDELINES COULD BE

5102
03:26:51,214 --> 03:26:58,388
EVOLVED IN THE FUTURE.

5103
03:26:58,388 --> 03:26:59,789
CHRISTINE JOHNAJON, PHARMACIST,

5104
03:26:59,789 --> 03:27:03,860
NO AFFILIATION, KEEP THE

5105
03:27:03,860 --> 03:27:06,463
GUIDELINES, THEY PROVIDE THE

5106
03:27:06,463 --> 03:27:07,564
BEST UP-TO-DATE CARE, 30 YEARS

5107
03:27:07,564 --> 03:27:09,299
OF HER CAREER TAKING CARE OF

5108
03:27:09,299 --> 03:27:16,139
THESE PATIENTS THEY HAVE RELIED

5109
03:27:16,139 --> 03:27:17,741
HEAVILY ON THEM.

5110
03:27:17,741 --> 03:27:22,512
SPECIFICALLY REGARDING NEXT

5111
03:27:22,512 --> 03:27:25,649
GENERATION OF PHARMACISTS.

5112
03:27:25,649 --> 03:27:28,685
NEXT FROM DR. ALLISON ROCKSBY,

5113
03:27:28,685 --> 03:27:30,587
UNIVERSITY OF WASHINGTON,

5114
03:27:30,587 --> 03:27:32,222
GUIDELINES ARE INVALUABLE,

5115
03:27:32,222 --> 03:27:33,223
REFERENCES THEM ALL THE TIME,

5116
03:27:33,223 --> 03:27:36,126
HOPE THEY CAN CONTINUE AS

5117
03:27:36,126 --> 03:27:37,627
TRUSTED SOURCE OF INFORMATION.

5118
03:27:37,627 --> 03:27:39,696
THERE'S NO OTHER EASILY

5119
03:27:39,696 --> 03:27:47,537
ACCESSIBLE RESOURCE FOR THIS

5120
03:27:47,537 --> 03:27:47,771
PURPOSE.

5121
03:27:47,771 --> 03:27:52,375
FROM THE AMERICAN COLLEGE OF

5122
03:27:52,375 --> 03:27:55,545
CLINICAL PHARMACY RESEARCH

5123
03:27:55,545 --> 03:27:56,479
NETWORK.

5124
03:27:56,479 --> 03:27:58,415
EXPRESSES PROFOUND CONCERN AND

5125
03:27:58,415 --> 03:27:59,349
THAT THEIR ORGANIZATION IS

5126
03:27:59,349 --> 03:28:01,451
COMPRISED OF PHARMACISTS FROM

5127
03:28:01,451 --> 03:28:03,853
THE U.S., CANADA, SAUDI ARABIA.

5128
03:28:03,853 --> 03:28:07,257
THEY RELY EXTENSIVELY ON THE

5129
03:28:07,257 --> 03:28:09,726
GUIDELINES AS TO PROVIDE

5130
03:28:09,726 --> 03:28:11,061
EVIDENCE-BASED CARE AND

5131
03:28:11,061 --> 03:28:12,729
RECOMMENDATIONS THAT PROMOTE

5132
03:28:12,729 --> 03:28:16,399
CONSISTENT AND LIFE SAVING CARE,

5133
03:28:16,399 --> 03:28:18,768
TO ALL IN NEED.

5134
03:28:18,768 --> 03:28:20,237
PLANNED DISCONTINUATION OF NIH

5135
03:28:20,237 --> 03:28:22,906
SUPPORT THREATENS THE INTEGRITY,

5136
03:28:22,906 --> 03:28:24,808
RELIABILITY, AVAILABILITY OF THE

5137
03:28:24,808 --> 03:28:25,875
VITAL RESOURCE, PARTICULARLY

5138
03:28:25,875 --> 03:28:27,477
CONCERNED ABOUT THE IMPLICATIONS

5139
03:28:27,477 --> 03:28:28,311
OF TRAPS FERG RESPONSIBILITY

5140
03:28:28,311 --> 03:28:36,019
WITHOUT A CLEAR AND TRANSPARENT

5141
03:28:36,019 --> 03:28:38,088
PLAN, TO RESEARCH STANDARDS,

5142
03:28:38,088 --> 03:28:39,356
SUCH A MOVE RISKS UNDERMINING

5143
03:28:39,356 --> 03:28:42,058
DECADES OF PROGRESS THAT COULD

5144
03:28:42,058 --> 03:28:46,696
HINDER EFFORTS TO END THE HIV

5145
03:28:46,696 --> 03:28:47,130
EPIDEMIC.

5146
03:28:47,130 --> 03:28:51,635
THEY URGE NIH AND OAR TO

5147
03:28:51,635 --> 03:28:53,003
REEVALUATE AND REVERSE AND STATE

5148
03:28:53,003 --> 03:28:55,105
CONTINUED SUPPORT IS ESSENTIAL

5149
03:28:55,105 --> 03:28:57,207
TO SAFEGUARD INTEGRITY,

5150
03:28:57,207 --> 03:29:00,243
AUTHORITY, GLOBAL UTILITY OF THE

5151
03:29:00,243 --> 03:29:01,011
GUIDELINES, IRREPLACEABLE

5152
03:29:01,011 --> 03:29:03,647
CORNERSTONE OF HIV CLINICAL

5153
03:29:03,647 --> 03:29:06,683
PRACTICE. 

5154
03:29:06,683 --> 03:29:09,352
I ALREADY READ THAT.

5155
03:29:09,352 --> 03:29:14,591
THERE'S FOUR LEFT.

5156
03:29:14,591 --> 03:29:17,494
THIS IS FROM BRIGHAM AND WOMEN'S

5157
03:29:17,494 --> 03:29:17,794
HOSPITAL.

5158
03:29:17,794 --> 03:29:19,062
WRITING TO EXPRESS STRONG

5159
03:29:19,062 --> 03:29:20,463
FEELING ABOUT THE GUIDELINES AND

5160
03:29:20,463 --> 03:29:23,700
ALL THEIR FORMS THEY SHOULD BE

5161
03:29:23,700 --> 03:29:25,001
MAINTAINED AND SUPPORTED BY

5162
03:29:25,001 --> 03:29:26,303
FEDERAL GOVERNMENT, THE SINGLE

5163
03:29:26,303 --> 03:29:27,170
MOST IMPORTANT SOURCE OF

5164
03:29:27,170 --> 03:29:29,539
CLINICAL INFORMATION WE USE AT

5165
03:29:29,539 --> 03:29:30,707
THE POINT OF CARE, MISSION

5166
03:29:30,707 --> 03:29:32,442
CRITICAL AND A WORTHY GOVERNMENT

5167
03:29:32,442 --> 03:29:35,578
FUNCTION THAT CONTRIBUTES TO

5168
03:29:35,578 --> 03:29:36,780
MAKING AMERICA GREAT.

5169
03:29:36,780 --> 03:29:38,782
THEY DEFINE CARE FOR THE WORLD.

5170
03:29:38,782 --> 03:29:42,886
WE'RE LEADERS IN THIS SPACE AND

5171
03:29:42,886 --> 03:29:51,995
PROVIDE   VALUE.

5172
03:29:51,995 --> 03:30:00,403
MAKE AMERICA GREAT AND KEEP

5173
03:30:00,403 --> 03:30:03,740
THESE GUIDELINES.

5174
03:30:03,740 --> 03:30:07,310
THIS IS FROM NICOLA DEE, RETIRED

5175
03:30:07,310 --> 03:30:08,345
P.A. FROM NIH.

5176
03:30:08,345 --> 03:30:12,916
SHE STATES THAT TAKING CARE OF

5177
03:30:12,916 --> 03:30:14,617
PATIENTS WITH HIV RELIES ON THE

5178
03:30:14,617 --> 03:30:17,754
EXPANSIVE GUIDELINES AS A

5179
03:30:17,754 --> 03:30:22,392
ROADMAP TO PROVIDE CORRECT

5180
03:30:22,392 --> 03:30:23,193
ARVs, RECOMMENDATION REGARDING

5181
03:30:23,193 --> 03:30:25,995
TRANSMISSION AND TREATING

5182
03:30:25,995 --> 03:30:29,099
O.I.s, REFER TO THE GUIDELINES

5183
03:30:29,099 --> 03:30:32,335
ON A REGULAR BASIS, MADE BY

5184
03:30:32,335 --> 03:30:34,804
DEDICATED PANELS OF EXPERTS WHO

5185
03:30:34,804 --> 03:30:36,840
CREATE DOCUMENTS AFTER INTENSE

5186
03:30:36,840 --> 03:30:39,476
FOCUS AND ATTENTION TO DETAIL

5187
03:30:39,476 --> 03:30:46,249
AND DISCUSSION TO REACH

5188
03:30:46,249 --> 03:30:47,650
CONSENSUS.

5189
03:30:47,650 --> 03:30:52,455
NEXT FROM JENNIFER JANEL,

5190
03:30:52,455 --> 03:30:53,289
GAINESVILLE FLORIDA, DOCTOR

5191
03:30:53,289 --> 03:30:55,325
JANELLE, HIV PROVIDER AND

5192
03:30:55,325 --> 03:30:59,863
EDUCATOR, LOCAL MEDICAL SCHOOL,

5193
03:30:59,863 --> 03:31:00,997
REGIONALLY THROUGH FEDERALLY

5194
03:31:00,997 --> 03:31:03,299
FUNDED TRAINING CENTER.

5195
03:31:03,299 --> 03:31:06,369
USES GUIDELINES NEARLY DAILY IN

5196
03:31:06,369 --> 03:31:08,505
CARE AND TEACHING, BELIEVES LOSS

5197
03:31:08,505 --> 03:31:10,173
WILL RESULT IN SIGNIFICANT

5198
03:31:10,173 --> 03:31:13,009
REDUCTION IN PEOPLE PROVIDING

5199
03:31:13,009 --> 03:31:14,244
OPTIMAL CARE, QUICKLY MAKING

5200
03:31:14,244 --> 03:31:18,081
CARE DECISIONS IN REAL TIME.

5201
03:31:18,081 --> 03:31:19,516
THESE DECISIONS CAN MEAN THE

5202
03:31:19,516 --> 03:31:22,051
DIFFERENCE BETWEEN LIFE AND

5203
03:31:22,051 --> 03:31:22,452
DEATH.

5204
03:31:22,452 --> 03:31:25,121
NOTE THERE HAVE BEEN EFFORTS TO

5205
03:31:25,121 --> 03:31:29,993
EXPAND HIV WORKFORCE OUTSIDE OF

5206
03:31:29,993 --> 03:31:32,495
I.D. PROVIDERS, PRIMARY CARE

5207
03:31:32,495 --> 03:31:34,831
PROVIDERS WILLING TO CARE FOR

5208
03:31:34,831 --> 03:31:35,832
PATIENTS IN UNDERSERVED PARTS OF

5209
03:31:35,832 --> 03:31:37,133
OUR NATION BECAUSE THEY DON'T

5210
03:31:37,133 --> 03:31:39,502
HAVE TO FILTER THROUGH NUMEROUS

5211
03:31:39,502 --> 03:31:41,838
PAPERS BUT CAN RELY ON CAREFULLY

5212
03:31:41,838 --> 03:31:45,008
VETTED STUDIES WITH OUTCOMES

5213
03:31:45,008 --> 03:31:46,075
SUMMARIZED IN THE GUIDELINES.

5214
03:31:46,075 --> 03:31:47,510
SHE BELIEVES WITHOUT THE

5215
03:31:47,510 --> 03:31:49,946
GUIDELINES WE WILL LOSE

5216
03:31:49,946 --> 03:31:51,915
PROVIDERS WHO LACK FOCUS HIV

5217
03:31:51,915 --> 03:31:53,683
EXPERTISE BUT WILLING TO PROVIDE

5218
03:31:53,683 --> 03:31:57,353
CARE WITH THE SUPPORT OF THE

5219
03:31:57,353 --> 03:31:58,421
GUIDELINES.

5220
03:31:58,421 --> 03:31:59,456
COMBINED WITH PROPOSED CHANGES

5221
03:31:59,456 --> 03:32:07,697
AND SUBSTANTIAL CUTS TO PART F

5222
03:32:07,697 --> 03:32:11,801
OF RYAN WHITE TO DEVELOP --

5223
03:32:11,801 --> 03:32:12,535
SORRY.

5224
03:32:12,535 --> 03:32:13,703
DEVELOP AND DISSEMINATE RESEARCH

5225
03:32:13,703 --> 03:32:17,874
AND EDUCATION TO ORGANIZATIONS

5226
03:32:17,874 --> 03:32:19,209
AND PROVIDERS, THESE LOSSES WILL

5227
03:32:19,209 --> 03:32:21,177
RESULT IN LOSS OF KNOWLEDGE AND

5228
03:32:21,177 --> 03:32:24,247
EXPERTISE, AND WILL SET BACK

5229
03:32:24,247 --> 03:32:25,815
PROGRESS WE'VE MADE IN ENDING

5230
03:32:25,815 --> 03:32:27,951
THE EPIDEMIC IN THE U.S.

5231
03:32:27,951 --> 03:32:30,220
PROVIDERS WILL LIKELY RELY ON

5232
03:32:30,220 --> 03:32:32,322
BIASED INFORMATION FROM THE

5233
03:32:32,322 --> 03:32:33,323
PHARMACEUTICAL INDUSTRY WITHOUT

5234
03:32:33,323 --> 03:32:34,624
THE GUIDELINES THAT MAY NOT BE

5235
03:32:34,624 --> 03:32:37,327
IN THE BEST INTEREST OF PUBLIC

5236
03:32:37,327 --> 03:32:38,228
HEALTH, HEALTH OF INDIVIDUALS,

5237
03:32:38,228 --> 03:32:40,997
FINANCIAL HEALTH OF OUR

5238
03:32:40,997 --> 03:32:41,764
HEALTHCARE SYSTEM.

5239
03:32:41,764 --> 03:32:45,969
PLEASE MAKE STEPS TO ENSURE

5240
03:32:45,969 --> 03:32:46,836
ONGOING SUPPORT OF GUIDELINES

5241
03:32:46,836 --> 03:32:49,973
AND SO THEY CAN CONTINUE TO BE

5242
03:32:49,973 --> 03:32:53,343
LIVING DOCUMENT MADE BY UNBIASED

5243
03:32:53,343 --> 03:32:54,344
EXPERTS.

5244
03:32:54,344 --> 03:32:56,846
AND THE LAST IS FROM EILEEN

5245
03:32:56,846 --> 03:33:04,053
SCULLY,  DR. EILEEN SCULLY,

5246
03:33:04,053 --> 03:33:05,822
EXPRESSING CONCERN, PROVIDER

5247
03:33:05,822 --> 03:33:08,324
FORE20 YEARS, MEMBER OF THE

5248
03:33:08,324 --> 03:33:09,959
PANEL FOR THREE YEARS,

5249
03:33:09,959 --> 03:33:12,462
GUIDELINES ARE DEFINITIVE OF THE

5250
03:33:12,462 --> 03:33:14,597
PUBLIC SERVICE THAT HHS SHOULD

5251
03:33:14,597 --> 03:33:15,565
BE SUPPORTING.

5252
03:33:15,565 --> 03:33:19,669
NOTES VOLUME OF DATA REVIEWED

5253
03:33:19,669 --> 03:33:21,304
AND SYNTHESIZED IS IMMENSE AND

5254
03:33:21,304 --> 03:33:22,839
RESOURCE FOR BOTH QUICK DECISION

5255
03:33:22,839 --> 03:33:25,208
MAKING AND DEEPER CONSIDERATION

5256
03:33:25,208 --> 03:33:28,111
OF EVIDENCE-BASED WHEN UNUSUAL

5257
03:33:28,111 --> 03:33:29,012
CASES ARISE.

5258
03:33:29,012 --> 03:33:31,014
CLEAR PUBLIC SERVICE THAT CANNOT

5259
03:33:31,014 --> 03:33:31,748
BE REPLACED.

5260
03:33:31,748 --> 03:33:33,683
RECONSIDER THIS DECISION AND

5261
03:33:33,683 --> 03:33:36,753
TAKE A CLOSER LOOK AT THE

5262
03:33:36,753 --> 03:33:38,788
INCREDIBLE LEVEL OF EFFICIENCY,

5263
03:33:38,788 --> 03:33:40,557
SCOPE OF VOLUNTARY TIME AND

5264
03:33:40,557 --> 03:33:43,459
EFFORT OF EXPERTS IN THE FIELD.

5265
03:33:43,459 --> 03:33:44,627
CONFIDENT YOU'LL CONTINUE TO

5266
03:33:44,627 --> 03:33:46,329
SUPPORT THIS PUBLIC GOOD WHICH

5267
03:33:46,329 --> 03:33:48,831
HAS DIRECT BENEFITS TO THE

5268
03:33:48,831 --> 03:33:50,633
AMERICAN PEOPLE.

5269
03:33:50,633 --> 03:34:01,044
THAT'S THE LAST ONE, DR.

5270
03:34:04,514 --> 03:34:05,014
MONTANER.

5271
03:34:05,014 --> 03:34:10,086
I THINK YOU'RE ON MUTE, DR.

5272
03:34:10,086 --> 03:34:10,353
MONTANER.

5273
03:34:10,353 --> 03:34:10,753
>> THANK YOU.

5274
03:34:10,753 --> 03:34:12,989
DO YOU HAVE ANY FINAL COMMENTS

5275
03:34:12,989 --> 03:34:14,357
BEFORE WE CLOSE, DR. DONENBERG?

5276
03:34:14,357 --> 03:34:16,226
>> I WANT TO THANK
EVERYONE FOR

5277
03:34:16,226 --> 03:34:18,461
SUBMITTING THE COMMENTS AND

5278
03:34:18,461 --> 03:34:22,732
MAKING VERY CLEAR HOW IMPORTANT

5279
03:34:22,732 --> 03:34:25,301
THE CLINICAL PRACTICE GUIDELINES

5280
03:34:25,301 --> 03:34:29,505
ARE FOR CARE AND TREATMENT AND

5281
03:34:29,505 --> 03:34:29,772
EDUCATION.

5282
03:34:29,772 --> 03:34:30,273
THANK YOU.

5283
03:34:30,273 --> 03:34:30,640
>> THANK YOU.

5284
03:34:30,640 --> 03:34:32,442
THANK YOU VERY MUCH.

5285
03:34:32,442 --> 03:34:34,677
THANK YOU, EVERYONE, FOR JOINING

5286
03:34:34,677 --> 03:34:35,745
THIS MEETING.

5287
03:34:35,745 --> 03:34:38,014
TODAY'S MEETING IS NOW

5288
03:34:38,014 --> 03:34:40,416
ADJOURNED. 

5289
03:34:40,416 --> 03:34:50,727
[END OF PROGRAM]